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Abstract 
Tacrolimus is one of the most potent immunosuppressive agents. It has almost replaced 
ciclosporin (CsA) as the drug of first choice for the prevention of graft rejection after 
kidney transplantation (Bouamar et al, 2013). Tacrolimus was initially available as a 
preparation requiring twice daily administration: Prograf®. A prolonged release 
preparation, Advagraf®, has become available recently with proven efficacy and safety 
following once daily dosing. Tacrolimus has a narrow therapeutic window and its high 
pharmacokinetic variability renders dose selection challenging. Therefore, therapeutic 
drug monitoring (TDM) is used routinely to direct tacrolimus dosing. To some extent, 
this variability is influenced by genetic factors. Enzymes in the cytochrome P4503A 
family (CYP3A) and the drug transporter P-glycoprotein (P-gp) play important roles in 
the absorption and metabolism of tacrolimus (MacPhee et al, 2002). The influence of 
the CYP3A5*3 and ABCB1 3435C>T genotypes on the pharmacokinetics of immediate 
release tacrolimus; Prograf® is well-defined. However, it is unclear for prolonged 
release tacrolimus; Advagraf®. Recently identified polymorphisms CYP3A4*22 and 
P450 Oxidoreductase (POR*28) were reported to have additional effects on tacrolimus 
pharmacokinetics and dose requirement (Jonge et al., 2011; Elens et al., 2013). 
Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous 
marker of P450 3A activity in clinical practice (Diczfalusy et al., 2011). Prednisolone is 
a known inducer of both CYP3A and P-gp. The role of CYP3A4*22 and POR*28 in 
prednisolone metabolism is unknown. An inverse correlation between corticosteroid 
daily dose and tacrolimus exposure was demonstrated in renal transplant recipients 
(Anglicheau et al., 2003a). Achieving therapeutic trough concentration is of vital 
importance during the period immediately after transplantation. Therefore, the 
identification of parameters predictive of the optimal tacrolimus dosage would be a 
great clinical asset in the determination of adequate tacrolimus administration.  
Furthermore, high within-patient variability (WPV) in tacrolimus exposure is 
considered as a risk factor for allograft loss and late acute rejection (Wu, et al. 2011). 
The causes of this variability are not completely understood. 
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The studies outlined in this thesis were carried out on stable renal transplant patients 
treated with twice daily tacrolimus (Prograf®or Adoport®) and were switched to the 
same total daily dose of Advagraf®. 24 hours pharmacokinetic profiles were performed 
before and two weeks after the change. In order to exclude the use of prednisolone as a 
confounding factor, only patients on not more than 5 mg prednisolone daily were 
included. The within-patient variability (WPV) was calculated based on the dose-
normalized tacrolimus trough blood concentrations (C0). Analysis of C0 was also made 
during periods of stable tacrolimus doses. This study was designed to assess the 
influence of genetic polymorphisms CYP3A5*3 and ABCB1 3435C >T on tacrolimus 
pharmacokinetics of immediate- and prolonged- release tacrolimus formulations and 
their correlation with tacrolimus dosing in 64 stable renal transplant recipients. 
Genotyping at CYP3A4*22 and POR*28 loci in this study was undertaken to ascertain 
any influence of these genes on the pharmacokinetics of twice and once daily tacrolimus 
formulations. The influence of switching stable renal transplant patients to once daily 
tacrolimus formulation (Advagraf®) on WPV was investigated. In a secondary 
exploratory study to investigate the potential utility of 4β-OHC as a CYP3A biomarker 
in informing tacrolimus dosing, 4β-OHC concentrations in plasma samples was 
measured and the relationship between 4β-OHC, CYP3A5*3 genotype and tacrolimus 
exposure was examined. As another secondary exploratory study, prednisolone plasma 
concentrations were measured to explore the relationship between the above mentioned 
genetic polymorphisms and prednisolone exposure and its effect on tacrolimus dose. 
A significantly lower tacrolimus exposure was observed in CYP3A5 expressers 
compared with CYP3A5 non-expressers for both formulations. In contrast to CYP3A5*3 
genotype, ABCB1 3435C>T gene had a minor influence on tacrolimus exposure 
irrespective of tacrolimus formulation. When combined, tacrolimus pharmacokinetics 
and dose requirements were significantly correlated with the combined-genotype 
grouping. The CYP3A4*22 CT genotype was associated with significantly greater 
tacrolimus exposure (AUC0-24, Cmax) compared with the CYP3A4*22 CC genotype. 
POR*28 CT/TT genotype was associated with significantly lower tacrolimus exposure 
compared with the POR*28 CC genotype in CYP3A5 non-expressing subjects. 
 Abstract 
Page 6 of 377 
Switching from immediate to prolonged release tacrolimus formulations in kidney 
transplant patients was associated with a significantly lower tacrolimus trough 
concentration (C0), but had no influence on WPV. CYP3A5 genotype had no impact on 
WPV. Plasma concentration of 4β-OHC was greater in CYP3A5 expressers. The 4β-
OHC/C ratio was significantly correlated with tacrolimus exposure and dose 
requirement. Prednisolone exposure was not influenced by CYP3A5*3, CYP3A4*22, 
ABCB1 3435C>T or POR*28 genotype.  
Our results indicate that CYP3A5*3, ABCB1 3435C>T and CYP3A4*22 polymorphisms 
are important determinants of tacrolimus disposition and may explain part of the 
clinically observed high between-individual variability in tacrolimus pharmacokinetics. 
POR*28 is associated with tacrolimus dose requirement in CYP3A5 non-expressers. 
Thus, genotyping at these loci before renal transplantation may provide important 
information about the optimal initial dose of tacrolimus. Pharmacogenetic dosing 
strategies based on these genotypes are likely to be equally applicable to prescribing the 
once daily tacrolimus formulation, Advagraf®, as to twice daily formulations. 
Moreover, switching from immediate to prolonged release tacrolimus formulations had 
no influence on WPV. 4β-OHC/C ratio may be a useful biomarker for tacrolimus dosing 
in renal transplanted patients. Genotyping at CYP3A5*3, CYP3A4*22, POR*28 and 
ABCB1 3435C>T loci is unlikely to allow individualization of prednisolone dose. 
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1 Chapter 1. General Introduction and Thesis 
Summary 
The immunosuppressive drug tacrolimus is widely used to prevent the rejection of renal 
transplants. Tacrolimus was initially available as a preparation requiring twice daily 
administration: Prograf®. A modified-release formulation of tacrolimus (once-daily; 
Advagraf®) has been developed to provide more consistent exposure and facilitate better 
adherence. Tacrolimus has a narrow therapeutic index with wide variation between 
individuals in the blood concentration achieved by a given dose. To some extent, this is 
influenced by genetic factors. The influence of the CYP3A5*3 and ABCB1 3435 
genotypes on the pharmacokinetics of immediate release tacrolimus; Prograf® is well-
defined. However, the influence is unclear for prolonged release tacrolimus; Advagraf®. 
High within-patient tacrolimus trough concentration variability is a risk factor for long 
term chronic allograft nephropathy and graft loss. Therapeutic drug monitoring is used 
routinely to direct tacrolimus dosing within a defined therapeutic range of whole blood 
concentrations. Maintenance of the target blood concentration of immunosuppressive 
drugs is one of the main factors determining transplant function. Finding the optimal 
dose that gives the right balance between efficacy and toxicity remains the challenge for 
immunosuppressive drugs, especially during the period immediately after 
transplantation. Therefore, the identification of parameters predictive of the optimal 
initial tacrolimus dose has the potential to improve clinical outcomes. In chapter 2 of 
this thesis, a description of renal failure stages, epidemiology and risk factors leading to 
its development are included. An overview of the role of the immune system in 
transplant rejection and the importance of use and monitoring immunosuppressive drugs 
is described. Following this general background, the concept of bioequivalence and 
genotyping studies is given. In chapter 3, an overview of tacrolimus and its 
pharmacokinetics is covered. Tacrolimus exposure has been related to clinical outcome 
and therapeutic drug monitoring is often applied in clinical practice to guide 
personalized dosing. Tacrolimus has a large between- and within-patient variability in 
its exposure. Factors considered to cause this variability are outlined in this chapter. In 
chapter 4 and 5 genetic markers that are related to between-patient variability in 
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tacrolimus exposure are determined. The influence of CYP3A5*3, CYP3A4*22, 
POR*28 and ABCB13435C>T SNPs on the pharmacokinetics of immediate release 
tacrolimus; Prograf® or Adoport® and prolonged release; Advagraf® was carried out 
within individual patients. Moreover, in chapter 4, genes encoding for CYP3A5 
(CYP3A5*3), ABCB1 gene 3435C>T functional polymorphism and their combination 
were analysed in relation to tacrolimus pharmacokinetics in 64 adult renal transplant 
patients for both immediate and prolonged release formulations. In this study a strong 
association of CYP3A5*3 genotype (rs776746) with tacrolimus exposure for Advagraf® 
as well as for Prograf®/Adoport® was observed. CYP3A5 expression had a major 
influence and ABCB1 3435 genotype had a minor influence on tacrolimus exposure for 
both formulations. Tacrolimus exposure and dose requirement were significantly 
associated with the combined-genotype grouping. The daily doses for CYP3A5 
expressers/Pg-p high-expressers and CYP3A5 expressers/Pg-p intermediate- and poor-
expressers were 2.6- and.1.8-fold higher than CYP3A5 non-expressers/Pg-p 
intermediate- and poor-expressers, respectively. In chapter 5, a comprehensive 
pharmacogenetic analysis was performed for recently identified genes encoding for 
CYP3A4 (CYP3A4*22) and for POR*28 in relation to tacrolimus exposure for both 
immediate and prolonged release formulations. In this study, novel methods were 
developed for genotyping CYP3A4*22 and POR*28 SNP using real time PCR; 
LightCycler® based technique. In this study only CYP3A4*22 SNP was significantly 
associated with tacrolimus exposure. POR*28 genotype was only associated with 
tacrolimus exposure in CYP3A5 non-expressers. The influence of the CYP3A4*22 and 
POR*28 genotype on tacrolimus exposure was the same for the prolonged release 
preparation Advagraf® as for the immediate release preparation, Prograf® or Adoport®. 
In chapter 6, the study was conducted with the intention of exploring the relationship 
between 4β-hydroxycholesterol, a plasma biomarker of cytochrome P4503A activity, 
and CYP3A5*3 genotype and tacrolimus exposure. In this study CYP3A5*3 allele was 
found to have a significant effect on the plasma 4β-OHC concentration in stable kidney 
transplant recipients. The 4β-OHC/C ratio was significantly correlated with CYP3A5*3 
and tacrolimus dose requirement. Chapter 7 focuses on tacrolimus within-patient 
variability in 100 stable kidney transplant recipients. Only few studies have focused on 
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comparing within-patient variability of tacrolimus trough concentration after conversion 
from immediate to prolonged tacrolimus formulations in stable renal transplant 
recipients. In this study, switching from immediate to prolonged release tacrolimus 
formulations had no influence on within-patient variability. This study also investigated 
the correlation between tacrolimus within-patient variability and CYP3A5*3 genotype in 
stable kidney transplant recipients for twice daily tacrolimus (Prograf® or Adoport®) 
and once daily tacrolimus, Advagraf®. Very few studies have focused on the relation 
between within-patient variability and genetic polymorphisms, particularly CYP3A5*3 
polymorphism in twice daily tacrolimus formulation. In this study, CYP3A5*3 genotype 
was not related to the within-patient variability of tacrolimus trough concentration in 
both immediate and prolonged tacrolimus formulations. In chapter 8 a new simple and 
rapid bioanalytical method for measurement of prednisolone and its metabolite in 
plasma using LC-MS/MS was developed and validated. This method provides the 
opportunity to assess prednisolone and prednisone pharmacokinetics in a large cohort of 
renal transplant patients. In this study the relationship between the CYP3A5*3, ABCB1, 
CYP3A4*22 and POR*28 SNPs and prednisolone exposure was investigated. None of 
the investigated SNPs were associated with prednisolone pharmacokinetics. In chapter 
9, the results presented in the studies described earlier were analysed with reference to 
findings of previous research in the same area of interest or using similar techniques. 
Discussion of the genotype–phenotype associations with Advagraf® daily dose 
requirements was then made. The discussion focuses on evaluating the effects of 
conversion from immediate to prolonged released tacrolimus formulation from three 
perspectives: 1) Genetic influence on tacrolimus pharmacokinetics, 2) Within-patient 
variability differences, and 3) Suggestions for a pharmacogenetic strategy to guide 
individualisation of twice daily tacrolimus and Advagraf® dose. Chapter 10 will 
describe briefly the potential studies that will be performed in the future. 
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2 Chapter 2. Background 
2.1 Renal Failure and Immunosuppression Therapy 
2.1.1 Renal Failure 
Chronic kidney disease (CKD) is a public health problem with a growing prevalence 
worldwide. Glomerular filtration rate (GFR) is considered the best general guide of 
deteriorating renal function. Low GFR is associated with an increased risk of kidney 
failure requiring dialysis and complications such as cardiovascular disease, 
hypertension, anaemia, and other metabolic complications (Himmelfarb and Sayegh, 
2010). Renal failure is defined as the loss of renal function leading to a fall of GFR 
below 90 mL/min and to an accumulation of creatinine, urea and other nitrogenous 
wastes. Based on the level of estimated GFR normalized to body surface area, CKD has 
been classified into five stages (Table 1), with stage 1 being the mildest and stage 5 the 
most severe (NHS, 2010).  
Table 1: Stages of Chronic Kidney Disease. 




1 Slight kidney damage with normal or increased GFR ≥ 90 
2 Mild decrease in kidney function 60-89 
3a 
Moderate decrease in kidney function 
45–59 
3b 30–44 
4 Severe decrease in kidney function 15-29 
5 Kidney failure < 15 
*All GFR values are normalized to an average surface area (size) of 1.73m
2
 
2.1.1.1 Epidemiology of Chronic Kidney Disease  
The number of patients with CKD is increasing worldwide and it reflects the increase in 
end stage renal disease (ESRD) patients treated by renal replacement therapy (RRT) 
including dialysis or transplantation. In the UK, in 2013 the annual incidence of ESRD 
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was 109 new patients per million of population with a stable incidence in England over 
the last 8 years (Gilg et al., 2015). However, this figure remains below the European 
average (about 135 per million) and that of the United States (336 per million) (Hamer 
and El Nahas, 2006). At the end of 2013, the number of adult patients in UK receiving 
RRT was 56,940, giving a prevalence of 888 per million population (pmp). The growth 
in the prevalent UK RRT population from the previous year was 4.0%. The annual 
growth rate has been fairly consistent over the last 10–15 years (Rao et al., 2015).  
2.1.1.2 Risk Factors for Chronic Kidney Disease 
The common aetiologies for chronic renal failure include arteriopathic renal disease, 
hypertension, glomerulonephritis, diabetes mellitus, infective, obstructive and reflux 
nephropathies, hereditary kidney disease, hypercalcaemia, connective tissue diseases 
and myeloma (Brown et al., 2009, Arora, 2013). Several factors play a role in the rising 
incidence of ESRD. 
2.1.1.2.1 Advancing Age 
Chronic kidney disease is a major health problem, mainly a disease of elderly people. 
The annual incidence rate of CKD in the UK rose from 60 per million among patients 
aged 20-49 to 282 per million among those in their 60s and 588 among those in their 
80s (Feest et al., 1990). The prevalence is less than 1% in people aged 18 to 25, this 
increases to more than 40% in the 85 and over age population (NHS, 2010). A growing 
incidence of ESRD in elderly patients has also been observed in other countries. The 
overall annual incidence of chronic renal failure (CRF) in France  rose from 64/million 
in patients under 40 years old up to 356/million in patients over 75 (Jungers et al., 
1996). The incidence rate of ESRD per year in the United States has been generally 
stable for the past two decades among people aged 20-44 years old. On the other hand, 
the number of patients aged greater than 45 years and above had been increasing for 
many years, with particularly dramatic increases for age 65 and above. The prevalence 
of ESRD steeply rises among patients aged greater than 45 patients years (USRDS, 
2014). In the UK, the incidence rates for all age groups have plateaued in the last eight 
years. People up to 44 years old have the lowest incidence rate followed by the 45–64 
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age group. However, over 65 years old population have the highest incidence rate (Gilg 
et al., 2015). The considerable increase in the incidence of CRF with advanced age is 
mainly due to the presence of additional factors and / or complications that might be 
linked with a reduction in the number or the function of nephrons. The high incidence 
of chronic renal failure in elderly patients is probably due to the high prevalence of 
renal vascular disease in this age group (Jungers et al., 1996). 
2.1.1.2.2 Sex  
Although, the increase in the incidence of CRF with age was similar in both males and 
females, the incidence of CRF was strikingly higher in male as compared to female 
patients. The annual incidence was twice as high in males compared to females up to 75 
years and three times as high in patients above 75 years (Jungers et al., 1996). End stage 
renal disease prevalence rate in males exceeded that of females for all age groups, 
reaching the highest point in the age group 75–79 years at 3,010 pmp in men and for 
women at 1,560 pmp (Rao et al., 2015). Typically, renal replacement populations are 
around 60% male and 40% female. 
2.1.1.2.3 Ethnicity 
Some ethnic groups have higher rates of CKD than others. For example, in the UK and 
USA, the incidence of RRT in African-Caribbean and South Asian populations in any 
age group is 3 to 5 times higher than in Caucasians. In addition, in the USA, Black 
Americans have at least 4 to 5 times higher RRT rate than whites. The annual incidence 
is 256/1 000 000 among white people compared with 982/1 000 000 in African-
Americans (Hamer and El Nahas, 2006, El Nahas and Bello, 2005). Moreover, in the 
year 2012, the prevalence rate per million in the USA remains much higher in 
blacks/African Americans than in other ethnic groups, at approximately 2.5-fold higher 
as compared to Asians, and 4-fold higher compared to Whites. The prevalence rate was 
5,671 per million in black/African Americans, 2,272 per million in Asians, and 1,432 
per million in Whites (USRDS, 2014). 
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2.1.1.2.4 Diabetes 
Impaired kidney function is a common and serious complication of diabetes mellitus. 
Estimates indicate that 25–40% of patients with Type 1 or Type 2 diabetes develop  
diabetic nephropathy within 20–25 years of disease onset (New et al., 2007). Several 
studies have highlighted that diabetes is strongly associated with the increased risk for 
CKD. The prevalence of a reduced GFR 60 ml/min per 1.73 m
2
 was threefold higher in 
those with diabetes mellitus compared with those without (Chadban et al., 2003). A 
linear relationship was reported between hyperglycemia and both the development and 
progression of diabetic nephropathy in type 1 and type 2 diabetes patients (Hall, 2006). 
In 2013, the UK Renal Registry found that diabetes accounted for 15.9% of renal 
disease in prevalent patients on RRT, and it was more common among patients aged 65 
than among younger patients (Rao et al., 2015). It has been reported that Type 1 and 
Type 2 diabetes patients had more than twice the risk of  ESRD compared with non-
diabetic patients and the highest risks of moderate-severe CKD occurred with Type 1 
diabetes (Hippisley-Cox and Coupland, 2010). Another study demonstrated that diabetic 
patients had 1.5 fold higher chances for developing CKD than individuals without 
diabetes after adjustment for age (Hallan et al., 2006). 
2.1.1.2.5 Hypertension 
High blood pressure (BP) is strongly associated with CKD in men and women (Haroun 
et al., 2003). Several studies have shown that hypertension is a risk factor for CKD. The 
prevalence of proteinuria and reduced GFR <60 ml/min per 1.73 m
2 
were fivefold 
higher in hypertensive participants compared with those without hypertension (Chadban 
et al., 2003). Hallan et al. (2006) found that individuals with hypertension had five-
times more prevalence of CKD than those with normal BP and after adjustment for age 
the risk ratio was 1.5. A recent UK study showed that hypertensive patients had more 
than double the risk of ESRD compared with patients without hypertension (Hippisley-
Cox and Coupland, 2010). In the USA, the incidence rates of ESRD due to hypertension 
in all age groups are dramatically greater in Blacks/African Americans compared with 
the other ethnic groups. Incidence rates in Blacks/African Americans are over ten-fold 
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higher than in Whites in the young population and 2.5 times more than whites in the age 
group 70 and over (USRDS, 2014).  
2.1.2 Renal Replacement Therapy 
In chronic renal failure, the loss of renal function is slow and progressive and in most 
cases the damage is irreversible. Eventually, the kidneys cease to function. This 
condition is referred to as end-stage renal failure (ESRF) (Abuelo, 1995). In this case, 
renal replacement therapy is required. Treatment methods cannot cure the renal failure. 
However, it is possible to replace renal function through the use of alternative methods 
that include dialysis and kidney transplantation (Stein and Wild, 2002). The process of 
dialysis bypasses the kidneys, in order to remove metabolic wastes and foreign 
compounds artificially. This maintains fluid and electrolyte balance within acceptable 
limits and removes toxins. However, the plasma cleansing technique does not make up 
for the kidneys’ reduced ability to produce hormones such as erythropoietin and renin 
and to activate vitamin D (Sherwood, 2008). Additionally, there is a considerable time 
commitment for patients undergoing dialysis. Consequently, kidney transplantation is 
the replacement therapy of choice for end-stage renal disease. Quality of life is greatly 
enhanced by renal transplantation and survival is probably better than that for patients 
on dialysis (Wolfe et al., 1999). It is also the most cost-effective mode of renal 
replacement therapy (Singh and Bhandari, 2004). 
Early graft survival has improved markedly in recent years, but long-term survival 
remains a significant challenge (Chandraker et al., 2011). The risk of acute renal 
allograft rejection is greatest during the first three months following transplantation. 
Therefore, developing protocols that optimise immunosuppression during the high 
immunologic risk period has the potential to limit damage to the graft that has an 
adverse influence on long term graft function (Velia, 2005). 
2.1.3 The Role of the Immune System in Transplantation 
The immune system defends the body from harmful substances by distinguishing and 
reacting to antigens that include toxins, viruses, bacteria, transferred blood cells, and 
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transplanted organs  (Male et al., 2006). A transplanted kidney is recognized by the 
immune system as an antigen and this triggers the immune response and the subsequent 
rejection of the organ. Based on the speed and specificity of the response, the immune 
system is divided into two main parts; innate and the adaptive immunity (Parkin and 
Cohen, 2001). 
2.1.3.1 Innate Immune Response  
It is a series of nonspecific defence mechanisms to protect the body against infection. 
These defence mechanisms are natural, do not require exposure to a specific antigen and 
work immediately or within few hours after exposure to an inflammatory stimulus. The 
components of the innate immune system include anatomical barriers, secretory 
molecules and cellular components. The mechanical anatomical barriers comprise the 
mechanical, chemical and biological elements. Mechanical barriers are well-known as 
skin, mucous membrane and ciliated epithelial cells while chemical barriers include the 
low pH of sweat and gastric secretions, lysozymes, phospholipase, and interferons and 
biological barriers contain the normal microbial flora of the skin and in the 
gastrointestinal tract. Innate immunity also has some cellular barriers, which are the 
primary defence line of the immune system. The cells can be divided into granulocytes 
(neutrophils, basophils and eosinophils), monocytes which develop into macrophages 
and lymphocytes (B, T and natural killer (NK) cells), see Figure 1. Monocytes and 
macrophages attract, engulf, and ingest foreign bodies. Basophils release histamine and 
they are important in defence against parasites. Once activated, eosinophils produce a 
range of highly toxic proteins and free radicals that are extremely efficient in destroying 
bacteria and parasites. Natural killer cells and lymphokine activated killer cells can non-
specifically kill virus infected and tumour cells. The complement system is the major 
humoral non-specific defence mechanism. Upon activation, complement can lead to 
increased vascular permeability, recruitment of phagocytic cells, and lysis and 
opsonization of bacteria. Some coagulation system products can participate in the non-
specific defences, as they have the ability to increase vascular permeability and act as 
chemotactic agents for phagocytic cells (Mayer, 2011, Williams et al., 2012).  
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Figure 1: The Main Components of the Innate and Adaptive Immune Systems 
(Dranoff, 2004). The innate immune response is the short-term reaction. It 
consists of granulocytes (basophils, eosinophils and neutrophils), mast cells, 
macrophages, dendritic cells, complement proteins and natural killer cells. 
The adaptive immune response is the longer-term reaction. It consists of 
antibodies, B lymphocytes, and helper (CD4+) and cytotoxic (CD8+) T 
lymphocytes. Natural killer T lymphocytes and gammadelta T lymphocytes 
are cytotoxic lymphocytes that straddle the interface of innate and adaptive 
immunity. 
2.1.3.2 Adaptive Immune Systems 
The adaptive immunity is an antigen-specific immune reaction. It is more complex than 
innate immunity. The antigen first must be processed and identified. Once an antigen 
has been recognized, the adaptive immune system stimulates potent mechanisms for 
neutralizing or killing pathogens. The adaptive immune system components are 
normally silent and require activation with the innate immune response promoting 
activation initially.  In transplantation the surgery promotes an inflammatory response 
that is an important factor in triggering the adaptive immune response to cause 
transplant rejection. The response is slower compared with the innate immune response 
but it is much more potent. There are two categories of adaptive immune responses: 
humoral immunity, which mediated by B-lymphocytes producing antibodies, and cell-
mediated immunity which mediated by T lymphocytes, see Figure 1 (Alberts et al., 
2002). The acquired immune system also plays a fundamental role in the rejection of 
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transplanted organs and destroying the graft.  After maturation, mature T lymphocytes 
move through the circulation to lymph nodes, mucosa-associated lymphoid tissue or the 
spleen. B lymphocytes on the other hand, pass through the circulation to various sites 
throughout the body.  
Once activated with a foreign antigen, B lymphocytes develop to mature antibody 
secreting cells called plasma cells and start producing antibodies, which contribute to 
the immunity in three different mechanisms: neutralisation via binding to antigens and 
preventing them from invading cells and directly neutralize them; opsonisation 
stimulates pathogens elimination by phagocytic cells and complement fixation where 
antigen-antibody complex triggers cascade complement activation and consequently 
antigen lysis. Antibodies are also known as immunoglobulins and they are divided into 
5 major types IgA, IgE, IgG, IgM and IgD. B lymphocytes are important in the fight 
against pyogenic bacteria and facilitate hyper acute rejection and can destroy a graft by 
producing antibodies (Atluri et al., 2006). 
Unlike B lymphocytes, T lymphocytes do not recognize antigens directly. Instead, there 
are receptors located in their surfaces that identify peptide fragments of antigens 
associated with major histocompatibility complex (MHC) molecules on the surfaces of 
infected or cancerous cells. The major histocompatibility complex is a set of genes that 
encodes a group of proteins that are located on the cell surface. There are several types 
of T lymphocytes: T helper lymphocytes (Th or CD4+), cytotoxic T (Tc or CD8+) 
lymphocytes, memory T (Tm) lymphocytes and suppressor T (Ts) or regulatory T 
(Treg) lymphocytes. Cytotoxic T lymphocytes (Tc) and memory T lymphocytes (Tm) 
lymphocytes are the effector cells, whereas helper lymphocytes (Th) and suppressor 
lymphocytes (Ts) are regulatory cells. T lymphocytes contribute to the immune 
defences in two major ways: some direct and regulate immune responses, whereas 
others directly attack infected or cancerous cells. Th lymphocytes are divided into Th1 
and Th2, where Th1 produces cytokines and lymphokines (IL-2, IL-12 and gamma-
interferon) that activate macrophages and participate in the production of cytotoxic 
lymphocytes. In contrast cytokines produced by Th2 lymphocytes help to activate B 
lymphocytes, resulting in antibody production. Cytotoxic T (Tc) lymphocytes directly 
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attack and destroy infected cells. Two main proteins, granzymes and perforin are stored 
in cytoplasmic vacuoles within the resting Tc lymphocytes. When a Tc lymphocyte 
encounters an infected cell presenting on its surface MHC-bound antigenic peptide, it is 
stimulated to release perforin into the intracellular space between the Tc and the target 
cell, which form holes in the surface membrane of the target cell and this results not 
only in direct cell damage, but also provide means for granzymes to enter the cell. 
Granzymes induce target cells to undergo apoptosis. Regulatory T (Treg) lymphocytes 
inhibit immune response after invading organisms are destroyed by release chemicals 
that decrease B- and T- lymphocytes activity and division. Memory T lymphocytes 
remain in the body for several years. Once they have encountered an antigen and cloned 
to remember it, they are responsible for defence on repeated exposure (Atluri et al., 
2006). 
The antigen can only be recognized by T lymphocytes if one of the body’s own MHC 
molecules carries it on the cell surface. In humans, MHC antigens are called human 
leukocyte antigens, or HLA and the genes are located in the short arm of chromosome 
6. T lymphocytes recognize MHC molecules when they differentiate between self and 
non-self. A self-MHC molecule provides an identifiable scaffolding to display a foreign 
antigen to the T lymphocytes. MHC Class I proteins are found on all nucleated cell 
surfaces and they present antigens to cytotoxic T lymphocytes (Tc). In the resting state 
MHC Class II proteins are found only on B lymphocytes, macrophages, and other 
antigen presenting cells.  Inflammatory cytokines promote the expression of MHC class 
II molecules by other tissues. There is a wide diversity between individuals in the 
protein sequence of the MHC molecules expressed on the cell surface which has 
probably minimised the risks of microbial evolution to evade the immune response. A 
consequence of this is that MHC moleules on transplanted organs are recognised as 
being ‘foreign’ triggering an immune response against the organ (Penn, 2002). 
Consequently, organ donors should ideally have the closest MHC match with recipients 
to minimise the risk of graft rejection. 
Background 
Page 47 of 377 
2.1.3.3 Mechanism of Alloimmune Responses 
The transplanted organ is a permanent source of antigens and it can induce rejection at 
any time following transplantation. The immune system establishes effective 
mechanisms to fight the transplanted organ, which are recognized by the immune 
system as a foreign agent and is termed transplant rejection. Rejection is an acquired 
immune response via cellular immunity (mediated by T-lymphocytes) and this involves 
the production of cytotoxic T-lymphocytes, activated macrophages, activated NK cells, 
and cytokines in response to the foreign antigen inducing apoptosis of target cells. It 
also involves humoral immunity, which includes the production of antibody molecules 
in response to the transplanted organ and is mediated by B-lymphocytes though the 
action is joined by components of innate immune response (phagocytes and soluble 
immune proteins). The degree to which allografts undergo rejection depends partly on 
the degree of similarity or histocompatibility between the donor and the recipient 
(Malhotra et al., 2013). 
Following organ transplantation, a series of immunological reactions occurs, which 
comprise inflammation, immunity, and tissue repair, as well as structural reinforcement 
of damaged cells. Inflammation occurs at the site of transplantation and is mediated by 
macrophages, T lymphocytes and pro-inflammatory mediators (eg, IL-2). Complement 
activation results in the elaboration of bioactive intermediates such as C3a and C5a. 
Once the immune system destroys the antigens, macrophages, endothelial cells, smooth 
muscle cells, and fibroblasts begin to promote tissue repair and reinforcement. 
However, rejection takes place when a strong inflammatory response develops or when 
tissue repair and remodeling fail (Prescilla, 2013). 
Rejection is classified into 3 broad categories according to the timing of the rejection. 
The first category is termed hyperacute rejection, which may develop within minutes to 
hours of graft implantation because of the presence of pre-formed anti-donor antibody. 
The antigen-antibody complexes activate the complement system, causing massive 
thrombosis in the capillaries, resulting in ischemic damage of the graft. However, this 
condition is rare nowadays as a routine pre-transplant anti-donor antibody screen is 
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introduced. The second type of rejection is acute rejection which most commonly 
occurs during the first 3 months after transplantation. The reaction is unusual before 1 
week after transplantation, the typical time lag for development of a primary immune 
response. Once T lymphocytes encounter the graft alloantigens, they stimulate the 
release of cytokines and consequently results in tissue distortion, vascular insufficiency, 
and cell damage. However, this reaction can be prevented by the use of 
immunosuppressant drugs, allowing tissue repair to progress. The third rejection 
category is termed chronic rejection, where pathologic tissue remodelling and 
reinforcement takes place. Blood flow is reduced, which contribute to regional tissue 
ischaemia, fibrosis, and cell death. This type of rejection cannot be cured as there is no 
treatment available (Prescilla, 2013). There is increasing recognition of the importance 
of alloantibody in chronic allograft rejection (Sellares et al., 2012). 
2.1.4 Immunosuppressive Therapy 
Rejection is the main barrier to successful transplantation. Therefore, the use of 
immunosuppressive drugs is very important in order to suppress the immune system and 
to prevent rejection of the transplanted organ. Large doses are used immediately after 
the transplantation and reduced over time as the risk of acute rejection reduces. 
Immunosuppressive drugs have many unpleasant adverse effects both due to inhibition 
of protective immune responses leading to increased risk of infection and malignancy 
and a number of drug-specific complications, including nephrotoxicity and weight gain. 
The use of combination immunosuppressive therapy has developed over a number of 
years in order to maximise synergistic effect and to minimize side effects and toxicity 
(Meier-Kriesche et al., 2011). In current practice, most patients are given an induction 
antibody that either depletes or blocks the activation of lymphocytes at the time of 
transplantation and maintenance immunosuppression that is generally orally 
administered small molecule drugs. The mechanisms of action of the most commonly 
used immunosuppressive drugs in organ transplantation are shown in Figure 2 and 
summarized in Table 2. 
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Figure 2: Mechanisms of Action of Immunosuppressive Drugs (modified from 
(Kobashigawa and Patel, 2006).  
Immunosuppressive drugs inhibit a number of steps in the mechanisms leading to T- 
lymphocytes proliferation. Steroids inhibit antigen presentation, cytokine production. 
Ciclosporin and tacrolimus inhibit calcineurin activation and interleukin-2 production that 
resulted from donor peptide presentation by antigen-presenting cells in conjunction with 
the major histocompatibility complex class II and B7 complex. Interleukin-2 production 
leads to cell proliferation by a pathway involving target of rapamycin and cyclin/cyclin-
dependent kinase that known for their role in regulating the cell cycle. IL-2R Ab blocks 
Interleukin (IL)-2 receptors and inhibits IL-2-induced T- lymphocytes proliferation. 
Sirolimus and everolimus inhibit target of rapamycin and interleukin-2-driven T- 
lymphocytes proliferation. Mycophenolate and Azathioprine inhibit synthesis of the 
purine building blocks of DNA and prevent T lymphocytes proliferation. Belatacept 
inhibits the CD28-CD80/CD86 (B7) interaction resulting in the blockade of T- 
lymphocyte activation. 
APC, antigen-presenting cell; CDK, cyclin-dependent kinase; IL-2, interleukin-2; IL-
2R, interleukin-2 receptor; IL-2R Ab, interleukin-2-receptor antibody; MHC, major 
histocompatibility complex; MMF, mycophenolate mofetil; mRNA, messenger RNA; 
NFAT, nuclear factor of activated T lymphocytes; TCR, T-cell receptor; TOR, target 
of rapamycin protein. G1 (first growth phase), S (synthesis of DNA), G2 (second 
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Table 2: Classification and Mechanisms of Action of Drugs Commonly Used in 
Transplantation. 
Drug Class/ Drug Mechanism of Action 
Corticosteroid 
Prednisone/Prednisolone 
Corticosteroids inhibit antigen presentation and cytokine 




CNIs block the intracellular T- lymphocytes signals responsible 
for the production of cytokines CNIs block the intracellular T- 
lymphocytes signals responsible for the production of cytokines 
(in particular IL-2, interferon-gamma and tumour necrosis factor 
alpha). 
Ciclosporin (CsA) CsA binds to cyclophilin; complex inhibits calcineurin 
phosphatase and T- lymphocytes activation. 
Tacrolimus (TAC)  TAC binds to FKBP12; complex inhibits calcineurin phosphatase 
and T- lymphocytes activation. 
Antimetabolite  Antimetabolites inhibit synthesis of the purine building blocks of 
DNA, namely guanine and adenine. 
Azathioprine (AZA) AZA is converted to 6-mercaptopurine and then to 6-thioinosine 
monophosphate – a precursor of thioguanine nucleotides that 
inhibit purine synthesis and interfere with DNA and RNA 
replication. 
Mycophenolate  
(MMF & MPS) 
Mycophenolic acid (mycophenolate) inhibits synthesis of 
guanosine monophosphate nucleotides and blocks purine 
synthesis, preventing proliferation of T and B lymphocytes.  
Mammalian target of 
rapamycin (mTOR) 
mTOR inhibitors act by blocking the serine-threonine kinase 
mTOR.  
Sirolimus (SRL) SRL binds to FKBP12; complex inhibits target of rapamycin and 
interleukin-2-driven T- lymphocytes proliferation. 
Everolimus (ERL) ERL binds to FKBP12; complex inhibits target of rapamycin and 
interleukin-2-driven T- lymphocytes proliferation. 
Interleukin (IL)-2 
receptor antagonist  
The anti-IL-2R mAbs are specific for the alpha subunit (CD25) of 
IL-2Rs on activated T lymphocytes. They saturate IL-2Rs and, 
thus, are competitive antagonists of IL-2-induced T- lymphocytes 
proliferation.  
Basiliximab Basiliximab binds to and blocks the IL-2R alpha chain (CD25 
antigen) on activated T lymphocytes, inhibiting IL-2-induced T-
cell activation. 
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Lytic monoclonal 
antibodies  
Monoclonal antibodies are monospecific antibodies made by one 
type of immune cell that are all clones of a unique parent cell that 
specifically bind to a target cell.  
Alemtuzumab Alemtuzumab binds to CD52, a protein present on the surface of 
mature lymphocytes, leading to lymphocyte lysis via complement 
activation and antibody dependent cellular cytotoxicity. 
Rituximab Rituximab binds to CD20, a protein present on the surface of 
immune system B lymphocytes, the combined effect results in the 
elimination of B lymphocytes. 
Polyclonal antibody  Polyclonal antibody preparations are purified immunoglobulin 
preparations derived from animals after immunization with human 
thymocytes. The polyclonal antibodies currently available are all 
ATGs obtained by immunization of horses (equine antithymocyte 
globulin (eATG) or rabbits (rATG) that blocks T- lymphocyte 
membrane proteins, causing altered function, lysis, and prolonged 
T- lymphocyte depletion.  
Belatacept Belatacept inhibits the CD28-B7 interaction resulting in the 
blockade of T-cell activation. 
Immunosuppressive drug therapy following transplantation is divided into three main 
phases: induction phase, which is used immediately following transplantation to provide 
an intense immunosuppression, Maintenance phase where drugs are used for long term 
prophylaxis of immunosuppression as well as rejection reversal or rescue phase where 
drugs are used for treatment of an established problem (Fogel and Greenberg, 2015). 
The patients are usually maintained using a triple therapy consisting of calcinurin 
inhibitor, low dose prednisolone and mycophenolate or azathioprine. Moreover, the  
prednisolone dose is gradually reduced over time and completely withdrawn in some 
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2.1.4.1 Corticosteroids 
Corticosteroids interrupt multiple steps in immune activation because of the ubiquitous 
expression of corticosteroid receptors. Prednisolone is a synthetic adrenocortical steroid 
derivative with predominantly glucocorticoid properties possessing anti-inflammatory 
and immunosuppressive action (Adcock and Ito, 2000). Its anti-inflammatory properties 
are apparent through preventing or suppressing the tissue response to the inflammatory 
process. Complications of corticosteroid therapy are numerous and virtually any organ 
system in the body may be affected. Short-term or acute adverse effects, which usually 
occur with initiation of therapy, include central nervous system effects, psychosis, 
pseudotumor cerebri, impaired glucose tolerance, and retention of sodium and fluid. 
This may exacerbate congestive heart disease and may aggravate preexisting diabetes 
mellitus. Long-term adverse effects can lead to the development of iatrogenic Cushing 
syndrome with truncal obesity. It also increases the susceptability to infections of 
certain species including Aspergillus species, Pneumocystis jiroveci, and Herpes virus 
species (Stanbury and Graham, 1998). Prednisolone is readily absorbed from the 
gastrointestinal tract. It is extensively bound to plasma proteins and has a usual plasma 
half-life of 2 to 3 hours. Prednisolone is excreted in the urine as free and conjugated 
metabolites together with a considerable proportion of unchanged prednisolone 
(Martindale and Reynolds, 1996). Prednisolone is metabolised by enzymes in the 
CYP3A family (CYP3A4/CYP3A5) and it is a substrate of the efflux transporter P-
glycoprotein. Prednisolone is a CYP3A and P-glycoprotein inducer with consequent 
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2.1.4.2 Calcineurin Inhibitor (CNI) 
Calcineurin inhibitors block the intracellular T-cell signals responsible for the 
production of cytokines. This group of drugs includes ciclosporin (CsA) and tacrolimus 
(TAC). 
2.1.4.2.1 Ciclosporin (CsA) 
Ciclosporin CsA is a cyclic nonribosomal peptide of 11 amino acids and contains a 
single D-amino acid, which are rarely encountered in nature. It was initially isolated 
from a fungus called Tolypocladium inflatum (Beauveria nivea). It is the first 
calcineurin inhibitor used in transplantation and was approved by the US Food and 
Drug Administration in 1983. It remains the primary agent in immunosuppressive 
regimens in many transplant programmes worldwide. Ciclosporin acts through the 
production of a complex with cyclophilin that inhibits calcineurin phosphatase activity. 
Consequently, CsA inhibits translocation of the nuclear factor of activated T 
lymphocytes (NFAT) family of transcription factors from the cytoplasm to the nucleus 
of activated T lymphocytes. It also inhibits lymphokine production and interleukin 
release (in particular IL-2, interferon gamma and tumour necrosis factor alpha) and, 
therefore, inhibits T cell activation and proliferation (Finkel et al., 2009). The common 
adverse effects of CsA include nephrotoxicity, hypercholesterolaemia, systemic 
hypertension, gingival hyperplasia, hirsutism hypertrichosis, and neurotoxicity. 
Impairment of glucose tolerance is an important complication of the CNIs resulting in 
New Onset Diabetes After Transplantation (NODAT). In addition, it increases 
vulnerability to opportunistic fungal and viral infections and displays a possible role in 
promoting cancer progression and tumour cell invasion as well as metastasis (Prescilla, 
2013).  
Ciclosporin is available for intravenous or oral administration. It is provided as soft 
gelatin capsules and oral solutions. The absorption of the original soft gelatin capsule 
(SANDIMMUNE®) is slow, with 20% to 50% bioavailability. However, the modified 
microemulsion formulation (NEORAL®) has a slightly increased bioavailability 
compared to SANDIMMUNE®. After oral administration, Ciclosporin absorption is 
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incomplete and varies among the individual patient and the formulation used. 
Ciclosporin reaches its peak blood concentration within 1.5 to 2 hours and its absorption 
is greatly decreased by food.  Ciclosporin is extensively metabolized by CYP3A in the 
liver. It is mainly excreted through the bile into the faeces and only 0.1% of ciclosporin 
is excreted unchanged in the urine (Goodman et al., 2006). 
2.1.4.2.2 Tacrolimus (TAC)  
Tacrolimus is the most widely used calcineurin inhibitor in renal transplant recipients in 
the United Kingdom. It is a macrolide lactone antibiotic produced by Streptomyces 
tsukubaensis discovered in 1984 from the fermentation broth of a Japanese soil sample. 
Tacrolimus was first approved by the Food and Drug Administration in 1994 for use in 
liver transplantation and later also for use in kidney transplantation. Tacrolimus is 
considered as one of the most potent immunosuppressive agents used in managing 
rejection following renal transplantation and belongs, together with CsA to a unique 
class of immunosuppressive natural products known as Calcineurin inhibitors (Bekersky 
et al., 2001a, Pirsch et al., 1997). Tacrolimus binds to an immunophilin, FK506 binding 
protein (FKBP) which binds to and blocks CaN. This complex inhibits the activation of 
NF-ATc, thus preventing its entrance into the nucleus and T-cell activation (Fleischer, 
1999). Tacrolimus has demonstrated efficacy both as primary immunosuppressive 
therapy in patients undergoing various transplantation procedures and as a rescue 
therapy for patients with refractory acute allograft rejection after liver or kidney 
transplantation. It is up to 100 times more potent than CsA and clinically, it is 
associated with a greater reduction in the incidence of acute and chronic rejection and 
better long term graft survival (Tsunoda and Aweeka, 2000). The common adverse 
events of tacrolimus are nephrotoxicity, neurotoxicity, and diabetogenicity, which 
correlate with trough blood concentrations of tacrolimus. Hypertension, hyperkalemia, 
and thrombotic microangiopathy have also been reported. Neurotoxicity, alopecia, and 
NODAT develop more frequently with tacrolimus than with ciclosporin. However, 
tacrolimus is less likely to cause hyperlipidaemia, hypertrichosis and gingival 
hypertrophy compared with ciclosporin (Prescilla, 2013).  
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Tacrolimus gastrointestinal absorption is incomplete and variable with an oral 
bioavailability of approximately 25%. The rate and extent of tacrolimus absorption is 
greatly affected by food. Tacrolimus binds extensively to erythrocytes in blood and 
approximately 99% of tacrolimus partitioned into plasma is bound to plasma proteins, 
mainly albumin and alpha-1-acid glycoprotein. The unbound fraction of tacrolimus, 
comprising less than 0.1% of total blood concentration, is responsible for its 
pharmacological activity. Tacrolimus is extensively distributed in the body and at 
steady state the majority of tacrolimus exists in the tissue. Tacrolimus is predominantly 
metabolized by CYP 3A enzymes in the liver and the intestinal wall, with a half-life of 
approximately 12 hours. Most of the tacrolimus dose is ultimately excreted in faeces 
(Goodman et al., 2006). 
2.1.4.3 Antiproliferative Agents 
2.1.4.3.1  Azathioprine (AZA) 
Azathioprine (AZA) is an immunosuppressive drug used in organ transplantation and 
autoimmune diseases and belongs to the chemical class of purine analogues. 
Azathioprine acts as a pro-drug for 6-mercaptopurine, inhibiting an enzyme that is 
required for the synthesis of DNA. Thus, it most strongly affects proliferating cells, 
such as the T lymphocytes and B lymphocytes of the immune system  (Maltzman and 
Koretzky, 2003). AZA is converted to 6-mercatopurine and then to 6-thioinosine 
monophosphate – a precursor of thioguanine nucleotides which particularly inhibit the 
synthesis of purines required for DNA and RNA replication . Thus it most strongly 
affects proliferating cells, such as the T lymphocytes and B lymphocytes of the immune 
system. Moreover, azathioprine blocks the downstream effects of CD28 co-stimulation, 
a process required for T cell activation. The main adverse effect of azathioprine is bone 
marrow suppression. Azathioprine can also result in a decrease in the number of blood 
cells in the bone marrow, which may cause serious or life-threatening infections.  
Although not very common, hepatotoxicity has been found to be associated with 
azathioprine therapy (Patel et al., 2006). Additionally, azathioprine may increase the 
risk of developing certain types of cancers, especially skin cancer and lymphoma and 
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has therefore been  listed as a human carcinogen in the 12th Report on Carcinogens by 
the National Toxicology Program of U.S. Department of Health and Human Services 
(NTV, 2011).  
Azathioprine undergoes extensive metabolism to mercaptopurine, which is subsequently 
metabolized to 6-thioguanine nucleotides that are the presumed active moiety. The 
maximum concentration is reached within about 1-2 hours after administration and it is 
moderately bound to plasma protein. The half-life of azathioprine is about 10 minutes 
and that of the metabolite is 1 hour (Goodman et al., 2006). Thiopurine S-
methyltransferase (TPMT) contributes to the metabolism of all thiopurines and is 
responsible for inactivation of mercaptopurine. TPMT shows genetic polymorphism 
causing null or decreased enzyme activity. Patients who have two nonfunctional TPMT 
alleles commonly experience life-threatening myelosuppression. TPMT genotyping or 
phenotyping prior to starting treatment with azathioprine may help in identifying 
patients at increased risk for toxicity  and is recommended by  several guidelines (Dean, 
2012 ).  
2.1.4.3.2 Mycophenolate Mofetil (MMF) 
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid which is also available 
as an enteric-coated sodium salt (MPS), is used extensively in transplant medicine 
(Meier-Kriesche et al., 2011). MMF is an organic synthetic derivative of the natural 
fermentation product mycophenolic acid (MPA) that causes non-competitive reversible 
inhibition of inosine monophosphate dehydrogenase, a key enzyme in the de novo 
guanosine nucleotide synthesis pathway in B and T lymphocytes. This interferes with 
purine synthesis and prevents proliferation of T and B lymphocytes (Allison and Eugui, 
2000). One of the essential properties of mycophenolate is that it lacks cardiovascular 
risks and chronic nephrotoxic adverse effects. The most common adverse events are 
primarily gastrointestinal such as nausea and/or vomiting, diarrhoea, gastritis, 
duodenitis, oesophagitis and ulcers. Other adverse effects are related to bone marrow 
suppression, including leukopaenia, anaemia, and thrombocytopaenia (Prescilla, 2013).   
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Mycophenolate mofetil is rapidly absorbed from the gastrointestinal tract after oral 
administration and it is rapidly and completely metabolized to mycophenolic acid. 
MPA, in turn, is metabolized in the liver, gastrointestinal tract and kidney to the inactive 
metabolite, 7-O-MPA-glucuronide (MPAG) with a small proportion metabolysed to an 
acyl-glucuronide. MPAG is actively transported into bile and passes into urine. MPAG 
is de-conjugated back to MPA by the bacteria in the gut and then reabsorbed in the 
colon resulting in a second peak of absorption. MPA is highly bound to serum albumin 
and it reaches its maximum concentration within 1–2 hours (Staatz and Tett, 2007).  
2.1.4.4 Sirolimus 
Sirolimus is a potent immunosuppressive drug widely used in organ transplantation. It is 
a macrocyclic triene antibiotic produced by Streptomyces hygroscopicus. Sirloimus was 
first isolated as an antifungal drug. However, further studies showed its remarkable 
antitumor and immunosuppressive activities. Sirolimus has a potent inhibitory effect on 
antigen-induced proliferation of T and B lymphocytes, and inhibits antibody production. 
Sirolimus binds to the same intracellular protein as tacrolimus, FKBP12. The sirolimus: 
FKPB12 complex interacts with and blocks the activation of an essential cell-cycle 
kinase named mTOR (mammalian target of rapamycin). By interfering with the mTOR 
function, sirolimus prevents the mTOR-mediated signal-transduction pathways and 
consequently, this results in the blockage of cell-cycle progression in G1 phase (Sehgal, 
2003). The most common adverse effects attributed to sirolimus were hyperlipidemia, 
infection, lymphopenia, anemia, thrombocytopenia, mouth ulcers, peripheral oedema 
and diarrhoea. Sirolimus -induced pneumonitis has also been reported. In contrast to 
CNIs, sirolimus is not associated with nephrotoxicity. Therefore, it can be used as an 
alternative immunosuppressive agent for transplant recipients who develop renal 
impairment with ciclosporin or tacrolimus therapy (Knechtle, 2014). Sirolimus is 
rapidly absorbed from the gastrointestinal tract following oral administration and 
reaches its peak concentration in 1-2 hours. After absorption, sirolimus is extensively 
bound to red blood cells and less than 5% of the drug remains free in the plasma. 
Sirolimus has a relatively low bioavailability (around 25%). It is metabolized in the 
liver and the intestinal wall by the CYP3A enzyme subfamily (CYP3A4 and CYP3A5) 
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and to a minor extent by CYP2C8. Sirolimus has a long elimination half-life of about 60 
hours in renal transplant recipients. It has a narrow therapeutic index and theraputic 
drug monitoring of blood concentrations is essential to ensure safe and effective 
treatment (Knechtle, 2014).  
2.1.4.5  Antibody Immunosuppressive Therapy 
2.1.4.5.1 Monoclonal Antibody  
A series of monoclonal antibodies (mAbs) are commonly used as induction therapy in 
renal transplantation. Monoclonal antibodies have different mechanisms of action. They 
target specific CD proteins on the T or B lymphocyte surface, including mAbs against 
CD3, CD20 and CD52.  
Alemtuzumab (also known as Campath) binds to CD52, a protein present on the surface 
of mature lymphocytes, leading to lymphocyte lysis via complement activation and 
antibody dependent cellular cytotoxicity, leading to depletion of T and B lymphocytes 
in the peripheral circulation for several months after administration. Infusion related 
side effects can occur during or shortly after alemtuzumab infusion, including pyrexia, 
chills/rigors, nausea, hypotension, urticaria, dyspnoea, rash, emesis, and bronchospasm.   
Rituximab binds to CD20, a protein present on the surface of immune system B 
lymphocytes, the combined effect results in the elimination of B lymphocytes.The most 
common complications occurring with rituximab therapy is infection, pulmonary 
toxicity, neutropenia and thrombocytopenia (Mahmud et al., 2010, Zaza et al., 2014).  
2.1.4.5.2 Polyclonal Antibody  
The polyclonal antibodies are produced by immunizing animals with human 
lymphocytes and the created antilymphocyte serum is then purified to isolate 
antithymocyte globulins (ATGs) from horses (equine antithymocyte globulin (eATG)) 
or rabbits (rabbit-derived antithymocyte globulin (rATG)). Polyclonal antibodies 
prevent T lymphocyte activation and proliferation by its broad spectrum activity against 
T lymphocytes activation markers, including CD2, CD3, CD4, CD8, CD11a, CD18, 
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CD25, CD44, CD45, human leukocyte antigen (HLA). Polyclonal antibodies block T- 
lymphocytes membrane proteins, causing alteration of the function, lysis, and prolonged 
T- lymphocyte depletion. By using ATGs, the body identified the transplanted organ as 
non-foreign. In the last decade, rATG has been used as by more transplant centres as an 
induction agent. The elimination half-life is 2 to 3 days for rATG and 1.5 to 12 days for 
eATG. The most common side effects of polyclonal antibodies with first-dose infusion 
are fever, chills and rashes. Repeated doses are associated with myelosuppression, 
thrombocytopenia and leukopenia. However, these side effects generally diminish after 
lowering the dose or terminating the treatment (Mahmud et al., 2010).  
2.1.4.6 Belatacept 
Belatacept is the first biologic agent approved by FDA for maintenance 
immunosuppression in kidney transplantation combined with other immunosuppressants 
such as basiliximab, mycophenolate mofetil and corticosteroids in adult patients. 
Belatacept has comparable short-term outcomes to the CNIs, while avoiding their 
nephrotoxic potential and their cardiovascular and metabolic toxicities. It is a selective 
T-lymphocyte costimulation blocker. Belatacept binds to the B7-1/CD80 and B7-
2/CD86 receptors of antigen-stimulating cells and thereby prevents the CD28-mediated 
T-lymphocyte costimulation resulting in the inhibition of IL-2 expression and hence the 
blockade of T- lymphocyte activation. The most common adverse effects of belatacept 
include infection, hypophosphatemia, diarrhoea, and cough. The most serious side 
effect during belatacept therapy are post-transplant lymphoproliferative disorder and 
progressive multifocal leukoencephalopathy. Belatacept is administered as an 
intravenous infusion over 30 minutes. It exhibits linear pharmacokinetics. Belatacept 
has a consistent and predictable pharmacokinetic profile and the serum elimination half-
life is approximately 8-10 days. Belatacept has low variability in its exposure and 
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2.1.5 Therapeutic Index and Therapeutic Drug Monitoring  
The therapeutic index (TI), which is also known as therapeutic window or range —is 
defined as the ratio of the dose that produces toxicity to the dose that produces the 
clinically desired or effective response in a proportion of individuals (Figure 3). Hence, 
TI is an important indicator in efforts to achieve the safety–efficacy balance (Finkel et 
al., 2009).  
 
Figure 3: Therapeutic Index (Guzman, 2014). Therapeutic index (TI) = TD50/ED50. 
ED50 = the drug dose that produces a therapeutic or desired response in half 
the population. TD50 = the drug dose that produces a toxic effect in half the 
population.  
The therapeutic index varies widely among substances. Drugs which offer a wide 
therapeutic index are considered very safe. Patients have to take much higher doses of 
these drugs to reach the toxic levels. On the other hand, drugs with a narrow therapeutic 
range have little difference between toxic and therapeutic doses. Small changes in 
systemic exposure can lead to marked changes in their pharmacodynamic responses. 
Therefore, it is important to adjust the dose by measuring the plasma or blood 
concentration of these drugs for each individual patient to avoid the unnecessary 
administration of the drug and to maximise its efficacy. This may be achieved through 
therapeutic drug monitoring (TDM). Therapeutic drug monitoring enables drug dosage 
individualization by maintaining the plasma or blood concentrations within the targeted 
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therapeutic window and consequently, achieving the maximum efficacy and safety of a 
particular medication (Kang and Lee, 2009). 
Most immunosuppressant drugs are critical dose drugs with a large between- and 
within- individual variability in their pharmacokinetics (PK) and systemic exposure. 
The between-patient variability is the variation between individuals in the blood 
concentration achieved by a given dose. On the other hand, the within-patient variability 
is visualized by fluctuating concentration of the immunosuppressive drug within a 
certain period of time during which drug dosage was unchanged. High within-patient 
variability complicates therapeutic drug monitoring as the drug concentrations will 
frequently be above or below the therapeutic window, putting the patient at risk for 
toxicity in the case of overexposure or for acute rejection in the case of drug 
concentrations below the lower threshold of the therapeutic window.  
The between-patient variability of calcineurin inhibitor concentrations can lead to 
under- or over-immunosuppression putting some patients at risk for rejection or toxicity 
and hence it is an important risk factor for poor kidney allograft outcomes  and to some 
extent this is influenced by genetic factors (Staatz and Tett, 2004). For both CNIs, most 
of the between- and within-patient variability occurs in the absorption phase rather than 
in the elimination phase. Individual variation in response to these drugs is a major 
medical issue and to a certain extent it is genetically related  (Schiff et al., 2007). 
Therefore, regular monitoring and regulation of immunosuppressant drug doses is a 
crucial indicator to prevent possible rejection events and major adverse effects 
associated with toxic and sub-therapeutic drug concentrations. Efficacy and side effects 
of immunosuppressive drugs are highly correlated with the area under the concentration 
time curve (AUC). Recording a complete pharmacokinetic profile for every patient is 
not feasible in clinical practice (Op den Buijsch et al., 2007). Limited sampling strategy 
(LSS) including a limited number of samples such as trough and time points within a 
short time post-dose, offers a practical approach to investigate the potential of drug 
AUC monitoring in routine clinical application (Mathew et al., 2008). Some of the 
common TDM techniques include the following: 
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2.1.5.1 Trough Concentration Monitoring (C0) 
In this method, the drug concentration that is achieved just before the administration of 
the subsequent dose is measured. This method is the oldest and, most commonly used 
method applied in TDM. Despite the simplicity of this method, it provides just an 
approximate estimate of the drug exposure throughout the dosing interval which is 
considered as the major downsides of this technique (Norman and Turka, 2001). 
Whereas the advantages of C0 monitoring are that it requires only one sample and 
eliminates the patients need to stay long time in the hospital for multiple samples to be 
taken. 
2.1.5.2 Area under the Curve (AUC) Monitoring 
This method provides a more accurate measure of drug extent. AUC0-12 is a good 
indicator for measuring drug exposure but the main disadvantages of AUC monitoring 
are that it is expensive and requires multiple blood samples and patient requires to 
spend long hours in the hospital which is impracticable for both the clinician and the 
patient.  
2.1.5.3 Abbreviated Area under the Curve Monitoring 
The AUC monitoring method can be modified by targeting the blood concentration in 
the first four hours after dosing. This abbreviated AUC is a limited sampling (2-4) 
strategy over the dosing interval, making it more convenient and economical than the 
standard AUC monitoring (Norman and Turka, 2001). 
2.1.5.4 C2 Monitoring 
This method further limits the number of collected samples to one, 2 hours following 
the drug administration. It is a more accurate predictor of ciclosporin exposure and 
clinical events as compared to C0 monitoring as most of the between patient variability 
is in the absorption rather than the elimination phase (Jorga et al., 2004).  
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2.2 Introduction on Bioequivalence and Genotyping Studies 
2.2.1 Bioequivalence-Narrow Therapeutic Index Drugs 
Pharmacokinetics includes the kinetic study of drug absorption, distribution, 
metabolism, and elimination (ADME). Bioequivalence studies are the commonly 
accepted method to determine the therapeutic equivalence between two pharmaceutical 
products. Bioequivalence studies are normally performed using two-way crossover 
design on healthy adult subjects, aged between 18-25 years, with the aim to minimise 
variability and detect the differences between the drugs under the conducted study 
(FDA., 2003). Crossover design is a design in which each group receives different 
treatments at different dosing periods (Figure 4). 
 
Figure 4: Two-period Crossover Design. At period 1, members of one group receive a 
single dose of the test formulation and members of the other group receive a 
single dose of the reference formulation. This is followed by a washout 
period during which subjects receive no treatment. At period 2, members 
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The advantage of the crossover design is that it decreases the influence of between-
subject variability as each patient serves as his own control. There are two 
disadvantages of this design. The first disadvantage is that the treatment order may 
affect the outcomes. The second disadvantage, which is of the main concern, is the 
carry-over effect between the treatments that can be avoided with a sufficiently long 
"wash-out" period (Wang and Bakhai, 2006). This washout period should be equal to or 
more than five times of the drug elimination half-life, to ensure that drug concentrations 
are below the lower limit of bioanalytical quantification in all subjects at the beginning 
of the second period (FDA., 2003). 
Bioequivalence of two formulations of the same drug includes equivalence with respect 
to the rate and extent of absorption. The area under the concentration time curve (AUC) 
reflects the extent of exposure. The maximum plasma concentration (Cmax) and the time 
to maximum plasma concentration (tmax,) are parameters that are influenced by the 
absorption rate. FDA guidelines states that the 90% confidence intervals for the ratios 
(test: reference) of the areas under the drug concentration versus time curves (AUC 
ratio) and the maximum plasma drug concentrations (Cmax ratio) must fall between 0.8-
1.25, which is the bioequivalence acceptable range applied for any bioequivalence study 
(FDA., 2003).  
Many countries have established guidelines for the bioequivalence studies and 
formulated requirements for their design, conduct, and evaluation. However, all of these 
bioequivalence guidelines approved that the acceptable bioequivalence range for the 
bioavailability measures (AUC and Cmax) is 0.8-1.25. However, in recent years there 
have been large debates regarding the validity of this target interval for products with a 
narrow therapeutic index. It is sometimes claimed that the 80 to 125% limit means there 
can be a wide variation between the generic and the reference product (Birkett, 2003).  
Drugs with a narrow therapeutic index (NTI-drugs) are drugs with small differences 
between therapeutic and toxic doses. Moreover, there is a risk of clinically relevant 
difference in efficacy or safety between two NTI drug formulations even when the 
conventional criteria for bioequivalence (i.e. 90% confidence interval for test / reference 
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ratio for AUC and Cmax within 80-125%) are met (Borgheini, 2003, Burns, 1999). 
Several immunosuppressive drugs, including tacrolimus are considered to be examples 
of NTI drugs (Johnston and Holt, 1999, MacPhee et al., 2002). For this reason, the 
Health Canada guidelines were changed for critical dose drugs so that 90% confidence 
interval of relative mean AUC of the test to reference formulation were reduced to 90.0 
to 112.0%, but it is still 80.0 to 125.0% for relative mean Cmax. European Medical 
Agency guideline (EMA) was recently changed to recommend that in specific cases of 
products with a narrow therapeutic index, the acceptance interval for AUC should be 
tightened to 90.00-111.11%. Where Cmax is of particular importance for safety, efficacy 
or drug level monitoring the 90.00-111.11% acceptance interval should also be applied 
for this parameter (EMA, 2010a). In June 2015, the Efficacy Working Party (EWP) 
recommended that the bioequivalence acceptance criteria for tacrolimus should be [90-
111%] for AUC and [80-125%] for Cmax. This is because they considered the total drug 
exposure (AUC) is the key parameter of importance for tacrolimus dose titration; in 
comparison peak whole blood concentration does not seem to be critical for either 
safety or efficacy (EMA, 2015). Furthermore, NTI drugs often have steep concentration 
response relationships for efficacy, toxicity, or both. Dosing generally needs to be 
individualised based on blood/plasma concentration monitoring and there may be 
potentially serious clinical consequences in the event of concentrations outside the 
therapeutic window. Remarkably, it is not possible to define a set of criteria to 
categorize drugs as either NTIDs or not and a judgment must be made in each 
individual case. Likewise, the need for narrowing the acceptance interval for both AUC 
and Cmax or for AUC only should be determined on a case by case basis (NTV, 2011). 
2.2.2 Genotyping Procedure 
A gene is a chromosomal DNA sequence that is required for the making of a functional 
product (polypeptide or functional RNA molecule). An ''allele'' is one variant of the 
gene. SNPs or single nucleotide polymorphisms are alterations in a single base in the 
gene sequence and may code for a different protein altogether creating genetic mutation. 
Mutations of genes that are important for functions in the body can lead to a genetic 
condition that may affect the individual growth or health (Mandal, 2014). Some genes 
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are highly polymorphic, resulting in enzyme variants that may have variable drug-
metabolizing capacities among individuals. Many of the recorded polymorphisms relate 
to differences in the expression of drug metabolizing enzymes and transporters, and 
hence drug disposition (Flanagan et al., 2007). 
Genotyping is the process of determining differences in an individual genetic make-up 
by examining the individual's DNA sequence using biological assays and comparing it 
to another individual's sequence or a reference sequence. Two steps are required for 
single nucleotide polymorphisms (SNPs) genotyping. The first step is DNA region 
amplification, approximately 200 base pairs around the SNP, millions to billions of 
times by means of a PCR. Then the PCR product has to be sequenced or digested by an 
enzyme and followed by gel electrophoresis in order to genotype the polymorphic 
regions.  
2.2.2.1 Polymerase Chain Reaction (PCR) and DNA Sequencing  
2.2.2.1.1  Principle of PCR 
Polymerase chain reaction (PCR) is a biochemical technology in molecular biology and 
it is used to amplify a specific region of a DNA strand in a cyclic process to make a 
huge number of identical copies that can readily be analysed. This is necessary to have 
enough starting template for sequencing. PCR is commonly carried out in a thermal 
cycler. The thermal cycler heats and cools the reaction tubes to achieve the temperatures 
required at each step of the reaction in a very short time.  
I. Initialization Step: This step consists of heating the reaction to a temperature of 
94–96°C (or 98°C if extremely thermostable polymerases are used), which is 
held for 1–9 minutes. It is only required for DNA polymerases that require heat 
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II. The Cycling Reactions: 
There are three major steps in a PCR, which are repeated for 30 or 40 cycles (Figure 5). 
 Denaturation Step: This step is the first regular cycling step and consists of 
heating the reaction to 94–98 C for 20–30 seconds. During the denaturation, the 
double strand DNA and primers melt to a single stranded DNA by disrupting the 
hydrogen bonds between complementary bases and all enzymatic reactions stop. 
 Annealing Step: During this step, the reaction temperature is lowered to 50–
65°C for 20–40 seconds and this allows annealing of the primers to the single-
stranded DNA template. The primers are moving randomly and stable DNA-
DNA hydrogen bonds are only formed when the primer sequence very closely 
matches the template sequence. The polymerase binds to the primer-template 
hybrid and begins DNA formation. 
 Extension/Elongation Step: The temperature at this step depends on the DNA 
polymerase used and commonly a temperature of 72°C is used with this enzyme. 
At this step the DNA polymerase synthesizes a new DNA strand complementary 
to the DNA template strand by adding dNTPs (deoxynucleotide triphosphates) 
that are complementary to the template in 5' to 3' direction, condensing the 5'-
phosphate group of the dNTPs with the 3'-hydroxyl group at the end of the 
nascent (extending) DNA strand (Chien et al., 1976). The extension time depends 
both on the DNA polymerase used and on the length of the DNA fragment to be 
amplified. Normally, at its optimum temperature, the DNA polymerase will 
polymerize a thousand bases per minute. At each extension step, the amount of 
DNA target is doubled, leading to exponential (geometric) amplification of the 
specific DNA fragment. 
 Final Elongation: This single step is occasionally performed at a temperature of 
70–74°C for 5–15 minutes after the last PCR cycle to ensure that any remaining 
single-stranded DNA is fully extended. 
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Figure 5: The Different Steps of Polymerase Chain Reaction (Lee et al., 2007). The 
double strand DNA is denatured by heating to 94-98°C. At approximately 
55°C, the primers anneal to the single-stranded DNA template. At 72°C 
DNA polymerase extends the single-stranded DNA and synthesizes a new 
DNA strand complementary to the DNA template. This process is repeated 
for 30 or 40 cycles. 
In order to check whether the PCR generated the anticipated DNA fragment, agarose gel 
electrophoresis is employed for size separation of the PCR products. The size of PCR 
products is commonly determined by a comparison with a DNA ladder (a molecular 
weight marker), which contains DNA fragments of known size; run on the gel alongside 
the PCR products. The products with brighter fluorescence are the ones that are likely to 
produce the best sequences. 
2.2.2.1.2 Principle of Sequencing 
The purpose of sequencing is to determine the order of the nucleotides of a gene from 
PCR fragments or cloned genes. There are three major steps in a sequencing reaction 
(like in PCR), which are repeated for 30 or 40 cycles. 
 Denaturation Step at 94-98°C: During the denaturation, the double strand DNA and 
primers melt to a single stranded DNA by disrupting the hydrogen bonds between 
complementary bases and inhibiting enzymatic reactions. 
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 Annealing Step at 50-65°C: In sequencing reactions, only one primer is used, so 
there is only one strand copied (in PCR: two primers are used, so two strands are 
copied). During this step, this lowered temperature allows annealing of the primer to 
the single-stranded DNA template. The primer is moving randomly around and 
stable DNA-DNA hydrogen bonds are only formed when the primer sequence very 
closely matches the template sequence. The polymerase binds to the primer-template 
hybrid and begins DNA formation. 
 Extension Step at 60°C: At this step the DNA polymerase synthesizes a new DNA 
strand complementary to the DNA template strand by adding dNTPs or ddNTPs 
(dideoxynucleotide triphosphates) that are complementary to the template in 5' to 
3' direction. Normally, the ideal working temperature for the polymerase is 72°C but 
because it has to incorporate ddNTPs which are chemically modified with a 
fluorescent label, the temperature is lowered so it has time to incorporate the 'strange' 
molecules. When a ddNTP is incorporated, the extension reaction stops because a 
ddNTP contains a H-atom on the 3rd carbon atom compared to dNTPs that contain a 
OH-atom on that position). Since the ddNTPs are fluorescently labelled, it is possible 










Figure 6: Chain Termination Sequencing Showing the Different Lengths of 
Labeled DNA strands (Aliyu, 2014).  
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Sequencing reactions need to be cleaned up prior to injection on the ABI sequencer in 
order to remove both the unincorporated dideoxynucleotides as well as salts from the 
reaction buffers. This is achieved by filtration on sephadex column (Hutchison et al., 
2005). Addition of reagents such as formamide may increase the specificity and the 
yield of PCR (Sarkar et al., 1990). 
After the sequencing reactions, a mixture of strands with different length and ending on 
a fluorescently labelled ddNTP has to be separated. This can be done with gel 
electrophoresis using a fluorescence-based capillary electrophoresis (CE) system. When 
the DNA passes through the detection cell, the capillaries are simultaneously 
illuminated from both sides of the array by a laser beam. The fluorescent molecule 
sends out a light of a distinct colour. The emitted fluorescent light is collected, 
separated by wavelength, and focused onto a charge coupled device (CCD). This is 
followed by data transfer to the instrument computer where they are transformed by 
chemometric algorithmic processing into 4- or 5-dye electropherograms. Each base has 
its own colour, so the sequencer can detect the order of the bases in the sequenced gene, 
see Figure 7.  
 
Figure 7: An Electropherogram Showing a Sequence of Data Produced by an 
Automated DNA Sequencing Machine (Abouzeid et al., 2012). The four 
dideoxy nucleotides (A, G, C and T) have different fluorescent colours. A 
base =green colour, C base= blue colour, G base = black colour and T base= 
red colour. The DNA sequence can easily be identified by using these 
colour codes.  
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2.2.2.1.3 Real-time PCR (RT-PCR) 
Real-time PCR is a quantitative PCR technique in molecular genetics that follows the 
principle of PCR with simultaneous amplification and detection of specific DNA-
sequences.  It is an established method for DNA quantification that measures the 
accumulation of DNA product after each round of PCR amplification and it monitors 
the progress as it occurs, in real time (Higuchi et al., 1992, Higuchi et al., 1993). 
Consequently, it allows quantification of the target polymorphic DNA regions and 
genotyping of single nucleotide polymorphisms (SNPs) in one single PCR run. RT-PCR 
facilitates a high speed PCR analysis, about one hour/run. It also minimizes the risk of 
contamination during analysis, since no post PCR steps are involved and the PCR 
product remains in the machine for genotyping (Reuter et al., 2005). 
Melting curve analysis can only be implemented with real-time PCR detection 
technologies where the fluorophore, a fluorescent compound, remains linked to the 
target DNA sequence. Hybridization probes, sequence-specific oligonucleotides, are 
required for DNA amplification process and genotyping using melting curve analysis. 
The probes are usually 100-1000 bases long, labelled by fluorescence dyes; one probe is 
labelled on the 3’ end and the other is labelled on the 5’ end. The 3’ end contains a 
phosphorylation modification so that the probe is not participating in extension (Figure 
8). The probe that binds to the DNA strand and covers the polymorphic region, the 
predicted site of mutation, is called the sensor hybridisation probe and the probe that 
binds to a site with only 1–5 bases distance from the sensor probes is called the anchor 
probe that produces the fluorescent signal. The sensor probe is labelled by donor 
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Figure 8: Hybridization Probes. During annealing the two probes bind to their target 
sequences and an energy transfer occurs within the donor - acceptor pair. 
The increase in fluorescent activity of acceptor fluorophore is measured and 
the fluorescence signal is directly proportional to the target DNA amount.  
The primers amplify the target sequence and these two allele-specific probes are 
designed to hybridize to the target sequence only if they are perfectly matched. When 
the probes hybridize to their target sequence, they become fluorescent. During 
amplification the hybridisation probes anneal to the amplified DNA segment in a head 
to tail configuration and this separates the two fluorophores from each other. A 
fluorescence resonance energy transfer (FRET) can occur between them, providing real-
time monitoring of the amplification process. By means of a light-emitting diode 
(LED), energy transfer begins when the light source excites the donor fluorophore, the 
fluorescent dye of the sensor probe which then emits fluorescent light. Through FRET, 
the energy of that light in turn excites the acceptor reporter fluorophore in the anchor 
probe which then emits another fluorescent light. The optical unit of RT-PCR machine 
measures the intensity of the emitted light. The energy transfer is referred to as FRET. 
The FRET signal becomes stronger when more new copies of the target DNA sequences 
are produced and more probes hybridise to the DNA. Consequently, the FRET signal 
represents the amount of DNA copies in a PCR run. During the PCR elongation phase, 
the hybridization probes set free from the DNA as the temperature increases. After PCR 
completion, melting-curve analysis can be used to detect the point mutations. 
Fluorescence can be monitored as the temperature slowly elevated from 40°C to 75°C 
through the melting temperature (Tm), where the hybridization probes are melted off 
the DNA strand and the presence or absence of a mutation can be detected by the 
obtained characteristic melting profile for each genotype. If the sensor probe is 
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completely annealed to the DNA strand, it melts off at a higher temperature than the 
lower temperature required to melt off a probe with a mismatch of one base, single 
nucleotide mutation. The melting curve analysis can show three characteristic curves: a 
curve with a single early peak (homozygous mutant, Mut), a curve with a single late 
peak (homozygous wild type, Wt) and a curve with two peaks (heterozygous genotype, 













Figure 9: Melting Curve Analysis for Hybridization Probes Designed for Wild 
Type DNA Sequence. The early and late single peaks indicate homozygous 
mutant (Mut/Mut) and homozygous wild (Wt/Wt) samples, respectively. 
The dual peak indicates heterozygous samples (Wt/Mut). 
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3 Chapter 3. Pharmacokinetics and 
Pharmacogenomics of Tacrolimus: A Review 
Tacrolimus is a natural macrolide lactone antibiotic with potent immunosuppressive 
properties (Figure 10). Its molecular formula is C44H69NO12 with a molecular weight of 
804.02 g/moL. Although structurally unrelated to Ciclosporin (CsA), its mode of action 
is similar. Tacrolimus is considered as one of the most potent immunosuppressive 
agents used in the prevention of rejection following renal transplantation (Pirsch et al., 
1997). 
 
Figure 10: Structure of Tacrolimus. 
Tacrolimus acts as an immunosuppressant via inhibiting the proliferation and activation 
of CD4+ T helper cells through binding to a cellular receptor known as FK506-binding 
protein (FKBP). The tacrolimus-FKBP complex further binds to calcineurin (CaN), 
preventing the dephosphorylation of the nuclear factor of activated T cells (NF-ATc).  
The cascade of cytokine gene transcription is then blocked by inhibiting NF-ATc 
transport to the nucleus and preventing its binding to the nuclear component of the 
nuclear factor of activated T cells (NF-ATn). Consequently, T cells do not produce IL-
2, which is necessary for full T-cell activation (Figure 11). The net result is the 
inhibition of T-lymphocyte activation: immunosuppression (Fleischer, 1999). 
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Figure 11: Mechanism of Action of Tacrolimus (Stepkowski, 2000). In the 
cytoplasm, tacrolimus (FK506) binds to FK506-binding protein (FKBP). 
The FK506–FKBP complex binds to and blocks the function of the enzyme 
calcineurin (CaN), which has a serine/threonine phosphatase activity. 
Accordingly the FK506–FKBP–CaN complex prevents the cytoplasmic 
nuclear factor of activated T cells (NF-ATc) dephosphorylation and its 
transport to the nucleus. Consequently, it inhibits IL-2 production, which is 
necessary for full T-cell activation. FKBP: FK506-binding protein; CaN: 
Calcineurin; Ca2+: Calcium; NF-ATc: The nuclear factor of activated T 
cells (Inside the cytoplasm); NF-ATn: The nuclear factor of activated T 
cells (Inside the nucleus).  
Moreover, tacrolimus also has important anti-inflammatory properties that are apparent 
through inhibiting the release of mast cell and basophil preformed mediators, down 
regulating IL-8 receptor expression, decreasing intercellular adhesion molecule-1 
(ICAM-1) and E-selectin lesional blood vessel expression. This broad range of the 
inflammatory inhibition mechanism may reduce antigen recognition and down regulate 
the entire inflammatory cascade leading to clinical disease (Fleischer, 1999). 
Tacrolimus was initially available for over 10 years as a preparation requiring twice 
daily administration: Prograf®; 0.5, 1 and 5 mg capsules (Pirsch et al., 1997). The initial 
tacrolimus dosage is usually between 0.1 to 0.2 mg/ kg of body weight per day, given in 
two divided doses. The maintenance tacrolimus dosing is based on a standard protocol 
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employing therapeutic drug monitoring with the target whole blood 12 hour post-dose 
(trough) concentrations, depending on the time since transplantation.  
The therapeutic range for tacrolimus trough blood concentrations (C0) lies between 5 
and 15 µg/L with a recent trend towards lower target concentrations based on the 
SYMPHONY study where the target was 3-7 µg/L and the achieved range was 5-10 
µg/L (Ekberg et al., 2007). The current regimen for tacrolimus at St George’s employs a 
target range of 8-12 µg/L during the first 3 months after renal transplantation when the 
risk of rejection is greatest, dropping to 5-8 µg/L thereafter. A number of generic twice 
daily tacrolimus preparations have become available recently. A prolonged release 
preparation, Advagraf®, has been available in the UK since 2007. Advagraf® has 
equivalent efficacy and safety to Prograf® following once daily dosing. This preparation 
is licensed in the UK for the prevention of renal allograft rejection and it is available in 
0.5, 1, 3, and 5 mg capsules.  The aim of developing a once daily preparation was to 
reduce the frequency of dosing and simplify dosing regimens for kidney, liver, and heart 
transplant recipients currently using the twice daily tacrolimus formulation (Alloway et 
al., 2007, Silva et al., 2007). A study assessing the adherence to immunosuppressant 
regimens in kidney transplant patients demonstrated that once-daily tacrolimus dosing 
improved patients’ compliance (Kuypers et al., 2013). Tacrolimus adherence was 
improved in the majority of liver transplant patients after switching to once-daily 
tacrolimus and mainly caused by the lack of the evening dose (Beckebaum et al., 2011). 
Upon change from Prograf® to Advagraf®, the same total daily dose is given as a single 
dose in the morning with adjustment of the dose to maintain exposure within the range 
specified above. Prograf® and Advagraf® should be taken on an empty stomach, either 
one hour before or two hours after a meal. In Phase II studies on Advagraf, a given dose 
of Advagraf delivered 90% of the area under the concentration-time curve (AUC) 
obtained with Prograf (EMEA, 2007). 
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3.1 Tacrolimus Pharmacokinetics  
3.1.1 Absorption 
After oral administration, tacrolimus is absorbed rapidly in most patients and reaches its 
peak plasma/blood concentration in 30 minutes to one hour. While in some patients it is 
absorbed slowly over a prolonged period, resulting in a flat absorption profile. 
Tacrolimus has a large variability in the rate of absorption and absolute bioavailability 
between individuals. It ranges from 5%–93% and approximately 25% of the oral dose is 
bioavailable due to an active barrier to drug absorption (Venkataramanan et al., 1995). 
The poor water solubility of tacrolimus and reduced gut motility in transplant recipients 
is responsible for the poor and erratic absorption of tacrolimus. Since tacrolimus is well-
known as a substrate of CYP3A iso-enzymes, its poor bioavailability is to a large extent 
caused by presystemic metabolism of tacrolimus in the gut wall and liver (Tuteja et al., 
2001). Tacrolimus is also known as a substrate of P-glycoprotein (P-gp), a multidrug 
efflux transporter. P-glycoprotein lowers the intracellular concentration of tacrolimus by 
pumping the absorbed tacrolimus back out into the intestinal lumen, it is repeatedly 
transported out of the intestinal mucosa cells and then passively reabsorbed. This 
extensive presystemic metabolism limits the oral bioavailability of tacrolimus to ~25%. 
Therefore, it is very likely that the poor and the variable bioavailability of tacrolimus is 
at least partly caused by the activity of this efflux pump in the intestine and genetic 
polymorphism of the P-glycoprotein (Hoffmeyer et al., 2000). Polymorphisms, or 
genetic variations, of these isoenzymes affect the dosage requirement and trough levels 
of tacrolimus in stable transplant patients (Haufroid et al., 2006).  The impact of genetic 
variations in expression of CYP3A and P-glycoprotein will be discussed in detail below. 
Tacrolimus absorption is significantly inhibited by food. A study comparing the 
influence of food on both the rate and extent of Prograf® absorption in healthy 
volunteers showed that food in general significantly decreases the rate and extent of 
tacrolimus absorption and slows it down compared with the fasting state. Relative to the 
fat content of the food, high-fat meals had more pronounced effect than low-fat meals, 
see Figure 12 (Bekersky et al., 2001b). 
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Figure 12: Effect of Food on Tacrolimus Absorption after Administration of 5mg 
Prograf® (Bekersky et al., 2001b). Food in general and fat in particular, 
has a clinically significant effect on tacrolimus absorption. 
Another study demonstrated that tacrolimus ingestion in the fasting state (10 hours) 
provides the greatest relative bioavailability in comparison to taking the drug one hour 
prior to a meal, which had a relatively minor impact on the relative bioavailability 
extent (~12%). Furthermore, ingestion of tacrolimus immediately after a meal or 1.5 
hours subsequent to a meal had a more pronounced influence (Figure 13). Hence, the 
standard recommendation is that tacrolimus must be taken either 1 hour before or 2 
hours after eating (Bekersky et al., 2001a). 
 
Figure 13: Effect of Time of Meal Consumption on Tacrolimus Absorption after 
Administration of 5mg Prograf® (Bekersky et al., 2001a). Timing of 
meals has a significant effect on the rate and extent of drug absorption. 
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As will be seen in the pharmacokinetic profiles above, while food impacts significantly 
on the absorption phase and area under the concentration-time curve (AUC), it has 
relatively little impact on 12 hour post-dose trough concentrations.  This is an important 
practical point as trough concentration monitoring in patients taking tacrolimus along 
with food may result in false reassurance on drug exposure.  Standard guidance is to 
take tacrolimus either at least one hour before or at least two hours after a meal.  
Variable compliance with this advice may be one of the factors contributing to within-
patient variability in tacrolimus exposure. 
Prograf® is predominantly absorbed in the upper part of the gastrointestinal tract; 
around the stomach and proximal small intestine. Advagraf® is modified to release 
tacrolimus slowly. Ethylcellulose, hypromellose, and lactose monohydrate was added in 
order to control water penetration and produce a protective polymer layer around the 
drug. Due to different dissolution properties, Advagraf® is typically released further 
along the gut, which provides a more distal area of tacrolimus absorption and this 
increases the contact interval with the absorption site (Barraclough et al., 2011a).  
3.1.2 Distribution 
After absorption, tacrolimus is extensively bound to both red blood cells and plasma 
proteins. In the systemic circulation, tacrolimus binds strongly to erythrocytes in the 
region of 95% because of its high affinity for the FK-binding proteins which are found 
abundantly in erythrocytes and lymphocytes. In plasma, approximately 99% is bound to 
plasma proteins, mainly albumin and alpha-1-acid glycoprotein. The mean tacrolimus 
whole blood concentration is about 20 times higher than that of plasma. Tacrolimus 
distribution between plasma and erythrocytes is dependent on several factors including; 
haematocrit, tacrolimus concentration, plasma protein concentration and temperature at 
the time of plasma separation (Nagase et al., 1994, Venkataramanan et al., 1995). Less 
than 0.1% of the unbound fraction of tacrolimus is responsible for its pharmacological 
activity. Whole blood concentrations of tacrolimus, which consists of both bound and 
unbound fractions of tacrolimus, are routinely monitored to ensure appropriate exposure 
to the drug. Tacrolimus is distributed extensively in the body with most partitioned 
outside the blood compartment (Undre, 2003). Lipophilic drugs such as tacrolimus 
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readily cross membranes and are taken up by adipose tissue. In animal studies 
tacrolimus is widely distributed in tissues; lung, spleen, kidney, heart, pancreas, brain, 
muscle with liver exposed to the greatest accumulation (Burton, 2006) 
3.1.3 Metabolism 
Tacrolimus undergoes O-demethylation, hydroxylation, or oxidative metabolic 
reactions. The CYP 3A enzyme system is mainly responsible for tacrolimus 
metabolism. The CYP3A subfamily consists of four genes, CYP3A4, CYP3A5, 
CYP3A7, and CYP3A43. Tacrolimus is metabolized predominantly by CYP3A4 and 
CYP3A5 in the liver and the intestinal wall, with <1% of the parent drug is excreted 
unchanged in the urine or faeces. CYP3A4 in the gastrointestinal epithelium is 
responsible for presystemic elimination of approximately 50% of the absorbed dose, 
whereas first-pass metabolism by CYP3A4 in the liver accounts for an additional 10% 
of elimination. When CYP3A5 is expressed, it accounts for 50% of the total hepatic 
CYP3A content (Burton, 2006, Undre, 2003). An in-vitro study revealed that CYP3A5 
contribution in tacrolimus conversion to its metabolite (13-O-demethyltacrolimus) was 
higher than CYP3A4 contribution (Kamdem et al., 2005). Another in-vitro study 
reported that CYP3A5 is a more efficient enzyme for tacrolimus metabolism than 
CYP3A4 (Dai et al., 2006). Moreover, P-glycoprotein inhibits drug absorption from the 
gut by promoting efflux into the lumen of the intestine; it also has a role in systemic 
clearance of drugs by promoting efflux into the bile for excretion (Burton, 2006, Undre, 
2003).  
3.1.4 Elimination 
The metabolites of tacrolimus are mainly eliminated via the biliary route and more than 
95% of the oral dose was recovered in faeces. Only an average of 2.4% of tacrolimus 
dose was excreted in urine. However, less than 1% of tacrolimus appears unchanged in 
urine and stool indicating that tacrolimus metabolism plays a major role in its 
elimination (Burton, 2006, Dalal et al., 2010).  
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3.2 Tacrolimus Pharmacogenomics 
Genetic differences in drug response may arise from differences in pharmacodynamics 
or in drug disposition. Many of the recorded polymorphisms relate to differences in the 
expression of drug metabolizing enzymes and transporters, and hence drug disposition. 
Some genes are highly polymorphic, resulting in enzyme variants that may have 
variable drug-metabolizing capacities among individuals. A single-nucleotide 
polymorphism (SNP) is a DNA sequence variation occurring when a single nucleotide 
(A, T, C or G ) in the genome differs between individuals (Flanagan et al., 2007).  
Despite tacrolimus success in improving graft survival, tacrolimus therapeutic use is 
complicated by its narrow therapeutic index (between 5 and 15 µg/L). The routine 
therapeutic monitoring of tacrolimus reveals a large between individual variability in 
tacrolimus pharmacokinetics and dose requirement. Many studies have focused on the 
possible causes of this variability in tacrolimus pharmacokinetics. Among various 
factors investigated, genes coding polymorphisms in biotransformation enzymes 
(CYP3A4/5 isoenzymes) and drug transporters (ABCB1, previously known as MDR1) 
have received much attention (Patel et al., 2012, Haufroid et al., 2006). These genetic 
polymorphisms may explain the observed variability in tacrolimus pharmacokinetics. 
They have been studied in relation to tacrolimus dosing and shown to be the most 
promising. In addition to these genes, a number of recently identified variants have been 
reported to have a potential influence in tacrolimus pharmacokinetics and dose 
requirement.  
3.2.1 Cytochrome P450 (CYP450) 3A 
The cytochrome P450 family (CYP450) is a super-family of related, but distinct, drug-
metabolizing enzymes. CYP450s are proteins bound to heme (membrane-bound heme-
containing proteins). They are classified on the basis of cDNA cloning according to 
similarities in amino acid sequence. Members of a subfamily (denoted by a letter) must 
have at least 55% identity (Flanagan et al., 2007). The most important cytochrome P450 
isoforms responsible for drug metabolism are the CYP3A family and mainly present in 
critical tissues such as liver and the gastrointestinal tract. 
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The CYP3A family is composed of four enzymes: CYP 3A4, CYP 3A43, CYP 3A5, 
and CYP 3A7. The expression of CYP3A43 in adult livers is at very low levels, only 
0.1–0.2% of CYP 3A transcripts. It does not play a major role in drug metabolism. 
CYP3A7 is mainly expressed in the foetal liver, but it is expressed in small amounts in 
some adult livers and extrahepatically. The participation of CYP3A43 and CYP3A7 in 
CYP3A substrates metabolism in adults is therefore regarded to be negligible (Burk et 
al., 2002). CYP3A4 and CYP3A5 are highly expressed in the liver as well as extra-
hepatic tissues, including the gastrointestinal tract and they have an important role in 
first-pass metabolism (Flanagan et al., 2007). CYP3A enzymes are estimated to 
contribute to the metabolism of 40 to 60% of all medicines. In particular, they play a 
fundamental role in the oxidative, peroxidative, and reductive metabolism of numerous 
clinically useful therapeutic agents (Burk et al., 2002).  
The CYP3A5 and CYP3A4 genes are part of a cluster of CYP3A genes located on 
chromosome 7q22.1 along with other CYP3A family members. The CYP3A4 gene 
spans 13 exons covering 27 kb sequence and encodes 502 amino acids with a molecular 
weight of 57 kDa. CYP3A5 is a 52.5 kDa protein made up of 502 amino acids and 
encoded by the CYP3A5*1 allele. CYP3A5*3 allele is the most common CYP3A5 
variant. CYP3A5 shares 85% sequence similarity with CYP3A4. Both CYP3A4 and 
CYP3A5 are expressed in the liver and intestine, with CYP3A5 being the predominant 
form expressed in extrahepatic tissues. CYP3A4 and CYP3A5 have similar substrates 
(Lamba et al., 2012). 
3.2.1.1 CYP3A5 
The most frequent variant of functional importance in the CYP3A5 gene is CYP3A5*3. 
The functional SNP located in CYP3A5 intron 3 (rs776746 A>G), for which A and G 
nucleotides are designated as CYP3A5*1 (wild-type) and CYP3A5*3 (mutant-type) 
alleles, respectively. The CYP3A5*1 allele expresses large amounts of CYP3A5, while 
the CYP3A5*3 allele creates a cryptic splice site, resulting in a premature stop codon 
and the absence of functional CYP3A5 (Kuehl et al., 2001). The distribution of 
CYP3A5*1 wild type allele is different among ethnic groups and varies in frequency of 
5%-15% in Caucasians, 15%-35% in Asians, 25% in Mexicans, and 45%-73% in 
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African-Americans (Provenzani et al., 2013). The influence of CYP3A5*3 variant on 
tacrolimus (Prograf®) metabolism has been extensively studied. It has been reported that 
CYP3A5 activity explains 29–35% of the variability in the studied tacrolimus 
pharmacokinetic parameter (de Jonge et al., 2012). 
Originally, MacPhee et al. (2002) reported that the variable dose requirement of 
tacrolimus in kidney transplant recipients was associated with the CYP3AP1 
pseudogene. At 3 months after transplantation, patients with a CYP3AP1*1 allele had 
twofold lower dose-normalized tacrolimus concentrations than CYP3AP1*3/*3 
homozygotes to achieve target blood concentrations. They also showed that there is an 
association between CYP3AP1 pseudogene and CYP3A5 expression. CYP3AP1*1 
genotype is tightly linked with CYP3A5*1, indicating CYP3A5 expression. While 
CYP3AP1*3 allele is in tight linkage with CYP3A5*3 with no CYP3A5 expression. The 
authors further confirmed these findings during the first 2 weeks after transplantation in 
a single centre retrospective study involving data from 178 kidney transplant patients 
between 1995 and 2001, suggesting a link between the variability in tacrolimus 
pharmacokinetics and the CYP3A5genotype (MacPhee et al., 2004). Since then many 
studies have been conducted to study the effect of CYP3A5 genotype on tacrolimus dose 
and dose-corrected tacrolimus concentration in heart, liver and most extensively in 
kidney transplantation including healthy volunteers and adult and paediatric patients.  
In healthy individuals, a pharmacokinetic study, involving 22 healthy Korean subjects, 
demonstrated that CYP3A5 expressers yield much lower AUC0–∞ and Cmax 
concentrations than the CYP3A5 non-expressers (Choi et al., 2007). This was 
confirmed by another study in 20 healthy Japanese subjects and the study showed that 
subjects with CYP3A5*3/*3 achieved 1.8-fold higher tacrolimus AUC0-8h than 
CYP3A5*1 carriers. Besides, the estimated tacrolimus apparent clearance (CL/F) in 
CYP3A5*1 carriers was 1.5 times higher than CYP3A5 non-expressers (Suzuki et al., 
2008).  
In kidney transplantation, the influence of CYP3A5 genotype on tacrolimus dose and 
dose-adjusted concentration has been extensively studied in either adult or paediatric 
patients. Table 3 summarises the key tacrolimus pharmacogenetic studies conducted in 
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renal transplant recipients. It has been consistently demonstrated that recipients carrying 
at least one CYP3A5*1 allele have significantly lower tacrolimus dose-adjusted trough 
concentrations and required 1.5 to 2 times the tacrolimus dose to achieve the same 
target blood concentrations than those carrying CYP3A5*3/*3 genotype. These findings 
have been demonstrated in renal transplant patients with different ethnic backgrounds 
(Caucasian, African, Japanese, Chinese and Mexican). 
In heart transplant patients, the CYP3A5*3 genotype effect on tacrolimus dose and 
concentration was similar to that obtained from kidney transplant patients. A study in 65 
heart transplant recipients demonstrated that CYP3A5 expressers required higher 
tacrolimus doses compared with CYP3A5 non-expressers (Díaz-Molina et al, 2012). 
This was confirmed by a retrospective observational study in 52 heart transplant 
patients during the first year after transplantation and again showed that CYP3A5 
expressers had lower dose-adjusted trough concentrations throughout the study period 
and required 2.2- to 2.6-fold higher tacrolimus dose to reach the target concentration 
compared with CYP3A5 non-expressers (Lesche et al., 2014). However, a paediatric 
study in 38 Jordanian patients found no significant differences in tacrolimus dose, C0 or 
C0/dose among each genotype group of CYP3A5 polymorphisms in either the early or 
the maintenance phase after transplantation (Shilbayeh et al, 2013). 
Furthermore, CYP3A5*3 genotype has a strong association with tacrolimus dose and 
dose-adjusted concentration in liver transplant patients. A study in 216 Chinese liver 
transplant patients revealed that recipient with CYP3A5*1/*1 genotype required a 
higher tacrolimus dose than patients with CYP3A5*3/*3 allele. Besides, the 
concentration/dose (C/D) ratio of tacrolimus was lowest in the CYP3A5*1/*1 than the 
CYP3A5*1/*3 and *3/*3 genotypes, indicating that the enzymatic activity of CYP3A5 
increased proportionally with the number of CYP3A5*1 allele (Shi et al., 2013). A 
retrospective study in 90 Chinese pediatric liver transplant patients showed that despite 
using the same induction and initial dose of tacrolimus, CYP3A5 non-expressers had a 
significantly higher C/D ratio than CYP3A5 expressers. CYP3A5 expressers required 
larger doses during the late induction and the maintained phases to reach the target 
trough concentration (Chen et al., 2014). 
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Despite that the CYP3A5*3 genotype effect on tacrolimus dose and dose-adjusted 
concentration may differ from that obtained from kidney transplant patients. The reason 
for this is that the CYP3A5 genotype of the grafted liver in some cases may differ from 
the CYP3A5 genotype of the recipient intestine with the consequences of the relative 
effect of the donor and recipient genotypes on tacrolimus disposition and when it 
appears post transplantation.  
In all studies where the donor and recipient genotypes are different, the donors' CYP3A5 
gene polymorphisms significantly influence tacrolimus dose and dose-adjusted C0 and 
its effect can be found very early from the first week after transplantation or can begin 
later after transplantation. The recipient genotype effect on tacrolimus dose and dose-
adjusted C0 appears only in some of these studies. Ji et al. (2012) studied 58 Korean 
adult liver transplant recipients on tacrolimus-based immunosuppression therapy for 4 
years of follow-up and reported that throughout the entire study period, CYP3A5 
expresser recipients grafted from CYP3A5 expresser donors consistently had the least 
concentration/dose (C/D) ratio. Whereas CYP3A5 expressed recipients grafted from 
CYP3A5 non-expresser donors had an intermediate C/D ratio, and CYP3A5 non-
expresser recipients grafted from CYP3A5 non-expresser donors had the largest C/D 
ratio. Another study again showed that CYP3A5 non-expresser recipients who received 
organs from CYP3A5*1 allele carriers have a significantly lower C/D ratio than those 
who received organs from CYP3A5*3/*3 carriers over 6 months. CYP3A5 expresser 
recipients who received organs from CYP3A5*3/*3 carriers have a significantly lower 
C/D ratio than CYP3A5 non-expresser recipients who received organs from 
CYP3A5*3/*3 carriers from 2 weeks through 6 months (Muraki et al., 2011). A 
retrospective study in 70 Chinese liver transplant recipients and donors during the first 
three weeks after transplantation found a strong association between tacrolimus C/D 
ratio and  CYP3A5*3 variant in donors from the first week post-transplant. Tacrolimus 
C/D ratio was significantly lower in patients engrafted with CYP3A5*1 carrier liver than 
those engrafted with CYP3A5*3/*3 genotype liver (Li et al., 2007). In a study on 50 
Chinese liver transplant patients, Wei-lin et al. (2006) reported that at 2 weeks and at 
one month after transplantation, patients receiving CYP3A5*1 allele–carrying livers had 
a higher tacrolimus daily dose or lower tacrolimus C/D ratios compared with patients 
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receiving the CYP3A5*3/*3 genotype livers. A study in 60 de novo Japanese liver 
transplant recipients early after transplantation found that the CYP3A5*1 allele in both 
donors and recipients had a significant effect on tacrolimus dose and C/D on day 7 
posttransplant. After the first month, the CYP3A5*1 allele in donors, but not in 
recipients had a significant effect on tacrolimus dose and C/ D ratio. Moreover, patients 
having  the CYP3A5*3/*3 allele in their native intestine and in the graft liver, showed a 
1.47 times lower tacrolimus oral clearance (CL/F) recovery with time compared with 
patients carrying at least one CYP3A5*1 allele in their native intestine (Fukudo et al., 
2008). In another study involving 51 Caucasian liver transplant recipients confirmed 
that tacrolimus dose requirements were dominantly influenced by the donors’ CYP3A5 
gene polymorphisms. At 1, 3 and 6 months post transplantation, patients receiving a 
liver with at least one copy of CYP3A5*1 allele had a  significantly higher tacrolimus 
dose to reach the target trough concentrations compared to the patients receiving a liver 





Pharmacokinetics and Pharmacogenomics of Tacrolimus 
Page 87 of 377 
Table 3: Pharmacogenetic Studies of Tacrolimus in Kidney Transplant Recipients 
Study 












South Asian  
Middle Eastern 
178 2 Weeks Patients with a CYP3A5*1 allele had 2-fold lower dose-
normalized tacrolimus concentrations than 








64 12 Months CYP3A5*1 allele carriers require higher tacrolimus dose 
to reach target trough concentrations than patients with 
the CYP3A5*3/*3 genotype 
(Thervet et al., 
2003) 
adult Caucasian 80 1 Month The weight-adjusted tacrolimus dose was significantly 
lower in patients with the CYP3A5*3/*3 genotype than 
in those with the CYP3A5*1/*1 genotype  
CYP3A5*1 allele  carriers showed a significantly lower 
C0 /D ratio compared to CYP3A5 non-expressers 
(Tsuchiya et al., 
2004) 
adult Japanese 30 28 Days The dose-adjusted Cmax, AUC0-12 and C0 in CYP3A5*1 
carriers had a significantly lower value than the 
CYP3A5*3/*3 carriers, though the daily dose of 
tacrolimus was significantly higher 






180 3 Months CYP3A5 expressers require two fold higher doses of 
tacrolimus to achieve target blood concentration than 
non-expressers 
Pharmacokinetics and Pharmacogenomics of Tacrolimus 
Page 88 of 377 
(Zhao et al., 
2005) 
adult Chinese 30 3, 6, 12 Months Patients with the CYP3A5*1/*3 required more 
tacrolimus to achieve the same target blood 
concentrations than those with the CYP3A5*3/*3 
(Tada et al., 
2005) 
adult Japanese 39 28 Day Recipients who were CYP3A5*1 carriers had a 
significantly lower tacrolimus dose-adjusted AUC0-12 
and required a higher tacrolimus dose than 
CYP3A5*3/*3 carriers 
(Zhang et al., 
2005) 
adult Chinese 118 1 Week; 
1 , 3 Months 
CYP3A5 expressers had a 2.2–4.3 times higher 
tacrolimus dose-adjusted C0 than the CYP3A5 non-
expressers.   
Patients with CYP3A5*1*1 genotype had the lowest 
dose-adjusted C0 compared to CYP3A5*3/*3 carriers 





44 3 Months CYP3A5 expressers required a higher daily tacrolimus 
dose compared to non-expressers and achieved lower 
tacrolimus dose-adjusted trough blood concentrations 
compared to CYP3A5*3/*3 allele carriers.  
(Ferraresso et 
al., 2007) 
paediatric Caucasian 30 12 Months  Patients with CYP3A5*1/*3 genotype required almost 
twice the daily dose of tacrolimus to achieve the target 
blood trough concentration and had lower tacrolimus 
trough blood concentrations than those with CYP3A5 
*3/*3 genotype 





136 1 Week; 
1, 6, 12 Months 
Patients possessing at least one CYP3A5*1 allele 
(CYP3A5 expressers) needed significantly higher 
tacrolimus doses to achieve the same target trough 
concentration compared to patients with CYP3A5*3/*3 
genotype 
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(Lopez-
Montenegro 
Soria et al., 
2010) 
adult Spanish 35 6 Weeks Patients with the heterozygote CYP3A5*1/*3  genotype 
showed a lower tacrolimus concentration/dose ratios 
compared to the homozygote CYP3A5*3/*3 genotype 
patients and required higher tacrolimus doses to achieve 





209 2 Weeks; 
1, 3, 12 Months 
Patients with at least one CYP3A5*1 allele had 
significantly higher dose requirements and lower blood 
C0 and C0/daily dose ratio than patients homozygous for 
the *3 allele 
(Provenzani et 
al., 2011) 
adult Caucasian 50 1, 3, 6 Months The tacrolimus dose required to reach and maintain the 
desired trough concentrations was lower in the patients 
homozygous for CYP3A5*3 allele compared to the 
heterozygous patients 
(Ferraris et al., 
2011) 
paediatric Caucasian 48 12 Months Tacrolimus dose requirement was more than twofold 
higher in CYP3A5*1/*3 than in CYP3A5*3/*3 patients.                          
CYP3A5*3/*3 patients displayed higher C0 and dose-









291 6 Months Both homozygous CYP3A5*1/*1 and heterozygous 
CYP3A5*1*3 expressers required higher tacrolimus 
doses than non-expressers CYP3A5*3/*3.  
No significant difference in tacrolimus dose was 
observed when comparing children with adults. 
(Chen et al., 
2013) 
adult Chinese 120 2 Week; 
6, 18 Months 
CYP3A5 expressers required significantly more 
tacrolimus than non-expressers to reach a comparable 
C0 concentration. Although no significant difference in 
dose-adjusted C0 , Cmax, and AUC0–12h t was observed 
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(Vannaprasaht 
et al., 2013) 
adult Asian 68 6 Months The induction dose of tacrolimus required for patients 
with CYP3A5*1/*1 was 1.46- and 1.84-fold greater than 
that required in the CYP3A5*1/*3 and in the 
CYP3A5*3/*3 patients. 
The tacrolimus dose required for the maintenance phase 
was 1.3-fold higher than that in the CYP3A5*1/*3 
genotype and 2.4-fold higher than in the CYP3A5*3/*3 
genotype 
(Li et al., 2014) adult Chinese 240 40 Days Tacrolimus C0/D of the patients with CYP3A5*3/*3 was 
highest among the different CYP3A5*1 allele genotype 
groups  





108 12 Months The presence of the CYP3A5*1 allele was strongly 
associated with lower dose-normalized concentration                                   
CYP3A5*1 carriers and required a higher tacrolimus 
dose than CYP3A5 non-expressers 
(Lunde et al., 
2014) 
adult Caucasian 177 2, 7 Weeks Heterozygous CYP3A5*1 recipients had 42 % lower 
mean C0/D ratio compared with homozygote carriers of 
CYP3A5*3 






298 12 Months Tacrolimus dose requirements were significantly higher 
in recipients carrying at least one CYP3A5*1 allele as 
compared with homozygous CYP3A5*3/*3 patients 
(Xing et al., 
2015) 
adult Chinese 96 1 Month Patients carrying at least one the CYP3A5*1 allele  
showed a significantly lower C0/D ratio compared to 
CYP3A5 non-expressers 
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CYP3A5 could be useful to predict the optimal tacrolimus dose prior to transplantation 
for rapid achievement of therapeutic tacrolimus concentrations. This was illustrated in a 
clinical trial by Thervet et al. (2008) who found that tacrolimus dosing based on the 
CYP3A5 genotype allows earlier attainment of target blood concentrations. A 
randomized controlled study showed that kidney transplant recipients using tacrolimus 
doses according to the CYP3A5 genotype reached the target C0 significantly earlier than 
recipients used a standard regimen. Although more patients were within the desired 
tacrolimus target range early after transplantation, the improvement was modest with 
29% of patients in target on the third day of tacrolimus dosing in the control group and 
43% in the genetically adjusted group (Thervet et al., 2010). The study did not have 
sufficient statistical power to address clinically significant markers of efficacy failure 
and toxicity. 
Twice daily tacrolimus, Prograf® (TD-Tac) and once a day tacrolimus (OD-Tac), 
Advagraf® have different dissolution properties. The prolonged release formulation of 
tacrolimus, Advagraf® is typically released further along the gastrointestinal tract. The 
immediate release formulation of tacrolimus, Prograf® is absorbed primarily in the 
jejunum and duodenum. The CYP3A protein expression may be higher in the jejunum 
than ileum. Consequently, CYP3A5 expression in the gastrointestinal tract may have 
less effect on the pharmacokinetics of OD-Tac than TD-Tac among both switching and 
de novo transplant patients (MacPhee, 2012). 
Black subjects have a higher prevalence of CYP3A5 expression in comparison to 
individuals from other ethnic groups. In the Phase III study comparing Advagraf® to 
Prograf®, black subjects achieved approximately 70% of the trough blood concentration 
achieved by Caucasians for a given dose of both the Prograf® and Advagraf® 
preparations (Silva et al., 2007).  
To date, few studies have focused on the impact of CYP3A5 polymorphisms on the 
pharmacokinetics of conversion from twice- to once- daily tacrolimus formulations in 
renal transplant recipients. For the first time, Wehland et al. (2011) studied the 
pharmacogenetic effect of CYP3A5*3 on two different tacrolimus formulations in a 
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cohort of 41 renal transplant patients over a period of 1 year before and after 
conversion. They reported that after conversion from Prograf® to Advagraf®, patients 
with CYP3A5*3/*3 genotype required significantly lower tacrolimus doses to reach the 
target trough concentrations compared with patients with *1/*3 genotype in both 
formulations. Tacrolimus trough and dose-normalized trough concentrations of *3/*3 
patients declined significantly after conversion to identical Advagraf® doses. However, 
they remained almost constant in *1/*3 patients. Conversely, a prospective single-centre 
study in stable kidney transplant recipients reported that the daily tacrolimus dose was 
significantly higher and the dose-adjusted AUC0-24 was significantly lower in the 
CYP3A5 expressers for both Prograf® and Advagraf®. Additionally, the tacrolimus 
dose-adjusted AUC0-24 and C0 decreased significantly after the switch from TD-Tac to 
OD-Tac in CYP3A5 expressers (Glowacki et al., 2011b). 
 Again for the first time, Niioka et al. (2012) conducted a study in de-novo Japanese 
kidney transplant patients to investigate the pharmacokinetic and pharmacogenetic 
differences between once a day (OD-Tac) and twice-daily (TD-Tac) tacrolimus 
formulations. Twenty five patients received Tac-OD and 75 patients received TD-Tac. 
The authors found that despite no difference in the dose-adjusted AUC0-24 and C0 
between the two formulations, CYP3A5 expressers had lower dose-adjusted AUC0-24 
and C0 compared to non-expressers for each formulation. Among CYP3A5 expressers, 
but not non-expressers, the dose-adjusted AUC0-24 and C0 values were lower for OD-Tac 
than for TD-Tac. Another study in 34 Korean stable paediatric kidney transplant 
recipients showed that conversion from TD-Tac to OD-Tac did not affect the mean C0 
and AUC0–24 in patients carrying CYP3A5*1 allele but patients with CYP3A5*3/*3 had a 
significantly lower C0, Cmax and AUC0–24 after conversion (Min et al., 2013). Finally, a 
more recent study in paediatric kidney transplant recipients demonstrated that in 
CYP3A5 non-expressers dose normalized C0 levels were higher compared to CYP3A5 
expressers with TD-Tac, but not with OD-Tac (Lapeyraque et al., 2014). Further 
investigations into this controversial influence of CYP3A5 polymorphisms during 
formulation switching are required. 
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3.2.1.2 CYP3A4 
CYP3A4 is the most abundant cytochrome P450 expressed in the liver and the intestine. 
It accounts for approximately 60% of the total hepatic cytochrome P450 content. 
CYP3A4 is the most important drug-metabolizing cytochrome P450 enzyme in humans, 
it is involved in the metabolism of 45–60% of all currently used drugs (Danielson, 
2002). CYP3A4 activity and protein content vary widely in the population, with a 10–
100-fold between-individual variability. Most of the CYP3A4 polymorphisms have 
very low frequencies, and the phenotypic effects are weak and often controversial. 
Currently known genetic variants of CYP3A4 that change amino acids are rare and 
therefore can only explain a small portion of the observed variability (Elens et al., 
2012). The most common CYP3A4 polymorphism is CYP3A4*1B. The frequency of 
CYP3A4*1B allele is 2%-10% of Caucasians, 4.2%-11% of Hispanics, 35%-67% of 
African-Americans, and about 0% of Asians (Chinese, Taiwanese and Japanese). The 
functional significance of this SNP is debatable and generally in-vivo studies are unable 
to prove an association between this polymorphism and the transformation of various 
drugs (Provenzani et al., 2013). Extrahepatic metabolism of tacrolimus by CYP3A4 in 
the gastrointestinal epithelium is responsible for the presystemic elimination of about 
half of the absorbed dose, whereas first-pass metabolism by CYP3A4 in the liver 
accounts for an additional 10% of elimination (Undre, 2003). Up to recently only one 
study has shown an association between the CYP3A4*1B allele and the required 
tacrolimus dose. It reported that dose-adjusted tacrolimus trough levels were lower in 
patients with the CYP3A4*1B allele than those with the CYP3A4*1/*1 genotype (wild-
type), however, this effect was not observed when the analysis was made only in the 
Caucasian population (Hesselink et al., 2003). A more recent study confirmed the 
relationship between CYP3A4*1/*1B genotype and tacrolimus dose-adjusted trough 
concentration. Among CYP3A5 non-expressers, a significant decrease in dose 
normalized tacrolimus concentrations was observed in CYP3A4*1B allele carriers 
compared to CYP3A4*1*1 carriers at 6 months post-transplantation. However, in 
CYP3A5 expressers, the difference was not statistically significant. Therefore, 
CYP3A4*1B allele appears to be responsible for the decrease in dose normalized 
tacrolimus concentrations although the numbers were very small (Tavira et al., 2013).  
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The phenotypic significance of a recently identified SNP located in CYP3A4 intron 6 
(rs35599367 C > T) is much more certain. The T-variant allele was linked both to 
reduced hepatic CYP3A4 mRNA expression and with decreased CYP3A4 enzymatic 
activity. This so-called CYP3A4*22 allele also proved to have clinical implications, as it 
associated with the statin dose requirement for optimal plasma lipid control. mRNA 
levels in livers were 1.7-fold higher in CYP3A4*22 wild-type CC; CYP3A4*1/*1 than in 
CYP3A4*22 (CT or TT) variant allele carriers (Wang et al., 2011). The CYP3A4*22 
allele is responsible for 7% of the variability in CYP3A4 mRNA expression (Elens et 
al., 2013b). This CYP3A4 SNP is relatively infrequent in Caucasians, 2.5%-6.9%. 
CYP3A4*22 genotyping is classified into three groups CC, CT and TT genotypes that 
show high, moderate and low CYP3A4 expression activity, respectively (Elens et al., 
2012, Wang et al., 2011).  
A number of clinical studies have been designed to estimate the influence of this 
CYP3A4 SNP on tacrolimus clearance and dose requirement. An initial study by Elens 
et al. (2011b) revealed that the CYP3A4 rs35599367C>T polymorphism is correlated 
with a significantly altered tacrolimus metabolism. The dose-adjusted concentration in 
the intermediate metabolizer group was about 1.5- fold higher than the poor metabolizer 
group. While in extensive metabolizer group it was 4.4-fold higher for tacrolimus than 
the poor metabolizer group. When the CYP3A4*22 and CYP3A5*3 genotypes were 
combined, the results were more pronounced. In a second study, the same group 
demonstrated that early after transplantation, CYP3A4*22 genotype is associated with 
tacrolimus metabolism alteration and lower tacrolimus dose requirements. T allele 
carriers require 33% lower tacrolimus doses than wild-type CC carriers to reach the 
target C0 (Elens et al., 2011a). On the other hand, Tavira et al. (2013) found no 
significant differences in tacrolimus daily dose between the CYP3A4*22 genotypes, 
either nominally or according to the CYP3A5 genotype. Another study in 140 Brazilian 
renal transplant recipients, evaluated the impact of CYP3A4 and CYP3A5 SNPs and 
haematocrit on tacrolimus C0/dose. There was no association between CYP3A4*22 and 
tacrolimus dose requirement at 3 months after transplantation (Santoro et al., 2013). A 
study of paediatric heart transplant patients reported that CYP3A4*22 SNP is linked to 
the changes in dose requirement of tacrolimus in the first 2 weeks following 
Pharmacokinetics and Pharmacogenomics of Tacrolimus 
Page 95 of 377 
transplantation. However, tacrolimus trough concentration (C0) and C0/dose ratio didn’t 
change. CYP3A combined genotypes have a strong correlation with tacrolimus 
disposition. During the follow-up period, CYP3A poor metabolizers required 
approximately 20% and 50% less tacrolimus dose than intermediate and extensive 
metabolizers, respectively (Gijsen et al., 2013). Another study showed that steady-state 
oral clearance of tacrolimus was reduced in CYP3A4*22 T-allele carriers compared with 
CC carriers, resulting in 50% lower tacrolimus daily dose requirements (de Jonge et al., 
2014). It was confirmed that CYP3A4*22 allele has a significant impact on tacrolimus 
pharmacokinetics by altering dose-adjusted blood concentrations of tacrolimus in renal 
transplant patients (Kurzawski et al., 2014). Pallet et al. (2015) in a brief 
communication reported that CYP3A4*22 polymorphism is related to a slower 
metabolism of tacrolimus and a higher systemic exposure early after transplantation. 
Patients carrying CYP3A4*22 variant may require 30% less tacrolimus dose than 
patients with the CYP3A4 *1/*1 genotype. They also revealed that CYP3A4*22 allele 
was predominantly found in CYP3A5 non-expressers and suggested that combining 
CYP3A4 and CYP3A5 genotypes might result in a better prediction of the optimal 
tacrolimus starting dose. However, a study by Lunde et al. (2014) found no association 
between CYP3A4*22 polymorphism and tacrolimus C0/D ratios. Furthermore, CYP3A 
combined allelic status did not give any additional information. Another study of 298 
de-novo renal transplant recipient demonstrated that the dose requirements of tacrolimus 
were significantly lower in CYP3A5 non-expressers carrying at least one CYP3A4*22 
allele (slow metabolizers) compared with homozygous CYP3A4*1/*1 CYP3A5 non-
expressers (Kuypers et al., 2014). Moreover, Bruckmueller et al. (2014) reported that 
CYP3A extensive metabolizers (CYP3A5 expressers combined with CYP3A4*1/*1) 
required 2.1-fold higher doses than intermediate CYP3A metabolizers (CYP3A5*3/*3 
combined with CYP3A4*1/*1) or 2.7-fold higher doses than CYP3A poor metabolizers 
(CYP3A5*3/*3 combined with CYP3A4*1/*22 or *22/*22). 
3.2.1.3 POR*28 
P450 oxidoreductase (POR) is essential for cytochrome P450 activity in humans. It 
transfers electrons from NADPH to microsomal cytochrome P450 enzymes, enabling 
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their activity and has been associated with increased in vivo CYP3A activity (de Jonge 
et al., 2011). POR mutations could alter the distribution of charge in the electron-
donating domain, which might have quite different effects on the interaction of POR 
with different P450 enzymes (Flück et al., 2007). Consequently, POR might be a 
general limiting factor for drug metabolizing capacity. The POR*28 (rs1057868C>T) 
mutation was the most common allelic variant on approximately 28% of all alleles.  
POR*28 Genotype is classified into three allelic categories with high, moderate and low 
POR protein production, that are represented as TT, CT and CC, respectively (Zhang et 
al., 2013). POR*28T allele is also referred to as POR*28 and POR*28CC allele is also 
known as POR*1/*1 (Gijsen et al., 2014). POR*28 SNP varies in frequency:19.1 % in 
African Americans, 26.4 % in Caucasian Americans, 36.7 % in Chinese Americans, and 
31.0 % in Mexican Americans (de Jonge et al., 2011). In vitro studies showed that the 
POR*28 C>T mutation affected CYP3A4 activity and the impact of this variant on 
catalysis by CYP3A4 was substrate-specific (Agrawal et al., 2010). Up to date, very few 
studies were carried out to explore the influence of genetic variations in the POR gene 
on tacrolimus metabolism. A study in healthy Chinese volunteers reported that no 
significant difference in tacrolimus pharmacokinetics was observed between POR*28 
CC and POR*28 CT/TT genotypes. However, the POR*28 CT genotype had a 
significantly lower level of tacrolimus exposure (AUC, Cmax) compared to the POR*28 
CC genotype in CYP3A5-expressing subjects (Zhang et al., 2013). Another study in 298 
adult renal transplant recipients showed that POR*28T allele carriers had significantly 
higher tacrolimus dosing requirements compared with POR*28CC homozygous 
patients. Additionally, the POR*28 SNP is associated with significant increases in early 
tacrolimus dose-requirements in patients carrying a CYP3A5*1 allele (CYP3A5 
expressers) and did not affect tacrolimus trough blood concentrations and daily dose 
requirements in CYP3A5 non-expressers (de Jonge et al., 2011). A retrospective 
observational study in 52 heart transplant patients during the first year after 
transplantation found that the POR*28 variant carriers had higher dose-adjusted trough 
concentrations with significant differences at 3 and 6 months after transplantation 
(Lesche et al., 2014). Another retrospective pilot study in 43 paediatric kidney 
transplant recipients in the first two weeks post-transplantation demonstrated that 
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CYP3A5 expressers carrying at least one POR*28 allele had lower tacrolimus trough 
concentrations and lower concentration/dose ratios compared with CYP3A5 expressers 
with POR*1/*1 genotype. In CYP3A5 non-expressers, tacrolimus disposition did not 
significantly change between POR genotypes. They also observed no significant 
differences in the tacrolimus dosing requirements between the POR genotype groups, 
neither in the CYP3A5 expressers nor in the CYP3A5 non-expressers (Gijsen et al., 
2014). In a cohort of 298 de-novo renal transplant recipients, Kuypers et al. (2014) 
demonstrated that the CYP3A5 expressers with at least one variant POR*28 T allele 
(high metabolizers) had a significantly higher tacrolimus dose requirements than 
POR*28 CC homozygous patients, to maintain tacrolimus target C0. This was from day 
2 onward and continued throughout the first year after transplantation.  
3.2.2 PXR 
Pregnane X receptor (PXR), also known as steroid X receptor (SXR) or nuclear receptor 
subfamily 1, group I, member 2 (NR1I2) is a protein encoded by the NR1I2 gene. It is 
highly expressed in the liver and the intestine. A variety of endogenous ligands such as 
steroids and bile acid salts, and exogenous ligands including drugs activate PXR, which 
alters their metabolism and regulates CYP450 and the ABCB1 gene expression (di Masi 
et al., 2009). The most frequent PXR polymorphisms are -25385C>T (rs 3814055) and 
7635A > G (rs 6785049) single nucleotide polymorphisms.  A study in 32 renal 
transplant recipients showed that PXR −25385C>T single nucleotide polymorphism was 
identified as a significant covariate for apparent oral clearance of tacrolimus. However, 
it was not clinically relevant in estimating the individual pharmacokinetic parameters of 
tacrolimus (Benkali et al., 2009). Moreover, Miura et al. (2008) reported that 
PXR  7635A>G SNP had no effect on tacrolimus pharmacokinetics, but was strongly 
associated with prednisolone pharmacokinetics. Conversely, a study in 31 de-novo renal 
transplant recipients reported an increase in tacrolimus clearance in subjects with the 
PXR 7635GG genotype (Press et al., 2009). An observational study in 35 renal 
transplant recipients found no effect of PXR −25385C>T polymorphisms on tacrolimus 
concentration/ dose ratio between heterozygote and homozygote genotypes (Lopez-
Montenegro Soria et al., 2010). The clinical relevance of the influence of PXR receptor 
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genetic variants on tacrolimus metabolism is still unclear, especially immediately after 
transplantation where high doses of steroids are used. 
3.2.3 ABCB1 
P-glycoprotein (PGP) (1280 amino acids) is an efflux ‘pump’ that transports substances 
from the intracellular to the extracellular side of the cell membrane. It is a member of 
adenosine triphosphate (ATP)-binding cassette family of transport proteins (ABC 
transporters). The energy required for PGP to function is derived from its binding with 
ATP. The human gene encoding PGP is known as the ABCB1gene, previously known as 
MDR1 (multidrug resistance protein 1). It is highly expressed in the apical membrane of 
enterocytes lining the gastrointestinal tract, renal proximal tubular cells, the canalicular 
membrane of hepatocytes and other important blood-tissue barriers such as those of the 
brain, testes and placenta (Flanagan et al., 2007). The most commonly studied ABCB1 
SNP is the 3435C>T polymorphism with a C to T substitution at position 3435 on exon 
26 (rs1045642). According to P-gp expression, ABCB1 genotyping is classified into 
three groups CC, CT and TT genotypes that show high, moderate and low P-gp 
expression activity, respectively (Li et al., 2006b). Consequently, The ABCB1 CC 
genotype is associated with a higher P-gp function compared with the CT and TT 
genotypes. The homozygous T-allele had more than 2-fold lower MDR-1 expression 
levels compared with homozygous CC genotype. The gastrointestinal absorption of P-
gp substrates is inversely proportional to the P-gp expression level in the gut 
(Hoffmeyer et al., 2000). The variation in the oral bioavailability of tacrolimus is 
primarily caused by heterogeneity in the level of intestinal P-gp expression (MacPhee et 
al., 2002).  However, this relationship is not confirmed in some studies (Tsuchiya et al., 
2004, Haufroid et al., 2004). The frequency of ABCB1 3435 T allele occurs in 5% of 
African-Americans, 27% of Asians, 32% of Caucasians and 35% of Mexicans 
(Provenzani et al., 2013).   
Some studies have reported a correlation between ABCB1 3435 polymorphism and 
tacrolimus pharmacokinetics. Originally, MacPhee et al. (2002) in a study including 180 
kidney transplant recipients found a significant association between the ABCB1 3435 
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polymorphisms and tacrolimus blood concentration at 3 months after transplantation. A 
study by Zheng et al. (2003) studied tacrolimus pharmacokinetics in relation to ABCB1 
3435 polymorphisms in 65 pediatric heart transplant patients and found a significant 
association between the ABCB1 polymorphisms and tacrolimus dose, showing that CC 
recipients require a higher dose than the CT/TT patients at 6 and 12 months after heart 
transplantation (Zheng et al., 2003). Another study in 50 Chinese liver transplant 
patients investigating the relationship between ABCB1 SNP and the tacrolimus daily 
dose and C/D ratio demonstrated that during the first month after transplantation, 
recipients carrying ABCB1 T allele had a lower tacrolimus daily dose and higher C/D 
ratios than among 3435CC recipients (Wei-lin et al., 2006). An observational study in 
35 Spanish renal transplant recipients found a significant association between the 
ABCB1 3435 T allele and higher concentration/dose ratios of tacrolimus. CC genotype 
carriers showed up to 40% lower concentration/dose ratios compared with T variant 
allele carriers, suggesting that lower tacrolimus doses may be required  for the T-allele 
carriers compared to C/C homozygotes (Lopez-Montenegro Soria et al., 2010). A study 
including 62 Han Chinese liver transplant recipients showed that Patients with 
ABCB1C/C homozygotes had significantly lower C/D ratios compared with ABCB1 
CT/TT variant carriers and required a little higher tacrolimus dose compared to those 
with C/T and T/T genotypes (Yu et al., 2011). 
Most studies have failed to find any association between ABCB1 genotype and 
tacrolimus pharmacokinetics. A study in 30 Japanese renal transplant recipients showed 
no significant difference in the tacrolimus dose, the dose-adjusted trough concentration, 
Cmax, and AUC0–12 between the ABCB1CC and CT/TT genotypes (Tsuchiya et al., 
2004). In a study on 100 Caucasian renal transplant patients, Haufroid et al. (2004) 
found no significant association between tacrolimus dose-adjusted trough blood 
concentration or dose requirement and ABCB1 genotype. Another study in 118 Chinese 
renal transplant patients reported no obvious correlation between ABCB1 C3435T 
polymorphisms and tacrolimus dose-adjusted C0 from 1 week to 3 months after 
transplant (Zhang et al, 2005). Another study in Japanese renal transplant patients was 
carried out to investigate the influence of the ABCB1 C3435T mutation on tacrolimus 
pharmacokinetics between CYP3A5 expressers and non-expressers. They found no 
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association between the ABCB1 C3435T polymorphisms and tacrolimus 
pharmacokinetic parameter in either group (Tada et al., 2005). Moreover, Quteineh et 
al. (2008) in a study on 136 renal transplant recipients demonstrated that ABCB1 
polymorphisms did not have a significant association with tacrolimus daily dose and 
concentration/dose ratio. A Korean study in 321 livers and 185 kidney transplant 
patients demonstrated that ABCB1 genotype had no correlation with tacrolimus 
concentration to adjusted-dose ratios in both liver and kidney transplant recipients (Jun 
et al., 2009). Gijsen et al. (2011) also demonstrated that, in 30 Canadian paediatric heart 
transplant patients, none of the ABCB1 3435C>T genotypes were associated with 
tacrolimus dosing requirements, tacrolimus trough concentrations, or concentration/dose 
ratio. This was supported by Provenzani et al. (2011) in a study on 51 liver and 50 
kidney transplant Caucasian recipients and they found that during the first 6 months 
after transplantation, the ABCB1 C3435>T polymorphism had no effect on the dosage 
or the level / dose ratio. A retrospective study in 68 kidney transplant recipients also 
confirmed that no statistically significant correlation was noticed between the 
tacrolimus doses required for the induction and maintenance phases and ABCB1 
polymorphism (Vannaprasaht et al., 2013). A Chinese study in 216 liver transplant 
recipients confirmed these results and showed no obvious correlation of ABCB1 
polymorphisms with tacrolimus dose-adjusted C0 and daily dose after transplant (Shi et 
al., 2013). Another retrospective study involving 90 paediatric de novo liver graft 
recipients also evidenced that the variants of ABCB1 has minimal impact on tacrolimus 
disposition. They found no significant difference of the C/D ratios among the recipients 
with ABCB1 polymorphisms (Chen et al., 2014). Further supporting these results, 
Lapeyraque et al. (2014) found no association between the concentration/dose ratio and 
ABCB1 genotypes for either tacrolimus formulations (Prograf® and Advagraf®) in 19 
stable paediatric renal transplant recipients. 
Some other studies have reported the same outcome when combined between ABCB1 
variants and CYP3A5 genotypes. MacPhee et al. (2002) reported that a minor 
association was found in the ABCB1 allele variants on tacrolimus trough concentrations 
in CYP3A5 non-expressers. A Japanese study involving 39 kidney transplant recipients 
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showed that the ABCB1 CC and the CT/TT genotype subgroups had no significant 
differences in tacrolimus bioavailability in both CYP3A5*1/*1+*1/*3  and 
CYP3A5*3/*3 genotype groups (Tada et al., 2005). Furthermore, Loh et al. (2008), in a 
study on 18 Asian renal transplant recipients, found that upon evaluating the 2 
genotypes for CYP3A5 and ABCB1 in combination, significant differences in tacrolimus 
Concentration/Dose ratios for the various groups reflected mainly the CYP3A5 
polymorphism. A French study in 136 renal transplant recipients investigating the 
combined effect of CYP3A5 and ABCB1 polymorphisms on tacrolimus daily dose and 
concentration/dose ratio showed that the significant effect of CYP3A5 on tacrolimus 
daily requirements was not modified by the allelic variants of ABCB1 3435C>T 
polymorphisms (Quteineh et al., 2008). Another study in 63 Chinese renal transplant 
recipients was made by Rong et al. (2010) to investigate the influence of the ABCB1 
3435C>T polymorphism on tacrolimus pharmacokinetics between CYP3A5*1 carriers 
vs CYP3A5*3/*3 carriers. They concluded that no obvious influence on tacrolimus 
pharmacokinetics was observed between ABCB1 CC and CT/TT genotype subgroups in 
both CYP3A5 expressers and non-expressers. In summary, a minor influence of the 
ABCB1 3435C>T genotype on tacrolimus pharmacokinetics has been identified in 
studies with sufficient statistical power that has not been detected in smaller studies. 
3.3 Prednisolone Influence on Tacrolimus Pharmacokinetics 
Corticosteroids are an important component of clinical immunosuppressive therapy 
during induction and maintenance of immunosuppression. Corticosteroids are also very 
effective when used at high doses to treat episodes of acute rejection. Prednisolone, a 
synthetic corticosteroid, is widely used immunosuppressive agent and is commonly 
used to treat and prevent acute rejection after organ transplantation. Prednisolone 
mechanism of action involves the inhibition of neutrophil, leukocyte and monocyte-
macrophage accumulation at the site of inflammation. Prednisolone suppresses cell-
mediated immunity through inhibiting genes that code for the cytokines, especially IL-
2, which help T lymphocyte proliferation. Furthermore, prednisolone suppresses 
humoral immunity, causing B lymphocytes to express smaller amounts of IL-2 and IL-2 
receptors. This diminishes both B lymphocyte clone expansion and antibody synthesis 
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(Taylor et al., 2005). Treatment with prednisolone for a long time is associated with 
well documented complications which include hypertension, diabetes mellitus, 
cataracts, osteoporosis, hyperlipidemia, weight gain and infections. Corticosteroid-
avoidance or minimization is gaining popularity as the corticosteroid long term adverse 
effects can lead to transplant loss related to cardiovascular mortality and/or fatal 
infectious complications. The progressive improving potency of the other 
immunosuppressive drugs also helps to achieve corticosteroid-free immunosuppression. 
Although corticosteroid-free regimens have many advantages including lower rates of 
hypertension, diabetes mellitus and hyperlipidemia after transplantation, the rate of 
acute rejection remains lower in patients receiving corticosteroid-containing regimens 
(Abboudi and Macphee, 2012). 
CYP3A and P-gp are involved in the metabolism of both tacrolimus and steroids. 
Steroids are a well-known inducer of both CYP3A and P-glycoprotein activity. In an in-
vitro study investigating tacrolimus metabolism in liver microsomes prepared from 
normal rats and rats treated with dexamethasone showed that the rate of tacrolimus 
metabolism significantly increased in microsomes obtained from dexamethasone treated 
rats (Prasad et al., 1997). A study on animals showed that high dose steroid therapy in 
rats reduces tacrolimus blood concentrations due to the induction of CYP3A and P-gp in 
the liver and intestine (Shimada et al., 2002). Another study in renal transplant patients 
reported that the higher the steroid dosage used, the higher the tacrolimus dosage 
required to achieve target trough blood concentrations in these patients. The interaction 
also occurs even with low steroid dosage (Anglicheau et al., 2003a). Another study in 
kidney transplant recipients comparing the tacrolimus trough concentration and dose 
before and after prednisolone withdrawal found that withdrawal of steroids results in an 
increased systemic exposure to tacrolimus. The increase in systemic exposure to 
tacrolimus following 10 mg prednisolone withdrawal was higher (33-36%) than the 
increase after 5 mg prednisolone withdrawal (12-14%). This increase is only observed 
in AUC and is not associated with an increase in either Cmax or tmax indicating that the 
processes of absorption remain unaffected so P-gp role seems less likely. It also 
indicates that the increase in tacrolimus exposure following steroid withdrawal is due to 
the reduction in the metabolic clearance as CYP3A4 induction by steroid wears off (van 
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Duijnhoven et al., 2003). Furthermore, Park et al. (2009) found an inverse correlation 
between prednisolone daily dose and tacrolimus exposures. Prednisolone dose reduction 
was associated with an increase in tacrolimus drug exposures. A recent study in 30 
Serbian renal transplant patients demonstrated that during the first 6 months after 
transplantation, corticosteroid dose significantly influenced tacrolimus blood 
concentration. Corticosteroid tacrolimus interaction has more effect on male than 
female patients (Velickovic-Radovanovic et al., 2012). 
3.4 Tacrolimus Within-Patient Variability 
Tacrolimus is characterized by wide pharmacokinetics variation between individuals. 
To some extent, this variability is influenced by genetic and non-genetic factors and has 
been widely studied. In contrast to the between -patient variability, the within-patient 
variability is defined as fluctuating trough concentrations of a drug in a given period of 
time during which drug dosage was unchanged (Prytula et al., 2012).  
Ekberg et al. (2009) demonstrated that approximately 50% of patients on low-dose 
tacrolimus (6 mg/day) were within the target range and this proportion increased over 
time during the first year after transplantation. Individual patients’ analysis showed that 
only 11% of the patients were consistently within target range at all times during the 
first 2 months after transplantation. The within-patient coefficient of variation (CV) was 
28% suggesting that the major reason for the difficulty to achieve and keep tacrolimus 
target concentrations is presumably the great within -individual variation of tacrolimus 
blood concentrations. Consequently, therapeutic drug monitoring (TDM) is used 
routinely to direct tacrolimus dosing within a defined therapeutic range of whole blood 
concentrations to achieve maximum efficiency and thus minimize the risk of sub-
therapeutic or toxic blood concentrations which can lead to either rejection and graft 
loss or malignancy, serious infection and nephrotoxicity (Johnston and Holt, 1999). 
High within-patient variability complicates therapeutic drug monitoring as the drug 
concentrations will frequently be above or below the therapeutic window, putting the 
patient at risk for toxicity in the case of overexposure or for acute rejection in the case 
of underexposure (Prytula et al., 2012). 
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Borra et al. (2010) previously reported that high within-patient tacrolimus trough 
concentration variability was a risk factor long term chronic allograft nephropathy and 
graft loss in adult renal transplant recipients. Furthermore, an observational retrospective 
study performed in two Dutch pediatric nephrology centres reported that children and 
adolescents treated for late acute rejection have significantly higher within-patient 
variability in tacrolimus exposure than those who do not experience late acute rejection 
(Prytula et al., 2012). 
Tacrolimus was initially introduced to the market as an immediate-release formulation, 
(Prograf®; Astellas Pharma Europe Ltd) that is administered twice a day. Recently, a 
prolonged -release formulation of tacrolimus (Advagraf®; Astellas Pharma Europe Ltd) 
has been developed to provide once-daily dosing with a similar efficacy and safety 
profile to twice-daily tacrolimus formulation, Advagraf®. Equivalent exposure is 
achieved at steady state with similar areas under the concentration/time curve (AUC), 
trough concentrations (C0), and reduced peak concentrations (Cmax). There is a good 
correlation between trough blood concentration and AUC allowing trough 
concentrations to be used for therapeutic drug monitoring, as is routine for twice-daily 
tacrolimus preparations (Alloway et al., 2005). 
High within-patient variability in tacrolimus exposure is considered as a risk factor for 
allograft loss and late acute rejection. The reasons for this variability within individual 
patients are still unclear. Some factors, such time of tacrolimus dosing and interaction 
with food and medication noncompliance could be the reasons for this variability. The 
impact of food and the adherence rate seem to be significantly lower in Prograf® 
evening versus the morning dose. The presence of food in the gastrointestinal tract, 
particularly its fat content, significantly influences both the rate and extent of drug 
absorption. Bekersky et al. (2001b) demonstrated that food had a clinically significant 
influence in reducing tacrolimus relative bioavailability, as well as slowing its 
absorption. The effect on the rate of tacrolimus absorption was more pronounced in 
high-fat meals relative to low-fat meals. They also found that, taking tacrolimus one 
hour prior to a meal provides minor influence in tacrolimus relative bioavailability 
extent compared to taking tacrolimus in the fasting state. Additionally, the ingestion of 
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tacrolimus immediately after a meal or 1.5 hours subsequent to a meal had a more 
pronounced influence (Bekersky et al., 2001a). Accordingly, tacrolimus should be taken 
at least 1 hour before or 2 hours after eating and at the same time every day and any 
small deviations in the timing of drug intake may cause fluctuation in tacrolimus blood 
concentrations outside the therapeutic window with increased risk for episodes of acute 
rejection or toxicity. 
Medication compliance remains a serious problem after transplantation. Non-adherence 
to medical treatment in transplant recipients is considered a major risk factor for graft 
rejection episodes and associated with graft loss. Even small deviations from the 
prescribed regimen (ie, <95% adherence) are associated with worse outcomes and 
significant financial implications (Laederach-Hofmann and Bunzel, 2000, Takemoto et 
al., 2007). Dosing complexity, including frequency of drug dosing and tablet or capsule 
burden for organ transplant patients may provide a motive for noncompliance to the 
therapeutic regimen (O'Grady et al., 2010). Claxton et al. (2001) confirmed that the 
prescribed number of doses per day is inversely related to compliance and reported that 
simpler, less frequent dosing regimens resulted in better compliance across a variety of 
therapeutic classes. In this situation drugs providing once a day administration can 
improve adherence ensuring appropriate drug blood concentration. Ichimaru et al. 
(2008) performed a study to survey the actual treatment adherence status of patients to 
Prograf® that need to be taken twice daily (morning and evening). They found that the 
adherence rate decreased over time following transplantation and this was more 
pronounced with the evening doses. Weng et al. (2005) demonstrated a significant 
association between dosing frequency (once-daily vs twice-daily) and adherence among 
adult transplant recipients. 
A change from Prograf® to Advagraf® reduces ‘pill-burden’, simplifies the once daily 
regimen and results in only having to coordinate one meal per day around drug 
administration. The recommended dose for conversion from Prograf to Advagraf is 
considered to be on 1:1 mg basis. Simpler dosing regimens have been shown to 
facilitate better adherence performance. Doesch et al. (2010) demonstrated a significant 
improvement in heart transplant patient adherence after a switch to modified-release 
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tacrolimus, Advagraf® which was generally safe and well tolerated. Another study in 
kidney transplant recipient found that compliance was improved among patients treated 
with once-daily tacrolimus compared with twice-daily tacrolimus (Alloway et al., 
2007). A more recent study reported an improvement in patients’ adherence after switch 
to OD-Tac due to lack of the evening dose associated with a higher rate of missed doses 
than the morning dose (Kuypers et al., 2013). 
In contrast to between-patient variability, only few studies have investigated the 
differences in within-patient variability (WPV) when Prograf® was changed to 
Advagraf®. A study by Wehland et al. (2011) investigating the impact of Prograf® to 
Advagraf® conversion on 41 stable Caucasian renal transplant recipients showed that 
both drugs exhibited similar within-patient variability of dose-normalized trough levels. 
However, a retrospective, single-centre, polish study in 52 renal transplant patients 
examined the impact of switching from Prograf to Advagraf on daily drug dose and 
blood concentration variability, showed that conversion from twice daily to once-daily 
tacrolimus late after transplantation ensure greater stability of drug blood concentrations 
compared to the standard tacrolimus form (Kurnatowska et al., 2011). Another 
prospective, single-centre study was performed to investigate the change of within-
patient variability in 129 stable Taiwanese kidney transplant recipients after conversion 
from twice-daily Prograf® to the same daily dose of once-daily Advagraf®. They found 
that conversion from Prograf to Advagraf® is associated with a significantly lower 
within-patient variability of tacrolimus C0 (Wu et al., 2011). Additionally, a multi-centre, 
prospective study performed in stable adult kidney transplant recipients showed that 
between- and within-subject variability in systemic exposure to tacrolimus (%CV for 
AUC0–24) were similar for both once and twice a day tacrolimus (van Hooff et al., 
2012). Recently, Shuker et al. (2014) studied two hundred and forty seven ethnically 
different stable renal transplant recipients and found that conversion from once to twice a 
day tacrolimus significantly reduces tacrolimus exposure and it does not reduce WPV in 
tacrolimus exposure. However, another recent mixed race study showed a significant 
reduction in within-patient variability on conversion to once daily, modified-release 
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tacrolimus in a subgroup of 58 liver transplant recipients in the late conversion cohort 
(Considine et al., 2015). 
Another explanation for this within-patient variability could be an individual’s 
cytochrome P450 3A (CYP3A) genotype. Very few studies have focused on the relation 
between within-patient variability and genetic polymorphism, particularly CYP3A5 
polymorphism in twice daily tacrolimus formulation. Recently, a bioequivalence study 
in healthy Korean volunteers suggested that not only between-individual variability, but 
also WPV is correlated with the CYP3A5 genotype (Yong Chung et al., 2010). In a 
single-centre retrospective study involving 249 Korean renal transplant patients 
concluded that within-individual variability in tacrolimus clearance is not related to 
CYP3A5 genotype and suggested a strong association between WPV of tacrolimus 
trough concentrations and the development of acute rejection (Ro et al., 2012). It has 
been recently reported that a significant reduction in within-patient variability (%CV) of 
tacrolimus C0 on conversion to once-daily tacrolimus among Taiwanese kidney 
transplant recipients. They also found that the %CV of tacrolimus C0 decreased 
significantly in patients with at least CYP3A5*1 allele and that there was no difference 
in tacrolimus trough concentration %CV between CYP3A5 expressers and non- 
expressers in both Prograf and Advagraf® (Wu et al., 2014). However, another study of 
non-Asian transplant patients with mixed ethnic background reported that within-patient 
variability of tacrolimus clearance is not associated with CYP3A5 genotype (Pashaee et 
al., 2011). These results were recently supported by Spierings et al. (2013) in a study of 
118 ethnically different renal transplant recipients, which concluded that within-patient 
variability of tacrolimus clearance was not associated with CYP3A5 genotype in stable 
renal transplant recipients. Further research is required to provide more clear vision into 
what are the causes of this within-patient variability of tacrolimus clearance in patients 
treated with different tacrolimus formulations. 
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3.5 4β-hydroxycholesterol as a Potential Biomarker for 
CYP3A5 Activity 
Phenotyping of CYP3A catalytic activity, determines to a large extent the substantial 
between-individual variation with respect to drug metabolic clearance and consequently, 
their bioavailability, elimination, and interaction with other drugs. Thus, having a 
marker for this activity seems to be of special importance for proper dose adjustments 
and induction potential screening of new drugs (Suzuki et al., 2013a).  Furthermore, 
CYP3A enzymes are responsible for the metabolism of endogenous compounds such as 
cholesterol, steroid hormones (e.g., testosterone), bile acids and vitamin D (van 
Waterschoot and Schinkel, 2011). 4β-hydroxycholesterol (4β-OHC) is found in the 
human circulation and is produced from the enzymatic conversion of cholesterol by 
members of the P450 3A subfamily (Figure 14).  
   
Cholesterol 4β-hydroxycholesterol 
Figure 14: Structure of 4β-hydroxycholesterol  
Several studies showed that patients treated with CYP3A4 inducers had a marked 
increase in 4β-hydroxycholesterol concentrations, while patients treated with CYP3A4 
inhibitors were shown to have markedly decreased levels of 4β-hydroxycholesterol 
(Josephson et al., 2008, Goodenough et al., 2011, Diczfalusy et al., 2009, Lutjohann et 
al., 2009). A study by Diczfalusy et al. (2008) found that the concentration of 4β-OHC 
increased with the number of active CYP3A5*1 alleles. They suggested that 4β-OHC is 
not only formed by CYP3A4, but also by CYP3A5. Recently, 4β-hydroxycholesterol 
(4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical 
CYP3A4/5 
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practice (Diczfalusy et al., 2011). Moreover, it has been reported that 4β-OHC 
concentration is associated with cholesterol plasma concentration which might be 
affected by some drugs. Therefore, 4β-OHC: cholesterol ratio may be more suitable to 
use as an alternative to 4β-OHC itself as a CYP3A measure (Diczfalusy et al., 2011). 
The immunosuppressive drug, tacrolimus has a narrow therapeutic index and its 
pharmacokinetics shows wide between- and within-individual variability (Amundsen et 
al., 2012). CYP3A5 has been identified as the major enzyme responsible for tacrolimus 
metabolism. It has been reported that CYP3A5 polymorphisms have a remarkable 
influence on tacrolimus trough blood concentration and dose requirements in stable 
kidney transplant patients (Glowacki et al., 2011a, Shi et al., 2013, Hesselink et al., 
2003). Estimation of CYP3A activity before transplantation or starting tacrolimus 
treatment may help to prevent the possibility of rejection or toxicity. Moreover, 4β-
OHC has been reported to be a potent and useful endogenous biomarker for CYP3A 
activity especially in kidney transplant patients. Therefore, 4β-OHC may be a useful 
biomarker for prediction of tacrolimus dosing in renal transplant patients. 
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4 Chapter 4. Comparative Pharmacokinetics 
Assessments of Immediate- and Prolonged-
Release Tacrolimus: Associations with 
CYP3A5 and ABCB1 Genotypes.  
4.1 Objective of the Study: 
1. To compare the pharmacokinetics of tacrolimus, measured by a validated 
LC/MSMS method, using two tacrolimus formulations: immediate-release Prograf® 
or Adoport® and prolonged-release Advagraf®. 
2. To study the Associations between CYP3A5*3 and ABCB1 3435C>T SNPs and the 
pharmacokinetics of these formulations within patients. 
4.2 Materials & Methods 
This study was sponsored and monitored by the Joint Research and Enterprise Office, 
St. George’s University of London and it has been supported by an unrestricted research 
grant from Astellas Pharma Ltd. The study protocol was approved by National Research 
Ethics Service Committee (REC Number: 09/H0707/91). The study is an open-label 
pharmacokinetic study with a crossover design.  
4.2.1 Eligibility Criteria 
4.2.1.1 Inclusion Criteria 
1) Renal transplant recipient at least 6 weeks after transplantation on treatment with 
twice daily tacrolimus with planned change in treatment to once daily Advagraf® 
(prolonged release tacrolimus) as part of standard care. 
2) Aged at least 18 years. 
3) Treatment with no more than 5 mg prednisolone daily. 
4) Signed and dated informed consent obtained before screening and before the 
performance of any protocol-specific tests. 
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4.2.1.2 Exclusion Criteria 
1) Unstable renal transplant patients.  
2) Aged less than 18 years old. 
3) Treatment with more than 5 mg prednisolone daily. 
4) Treatment with potent cytochrome P4503A and P-glycoprotein inducers (such as 
carbamazepine, phenytoin, and rifampicin) inhibitors (such as diltiazem, 
erythromycin, fluconazole, and verapamil) or any less commonly prescribed 
potent inducer or inhibitor.  
5) Development of intolerance to tacrolimus preparations.  
6) Inability to obtain satisfactory venous access.  
7) In the event of an adverse event where study continuation is considered to be 
inappropriate by the investigator. 
8) Withdrawal of consent. 
4.2.2 Study Design 
Stable adult renal transplant patients in follow-up at three sites of the local transplant 
network (St. George’s, St. Helier and Brighton Hospitals) were invited to participate in 
the study. At the time of enrolment, patients were informed of the purpose, duration and 
risks of the study, and they were requested to sign a written informed consent form 
(Appendix 1). After signing the consent form, patients were checked for their eligibility 
to participate in the study based on the inclusion and exclusion criteria. Eligible subjects 
were genotyped using DNA prepared from peripheral blood samples collected at a time 
when undergoing venepuncture as part of routine care as shown in Figure 15. The 
evaluations and tests performed also included: 
 Taking patient demographic data, including (Weight, Sex, Ethnic group, Age 
and date of birth, Original renal disease) 
  Recording any significant past medical history  
 Carrying out a physical examination  
 Checking vital signs (including Pulse rate, Blood pressure) 
 Recording all concurrent medications 
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 Recording full blood count from most recent outpatient clinic visit  
 Recording Biochemical series (including urea, creatinine, electrolytes, calcium, 
alkaline phosphatase, AST) from most recent outpatient clinic visit. 
Patients were informed about the possibility of withdrawing from the study at any time. 
They were requested to report any abnormality occurring throughout and after the study. 
The results of clinical evaluations and any abnormalities were documented in individual 
case report forms (Appendix 2).  
 
Figure 15: Study Flow Chart of Twice-Daily Tacrolimus and Advagraf® 
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4.2.3 Study Treatments 
This study measured drug concentrations for patients’ standard therapy. During twice 
daily tacrolimus treatment, tacrolimus dose is usually adjusted to achieve 12 hour post-
dose whole blood concentrations of 8-12 µg/L up until three months after 
transplantation and thereafter 5-8 µg/L.  When the treatment was changed from twice 
daily tacrolimus to Advagraf® the same total daily dose was administered and adjusted 
to maintain trough blood concentrations within the target range.  In order to standardise 
prednisolone CYP3A inducing effect, only patients treated with no more than 5 mg 
prednisolone daily were recruited.   
4.2.4 Genotyping Determination 
DNA was extracted from peripheral blood samples using QIAamp DNA Blood Mini Kit 
(QIAGEN®, West Sussex, UK). CYP3A5*1/*3 and ABCB1 3435C>T polymorphisms 
were genotyped using real time polymerase chain reaction (PCR), a LightCycler® based 
technique. The samples were amplified using specific primer sequences. 
4.2.4.1 Materials and Methods 
QIAamp DNA Blood Mini Kit was obtained from QIAGEN® (West Sussex, UK). The 
LightCycler FastStart DNA Master Hybridisation Probe kit was supplied from Roche® 
(West Sussex, UK). Custom-made primers and probes were purchased from Tib 
Molbiol® (Berlin, Germany). PCR was performed using LightCycler® 1.0 supplied from 
Roche® (Lewes, UK). Ethanol was supplied by VWR. Deionised water was prepared on 
site (Millipore). 
4.2.4.2 DNA Extraction and Purification Procedure  
Ethylenediaminetetraacetic acid anticoagulated whole blood samples were collected and 
stored at –20°C until DNA isolation. QIAamp DNA Blood Mini Kits were used to 
extract and purify DNA from 200 μl of stored EDTA anticoagulated whole blood 
according to the manufacturer instructions. The extracted DNA samples were stored at –
20°C until analysis. 
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4.2.4.3 CYP3A5*3 and ABCB1 3435C>T Genotyping 
4.2.4.3.1 CYP3A5*3 Genotyping 
FastStart DNA master Hybridization Probe kits was used for DNA amplification using 
two specific primers, forward and reverse primer. The forward primer sequence was 
ACTGCCCTTGCAGCATTTAG and the reverse primer sequence was 
CATACCCCTAGTTGTACGAC. Two hybridization probes were used, the anchor and 
sensor probes. The sequence of the Anchor probe was 5′-LCRed640-
GTTTGGACCACATTACCCTTCATC-3′- Phosphate and the sensor probe sequence 
was 5′-CTTTTGTCTTTCAATATCTCTTCCC-3′-fluorescein. The reaction mixture 
made up of 0.5 µM of each primer and 0.3 µM of the probe. The final Mg
2+
 
concentration in the reaction mixture was adjusted to 3 mM. 2 µL of DNA samples 
were loaded into composite glass capillaries (Roche Molecular Biochemicals) 
containing 18µL of the reaction mixture, centrifuged, and placed in the LightCycler 
sample carousel. Three control samples were included in each LightCycler run, two 
positive controls and one negative control (Deionized water).  
The programme was designed as follows: pre- incubation phase at 95°C for 10 min to 
activate the Taq polymerase enzyme, followed by amplification phase, which includes 
45 cycles of denaturation (95°C, 10s), annealing (55°C, 5 s) and extension (72°C, 15 s). 
Then this was followed by melting curve analysis stage, which involved annealing at 
40°C for 50s, followed by an increase in temperature at a rate of 0.1°C/s, with continual 
fluorescence detection up to 95°C. F2 mode was used for fluorescence display. Light 
Cycler Software was used to convert melting curves into melting peaks by plotting the 
negative derivatives of fluorescence against temperature (-dF/dT) (Fredericks et al., 
2005). 
4.2.4.3.2 ABCB1 3435C>T Genotyping 
FastStart DNA master Hybridization Probe kits were used for DNA amplification using 
two specific primers, forward and reverse primer. The forward primer sequence was 
TGTTTTCAGCTGCTTGATGG and the sequence of the reverse primer was 
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AAGGCATGTATGTTGGCCTC. Two hybridization probes were used. The sensor 
probe sequence was LC640-GGAAGAGATCGTGAGGGCAG--PH. The 3′-
fluorescein-labeled anchor probe sequence was GACAACAGCCGGGTGGTGTCA--
FL. PCR was performed in a reaction volume of 20μL with 0.2 μmoL each primer, 0.2 
μmoL anchor and sensor probes, and 2μL of genomic DNA. The final Mg
2+
 
concentration in the reaction mixture was adjusted to 3 mM. The samples were loaded 
into composite glass capillaries (Roche Molecular Biochemicals), centrifuged, and 
placed in the LightCycler sample carousel. After an initial denaturation step at 95°C for 
10.0 min, amplification was performed using 45 cycles of denaturation (95°C for 5 s), 
annealing (55°C for 10 s), and extension (72°C for 20 s). After amplification was 
complete, a final melting curve was recorded by annealing at 40°C for 20s, followed by 
an increase in temperature at a rate of 0.1°C/s, with continual fluorescence detection up 
to 85°C. F2 mode was used for fluorescence display. Light Cycler Software was used to 
convert melting curves into melting peaks by plotting the negative derivatives of 
fluorescence against temperature (-dF/dT) (Nauck et al., 2000). 
4.2.5  Determination of Ethnicity 
Patients were classified by ethnicity based on the patient’s transplant assessment records 
or their self-report as follows: 
 White: any Caucasians, white British and any other white background 
 Black: any ancestry from sub-saharan Africa or any other black background 
including Caribbean 
 Asian: ancestry from India and any other south Asian background, not including 
any East Asians (Koreans, Chinese and Japanese). 
4.2.6 Study Procedure 
Subjects were divided into four groups according to their genotype, as shown in Table 
4. The target size for each group was 30 patients. The sample size required was 
calculated using an anticipated CV of 20% and a power of 80%, within each of the four 
cohorts individually. From previous data, tacrolimus systemic exposure (AUC0-24) for 
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Prograf® was slightly higher than that for Advagraf® [ratio 1.10]. In order that the 90% 
confidence interval for the treatment ratio lies entirely within 0.8 – 1.25, the total 
number of subjects required in each group was 30. The sample size calculation was 
performed using nQuery Advisor 5.0 [table MTE3-1].  
Table 4: Study Genotype Groups of CYP3A5 and ABCB1 Alleles. 
CYP3A5 genotype ABCB1 genotype Number of patients 
*1/*1 or *1/*3 
CYP3A5 expressers 
CC 30 








Patients involved in the study adopted a dosing schedule for one week prior to the study 
where the current dose of twice daily tacrolimus was administered twice daily at 08:00 
and 20:00. An initial pharmacokinetic profile of the twice daily dose tacrolimus was 
measured. Treatment was then changed to the same daily dose of Advagraf®, which was 
administered once daily at 08:00 and then two weeks later, a further pharmacokinetic 
profile was measured after a single morning dose of Advagraf®, as shown Figure 16. 
 
Figure 16: Twice-Daily Tacrolimus – Advagraf® Study Design. 
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A series of blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 12.5, 13, 14, 16 and 
24 hours post-dose for twice daily tacrolimus and at  0, 1, 2, 3, 4, 6, 8, 10, 12 and 24 
hours post-dose for Advagraf® as shown in Figure 17. This required a 24 hour stay in 
the hospital for the first set of samples with the option to go home between the 12 hour 
and 24 hour samples on the second sampling day. Subjects were required to fast for 2 
hours before taking the drug dose and for 1 hour afterwards.  A venous cannula was 
placed into the hand or arm for blood sampling and was kept in place throughout the 
sampling period. Five mL of blood was collected at each time point into EDTA tubes. 
Blood samples were stored frozen at approximately -20ºC until the drug bioanalysis.  
 
Figure 17: Blood Sampling Schedule Following Administration of Twice-Daily 
Tacrolimus Formulations and Advagraf®. 
4.2.6.1 Tacrolimus Analysis 
This analysis procedure was conducted following the method previously validated 
according to FDA guidelines at Analytical Services International Ltd, St George’s - 
University of London titled “The Validation of an LC-MS/MS Assay to Measure 
Tacrolimus and Everolimus in Human Blood”. It allows the analysis of tacrolimus in 
whole blood at concentrations ranging from 1-50 µg/L with a correlation coefficient 
between concentration and peak area ratio (r) of 0.998. The lower limit of quantitation 
was 0.25µg/L. Both the intra-day and inter-day accuracy values were all within 93.1-
109.4% and 95.1-105.3%, respectively. In addition, the average of absolute recovery 
values was 80.8%. 
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4.2.6.1.1 Chemicals and Reagents  
Tacrolimus was supplied by Enzo Life Sciences and ascomycin (IS) was supplied by 
Sigma-Aldrich, together with Zinc sulfate heptahydrate. HPLC-grade methanol and 
Methyl-tert-butyl ether (MTBE) were obtained from Rathburn Chemicals Limited. 
Acetonitrile (HPLC grade) was supplied by VWR. Ammonium acetate, Sodium 
hydroxide, ethanol and ethanediol, were purchased from VWR. EDTA anticoagulated 
tacrolimus -free human whole blood was supplied from Biological Specialty Corp, 
Colmar, Pennsylvania, USA. Deionised water was prepared on site (Millipore). 
4.2.6.1.2 Stock Solutions 
Calibrators and control samples were prepared in EDTA-anticoagulated whole blood, 
using separate stock solutions prepared in methanol. Six non-zero calibrators (nominal 
values of 1.0, 2.5, 5.0, 10.0, 25.0, and 50.0 µg/L) and three control samples (nominal 
values of 3.0, 15.0, and 30.0 µg/L) were prepared. Calibrators and controls were 
aliquoted and stored at approximately 20°C before use. A stock solution of ascomycin 
(internal standard) was prepared in ethanol-ethanediol-water (50:25:25) to give a 
concentration of 50 µg/L.  
4.2.6.1.3 Extraction Procedure 
For sample preparation, 50µL of calibrators, quality control, or patient samples; 50µL 
of internal standard, 1 mL of precipitating solution (500 mL zinc sulphate solution (25 
g/L); 200 mL of acetonitrile; and 300 mL methanol) were pipetted into 2-mL Eppendorf 
vials. The vials were mixed for 5 min and then centrifuged at; 13,200 rpm for 5 min 
using Eppendorf 5415D Centrifuge (Eppendorf, England, UK). The supernatant was 
decanted into 4.5-mL polypropylene tubes with 100 µL of 0.1 mol/L sodium hydroxide 
and 2 mL of MTBE. After mixing for 5 min, the tubes were centrifuged at 3000rpm for 
5 min. The organic solvent was then transferred to 4.5-mL conical polypropylene tubes, 
placed in a Savant SpeedVac Sc200 (Thermo Life Sciences) at 60°C, and evaporated to 
dryness. The dried extracts were reconstituted with 250 µL of 80% methanol, mixed for 
5 min, and then transferred to autosampler vials, which were placed in an autosampler 
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tray set at ambient temperature. The autosampler injected a 10µL aliquot of each extract 
onto the analytical column (Figure 18). 
4.2.6.1.4 Chromatographic and Mass Spectrometric conditions: 
Validated LC-MS/MS method was used for the analysis of tacrolimus in the whole 
blood. The instrument used composed of Agilent HPLC comprises Pump, auto-sampler 
(Model: 1100 series) and auto injector coupled with Triple quadrupole AB Sciex API-
4000 LC-MS/MS system. The reverse phase Alltech Alltima C18, 5µm, 150×2.1 mm 
column (Merck (BDH) Limited, Poole, Dorset, England) was used for the separation of 
tacrolimus and internal standard at temperature of 65°C using an Agilent series 1100 
column oven. The mobile phase was pumped isocratically at a flow rate of 0.4 mL/min 
and consisted of a mixture of mobile phase A (Methanol) and mobile phase B (De-
ionized water + 5mL/L 2M ammonium acetate) at a ratio of 82:18 respectively. The 
retention times were 2.9 for tacrolimus and 2.8 for ascomycin and the total run time was 
4 min. The sample injection volume was 10 µL. Tandem mass spectrometric detection 
and quantification was performed in the positive electrospray ionization mode using 
multiple reaction monitoring (MRM) mode. The transitions selected were m/z 
821.5/768.5 for tacrolimus and m/z 809.5/756.5 for ascomycin. Nitrogen was used as 
the collision gas. The NM20ZA high purity nitrogen and air generators were supplied 
by Peak Scientific Instruments, Scotland. Gas settings in ml/min were: Collision gas: 8, 
curtain gas: 10, ion source gas 1: 35, ion source gas 2: 30. Ion spray voltage: 5500 V, 
and temperature: 450°C. Entrance potential (EP), collision energy (CE), and collision 
cell exit potential (CXP) in voltage were 10, 29 and 18 V, respectively for all 
compounds. The dwell times were set at 300 msec. Declustering Potential (DP) was 81 
for tacrolimus and 76 for ascomycin. A Windows PC running Analyst 1.3.2 software 
was used to control the LC-MS/MS, record the output from the detector, perform 
integration of peak areas and calculate the tacrolimus concentrations. The Analyst 
software was supplied by Applied Biosystems, England (Figure 18). 
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Figure 18: Schematic Diagram of the Tacrolimus Extraction Procedure. 
To a 2mL polypropylene tube add:
50µL blood calibrator / quality control / sample
50µL internal standard (Ascomycin appprox. 50ng/mL)
1mL precipitation reagent






Mix for 5 minutes (minimum)
Centrifuge for 2.5 minutes (Microfuge, 12,000 - 13,200 rpm)
Decant supernatant into a 4.5mL conical polypropylene tube
containing 0.1mL 0.1M sodium hydroxide and
2mL methyl-tert-butyl ether
Mix for 5 minutes (minimum)
Centrifuge for approximately 5 minutes (3000 - 3500 rpm)
Transfer top solvent layer to a 4.5mL conical propylene
 tube and evaporate to dryness in the SpeedVac
Reconstitute in 250µL 80% methanol
Mix for 5 minutes (minimum)
Centrifuge for approx. 2 minutes (3000 - 3500 rpm)
(Optional)
Transfer all the extract to labelled autosampler vials
Inject 5 - 30µL of each extract onto the analytical column
HPLC Conditions:
Column: Alltima C18 (150mm x 2.1mm, 5µm)
Mobile phase:
A - De-ionised water + 5mL/L 2M ammonium acetate: 18% (range allowed 10-20%)
B - Methanol :82% (range allowed 80-90%)
Elution: Isocratic
Flow rate: 0.40mL/minute (range allowed 0.20 - 0.40)
MS Conditions:
MS type: MRM
Ionisation type: Turbo Ion-Spray
Ionisation polarity: Positive
Resolution: Unit/Low
Tacrolimus: 821.5 / 768.5
Ascomycin: 809.5 / 756.5
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4.2.7 Statistical and Pharmacokinetic Analysis 
Statistical analysis was performed using Minitab statistical software (Minitab 17). 
According to the FDA and EMA guidelines patients’ data were log transformed (FDA., 
2003, EMA, 2010a). Then the log-transformed data were analysed using analysis of 
variance (ANOVA) with factors for genotype group and treatment. 90% confidence 
intervals around the ratio in means for twice-daily tacrolimus Prograf® and Adoport®: 
Advagraf® within each genotyping group was compared to the FDA bioequivalence 
margin of 0.8-1.25 where the differences in systemic drug exposure up to 20% are not 
clinically significant (FDA., 2003). EMA guidelines tightened the bioequivalence 
margin for tacrolimus AUC to 0.9-1.11, where the differences in systemic drug 
exposure up to 10% are not clinically significant (EMA, 2010a). See Section  2.2.1 page 
63. The area under the plasma concentration-time curve (AUC) was calculated using the 
linear trapezoidal method. The peak plasma concentration (Cmax) and tmax (the time to 
achieve Cmax) were obtained from direct visual inspection of plasma concentration 
versus time curves. The allele and genotype frequencies of the CYP3A5*3 and ABCB1 
3435C>T polymorphisms were assessed for deviation from the Hardy–Weinberg 
equilibrium using the chi-square test.  
4.3 Results 
4.3.1 Pharmacokinetics and Bioequivalence of Tacrolimus Preparations 
in Stable Renal Transplant Patients. 
The study was designed to compare the standard practice tacrolimus (Prograf®) versus 
Advagraf®. On the way through the study, the renal unit changed their standard practice 
tacrolimus to Adoport®. So we started with Prograf® and then we had to continue with 
Adoport®. Based on FDA guidelines and EMA guidelines both formulations were 
considered bioequivalent (Alloway et al., 2012, MEB, 2012). This had been checked in 
our study cohort and we confirmed that both formulations were bioequivalent according 
to FDA guidelines but not EMA criteria and therefore all patients treated with both 
formulations were combined in one group, twice daily tacrolimus group. 
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4.3.1.1 Patient Population 
Of 75 stable kidney transplant patients who were screened and considered eligible for 
participation, 11 withdrew before the study began. Therefore, 64 patients (43 men, 21 
women; 39 White, 12 Black, 13 Asian; mean [SD] age, 55 [13] years; age range, 21-78 
years; mean weight, 76.4 [15.2] kg; mean height, 170.4 [8.6] cm) was recruited, and all 
participants completed both study periods. The mean (SD) time post-transplant was 4.1 
(4.6) years (median 1.8 years, range 0.3–22.8). 34 patients had received a graft from a 
deceased donor (59.3%). Of these 64 patients, 25% had diabetes mellitus, and 61% were 
receiving maintenance steroids. 19 patients (29.7%) were receiving mycophenolate and 
14 were receiving Azathioprine (21.9%) at baseline and throughout the study. Forty-
eight patients (75%) were receiving with Prograf® and 16 patients (25%) were receiving 
Adoport®. The demographic characteristics and immunosuppression therapy are shown 
in Table 5.  
Table 5: Population Characteristics and Immunosuppression Therapy 
Characteristics Results 
Age (years), mean (SD) 55 (13) 
Male gender, n (%) 43 (67.2%) 
Ethnic group, n (%)  
White 39 (60.9%) 
Black 12 (18.8%) 
Asian 13 (20.3%) 
Body weight (kg), mean (SD) 76.4 (15.2) 
Height (cm), mean (SD) 170.4 (8.6) 
Diabetes mellitus, n (%) 16 (25%) 
Time since transplantation (years)  
Mean (SD)/ Median (range) 4.1 (4.6) / 1.8 (0.3-22.8) 
Donor type, n (%)  
Living / Deceased  26 (40.6%) / 38 (59.3%) 
Immunosuppression at baseline:  
Tacrolimus, n (%)  
Prograf®/ Adoport® 48 (75%) / 16 (25%) 
Corticosteroids, n (%) 39 (61%) 
Azathioprine, n (%) 14 (21.9%) 
Mycophenolate, n (%) 19 (29.7%) 
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4.3.1.2 Efficacy and Safety 
Overall, once-daily tacrolimus was well tolerated in this study. Serum creatinine 
concentrations remained stable after conversion to Advagraf®. No graft losses or 
episodes of rejection occurred during the PK treatment period. Only six patients (9.4%) 
experienced a total of nine adverse events during treatment with once-daily tacrolimus. 
The adverse effects were vomiting (n=1), nausea (n=1), diarrhoea (n=1), headache 
(n=1), cough (n=2), fatigue (n=1), tongue pain (n=1), fever (n=1) and dysuria (n=1). No 
unexpected adverse events were reported or observed during the study period, and most 
adverse events were mild and transient. None of the patients discontinued due to any 
adverse events during the study treatments. None of the concomitant medication 
changed during this study.  
4.3.1.3 Tacrolimus Pharmacokinetics 
Before the analysis, tacrolimus pharmacokinetic parameters between Prograf® and 
Adoport® were compared and no significant difference was observed. Tacrolimus 
pharmacokinetic parameters, AUC0-24, Cmax, tmax, C1, C2 and C0 are summarised in Table 
6. The ratios of the geometric means of Cmax, and AUC0-24 were 1.01and 1.06, 
respectively, with 90% confidence intervals of 0.82 to 1.24 and 0.91 to 1.23 falling 
within the FDA acceptance interval of 0.8 – 1.25 (Table 7). Therefore, the two 
formulations were bioequivalent. However, the 90 % CI for AUC0-24 was outside the 90 
% to 111% the EMA bioequivalence limits. This may be because we did not have a 
sufficient number of patients to give us sufficient power to compare the two 
formulations based on 90 % CI within 90-111% bioequivalence limits. However, an 
alternative possibility is that the two formulations are not actually bioequivalent. This is 
recognized as a weakness in the study. The mean time– concentration profiles for 
Prograf® and Adoport® are shown in Figure 19 A. The tmax of both profiles appear at 
different times however this may be an artefact of showing the mean of patients’ 
profiles in each formulation. The median tmax was the same in both formulations. 
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Table 6: Prograf® and Adoport® Tacrolimus Pharmacokinetic Parameters. 
Parameter Prograf® (n=48) Adoport® (n=16) P-value 
Cmax (µg/L) 16.6 ± 7.7 16.6 ± 7.5 1.0 
 
AUC0-24 (µg∗h/L) 191.2 ± 63.2 198.3 ± 56.3 0.5 
C0 (µg/L) 6.1 ± 1.9 6.3 ± 2.1 0.7 
C1 (µg/L) 13.6 ± 8.0 12.5 ± 8.6 0.2 
C2 (µg/L) 13.3 ± 6.7 14.7 ± 4.9 0.8 
tmax* 2 (1-16) 2 (1-16) 0.6 
Values were compared using ANOVA, general linear model (variables with a normal 
distribution) or the Kruskal–Wallis test (variables non-normally distributed). 
*median 
Table 7: Ratios of Geometric Means and 90% CI for AUC0–24, Cmax, for Prograf® 
and Adoport®  
Parameter Ratio of geometric means (%) 90% CI 
AUC0–24 106% (91% – 123%) 
Cmax 101% (82% – 124%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
Switching from Prograf® or Adoport® to Advagraf® was made on a 1mg: 1mg basis. 
One hundred and twenty-eight 24-h tacrolimus PK profiles were obtained from 64 
patients. The TD-Tac and OD-Tac pharmacokinetic parameters, AUC0-24, Cmax, tmax and 
C0 are summarised in Table 8. Based on the mean values of non-dose-normalized data 
obtained on days 1 and 14, the mean tacrolimus Cmax and C0 were lower for Advagraf® 
compared to twice-daily tacrolimus. There was a significant reduction in tacrolimus 
Cmax (p = 0.028). The mean tacrolimus Cmax concentration fell from 16.6 µg/L SD 7.6 to 
14.8 µg/L SD 5.6 with a 10% reduction [90%CI 3 to 16%]. The difference in tacrolimus 
C0 was highly significant (p = 0.009) with a 10% reduction [90%CI 4 to 16%]. 
However, no significant differences were observed for AUC0-24 between the two 
formulations in this population (p > 0.05, Table 10). The mean concentration-time 
profiles for tacrolimus preparations are shown in Figure 19 B. The individual time–
concentration profiles of the 64 patients are presented in Figure 20. The median tmax 
was the same for both formulations. At 90% confidence intervals (CI), the mean of Cmax 
and AUC0-24 ratio between the twice-daily tacrolimus and Advagraf® were restricted 
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within the bioequivalence margin (80 –125%). The mean AUC0-24 Advagraf®/AUC0-24 
twice-daily tacrolimus ratio was 96% (90% CI 91% –102%), and mean Cmax Advagraf®/ 
Cmax twice-daily tacrolimus ratio was 90% (90% CI 84% –97%). These data are 
summarized in Table 11.  
Tacrolimus daily doses (mg/kg) vary considerably between individuals. To achieve a 
proper association between the pharmacokinetic parameters and tacrolimus 
formulations, these parameters were normalized to unit dose (e.g., equivalent to 0.1 mg/ 
kg). Dose-normalized pharmacokinetic parameters, AUC0-24, Cmax, tmax and C0 are 
summarised in Table 9. There was no marked difference in dose-normalized AUC0-24 (p 
> 0.05). Although, dose-normalized Cmax and dose-normalized C0 were significantly 
higher for twice-daily tacrolimus compared to Advagraf® (p <0.05, Table 10). At 90% 
confidence intervals (CI), dose-normalized AUC0-24 and dose-normalized Cmax ratios 
between the twice-daily tacrolimus and Advagraf® were contained within the 
bioequivalence limit (80 –125%). Dose-normalized AUC0-24 Advagraf®/AUC0-24 twice-
daily tacrolimus was 98% (90% CI 93% –103%) and dose-normalized Cmax Advagraf®/ 
Cmax twice-daily tacrolimus was 91% (90% CI 85% –98%, Table 11). 
Switching from immediate to prolonged release tacrolimus had an impact on between-
patient variability of tacrolimus exposure in this cohort of patients. Although tacrolimus 
exposure (AUC0-24) tended to have less between patient variability, it was not 
statistically significant. The between-patient coefficients of variation (CV%) of dose-
normalized Cmax, AUC0-24 and C0 for twice-daily tacrolimus (TD-Tac) were 56.8%, 
66.8% and 78. 5%, respectively. Whereas, the between-patient coefficient of variation 
(CV%) of Cmax, AUC0-24 and C0 for Advagraf® (OD-Tac) were 48.1%, 57.3% and 
65.0%, respectively (Table 9). Figure 21 and Figure 22 displayed the plot of Test for 
Equal Variances for dose-normalized AUC0-24 (µg*h/L/ mg/kg) and dose-normalized 
Cmax (µg/L/mg/kg) obtained from OD-Tac and TD-Tac formulations. The plots clearly 
showed wider confidence interval for TD-Tac compared to OD-Tac for the Cmax, and 
AUC meaning that the variability is higher in the immediate release tacrolimus 
formulations results compared to the prolonged release tacrolimus formulation (p=0.022 
and p=0.085, respectively). 
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Figure 19: Time – Mean Concentration Profiles for Tacrolimus Formulations. (A) 
for Prograf® and Adoport® and (B) for Twice-Daily Tacrolimus and 
Advagraf®. Advagraf® is Equivalent to Twice-Daily Tacrolimus after a 
1mg: 1mg Basis Conversion.  
(A) 
(B) 
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Figure 20: Whole-Blood Tacrolimus Concentration-Time Profiles in 64 Stable 
Kidney Transplant Recipients on Twice-Daily Tacrolimus (A) and 
Advagraf® (B).  
(A) 
(B) 
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Table 8: Tacrolimus Pharmacokinetic Parameters for Tacrolimus Preparations. 
Patient Cmax (µg/L) AUC0-24 (µg∗h/L) *tmax (h) C0 (µg/L) 
 
TD-Tac OD-Tac TD-Tac OD-Tac TD-Tac OD-Tac TD-Tac OD-Tac 
1 16.3 15.3 239 282 1 2 8.40 9.90 
2 15.2 29.5 180 212 2 4 5.90 6.10 
3 20.2 19.1 203 220 4 3 6.20 5.40 
4 12.1 10.6 101 125 1 2 2.70 5.20 
5 16.2 14.3 281 258 4 6 10.90 9.80 
6 23.7 22.6 237 243 4 4 6.20 5.90 
7 11.3 13.8 140 188 4 1 3.80 5.00 
8 20.6 17.8 211 199 2 2 6.80 4.30 
9 9.2 17.6 111 177 4 4 4.10 5.40 
10 11.6 15.9 144 207 4 4 5.80 4.70 
11 20.9 21.0 300 324 2 3 9.30 10.00 
12 8.0 8.6 133 135 16 3 3.70 3.80 
13 11.2 3.2 113 54 1 24 3.00 3.20 
14 7.6 9.1 140 129 2 2 5.90 3.80 
15 23.4 19.3 274 218 1 1 7.30 6.80 
16 13.1 10.1 176 154 1 3 6.10 4.50 
17 39.0 18.7 371 245 2 1 10.10 7.60 
18 18.1 18.8 231 211 2 2 6.50 5.00 
19 7.9 5.3 112 90 2 6 4.10 2.50 
20 21.9 23.4 232 255 1 3 6.00 7.80 
21 13.8 7.7 201 138 2 4 8.50 4.10 
22 42.0 23.6 290 265 1 2 7.50 6.50 
23 29.0 23.0 290 309 1 2 7.60 8.30 
24 14.3 15.1 202 159 2 3 6.80 4.80 
25 19.1 12.3 270 167 1 2 8.50 4.90 
26 10.9 8.8 168 138 2 2 6.30 4.60 
27 12.5 9.4 174 137 1 3 6.40 4.60 
28 16.0 17.0 145 170 1 2 5.00 4.40 
29 19.3 11.9 241 199 2 2 7.20 6.10 
30 19.1 13.8 246 142 16 4 7.20 3.50 
31 9.8 12.0 150 175 2 4 6.40 5.60 
32 18.3 20.5 187 206 2 2 7.30 6.60 
33 11.8 11.1 158 130 1 4 4.30 3.90 
34 17.3 14.3 216 191 2 2 8.90 5.40 
35 33.9 16.0 189 182 1 1 4.74 3.69 
36 9.1 10.3 115 141 2 3 4.99 4.99 
37 17.7 12.6 213 199 1 3 7.29 6.36 
38 9.6 7.4 104 110 1 3 2.20 3.50 
39 9.4 12.8 105 162 2 2 3.96 4.57 
40 17.3 30.7 219 241 2 1 6.69 5.57 
41 6.6 8.4 137 162 16 6 5.24 5.03 
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42 11.1 12.4 165 205 2 2 5.11 6.62 
43 21.0 22.1 195 184 1 1 5.56 4.25 
44 19.3 19.3 318 272 14 2 10.60 8.70 
45 20.6 15.4 251 154 1 2 6.50 4.20 
46 11.0 10.9 167 137 2 2 5.80 4.30 
47 15.1 15.8 204 208 4 2 7.30 6.16 
48 11.3 10.5 177 147 2 3 7.56 3.90 
49 8.2 7.2 103 126 1 2 3.10 3.87 
50 15.7 11.6 147 154 1 4 5.30 3.50 
51 23.8 23.6 242 279 1 2 6.72 8.00 
52 39.5 16.0 321 239 1 1 9.68 6.00 
53 18.9 12.1 195 157 2 3 5.70 4.20 
54 16.3 11.0 194 177 2 1 5.40 5.70 
55 16.3 12.3 171 90 1 1 4.70 4.80 
56 25.4 15.2 246 234 2 1 8.30 6.80 
57 6.2 10.8 118 143 2 2 3.90 4.30 
58 15.7 13.1 144 227 1 2 4.90 11.70 
59 13.1 16.2 163 165 2 1 4.30 4.80 
60 15.7 8.2 219 132 0.5 3 9.20 4.10 
61 13.5 15.4 134 169 1 2 4.80 5.00 
62 9.5 13.9 149 196 16 2 4.20 5.70 
63 16.2 21.4 198 235 2 2 5.40 6.80 
64 16.6 19.1 192 205 2 2 4.90 5.70 
Mean 16.6 14.8 193.0 185.6 2.0 2.0 6.2 5.5 
SD 7.6 5.6 61.2 54.4 3.8 2.9 1.9 1.8 
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TD-Tac OD-Tac TD-Tac OD-Tac TD-Tac OD-Tac TD-Tac OD-Tac 
1 39.7 37.2 581 687 1 2 20.4 24.1 
2 30.0 58.3 356 419 2 4 11.7 12.0 
3 15.8 15.0 159 172 4 3 4.9 4.2 
4 9.3 8.1 77 96 1 2 2.1 4.0 
5 63.3 55.8 1097 1008 4 6 42.6 38.3 
6 11.5 11.0 115 118 4 4 3.0 2.9 
7 12.0 14.6 148 199 4 1 4.0 5.3 
8 29.1 25.2 298 281 2 2 9.6 6.1 
9 6.9 11.9 83 120 4 4 3.1 3.7 
10 10.5 14.4 130 187 4 4 5.2 4.3 
11 27.3 27.4 391 423 2 3 12.1 13.1 
12 8.8 9.4 145 148 16 3 4.1 4.2 
13 21.0 6.0 211 101 1 24 5.6 6.0 
14 25.5 30.5 469 433 2 2 19.8 12.7 
15 18.6 15.3 218 173 1 1 5.8 5.4 
16 21.1 16.3 283 249 1 3 9.8 7.3 
17 45.1 26.0 429 339 2 1 11.7 10.5 
18 9.1 9.4 115 106 2 2 3.3 2.5 
19 62.6 42.0 883 713 2 6 32.5 19.8 
20 17.5 18.7 185 204 1 3 4.8 6.2 
21 73.4 41.0 1067 732 2 4 45.2 21.8 
22 28.1 15.8 194 177 1 2 5.0 4.3 
23 38.5 30.6 385 410 1 2 10.1 11.0 
24 33.1 34.9 466 368 2 3 15.7 11.1 
25 58.2 37.5 822 508 1 2 25.9 14.9 
26 47.1 38.1 725 597 2 2 27.2 19.9 
27 69.2 52.0 963 756 1 3 35.4 25.5 
28 43.5 46.2 394 462 1 2 13.6 12.0 
29 24.3 18.7 303 313 2 2 9.1 9.6 
30 23.6 17.1 304 175 16 4 8.9 4.3 
31 19.2 23.5 294 342 2 4 12.5 11.0 
32 25.8 28.9 263 291 2 2 10.3 9.3 
33 25.6 24.1 342 283 1 4 9.3 8.5 
34 46.2 38.2 577 509 2 2 23.8 14.4 
35 36.0 17.0 200 193 1 1 5.0 3.9 
36 16.6 18.9 210 258 2 3 9.1 9.1 
37 47.4 33.7 571 533 1 3 19.5 17.0 
38 26.6 20.5 289 305 1 3 6.1 9.8 
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39 14.1 19.2 158 244 2 2 6.0 6.9 
40 9.7 17.2 123 135 2 1 3.8 3.1 
41 20.5 26.2 428 505 16 6 16.4 15.7 
42 20.5 23.0 306 380 2 2 9.5 12.3 
43 21.7 22.8 201 190 1 1 5.7 4.4 
44 41.2 41.2 679 582 14 2 22.6 18.6 
45 34.5 25.8 420 258 1 2 10.9 7.0 
46 26.2 25.9 397 327 2 2 13.8 10.2 
47 16.9 17.7 228 233 4 2 8.2 6.9 
48 37.7 35.0 590 488 2 3 25.2 13.0 
49 36.7 32.6 463 565 1 2 14.0 17.4 
50 13.5 10.0 126 132 1 4 4.6 3.0 
51 14.5 14.4 148 170 1 2 4.1 4.9 
52 22.0 8.9 179 133 1 1 5.4 3.3 
53 67.6 43.3 696 563 2 3 20.4 15.0 
54 26.6 17.9 316 288 2 1 8.8 9.3 
55 31.9 24.1 334 175 1 1 9.2 9.4 
56 28.3 16.9 274 261 2 1 9.2 7.6 
57 19.7 34.4 374 455 2 2 12.4 13.7 
58 21.7 24.1 199 418 1 2 6.8 21.5 
59 7.6 9.4 95 96 2 1 2.5 2.8 
60 40.6 25.4 564 409 0.5 3 23.8 12.7 
61 27.0 30.8 268 338 1 2 9.6 10.0 
62 20.9 30.6 328 431 16 2 9.2 12.5 
63 15.8 20.9 193 229 2 2 5.3 6.6 
64 13.8 15.8 159 170 2 2 4.1 4.7 
Mean 28.4 25.0 359.2 336.9 2.0 2.0 12.2 10.4 
SD 16.1 12.1 240.1 192.9 3.8 2.9 9.6 6.7 
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Table 10: Pharmacokinetic Parameters Comparison between Twice-Daily 
Tacrolimus (TD-Tac) and Advagraf® (OD-Tac). 
Parameter 
TD-Tac OD-Tac P-
value Prograf® or Adoport® Advagraf® 
Cmax (µg/L) 16.6 ± 7.6 14.8 ± 5.6 0.028 
AUC0-24 (µg∗h/L) 193.0 ± 61.2 185.6 ± 54.3 0.278 
C0 (µg/L) 6.2 ± 1.9 5.5 ± 1.8 0.009 
Dose-normalized Cmax (µg/L/mg/kg) 28.4 ± 16.1 25.0 ± 12.1 0.044 
Dose-normalized AUC0-24 (µg ∗h/L/ 
mg/kg) 
359.2 ± 240.1 336.9 ± 192.9 0.475 
Dose-normalized C0 (µg/L/mg/kg) 12.2 ± 9.6 10.4 ± 6.7 0.024 
Values were compared using ANOVA (General linear model). 
Table 11: Ratios of Geometric Means and 90% CI for AUC0–24, Cmax, Dose-
Normalized AUC0–24 and Dose-Normalized Cmax for Advagraf® to 
Twice-Daily Tacrolimus  
Parameter Ratio of geometric means (%) 90% CI 
AUC0–24 96% (91% – 102%) 
Cmax 90% (84% – 97%) 
Dose-normalized AUC0-24 98% (93% – 103%) 
Dose-normalized Cmax 91% (85% – 98%) 
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Figure 21: Plot of Test for Equal Variance with 95% Confidence Interval for Cmax 
of Once- and Twice-Daily Tacrolimus. The Cmax standard deviations for 
the two formulations are significantly different. 
 
Figure 22: Plot of Test for Equal Variance with 95% Confidence Interval for 
AUC0-24 of Once-(OD-Tac) and Twice-Daily (TD-Tac) Tacrolimus. The 









95% Bonferroni Confidence Intervals for StDevs








95% Bonferroni Confidence Intervals for StDevs
Test for Equal Variances: Dose-normalized AUC0-24 vs Form
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In this study, we found a strong correlation between AUC0–24 and trough blood 
concentrations (C0) for immediate and modified release tacrolimus at steady state, with 
similar correlation coefficients for both formulations (r = 0.86 and r = 0.82, 
respectively). The slopes of the lines of best fit were virtually identical (Figure 23). 
 
Figure 23: Scatter Plot of Individual Calculated Tacrolimus Exposure (AUC0–24) vs 
Tacrolimus Trough Concentration (C0) Represents the Correlation of 
Tacrolimus Exposure and Trough Concentration for Twice and Once-
Daily Tacrolimus. 
During analysis of the study samples, all the batches met the acceptance criteria for this 
study. Samples from these batches were successfully analysed. The quality control 
sample data for tacrolimus obtained during the analysis are shown in Table 12. The 





AUC0-24 = 25.61 + 27.13 C0 
AUC0-24 = 49.40 + 24.71 C0 
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Table 12: Quality Control (QC) Samples Achieved During Tacrolimus Analysis. 
Quality Control Levels QC1 QC2 QC3 
Nominal Concentrations (µg/L) 3 15 30 
Batch ID Measured Concentration (µg/L) 
Batch1 2.9 14.9 29.2 
Batch2 3.0 14.7 29.5 
Batch3 3.0 14.5 29.9 
Batch4 3.0 15.6 31.5 
Batch5 2.9 14.7 31.4 
Batch6 3.0 14.2 29.5 
Batch7 2.9 15.5 32.2 
Batch8 3.0 14.0 29.2 
Batch9 2.9 14.8 29.2 
Batch10 2.9 14.9 30.9 
Batch11 3.0 15.0 30.6 
Batch12 3.0 15.2 31.9 
Batch13 3.0 15.3 31.1 
Batch14 3.0 15.4 30.5 
Batch15 2.9 15.3 31.3 
Batch16 3.1 15.3 31.0 
Batch17 2.9 14.8 30.4 
Batch18 2.8 14.7 30.6 
Batch19 2.8 15.0 29.4 
Batch20 3.1 15.7 29.8 
Batch21 3.0 16.1 32.5 
Batch22 3.1 15.5 30.8 
Batch23 3.1 15.7 31.0 
Batch24 2.9 15.1 30.6 
Batch25 2.8 14.1 27.2 
Batch26 3.0 15.8 31.9 
Mean 3.0 15.1 30.5 
Standard Dev. 0.1 0.7 1.5 
%CV 4.9 4.7 4.8 
% Inaccuracy -1.7 0.3 1.7 
N= 111 of 111 121of 122 117 of 117 
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Table 13: Calibration Curve Parameters Data Achieved During Tacrolimus 
Analysis. 
Batch ID Curve parameters (y = A*x + B) 
 
Slope (A) Intercept (B) Correlation Coefficient (r) 
Batch1 0.016 -0.00169 0.9994 
Batch2 0.0155 -0.000433 0.9996 
Batch3 0.0156 -0.00129 0.9989 
Batch4 0.0144 -0.000228 0.999 
Batch5 0.0157 -0.00108 0.9996 
Batch6 0.016 -0.00181 0.9991 
Batch7 0.0153 -0.0004 0.9991 
Batch8 0.0164 -0.000264 0.9992 
Batch9 0.0156 -0.00087 0.9994 
Batch10 0.016 -0.000864 0.9992 
Batch11 0.0165 -0.00173 0.9993 
Batch12 0.0158 -0.00166 0.9988 
Batch13 0.0165 -0.00173 0.9993 
Batch14 0.0157 -0.000523 0.9994 
Batch15 0.0159 -0.000914 0.9996 
Batch16 0.0156 -0.000979 0.999 
Batch17 0.0153 -0.000397 0.9981 
Batch18 0.0159 -0.00167 0.9981 
Batch19 0.0161 -0.00206 0.9981 
Batch20 0.0158 -0.000591 0.9989 
Batch21 0.0142 -0.00146 0.9991 
Batch22 0.0147 -0.00219 0.999 
Batch23 0.016 -0.00149 0.999 
Batch24 0.0161 -0.000717 0.9962 
Batch25 0.0193 0.00361 0.9943 
Batch26 0.0158 0.00271 0.9986 
Mean 0.0158 -0.00080 0.9987 
Range 0.0142 – 0.0193 -0.00219 – 0.00361 0.9943 – 0.9987 
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4.3.2 Associations of CYP3A5 and ABCB1 3435C>T Genotypes with 
Doses and Pharmacokinetics of Tacrolimus Formulations. 
Patients were recruited from 2010 to 2014 in the transplant Clinic at St. George’s 
Hospital (London, United Kingdom). 64 patients who had received twice-daily 
tacrolimus were converted to Advagraf® on a mg: mg basis. The patients’ general 
demographics were shown previously in Table 5 Page.122. The list of the concomitant 
medications for 64 renal transplant patients included in the study is summarized in 
Appendix 3. 
4.3.2.1 CYP3A5*3 and ABCB1 3435C>T Genotype Analysis and Their Frequencies 
For CYP3A5 A6986G polymorphism, the melting point of the sensor probe was 
approximately 55°C and 61°C when hybridised to the CYP3A5 *3/*3 (G/G) and *1/*1 
(A/A) genotypes respectively. In the heterozygote polymorphism CYP3A5*1/*3 (A/G), 
both melting peaks appeared (Figure 24.A). Moreover, for the ABCB1 3435C>T 
polymorphism, the melting point of the sensor probe was 64°C and 57°C when 
hybridised to ABCB1 CC and TT genotypes respectively. The heterozygote 
polymorphism ABCB1 CT presented both melting peaks (Figure 24.B). Twenty PCR 
products were randomly selected from the three genotypes melting profiles for DNA 
sequencing conformation. CYP3A5*3 and ABCB1 allelic variants results obtained by 
real time PCR were confirmed by sequencing these genes.  
CYP3A5*3 and ABCB1 3435C>T Genotypes and allele frequencies are presented in 
Table 14. In our study cohort, the CYP3A5 *3/*3 genotype was observed in thirty-four 
patient (53.1%) and were thus classified as CYP3A5 non-expressers. The CYP3A5*1/*1 
and *1/*3 genotypes were observed in eighteen patients (28.1%) and twelve patients 
(18.8%), respectively and were classified as CYP3A5 expressers. The frequencies of the 
ABCB1 CC, CT, and TT genotypes were 15 (23.4%), 30 (46.9%), and 19 (29.7%), 
respectively. The ABCB1 genotype frequency of the recipients was consistent with 
Hardy-Weinberg equilibrium (p > 0.05). Whereas, CYP3A5*3 allele frequency deviated 
from Hardy–Weinberg equilibrium (p < 0.05). 
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Figure 24: Derivative Melting Curve Plots for CYP3A5*3 and ABCB1 3435C>T 
Genotyping using Specific Primers and Probes. A. The Derivative 
Melting Curve for the CYP3A5 Genotypes. Samples with the Homozygous 
*3 Allele (      ; Tm 55°C); Homozygous *1 Allele (       ; Tm 61°C) and 
Heterozygous *1/*3 Genotype (       ; Tm 55°C and 61°C). B. The 
Derivative Melting Curve for the ABCB1 Genotypes. Samples with the 
Homozygous T Allele (        ; Tm 57°C); Homozygous C Allele (       ; Tm 
64°C) and Heterozygous C/T genotype (      ; Tm 57°C and 64°C). The 
Melting Curve of a no Template Control in Both Assays (         ). 
Table 14: Genotype Frequencies for CYP3A5 and ABCB1 in Renal Transplant 
Patients 





CYP3A5 6986A>G *1/*1 12 18.8% *1 = 0.33 
  
*1/*3 18 28.1% *3 = 0.67 
  
*3/*3 34 53.1% 
 
      
ABCB1 3435C>T C/C 15 23.4% C = 0.47 
  
C/T 30 46.9% T = 0.53 
  
T/T 19 29.7% 
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4.3.2.2 Association of CYP3A5 Genotypes with Tacrolimus Pharmacokinetic 
Profiles 
Thirty patients were recruited into the CYP3A5 expressers group and 34 in the CYP3A5 
non-expressers group. The baseline characteristics of the recipients are summarized in 
(Table 15). We observed no differences in these characteristics between CYP3A5 
expressers and non-expressers, except for sex, diabetic status and ethnicity. In line with 
previous observations, the CYP3A5*1 allele was more prevalent among black transplant 
recipients compared with that among white patients (Table 15). 




*1/*1 (n = 12) & 
*1/*3(n = 18) 
CYP3A5 Non-expressers 
3/*3  
(n = 34) 
Sex   
Male/female 17/13 26/8 
Age (y), mean (SD) 54.8 ± 13.3 54.4 ± 12.4 
Ethnic group, n (%)   
White 10 (33.3%) 29 (85.3%) 
14.7 
 
Black 12 (40.0%) - 
- 
Asian 8 (26.7%) 5 (14.7%) 
14.7 
Body weight (kg), mean (SD) 74.5 ± 12.1 78.0 ± 17.5 
Height (cm), mean (SD) 170.3 ± 8.7 170.0 ± 8.5 
Diabetes mellitus, n (%) 11 (36.7%) 4 (11.8%) 
Time since transplantation (years)   
Mean (SD) 4.3 ± 3.8 3.9 ± 5.3 
Donor type, n (%)   
Living / Deceased 7 (23.3%) / 23 (76.7%) 19 (55.9%) / 15 (44.1%) 
Serum creatinine (µmol/L) 119.2 ± 39.1 127.6 ± 39.9 
Serum albumin (g/L) 38.4 ± 2.7 38.8 ± 3.4 
Haemoglobin (g/L) 127.7 ± 15.6 131.3 ± 27.0 
Immunosuppression therapy   
Tacrolimus, n (%)   
Prograf®/ Adoport® 23 (76.7%) / 7 (23.3%) 24 (70.6%) / 10 (29.4%) 
Corticosteroids, n (%) 20 (66.7%) 19 (55.9%) 
Azathioprine, n (%) 7 (23.3%) 7 (20.6%) 
Mycophenolate mofetil, n (%) 6 (20.0%) 13 (38.2%) 
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The analysis has been done on 128 24-h PK profiles obtained from 64 patients, pooling 
the data for TD-Tac and OD-Tac. Tacrolimus blood concentrations Cmax, AUC0-24 and 
C0 showed a log-normal distribution, and the data were therefore log-transformed before 
analysis. The CYP3A5 SNP was a significant predictor of tacrolimus dose. Individuals 
possessing at least one CYP3A5*1 allele (CYP3A5-expressers) required higher 
tacrolimus doses compared with CYP3A5*3/*3 carriers (CYP3A5 non-expressers). The 
mean required daily dose of tacrolimus per body weight was 0.05 ± 0.03 mg/kg in the 
CYP3A5*3/*3 allele carriers. This amount was significantly lower than the 0.11 ± 0.05 
mg/kg (P< 0.001) of dose for CYP3A5*1carriers. Furthermore, we observed that the 
presence of the CYP3A5*1 allele was strongly associated with lower dose-normalized 
tacrolimus blood concentration. CYP3A5-expressers achieved 1.8-fold lower dose-
normalized tacrolimus Cmax (19.1 ± 10.6 µg/L/mg/kg) than CYP3A5 non-expressers 
(33.5 ± 13.8 µg/L/mg/kg, P<0.001). In addition, CYP3A5*1 carriers showed a 
significant reduction in tacrolimus dose-normalized AUC0-24 and C0 than CYP3A5 non-
expressers. The dose-normalized AUC0–24 (µg*h/L per mg/kg) was significantly lower 
among the CYP3A5 expresser patients than CYP3A5*3/*3 carriers (223.4 ± 140.3 vs. 
458.0 ± 214.2, P<0.001). The dose-normalized C0 was significantly lower in CYP3A5 
expressers compared with that in CYP3A5 non-expressers: 6.9 ± 5.1 vs. 15.1 ± 8.7 µg/L 
per mg/kg, respectively (Table 16, Figure 25). 
Table 16: Tacrolimus PK Parameters According to Their CYP3A5*3 Genotypes 
for the Whole Data of Once-and Twice-Daily Tacrolimus. 
PK-parameter 
CYP3A5 Expressers  
(*1/*1 & *1/*3) 
(n= 60) 




Dose (mg/Kg/day) 0.11 ± 0.05 0.05 ± 0.03 <0.001 
Cmax (µg/L/mg/Kg) 19.1 ± 10.6 33.5 ± 13.8 <0.001 
AUC0-24 (µg*h/L/mg/Kg) 223.4 ± 140.3 458.0 ± 214.2 <0.001 
C0 (µg/L/mg/Kg) 6.9 ± 5.1 15.1 ± 8.7 <0.001 
 Values were compared using ANOVA (General linear model). 
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Figure 25: Associations between CYP3A5 Genotype and Tacrolimus Dose and Pharmacokinetic Parameters for the Whole Data of 
Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the box represents the median value, 
symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the values beyond the 
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Tacrolimus pharmacokinetic parameters following administration of twice-daily 
Prograf® or Adoport® and once-daily Advagraf® in CYP3A5 expresser and non-
expresser patients are summarized in Table 17.  
After the switch from twice to once daily tacrolimus, a slight decrease in the mean dose-
normalized Cmax and AUC0-24 was observed, regardless of the CYP3A5 genotype. The 
mean dose-normalized Cmax and AUC0-24 were comparable between tacrolimus 
formulations in CYP3A5 expresser and non-expresser groups. In the CYP3A5 expresser 
group the mean dose-normalized C0 was comparable for both formulations; however, in 
the CYP3A5 non-expresser patients, there was a significant reduction in the mean dose-
normalized C0 after the switch to once daily tacrolimus (twice daily tacrolimus: 16.6 ± 
10.2 µg/L/mg/Kg vs Advagraf®: 13.6 ± 6.7 µg/L/mg/Kg; P < 0.05; Table 17, Figure 
26). The blood concentration-time profiles of tacrolimus in stable kidney transplant 
recipients are presented in Figure 27. 
In CYP3A5 Expressers, AUC0-24 OD-Tac /AUC0-24 TD-Tac was 101% (90% CI 93% –
110%) and Cmax OD-Tac/ Cmax TD-Tac was 92.5% (90% CI 81.8% –104.7%). In 
CYP3A5 Non-expressers, AUC0-24 OD-Tac /AUC0-24 TD-Tac was 92.5% (90% CI 
86.1% –99%) and Cmax OD-Tac/ Cmax TD-Tac was 88.3% (90% CI 80.1% –97.4%, 
Table 18). The confidence intervals of the ratios were within the bioequivalence limits 
(80-125%). Therefore, the two formulations were bioequivalent. According to EMA 
guidelines, the confidence intervals of the AUC0-24 ratios were within the 
bioequivalence margin (90-111%) in CYP3A5 Expresser group. Consequently, the two 
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Table 17: Associations between CYP3A5*3 Polymorphism and Form and Dose-Normalized Tacrolimus Pharmacokinetic 
Parameters. 
PK-parameter 
CYP3A5 Expressers  








TD-Tac Advagraf® p-value TD-Tac Advagraf® p-value 
Dose (mg/Kg/day) 0.11 ± 0.05   0.05 ± 0.03   
AUC0-24 (µg*h/L/mg/Kg) 223.7 ± 152.1 223.0 ± 130.1 0.72 478.7  ± 241.5 437.4 ± 184.4 0.14 
Cmax (µg/L/mg/Kg) 20.1 ± 11.8 18.1 ± 9.2 0.33 35.8  ± 15.9 31.2 ± 11 0.06 
C0 (µg/L/mg/Kg) 6.7 ± 4.5 7.2 ± 5.7 0.46 16.6 ± 10.2 13.6 ± 6.7 < 0.05 
TD-Tac: Twice daily tacrolimus  
Values were compared using ANOVA (General linear model). 
Table 18: Ratios of Geometric Means and 90% CI for AUC0–24 and Cmax for Tacrolimus Formulations in CYP3A5 Genotype 
Groups 
Parameter 
CYP3A5 Expressers  





Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 101.3% (93.1% – 110.1%) 92.5% (86.1% – 99.4%) 
Cmax 92.5% (81.8% – 104.7%) 88.3% (80.1% – 97.4%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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Figure 26: Associations between CYP3A5*3 Genotype and Tacrolimus Dose-Normalized Pharmacokinetic Parameters of Twice-
Daily Tacrolimus (TD-Tac) and Advagraf®. Boxes represent the interquartile range, line in the box represents the median 
value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the values beyond 
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Figure 27: Summary of Blood Tacrolimus Concentration Time Profiles in Stable Adult Kidney Transplant Recipients on Twice-
Daily Tacrolimus (before the Switch) and Advagraf® (after the Switch) for CYP3A5 *1 allele carriers (A) and CYP3A5 
*3*3 carriers (B).  
A 
B 
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4.3.2.3 Associations between ABCB1 3435C>T Variants and Tacrolimus 
Pharmacokinetic Profiles 
A total of 64 patients was included. The demographic characteristics of the ABCB1 CC 
as well as the ABCB1 CT/TT carriers included in our study are presented in Table 19. 
There were no significant differences between the ABCB1 CC carriers and ABCB1 
CT/TT carriers, except for haemoglobin content, ethnicity and the proportion of the 
donor type. 
Table 19: Demographic Characteristics of Patients, According to ABCB1 3435C>T 
Polymorphism 
Characteristic 
ABCB1 CC carriers 
(n= 16) 
ABCB1 CT/TT carriers                              
CT (n= 29) & TT (n= 19) 
Sex  
  
Male/female 10/6 33/15 
Age (y), mean (SD) 55.4 ± 13.1 54.3 ± 12.7 
Ethnic group, n (%) 
  
White 5 (31.3%) 34 (73%) 
 Black 9 (56.3%) 3 (6%) 
 Asian 2 (12.5%) 11 (23%) 
Body weight (kg), mean (SD) 77.2 ± 16.5 76.1 ± 14.9 
Height (cm), mean (SD) 173.3 ± 8.8 169.0 ± 8.2 
Diabetes mellitus, n (%) 3 (18.8%) 12 (25%) 
Time since transplantation 
(years)   Mean (SD) 3.3 ± 2.7 
 
4.4 ± 5.1 
Donor type, n (%) 
  
Living / Deceased 4/12 22/26 
Serum creatinine (µmol/L) 125.3 ± 48.9 124.2 ± 36.8 
Serum albumin (g/L) 38.1 ± 1.9 39.1 ± 3.4 
Haemoglobin (g/L) 123.7 ± 20.9 131.6 ± 22.6 
Immunosuppression therapy 
  
Tacrolimus, n (%) 
  
Prograf®/ Adoport® 14 (81.3%) / 2 (12.5%) 33 (69%) / 15 (31%) 
Corticosteroids, n (%) 11 (69%) 28 (58%) 
Azathioprine, n (%) 1 (6%) 13 (27%) 
Mycophenolate mofetil, n (%) 7 (44%) 12 (25%) 
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The analysis has been done on 128 24-h PK profiles obtained from 64 patients pooling 
the data for TD-Tac and OD-Tac. The tacrolimus pharmacokinetic parameters 
according to ABCB1 3435C>T polymorphisms are shown in Table 20. A significant 
difference was observed at dose-normalized tacrolimus pharmacokinetic parameters 
(Cmax, AUC0-24 and C0) between the ABCB1 CC and the CT/TT genotypes. The dose-
normalized Cmax (µg/L/mg/kg) was significantly lower among the ABCB1 CC genotype 
than the ABCB1 T allele carriers (20.9 ± 14.2 vs. 28.7 ± 13.9, P<0.001). ABCB1 CC 
patients showed reduced dose-normalized AUC0-24 than ABCB1 CT/TT patients (248.6 ± 
184.7 vs. 381.2 ± 218.0 µg*h/L/mg/kg, P<0.001). A significantly lower dose- 
normalized C0 was achieved in patients homozygous for CC genotype (7.4 ± 5.9 
µg/L/mg/kg) compared with patients carrying at least one T allele (12.5 ± 8.6 
µg/L/mg/kg, P<0.001). Moreover, we found that recipients with CC genotype required a 
higher tacrolimus dose compared to those with CT/TT genotypes (0.10 ± 0.05 vs. 0.07 ± 
0.04, P<0.001, Table 20 & Figure 28). 
Table 20: Tacrolimus Dose-Normalized PK Parameters According to ABCB1 








Dose (mg/Kg/day) 0.10 ± 0.05 0.07 ± 0.04 <0.001 
Cmax (µg/L/mg/Kg) 20.9 ± 14.2 28.7 ± 13.9 <0.001 
AUC0-24 (µg*h/L/mg/Kg) 248.6 ± 184.7 381.2 ± 218.0 <0.001 
C0 (µg/L/mg/Kg) 7.4  ± 5.9 12.5 ± 8.6  <0.001 
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Figure 28: Associations between ABCB1 3435C>T Polymorphisms and Tacrolimus Dose and Dose-Normalized Pharmacokinetic 
Parameters for the Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the 
box represents the median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal 
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Table 21 shows tacrolimus exposure parameters following administration of twice-daily 
tacrolimus and once-daily Advagraf® in ABCB1 CC and ABCB1 CT/TT groups. In both 
ABCB1 groups, there was a slight decrease in tacrolimus dose-normalized Cmax, AUC0-
24 and C0 after the switch to once-daily tacrolimus. Regardless of the ABCB1 3435C>T 
genotype group, the mean dose-normalized Cmax, as well as mean dose-normalized 
AUC0-24 and C0 were comparable for both tacrolimus formulations (P >0.05; Table 21, 
Figure 29). The blood concentration-time profiles of tacrolimus in stable kidney 
transplant recipients are presented in Figure 30. 
The ratio of means (90% CI) of AUC0–24 for OD-Tac versus TD-Tac was as follows: 
ABCB1 CC carriers, 94.3% (82.1% –108.2 %); ABCB1 CT/TT carriers, 97.3% (91.7% –
103.2%). While the ratio of means (90% CI) of Cmax for OD-Tac versus TD-Tac was as 
follows: ABCB1 CC carriers, 85.4% (70.0% –104.3%); ABCB1 CT/TT carriers, 92.0% 
(84.9% –99.7%). As the OD-Tac/TD-Tac Cmax ratio in the ABCB1 CC group is outside 
the 90% CI of 80, 125, the two formulations were not bioequivalent. According to EMA 
guidelines, the confidence intervals of the AUC0-24 ratios were within the 
bioequivalence margin (90-111%) in ABCB1 CT/TT genotype group. Consequently, the 
two formulations were bioequivalent only in ABCB1 CT/TT carriers. These data are 
summarized in Table 22. 
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Table 21: Relationship of ABCB1 3435C>T Polymorphism and Tacrolimus Formulation with Dose-Normalized Tacrolimus 
Pharmacokinetic Parameters. 
PK-parameter 
ABCB1 CC                                                                            
(n= 15)  
ABCB1 CT/TT                                       
(n= 49)  
 
TD-Tac Advagraf® P-value TD-Tac Advagraf® P-value 
Dose (mg/Kg/day) 0.10 ± 0.06 0.10 ± 0.06  0.07 ± 0.04 0.07 ± 0.04  
C0 (µg/L/mg/Kg) 8.3 ± 7.2 6.5 ± 4.1 0.18 13.5 ± 10.0 11.6 ± 7.0 0.07 
Cmax (µg/L/mg/Kg) 23.3 ± 17.1 18.5 ± 10.5 0.16 30.1 ± 15.6 27.2 ± 11.8 0.15 
AUC0-24 (µg*h/L/mg/Kg) 268.0 ± 219.0 229.2  ± 147.5 0.41 389.6 ± 241.2 372.8 ± 194.1 0.79 
TD-Tac: Twice daily tacrolimus.  
Values were compared using ANOVA (General linear model). 
Table 22: Ratios of Geometric Means and 90% CI for AUC0–24 and Cmax for Tacrolimus Formulations in ABCB1 3435C>T 
Genotype Groups. 
Parameter 
ABCB1 CC ABCB1 CT/TT 
Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 94.3% (82.1% – 108.2 %) 97.3% (91.7% – 103.2%) 
Cmax 85.4% (70.0% – 104.3%) 92.0% (84.9% – 99.7%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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Figure 29: Associations between ABCB1 3435C>T Polymorphism and Tacrolimus Dose-Normalized Pharmacokinetic Parameters 
of Twice-Daily Tacrolimus (TD-Tac) and Advagraf®. Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the values 
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Figure 30: Summary of Blood Tacrolimus Concentration Time Profiles in Stable Adult Kidney Transplant Recipients on Twice-
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4.3.2.4 Associations between CYP3A5*3 and ABCB1 3435C>T Combined 
Genotypes and Tacrolimus Pharmacokinetic Profiles 
On the basis of the results described above, we subsequently divided all the patients, 
according to both CYP3A5*3 and ABCB1 3435C>T genotypes. 4 genotype 
combinations were identified in our study population: CYP3A5 expresser recipients 
(CYP3A5*1allele carriers) with ABCB1 CC genotype (n=12); CYP3A5 expresser 
recipients with ABCB1 CT/TT genotype (n=18); CYP3A5 non-expresser recipients 
(CYP3A5*3/*3 carriers) with ABCB1 CC genotype (n=4) and CYP3A5 non-expresser 
recipients with ABCB1 CT/TT genotype (n=30). CYP3A5*3*3 and ABCB1 CC genotype 
group, with 4 patients only, was excluded from the statistical analysis. The demographic 
and baseline clinical characteristics of the study participants are presented in Table 23. 
Demographic characteristics, except ethnicity (p< 0.001), donor type (p< 0.05) and 
diabetic status (p< 0.01) were not significantly different between the genotype groups. 
The analysis has been done on 128 24-h PK profiles obtained from 64 patients with data 
for TD-Tac and OD-Tac pooled. 
After excluding the four subjects with CYP3A *3*3 and ABCB1 CC genotype from the 
analysis, significant differences in tacrolimus pharmacokinetic parameters were 
observed between groups. The difference in these parameters increased progressively 
from CYP3A5 expresser /ABCB1CC group to CYP3A5 non-expresser/ABCB1 CT/TT 
group. No significant difference was noted in CYP3A5 non-expressers between ABCB1 
CT/TT and ABCB1CC carriers (the excluded group). When CYP3A5 non-
expresser/ABCB1 CT/TT group compared with CYP3A5 expressers/ABCB1CC and 
CT/TT genotype subgroup, significant differences in tacrolimus dose requirements, 
dose-normalized AUC0–24, dose-normalized Cmax and dose-normalized C0 were evident. 
CYP3A5 non-expresser/ABCB1 CT/TT group required significantly lower tacrolimus 
dose 0.05 mg/kg/day (SD: 0.02) compared with CYP3A5 expresser/ABCB1 CT/TT 
group who needed 0.10 (SD: 0.05) mg/kg/day (P<0.001) and CYP3A5 
expresser/ABCB1 CC, who needed 0.12 (SD: 0.05) mg/kg/day (P<0.001). In CYP3A5 
expresser/ABCB1 CT/TT group, tacrolimus dose was significantly lower than CYP3A5 
expresser/ABCB1 CC group (P=0.03). CYP3A5 non-expresser /ABCB1 CT/TT carriers 
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developed a significantly higher dose-normalized C0 than CYP3A5 expresser /ABCB1 
CT/TT carriers (p<0.001) and then CYP3A5 expresser /ABCB1 CC carriers (p<0.001). 
CYP3A5 expresser/ABCB1 CC group had a significantly lower tacrolimus dose-
normalized C0 compared with CYP3A5 expresser/ABCB1 CT/TT group (P<0.01). A 
significant difference was observed in tacrolimus dose-normalized Cmax in CYP3A5 
non-expresser/ABCB1 CT/TT group compared with CYP3A5 expresser/ABCB1 CT/TT 
(p<0.001) and CYP3A5 expresser/ABCB1 CC groups (p<0.001). Tacrolimus dose 
increase significantly in CYP3A5 expresser/ABCB1 CT/TT group compared with 
CYP3A5 expresser/ABCB1 CC group (P=0.02). In addition, CYP3A5 non- expresser 
/ABCB1 CT/TT carriers achieved 2.6-fold higher dose-normalized AUC0-24 compared 
with CYP3A5 expresser/ABCB1 CT/TT and 1.8-fold higher dose-normalized AUC0-24 
than CYP3A5 expresser /ABCB1 CC carriers. A significant difference was observed in 
tacrolimus dose-normalized AUC0–24 between the ABCB1 CC and the CT/TT genotype 
subgroup (P<0.05; Figure 31; Table 24). 
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Table 23: Patients Demographic Characteristics According to CYP3A5 and ABCB1 3435C>T Genotypes. 
Characteristic 
CYP3A5 Expressers  
(*1/*1 & *1/*3) 
CYP3A5 Non-expressers 
(*3/*3) 
ABCB1 CC ABCB1 CT/TT ABCB1 CC ABCB1 CT/TT 
Sex     
Male/female 7/5 10/8 3/1 23/7 
Age (y) , mean (SD) 55.8 ± 15.0 54.1 ± 12.4 54.3 ± 5.1 54.4 ± 13.1 
Ethnic group, n (%) 
    
White 2 (17%) 8 (44%) 3 (75%) 26 (87%) 
Black 9 (75%) 3 (17%) 0 (0%) 0 (0 %) 
Asian 1 (8%) 7 (39%) 1 (25%) 4 (13 %) 
Body weight (kg), mean (SD) 78.0 ± 16.4 72.2 ± 8.0 74.7 ± 19.3 78.5 ± 17.5 
Height (cm), mean (SD) 174.2 ± 9.2 167.7 ± 7.5 170.6 ± 7.6 169.9 ± 8.7 
Diabetes mellitus, n (%) 2 (17%) 9 (50%) 1 (25%) 3 (10%) 
Time since transplantation (years) 
    
Mean (SD) 3.7 ± 2.7 4.7 ± 4.4 1.9 ± 2.5 4.2 ± 5.6 
Donor type, n (%) 
    
Living / Deceased 1/11 6/12 3/1 16/14 
Serum creatinine (µmol/L) 120.9 ± 51.5 119.6 ± 31.1 138.3 ± 43.7 126.8 ± 40.0 
Serum albumin (g/L) 38.4 ± 1.9 38.8 ± 3.1 37.0 ± 1.4 39.3 ± 3.7 
Haemoglobin, g/L 124.0 ± 20.4 130.2 ± 11.4 122.8 ± 25.4 132.4 ± 27.4 
Immunosuppression therapy 
    
Tacrolimus, n (%) 
    
Prograf®/ Adoport® 11 (92%) /1 (8%) 12 (67%) / 6 (33%) 3 (75%) / 1 (25%) 21 (70%) / 9 (30%) 
Corticosteroids, n (%) 10 (83%) 11 (61%) 2 (50%) 17 (57%) 
Azathioprine, n (%) 1 (8%) 6 (33%) 0 (0%) 7 (23%) 
Mycophenolate mofetil, n (%) 5 (42%) 1 (6%) 2 (50%) 11 (37%) 
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Table 24: Tacrolimus Dose-Normalized PK Parameters According to CYP3A5*3 and ABCB1 3435C>T Genotypes for the Whole 
Data of Once-and Twice-Daily Tacrolimus. 
PK-parameter 
CYP3A5 Expressers 


















Dose (mg/Kg/day) 0.12 ± 0.05 0.10 ± 0.05 0.05 ± 0.05 0.05 ± 0.02 <0.001 <0.001 <0.05 
Cmax (µg/L/mg/Kg) 15.6 ± 6.8 21.4 ± 12.0 36.7 ± 19.0 33.1 ± 13.1 <0.001 <0.001 <0.05 
AUC0-24 (µg*h/L/mg/Kg) 172.3 ± 74.4 257.4 ± 163.0 477.6 ± 230.3 455.4 ± 213.9 <0.001 <0.001 <0.05 
C0 (µg/L/mg/Kg) 5.0 ± 2.2 8.2 ± 6.0 14.7 ± 7.5 15.1 ± 8.9 <0.001 <0.001 <0.01 
a  
p-Values refer to comparisons between CYP3A5 Expressers / ABCB1 CC group and CYP3A5 non-expresser/ABCB1 CT/TT group. 
b   
p-Values refer to comparisons between CYP3A5 Expressers/ ABCB1 CT/TT group and CYP3A5 non-expresser/ABCB1 CT/TT group. 
c   
p-Values refer to comparisons between CYP3A5 Expressers subgroups. 
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Figure 31: CYP3A5 and ABCB1 3435C>T Combined Genotypes and Dose-Normalized Tacrolimus Exposure and Dose 
Requirement for the Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the 
box represents the median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal 
value and the values beyond the whiskers (asterisks) are outliers. CYP Exp refers to CYP3A5 expressers (CYP3A5*1/*1 and 
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Additionally, when we compared changes in these different genotype groups by 
formulation, no difference was found between twice-daily tacrolimus and Advagraf® in 
mean weight-adjusted dose, dose-normalized C0, dose-normalized Cmax and dose-
normalized AUC0-24 between the different genotype groups (Figure 32 & Table 25). 
The blood concentration-time profiles of tacrolimus are presented in Figure 33.  
In CYP3A5 Expressers ABCB1 CC group, the ratio of OD-Tac/TD-Tac for AUC0–24 
was 97.9% with a 90% CI of 82.3% – 116.6% and for Cmax was 86.3% with a 90% CI of 
66.4% – 112.3%. In CYP3A5 Expressers ABCB1 CT/TT group, the ratio of the OD-
Tac/TD-Tac for AUC0–24 was 103.5% with a 90% CI of 94.5% – 113.4% and for Cmax 
was 96.6% with a 90% CI of 85.2% – 110.2%. While in the CYP3A5 Non-expressers 
ABCB1 CT/T group, the ratio of OD-Tac/TD-Tac was as follows for AUC0–24 was 
86.7% (90% CI of 93.7% – 101.3%) and for Cmax was 89.1% (90% CI of 80.1% – 
99.1%, Table 26). As the OD-Tac/TD-Tac Cmax ratio in CYP3A5 expressers ABCB1 
CC group is outside the 90% CI of 80, 125, both formulations were not bioequivalent. 
Whereas the other groups OD-Tac/TD-Tac ratios for AUC0–24 and Cmax are within the 
90% CI of 80, 125, bioequivalence was achieved with both tacrolimus formulations. 
According to EMA guidelines, the confidence intervals of the AUC0-24 ratios were 
outside the bioequivalence margin (90-111%) except in CYP3A5 expressers ABCB1 
CT/TT carriers. Therefore both formulations were bioequivalent only in CYP3A5 
Expresser ABCB1CT/TT carriers. 
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Table 25: Tacrolimus Dose-Normalized Pharmacokinetic Parameters for Different Combination of CYP3A5*3 and ABCB1 
3435C>T Genotypes in Both Once- and Twice-Daily Tacrolimus. 
PK-parameter 
CYP3A5 Expressers 
(*1/*1 & *1/*3) 






TD-Tac  Advagraf® P-value TD-Tac  Advagraf® P-value 
Dose (mg/Kg/day) 0.12 ± 0.05 0.12 ± 0.05 
 
0.10 ± 0.05 0.10 ± 0.05 
 
C0 (µg/L/mg/Kg) 5.3 ± 2.6 4.7 ± 1.8 0. 7 8.5 ± 6.8 8.0 ± 5.4 0. 6 
Cmax (µg/L/mg/Kg) 17.2 ±8.0 14.1 ± 5.2 0.3 22.0 ± 13.7 20.8 ±10.4 0.8 





ABCB1 CC  
(n= 4) 
  
ABCB1 CT/TT  
(n= 30) 
  
TD-Tac  Advagraf® P-value TD-Tac  Advagraf® P-value 
Dose (mg/Kg/day) 0.05 ± 0.05 0.05 ± 0.05  0.05 ± 0.02 0.05 ± 0.02 
 
C0 (µg/L/mg/Kg) 17.7 ± 9.0 11.7 ± 5.1 0.03 16.4 ± 10.5 13.9 ± 6.9 0.06 
Cmax (µg/L/mg/Kg) 41.8 ±  25.0 31.6 ± 12.2 0.3 35.0 ± 14.8 31.1±11.0 0.1 
AUC0-24 (µg*h/L/mg/Kg) 536 ± 291 418.8 ± 172.8 0.2 471.0 ± 238.9 439.9 ± 188.5 0.3 
Values were compared using ANOVA (General linear model). 
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Table 26: Ratios of Geometric Means and 90% CI for AUC0–24 and Cmax for Tacrolimus Formulations in CYP3A5 and ABCB1 
3435C>T Genotype Groups 
Parameter 
CYP3A5 Expressers   
(*1/*1 & *1/*3) 
CYP3A5 Non-expressers  
(*3/*3) 
ABCB1 CC ABCB1 CT/TT ABCB1 CT/TT 
Ratio of geometric 
means (%) 
90% CI 
Ratio of geometric 
means (%) 
90% CI 
Ratio of geometric 
means (%) 
90% CI 
AUC0–24 97.9% (82.3% – 116.6%) 103.5% (94.5% – 113.4%) 93.7%  (86.7% – 101.3%) 
Cmax 86.3% (66.4% – 112.3%) 96.6% (85.2% – 110.2%) 89.1% (80.1% – 99.1%) 
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Figure 32: Associations of CYP3A5 and ABCB1 3435C>T Genotypes with Tacrolimus Dose-Normalized Pharmacokinetic 
Parameters of Twice-Daily Tacrolimus and Advagraf®. Boxes represent the interquartile range, line in the box represents 
the median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the 
values beyond the whiskers (asterisks) are outliers. CYP Exp refers to CYP3A5 expressers (CYP3A5*1/*1 and *1/*3) and CYP 
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Figure 33: Summary of Blood Tacrolimus Concentration Time Profiles for CYP3A5 Expressers (CYP3A5*1/*1 and *1/*3) / ABCB1 
3435 CC (A), CYP3A5 Expressers (CYP3A5*1/*1 and *1/*3) /ABCB1 CT/TT (B) and CYP3A5 non-Expressers 




Comparative Pharmacokinetics Assessments of Tacrolimus Preparations 
Page 163 of 377 
4.3.2.5 Factors Associated with Dose Requirements of Tacrolimus 
Factors associated with dose requirements of tacrolimus were studied using univariate 
regression analysis. The analysis has been done on 128 24-h PK profiles obtained from 
64 patients with data for TD-Tac and OD-Tac pooled. The P value was highly 
significant with ethnicity, sex, CYP3A5*3 genotype and the combined CYP3A5 and 
ABCB1 genotype (p<0.001 for each) and haematocrit and ABCB1 genotype (p=0.001 
for each). The P values for age and time since transplant were less than 0.05. Although 
diabetic patients had higher tacrolimus dose-normalized Cmax and required lower 
tacrolimus dose than non-diabetic patients, the difference was not statistically 
significant. The p-value was 0.098 and 0.056, respectively. The CYP3A5*3 genotype 
explains 33.9% of the variability in tacrolimus dose requirements. Similarly, the 
combined CYP3A5 and ABCB1 genotype accounts for 36.9% of the between-individual 
variability in tacrolimus dose requirements. 
Multiple regression analysis by stepwise selection identified the combined CYP3A5*3 
and ABCB1 genotype, age, sex, ethnicity, haematocrit, corticosteroids treatment and 
diabetic status as independent variables associated with tacrolimus dose (Table 27). 
These factors explain 59.9% of the variability in tacrolimus dose requirements. After 
adjusting for these independent predictors of tacrolimus dose, CYP3A5/ABCB1 
combined genotype remained strongly associated with tacrolimus dose (p <0.001) and 
accounts for 36.9% of tacrolimus dose requirements variability. Moreover, patient 
diabetic status became strongly associated with tacrolimus dose (p=0.001) and 
responsible for 9.0% of the variability in tacrolimus dose requirements. Besides, patient 
sex effect was not statistically significant (P >0.05, Table 27). 
Regarding dose-normalized C0, multiple regression analysis by stepwise selection 
identified the combined CYP3A5*3 and ABCB1 genotype, haematocrit, tacrolimus 
formulation and diabetic status as independent variables associated with tacrolimus C0 
(Table 27). These factors explain 40.1% of the variability in tacrolimus trough 
concentration. The contributions of the individual variables are shown in Table 27. 
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CYP3A5/ABCB1 combined genotype had a strong relationship with tacrolimus dose (p 
<0.001) and accounts for 26.0% of the variability in tacrolimus trough concentration. 
For dose-normalized AUC0-24, multiple regression analysis by stepwise selection 
identified the combined CYP3A5*3 and ABCB1 genotype, sex, age, Time since 
transplantation, donor type and diabetic status as independent variables associated with 
tacrolimus AUC0-24 (Table 27). These factors explain 49.4% of the variability in 
tacrolimus exposure (AUC0-24). The contributions of the individual variables are shown 
in Table 27. CYP3A5/ABCB1 combined genotype had a strong association with 
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Table 27: Factors Associated with Tacrolimus Exposure and Dose Requirements (Multiple Regression Analysis). 
Stepwise regression equation R
2
 Independent variables  
 
Dose (mg/kg) = 0.2199 - 0.000622 * Age - 0.1636 * 
Haematocrit - 0.0387 (if Asian) - 0.0217 (if White) - 0.02665 (if 
diabetic) + 0.01043 (if treated with corticosteroids) + 0.00974 (if 
female) + 0.0017 (if CYP3A5*1/*1/*1/*3 /ABCB1CT/TT 
genotype) - 0.0457 (if CYP3A5*3/*3 /ABCB1CC genotype) - 
0.0534 (if CYP3A5*3/*3 /ABCB1CT/TT genotype). 
59.9% 
Age (p = 0.011, R
2 
= 1.8%) 
Sex (p = 0.137, R
2 
= 0.8%) 
Corticosteroids (p = 0.081, R
2 
= 1.2%) 
Ethnicity (p = 0.004, R
2 
= 4.7%) 
Haematocrit (p = 0.01, R
2 
= 5.6%) 
Diabetic status (p = 0.001, R
2 
= 9.0%) 




Dose-Normalized C0 (µg/L/ mg/kg) = -12.66 + 44.9 
*Haematocrit + 4.98 (if diabetic) + 1.69 (if CYP3A5*1/*1/*1/*3 
/ABCB1CT/TT genotype) + 10.31 (if CYP3A5*3/*3 /ABCB1CC 
genotype) + 10.07 (if CYP3A5*3/*3 /ABCB1CT/TT genotype) -




Formulation (p = 0.12, R
2 
= 1.2%) 
Diabetes (p = 0.001, R
2 
= 5.5%) 
Haematocrit (p < 0.001, R
2 
= 7.3%) 




Dose-Normalized AUC0-24 (µg*h/L/ mg/mL) = -154.8 + 
3.36*Age + 111.4*(if living donor type) + 105.6 (if diabetic) + 
9.70* time since transplantation (y) + 131.1 * (if male) + 21.9 * 
(if CYP3A5*1/*1/*1/*3 /ABCB1CT/TT genotype) + 223.8 * (if 




Age (p = 0.006, R
2 
= 3.6%) 
Sex (p < 0.001, R
2 
= 5.2%) 
Diabetes (p = 0.005, R
2 
= 4.5%) 
Donor type (p = 0.004, R
2 
= 3.7%)     
Time since transplantation (p = 0.007, R
2 
= 1.2%) 





 gives the % variability explained by the independent variables in the multiple regression analysis model.
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4.4 Discussion 
4.4.1 Pharmacokinetics and Bioequivalence of Once- and Twice-Daily 
Tacrolimus Preparations in Stable Renal Transplant Patients. 
Advagraf® showed a comparable pharmacokinetic profile to twice-daily tacrolimus, as 
assessed by comparing AUC0–24 and Cmax concentrations. The obtained data from 64 
renal transplant recipients confirm that once-daily tacrolimus, Advagraf® is 
bioequivalent to twice-daily tacrolimus preparations in kidney transplant patients 
according to the FDA and EMA guidelines. At 90% CI values for the ratios of the 
geometric means of AUC0–24 OD-Tac/TD-Tac (91% –102%) and of Cmax OD-Tac/TD-
Tac (84% –97%) were each within the stipulated range of 80–125%, which meets the 
FDA bioequivalence acceptable range applied for any bioequivalence study. These 
criteria allow no more than 20% higher or lower changes in AUC0–24 and Cmax ratios 
between the generic and the reference drugs (FDA., 2003). EMA guidelines which 
tighten the bioequivalence acceptable margin for AUC geometric mean ratio to 90.00 –
111.11% for narrow therapeutic index drugs including tacrolimus (EMA, 2010b) were 
also met. Our analysis showed that the Advagraf® was bioequivalent to twice-daily 
tacrolimus; however, it attained a lower Cmax and a lower systemic profile of tacrolimus 
than twice-daily tacrolimus preparations. The results obtained supported a safe mg: mg 
conversion from twice a day to modified release tacrolimus, Advagraf®. These results 
are in agreement with the previously published data, which showed that the steady state 
tacrolimus pharmacokinetics of modified release tacrolimus is equivalent to Prograf® 
after mg: mg daily dose conversion in stable kidney transplant patients regardless of sex 
or race. The ratio of the OD-Tac/TD-Tac for AUC0–24 was 95.0% with a 90% CI of 
90.7% –99.4%. The ratio of the OD-Tac/TD-Tac for Cmax was 88.2% with a 90% CI of 
82.7% –94.0% (Alloway et al., 2005).This is contained within the 90% CI of 80% –
125%. Our results confirm previous results obtained from a steady-state study in stable 
kidney transplant recipients and found an equivalence of exposure at steady-state. 
Likewise, the 90% CI values for the ratios of geometric means of AUC0–24 for days 14 
and 21 once-daily tacrolimus versus days 1 and 7 twice-daily tacrolimus were 91% and 
99%. They also demonstrate that kidney transplant recipients can be safely converted to 
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once-daily tacrolimus and tacrolimus concentration can be maintained using the same 
therapeutic monitoring and patient care techniques used for twice-daily tacrolimus 
(Alloway et al., 2007). Our results similar to the results obtained by van Hooff et al 
(2012).who found that tacrolimus AUC0–24 for both formulations are comparable after 
mg: mg conversion from Prograf® to Advagraf®. At 90% CIs, the AUC0–24 ratio was 
92.9% (89.8%–96.0%), within the FDA bioequivalence acceptance range of 80%–
125%. However, the treatment ratio (90% CI) for tacrolimus Cmax was 73.2% (67.7%–
78.7%), outside the range. Our results are in agreement with the AUC0–24 ratio results 
obtained from once-daily tacrolimus PK study in paediatric kidney recipients. The ratio 
of the geometric means for AUC0–24 was 90.8 %, with 90 % CI limits of 85.3%–96.7 %, 
falling within 80 % to 125 % the FDA bioequivalence limits. In contrast to our results, 
their Cmax did not significantly differ between both formulations in the investigated 
study population. They demonstrated that the two formulations were bioequivalent 
(Lapeyraque et al., 2014). In contrast to our results, Min et al (2013) found that at 
steady state, the tacrolimus exposure was not equivalent between both formulations in 
paediatric transplant patients. The ratio of lnAUC0–24 for OD-Tac/TD-Tac was 84.7 with 
90% CI of 79.1%–90.8% after mg: mg conversion. lnCmax was also not equivalent; the 
90% CIs was 70.7%–89.1%. Despite that the dose was adjusted, the ratio of lnAUC0–24 
was 87.8 (90% CI: 78.1%–98.9%) on day 28 of the study. In addition, there was a good 
correlation between AUC0–24 and C0 for immediate and modified release tacrolimus 
hence; it allows therapeutic monitoring via the same system as twice-daily Tacrolimus. 
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4.4.2 CYP3A5*3 and ABCB1 3435C>T Associations with Tacrolimus 
Preparations Pharmacokinetics and Dose Requirements. 
The present study assessed whether the well-defined association of the CYP3A5*3 and 
ABCB1 genotypes on the pharmacokinetics of immediate release tacrolimus also applies 
for the prolonged release preparation, Advagraf®.  
Based on the analysis of the data obtained from 64 stable renal transplant recipients, it 
can be demonstrated that CYP3A5 expressers (CYP3A5*1 allele carriers) required 
higher doses of tacrolimus than CYP3A5 non-expressers (CYP3A5*3/*3). In addition, 
tacrolimus dose-normalized C0, Cmax and AUC0-24 are significantly lower in CYP3A5 
expresser patients than CYP3A5 non-expressers. This is in agreement with the 
previously published data which showed that the CYP3A5 expressers required a higher 
daily tacrolimus dose compared to non-expressers (Roy et al., 2006). Moreover, it was 
reported that tacrolimus pharmacokinetics were heavily dependent on CYP3A5 allelic 
status. Subjects carrying at least one functional CYP3A5*1 allele (CYP3A5 expressers) 
metabolize tacrolimus more rapidly and require higher doses to reach target 
concentrations (MacPhee et al., 2002). Our findings confirmed the results obtained from 
a previous study in Japanese renal transplant recipients showing that the dose-adjusted 
Cmax (µg/L/mg/kg), AUC0-12 (µg*h/L per mg/kg) and tacrolimus trough blood 
concentrations in CYP3A5*1 carriers had a significantly lower value than the *3/*3 
carriers, though the daily dose of tacrolimus mg/kg/day was significantly higher 
(Tsuchiya et al., 2004). Our results are in conformity with these studies. This is in 
agreement with the fact that the CYP3A5*3 allele decreases CYP3A5 production and 
results in the loss of hepatic CYP3A5 activity (Hustert et al., 2001, Kuehl et al., 2001). 
CYP3A5 could be useful to predict the optimal tacrolimus dose prior to transplantation. 
A recent study showed that kidney transplant recipients using tacrolimus doses 
according to the CYP3A5 genotype reached the target C0 significantly earlier than 
recipients used a standard regimen (Thervet et al., 2010). Although more patients were 
within the desired tacrolimus target range early after transplantation, a considerable 
proportion of patients still did not have tacrolimus C0 levels within the target range 
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indicating that CYP3A5 genotype alone is unlikely to be sufficient for successful 
individualisation of initial tacrolimus dose. 
With regards to ABCB1 3435C>T, we found that the patients with the ABCB1 3435 CC 
allele have a significantly higher tacrolimus dose mg/kg/day and lower tacrolimus dose-
adjusted AUC0–24, dose-adjusted Cmax and dose-adjusted trough levels post 
transplantation compared to those with ABCB1 T variant homozygotes. Similarly, some 
studies have reported a correlation between ABCB1 3435C>T polymorphism and 
tacrolimus pharmacokinetics. Zheng et al. (2003) for instance, analysed tacrolimus 
pharmacokinetics in relation to ABCB1 3435C>T polymorphisms and found a 
significant association between the ABCB1 3435C>T polymorphisms and the dose of 
tacrolimus per day, showing that CC recipients require a higher dose than the CT/TT 
patients at 6 and 12 months after heart transplantation. Similarly, Patients with C/C 
homozygotes of ABCB1 3435C>T showed significantly lower dose-adjusted tacrolimus 
trough concentrations compared with ABCB1 CT/TT variant carriers in liver transplant 
recipients  (Yu et al., 2011). In contrast, other studies have reported a weak correlation 
with ABCB1 3435C>T polymorphism and high tacrolimus blood concentrations (Diaz-
Molina et al., 2012, Fredericks et al., 2006, Singh et al., 2011), whereas others found no 
effect (Jun et al., 2009, Quteineh et al., 2008). Other studies showed that there was no 
association of any tacrolimus parameter, such as tacrolimus dose/kg/day, dose-adjusted 
AUC0–12, dose-adjusted Cmax and trough concentration with ABCB1 CC and CT/TT 
genotype subgroups, indicating that ABCB1 3435C>T polymorphism was not an 
important factor in tacrolimus pharmacokinetics (Rong et al., 2010, Tada et al., 2005). 
Furthermore, Goto et al. (2002) found that none of the ABCB1 3435C>T variants 
studied showed a significant effect on tacrolimus concentration/dose ratio in the first 
week after transplantation. 
After categorizing the renal transplant patients in different groups based on their 
CYP3A5*3 and ABCB1 3435C>T genotype, no significant difference was observed in 
CYP3A5*3 carriers with any of ABCB1 3435C>T variant alleles. However, significant 
differences in tacrolimus pharmacokinetic parameters were evident between ABCB1 
3435C>T polymorphisms in CYP3A5*1 allele carriers. This suggests that CYP3A5 
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expression had a major influence on tacrolimus exposure and that ABCB1 3435C>T 
polymorphism was an important factor in tacrolimus pharmacokinetics particularly in 
case of CYP3A5 expressers. In contrast to our results, a minor association was found 
between the ABCB1 3435C>T polymorphisms and tacrolimus blood concentration in 
CYP3A5 non-expressers suggesting that the variation in tacrolimus oral bioavailability 
is primarily produced by heterogeneity in the level of intestinal P-glycoprotein 
expression (MacPhee et al., 2002). Some studies are in agreement with our findings 
showing no significant differences in tacrolimus bioavailability between the ABCB1 CC 
and the CT/TT genotype subgroups in the non-expresser group (Rong et al., 2010, Tada 
et al., 2005). Likewise, these studies have reported the same outcome between ABCB1 
3435C>T variants and CYP3A5 expressers which contrast with our findings. 
Furthermore, another study found that upon evaluating the 2 genotypes for CYP3A5*3 
and ABCB1 3435C>T in combination, significant differences in tacrolimus 
Concentration/Dose ratios for the various groups reflected mainly the CYP3A5 
polymorphism (Loh et al., 2008). This is in agreement with our finding. 
The role of CYP3A5*3 and ABCB1 3435C>T genotypes in metabolism and dose 
requirements of Advagraf® in renal transplant patients is currently unknown. It was 
reported that expression of CYP3A decreases and expression of P-gp increases along 
the length of the small intestine (Zhang and Benet, 2001). Theoretically, it cannot be 
assumed that the genetic factors known to influence the pharmacokinetics of the 
Prograf® preparation of tacrolimus will apply to the prolonged release preparation, 
Advagraf®, which is absorbed more distally. Contrary to expectations, however, the 
influence of the CYP3A5*3 and ABCB1 3435C>T genotype on tacrolimus exposure is 
the same for the prolonged release preparation Advagraf
®
 as for immediate release 
preparation of tacrolimus. This means that any pharmacogenetic algorithms based on 
these genotypes can be applied to both preparations. 
When data were analysed based on the presence or absence of diabetes, we did not find 
any statistically significant differences (p = 0.056). However, another recent study 
showed that diabetic patients have significantly higher dose adjusted tacrolimus levels 
compared to non-diabetic patients (Chitnis et al., 2013) and our study is likely to have 
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been statistically underpowered to pick this up. Age appeared to be associated with 
tacrolimus dosing requirements. Our findings demonstrated that tacrolimus dosing 
requirements were higher in younger than older patients. This is in line with previous 
reports showed that age correlated significantly with tacrolimus dose in both adults 
(Kim et al., 2012) and paediatric patients (Gijsen et al., 2011). In addition, patient sex 
greatly affected tacrolimus dose requirements. Tacrolimus dose was significantly lower 
in males compared to females. This is in accordance with the results of a recent study 
identified male sex as a significant risk factor for being slower tacrolimus metabolizers 
(Stratta et al., 2012). Similarly, our results also confirm a minor role of the ABCB1 
3435C>T variant allele. In contrast, CYP3A5*3 allele is a key factor in the 
interpretation of tacrolimus blood concentrations and dose requirement. Furthermore, 
the haematocrit value was significantly associated with tacrolimus dose requirements, 
consistent with previous reports (de Jonge et al., 2012, Stratta et al., 2012). Previous 
report has described higher tacrolimus dose requirement in black patients (Macphee et 
al., 2005), which is consistent with our findings. 
Finally, multiple regression analysis by stepwise selection identified the combined 
CYP3A5*3 and ABCB1 3435C>T genotype, sex, age, haematocrit value, ethnicity, 
corticosteroids treatment and diabetic status as independent variables associated with 
tacrolimus dose requirements. We found that the combined CYP3A5*3 and ABCB1 
3435C>T genotype may explain 36.9% of the variability in tacrolimus dose 
requirements. Age, sex, haematocrit value, ethnicity, corticosteroids treatment and 
diabetic status may partially explain the gap in the variability in tacrolimus dose 
requirement that cannot be explained by genetic factors in renal transplant patients. Our 
findings suggest that taking all these aforementioned factors into consideration may 
account for 59.9% of the between-individual variability in tacrolimus dose 
requirements. These findings may have potential clinical application for initiation and 
adjustment of tacrolimus therapy.  
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5 Chapter 5. Associations of CYP3A4*22 and 
POR*28 Genotypes with Pharmacokinetics of 
Immediate and Prolonged Release Tacrolimus 
Preparations. 
This study is part of a larger pharmacokinetic study; detailed information on the study 
participants and procedure can be found in Chapter 4. The objectives of the study were: 
1. To develop new methods for genotyping CYP3A4*22 and POR*28 SNPs using a 
LightCycler based technique. 
2. To study the relationship between CYP3A4*22 and POR*28 SNPs and the 
pharmacokinetics of immediate release tacrolimus; Prograf® and Adoport® and 
prolonged release; Advagraf® within individual patients. 
5.1 Rapid Genotyping Methods for CYP3A4*22 and POR*28 
Polymorphisms with Real-time Polymerase Chain Reaction 
Fluorescence Resonance Energy Transfer Assays. 
5.1.1 Introduction 
The cytochrome P450 family (CYP450) represents a family of proteins that have an 
important role in first-pass metabolism. The most important cytochrome P450 isoforms 
responsible for drug metabolism are the CYP3A family and mainly present in tissues 
such as the gastrointestinal tract and liver. CYP3A enzymes are involved in the 
oxidative biotransformation of numerous clinically useful therapeutic agents 
(Wilkinson, 1996). Within this subfamily, CYP3A4 is the most abundant CYP enzyme 
and involved in the metabolism of 45–60% of all currently used drugs (Danielson, 
2002). CYP3A4 activity shows 10- to 100-fold variation between individuals (Wang et 
al., 2011). Recently, a mutation associated with reduced CYP3A4 activity has been 
described: CYP3A4*22 rs35599367C>T. The CYP3A4*22 SNP was correlated with the 
dose requirements of some drugs, including statins and tacrolimus (Elens et al., 2011a, 
Wang et al., 2011). 
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Cytochrome P450 reductase also known as NADPH: P450 oxidoreductase (POR),a 
membrane-bound enzyme, serves as the electron donor to almost all cytochromes P450 
(Jensen and Møller, 2010). It supplies electrons to all microsomal P450s for catalytic 
activity and the POR*28 (rs1057868C>T) SNP is the most common sequence variant. It 
was reported that POR*28 was associated with CYP3A activity (Oneda et al., 2009). 
Recently, some studies showed a significant association between POR*28 and 
tacrolimus pharmacokinetics and dose requirement. CYP3A5 expressers carrying at 
least one POR*28 allele have shown higher tacrolimus dose requirements than CYP3A5 
expressers carrying no POR*28 alleles (de Jonge et al., 2011). RT-PCR allows 
quantification of the target polymorphic DNA regions and genotyping of single 
nucleotide polymorphisms (SNPs) in one single PCR run. It facilitates a high speed 
PCR analysis and minimizes the risk of contamination during analysis. 
5.1.2 Materials and Methods  
Ethylenediaminetetraacetic acid anticoagulated whole blood samples were collected 
from 22 patients and stored at –20°C until DNA isolation. DNA was isolated from 
200μl EDTA anticoagulated blood using QIAamp DNA Blood Mini Kit (QIAGEN®, 
West Sussex, UK). PCR was performed using LightCycler® 2.0 supplied from Roche® 
(Lewes, UK). The LightCycler FastStart DNA Master Hybridisation Probe kit was 
supplied from Roche® (West Sussex, UK). The primers and the fluorogenic probes used 
were designed and synthesised by TIB MOLBIOL (Berlin, Germany). Two primers and 
probes were received from TIB MOLBIOL for each SNP and several fluorescence 
resonance energy transfer (FRET) designs have been tested to get the best peak intensity 
and then Mg
2+
 concentration in the reaction mixture was also adjusted and optimized to 
get much better resolution.  
Restriction Fragment Length Polymorphism Analysis of PCR-Amplified Fragments 
(PCR-RFLP) for the CYP3A4*22 and POR*28 polymorphisms was used to confirm the 
results obtained by the real-time PCR FRET assays. In order to validate FRET 
genotyping methods, samples of different CYP3A4*22 and POR*28 polymorphisms 
were sequenced. PCR was performed using PTC 100 Peltier thermal cycler (Bio-Rad 
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Laboratories Ltd, Hertfordshire, UK) and a Mastercycler pro S vapo.protect Thermal 
Cycler (Eppendorf, USA). PCR products were electrophoresed on a 5% agarose gel 
(Sigma Aldrich, UK) containing 0.3 mg/l ethidium bromide at 75V for 1 hour and 
examined under ultraviolet illumination. The PCR products were sequenced according 
to a direct sequence procedure performed with the capillary sequencer ABI 3130xL 
Genetic Analyser (Applied Biosystems, Warrington, UK) using BigDye® Terminator 
v3. 1 Cycle Sequencing Kit was supplied from Applied Biosystems® (Warrington, UK).  
5.1.2.1 CYP3A4*22 and POR*28 Genotyping with Real-time PCR 
5.1.2.1.1 CYP3A4*22 C >T Genotyping 
In this method we used two primers, forward and reverse and one single probe. The 
sequence of the forward primer was TgATAgTgggTCTCTgTCTTCC and of the reverse 
primer AgCCACAgACTTTCAgATCTACTAg while the sequence of the probe was 
CTACACTgggTgTgA XI TggAgACACT—PH. The reaction mixture made up of 0.5 
µM of each primer and 0.3 µM of the probe. 2 µL of DNA samples was added to each 
reaction. Three control samples were included in each LightCycler run, two positive 
controls and one negative control (Deionized water). The samples were loaded into 
composite glass capillaries (Roche Molecular Biochemicals) containing 18µL of the 
reaction mixture, centrifuged, and placed in the LightCycler sample carousel. The 
program was designed using 60°C annealing temperature. After an initial denaturation 
step at 95°C for 10.0 min, amplification was performed using 45 cycles of denaturation 
(95°C for 5 s), annealing (55°C for 10 s), and extension (72°C for 20 s). After 
amplification was complete, a final melting curve was recorded by annealing at 40°C 
for 20s, followed by an increase in temperature at a rate of 0.1°C/s, with continual 
fluorescence detection up to 85°C. The florescence display was at F1 mode for 
fluorescence display. Melting curves were converted into melting peaks using the 
LightCycler Software by plotting the negative derivatives of fluorescence against 
temperature (- dF/dT). 
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5.1.2.1.2 POR*28 C >T Genotyping 
The sequence of the forward primer was CACAggTCCACCCCAACTCT and of the 
reverse primer CAggCggAACTgggACTT while the sequence of the probe was 
ggAgCCTgCCggggA XI AACg--PH. The method used for POR*28 was the same as 
CYP3A4*22. The reaction mixture consisted of 0.1 µM (2 pmoL in 20 µL) of the 
forward primer with 0.5 µM (10 pmoL) of the reverse primer and 0.5 µM probe. Three 
control samples were included in each LightCycler run, two positive controls and one 
negative control (Deionized water). 2 µL of DNA samples were loaded into composite 
glass capillaries (Roche Molecular Biochemicals) containing 18µL of the reaction 
mixture, centrifuged, and placed in the LightCycler sample carousel. The PCR protocol 
included the following steps: pre- incubation phase at 95°C for 10 min to activate the 
Taq polymerase enzyme, followed by amplification phase, which includes 45 cycles of 
denaturation (95°C, 10s), annealing (55°C, 5 s) and extension (72°C, 15 s). Then this 
was followed by melting curve analysis stage, which involved annealing at 60°C for 
50s, followed by an increase in temperature at a rate of 0.1C/s, with continual 
fluorescence detection up to 95°C.  The florescence display was at F1 mode for 
fluorescence display. Melting curves were converted into melting peaks using the 
LightCycler Software by plotting the negative derivatives of fluorescence against 
temperature (- dF/dT). 
5.1.2.2 CYP3A4*22 and POR*28 Genotyping with DNA Sequencing 
The PCR products of twenty two patients’ DNA samples were sequenced by the 
capillary sequencer ABI 3130xL Genetic Analyser® (Applied Biosystems, Warrington, 
UK) using BigDye® Terminator v3. 1 Cycle Sequencing Kit supplied from Applied 
Biosystems® (Warrington, UK). Electropherograms of each PCR fragment were 
obtained containing the SNPs of interest. DNA samples were amplified using the same 
primers used with the LightCycler for those four SNPs. These samples were analysed to 
confirm the genotypes obtained using the LightCycler. Each sequence of PCR fragment 
was confirmed in both directions, forward and reverse directions. The genotyping 
assays consisted of the following five steps.  
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5.1.2.2.1 PCR Amplification 
Each PCR was performed in a reaction volume of 20μL containing DNA master mix, 
MgCl2, forward and reverse primers, with the same protocol mentioned in its 
LightCycler method, and 2μL of genomic DNA.  The DNA master mix (Roche®, UK) 
consisted of Taq DNA polymerase, reaction buffer, dNTP mix (with dUTP instead of 
dTTP) and 10mM MgCl2. The PCR cycle protocol was done for the 2 SNPs and 
consists of the following steps, initial denaturation step at 95°C for 10.0 min, 
amplification was performed using 40 cycles of denaturation (95°C for 10 s), annealing 
(65°C for 10 s), and extension (72°C for 20 s), followed by a final extension at 72°C for 
10.0 min.  
In order to check whether the PCR generated the anticipated DNA fragment, agarose gel 
electrophoresis was employed.  PCR products were electrophoresed on a 5% agarose 
gel (Sigma Aldrich, UK) containing 0.3 mg/l ethidium bromide covered with TBE 
buffer, buffer solution containing a mixture of Tris base, boric acid and EDTA, at 75V 
for 1 hour and examined under ultraviolet illumination. TBE buffer was obtained from 
Sigma Aldrich, UK.  
5.1.2.2.2 Shrimp Alkaline Phosphatase (SAP) and Exonuclease I Treatment.  
In order to remove unincorporated deoxynucleotide triphosphates and primers from the 
PCR amplification step, the PCR products were treated with Fermantas® shrimp 
alkaline phosphatase and exonuclease I (Thermo Scientific®, UK). A 3.2 µL aliquot of a 
mixture of shrimp alkaline phosphatase (240 µL of 1unit/µL), exonuclease I (12 µL of 
20 unit/µL) and diluted SAP buffer (120 µL) was added to the PCR product and the 
mixture was incubated at 37°C for 120 min, followed by an incubation at 85°C for 20 
min (to denaturate the enzymes), in the pro S vapo.protect Thermal Cycler. The treated 
PCR products were then kept at -20°C until use. 
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5.1.2.2.3 DNA Sequencing using Dye-Terminator Cycle-Sequencing.  
To sequence the PCR product, BigDye-terminator cycle-sequencing kit (Applied 
Biosystems, UK) was used. In the cycle-sequencing  process, 2µL of the PCR template 
was added to 1 µL of the primer (forward or reverse), 0.5 µL of BigDye mix to each 
tube, and was brought to a final volume of 10 µL with dH2O (6.5µL). ABI-supplied 
BigDye mix consisted of Taq DNA polymerase, dNTPs (deoxy nucleotide 
triphosphates) in large concentration and ddNTPs (dideoxy nucleotide triphosphates) 
with fluorescent dyes in low concentration. In this reaction only one primer is used so 
we did one forward and one reverse reaction. After an initial denaturation step at 96°C 
for 5.0 min, amplification was performed using 30 cycles of denaturation (96°C for 10 
s), annealing (57°C for 5 s), and extension (60°C for 4.0 min), followed by termination 
at 4°C for 10.0 min. 
5.1.2.2.4 Reaction Clean Up 
Sequencing reactions need to be cleaned up prior to injection on the ABI sequencer in 
order to remove salts from the reaction buffers, unincorporated nucleotides, and dye 
terminators that can interfere with electrophoretic dynamics and laser function. Such 
cleaning was done by filtering through the sephadex column. The sephadex mixture was 
prepared using 10g of sephadex beads (Sigma Aldrich, UK) and 150 mL distilled water, 
the solution was microwaved with a normal setting for 1 minute, and then the solution  
was allowed to cool using magnetic stirrer and spinner for a few hours. Sephadex 
mixture (500 µL) was loaded on each tube and spun at 1000 x g to get rid of excess 
water. Then the sephadex columns were placed on top of a clean PCR plate. Following 
this step, 10 µL of the mixture was loaded directly into the centre of each sephadex well 
and it was spun again at 1000 x g to obtain the filtered sample. The filtrate was then left 
in the PCR plate, and was placed in a PCR machine at 90°C till dryness. It was then 
reconstituted with 12 µL of formamide (Sigma Aldrich, UK), and the plate was covered 
with an adhesive PCR film (Thermo Scientific, UK), heated at 95°C for 5.0 min, and 
fast frozen at -20°C until use. 
Associations of CYP3A4*22 and POR*28 Genotypes with Tacrolimus PK 
Page 178 of 377 
5.1.2.2.5 Genotype Determination on the Sequencer 
The labelled sequencing products were sequenced on the Applied Biosystems 3130xL 
Genetic Analyser. After the sequencing reactions, the plate was placed in the sequence 
analyser and linked with standard method. The first run took 45 min and the run after 
that took 30 min. The created raw files were analysed with sequencing analysis 5.3.1 
program to create the electropherograms. These electropherograms were visualized with 
FinchTV program to obtain the genotyping. 
5.1.2.3 Statistical Analysis 
The genotype distribution for each polymorphism was assessed for deviation from 
Hardy–Weinberg equilibrium, and differences in genotype frequency and in allele 
frequency between the groups were assessed using the Chi-squared test. 
5.1.3 Results 
For CYP3A4 rs35599367C>T polymorphism, the melting point of the sensor probe was 
61°C when hybridised to CYP3A4*22 CC genotype. While the heterozygote 
polymorphism CYP3A4*22CT presented two melting peaks, at 61ºC and 66ºC (Figure 
34 A). In our study population, there were no CYP3A4*22 TT homozygotes which 
would be anticipated to have a melting peak at 66ºC. For the POR*28 polymorphism, 
the melting peak for POR*28 CC homozygotes was at 62ºC, whereas melting peaks for 
POR*28 TT homozygotes were at approximately 50ºC. While in the heterozygote 
polymorphism POR*28 CT, both melting peaks appeared (Figure 34 B). Twenty PCR 
products were randomly selected from the genotype melting profiles for DNA 
sequencing conformation. CYP3A4*22 and POR*28 allelic variants and results obtained 
by real time PCR were confirmed by sequencing these genes. 100% concordance was 
obtained between the genotype and SNPs assessed by LightCycler. The DNA 
sequencing results for CYP3A4*22 and POR*28 are displayed in (Figure 35). 
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Figure 34: Derivative Melting Curve Plots for CYP3A4*22 and POR*28 
Genotyping using Specific Primers and Probes. A. The Derivative 
Melting Curve for the CYP3A4*22 Genotypes. Samples with the 
Homozygous C Allele (       ; Tm 61°C) and Heterozygous C/T genotype      
(      ; Tm 61°C and 66°C). B. The Derivative Melting Curve for the 
POR*28 Genotypes. Samples with the Homozygous T Allele (      ; Tm 
50°C); Homozygous C Allele (     ; Tm 62°C) and Heterozygous C/T 
Genotype (        ; Tm 50 °C and 62°C). The Melting Curve of a No 
Template Control in Both Assays (         ). 
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Figure 35: Sequencing of Representative Samples of CYP3A4*22 and POR*28 
SNPs Showing the Sequencing Results of the Representative Wild Type, 
Heterozygous and Homozygous Mutants of CYP3A4*22 and POR*28 
Polymorphisms. 
CYP3A4*22 and POR*28 genotypes and allele frequencies are presented in Table 28. 
The genotype frequencies of the recipients were consistent with Hardy-Weinberg 
equilibrium (p > 0.05).  
Table 28: Genotype Frequencies for CYP3A4*22 and POR*28 in Renal Transplant 
Patients 




CYP3A4*22 c.522-191 C>T C/C 59 92.2% C = 0.96 
  
C/T 5 7.8% T = 0.04 
  
T/T 0 0.0% 
 
      POR*28 A503V C/C 30 46.9% *1 = 0.71 
  
C/T 31 48.4% *3 = 0.29 
  
T/T 3 4.7% 
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5.1.4 Discussion and Conclusions 
In this study, we developed new methods for genotyping CYP3A4*22 and POR*28 
SNPs uses a LightCycler based technique. Recently, some studies explored the 
relationship between CYP3A4*22 and POR*28 alleles and tacrolimus exposure (Elens 
et al., 2011a, Elens et al., 2013a). These studies demonstrated that there is an effect of 
these genotypes on daily doses required for renal transplant patients. In our study, we 
determined the genotypes of CYP3A4*22 and POR*28 using the LightCycler method 
for 22 patients. The genotypes of patients’ samples were conducted using DNA 
sequence analysis. There was 100% concordance between the genotypes of the samples 
determined by sequencing and the genotypes determined by the LightCycler method. 
We present here a single-step method for homogeneous genotyping of the 
polymorphisms of the CYP3A4*22 and POR*28 genes that combines rapid-cycle PCR 
and fluorescent probe melting point analysis. Capillary PCR using the LightCycler is a 
reliable, convenient and simple method for genotyping CYP3A4*22 and POR*28 
polymorphisms. It shows excellent correlation with genotype determination by DNA 
sequencing. This is a rapid method and because of its robustness, speed, and accuracy, 
this assay is suitable to determine the CYP3A4*22 and POR*28 polymorphisms in small 
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5.2 CYP3A4*22 and POR*28 Genotype Associations with 
Tacrolimus Pharmacokinetics and Dose Requirements in 
Twice-Daily Tacrolimus and Advagraf®. 
5.2.1 Objective of the Study: 
The aim of this study is investigating the relationship between CYP3A4*22 and 
POR*28 SNPs and the pharmacokinetics of immediate release tacrolimus, Prograf® and 
Adoport® and prolonged release, Advagraf® within individual patients. 
5.2.2 Materials and Methods  
5.2.2.1 Study Design 
Tacrolimus pharmacokinetic data obtained from the previous study for 64 stable kidney 
transplant recipients were used in this study. Patients were genotyped for CYP3A4*22 C 
>T and POR*28 C >T polymorphisms using the same DNA samples extracted for 
CYP3A5*3 and ABCB1 3435 genotyping. The C and T alleles of POR*28 variant and in 
intron 6 of CYP3A4*22 variant were identified by the new developed RT-PCR using 
LightCycler as described previously. For each gene, subjects were divided into two 
groups according to their genotype. For CYP3A4*22, patients were divided into 
CYP3A4*22 CC and CYP3A4*22 CT/TT genotype groups and for POR*28, it was 
POR*28 CC and POR*28 CT/TT genotype groups. 
5.2.2.2 Pharmacokinetic and Statistical Analysis 
Statistical analysis was performed using Minitab statistical software (Minitab 17). 
Tacrolimus individual pharmacokinetic parameters were determined for each genotype 
group. The log-transformed data were analysed using analysis of variance (ANOVA) 
with factors for genotype group and treatment.  
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5.2.3 Results 
5.2.3.1 Patient Characteristics  
The characteristics of the 64 patients included in the study are reported in Table 29.  
According to CYP3A4*22 genotypes, 59 patients were homozygous for the C wild-type 
allele, while five patients carried one copy of the T-variant allele for the CYP3A4 intron 
6 SNP. This corresponds to a calculated allelic frequency of 7.8% in our study 
population. No significant differences were found between the CYP3A4 genotype 
groups except for the patients’ age (p = 0.014) and ethnicity (p = 0.015). All 
CYP3A4*22 CT carriers were CYP3A5 non-expressers and they were all from White 
ethnic background. 
Concerning POR*28 genotypes, 30 patients had the CC genotype, 31 patients had CT 
genotype and three were homozygous TT. We found no significant difference between 
the POR*28 genotype groups concerning the patients’ age (p = 0.123) and sex (p = 
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Table 29: Patients Demographic Characteristics and Immunosuppression Therapy. 
Characteristic 
CYP3A4*22 CC     
carriers (n = 59) 
CYP3A4*22 CT     
carriers (n = 5) 
POR*28 CC   carriers 
(n = 30) 
POR*28 CT/TT carriers    
CT (n = 31) & TT (n = 3) 
Sex 
   
 
Male/female 39/20 4/1 19/11 24/10 
Age (y), mean (SD) 55.4 ± 12.2 45.2 ± 16.7 56.4 ± 13.3 52.9 ± 12.2 
Race, n (%) 
   
 
White 34 (58%) 5 (100%) 19 (63%) 20 (59%) 
Black 12 (20%) - 6 (20%) 6 (18%) 
Asian 13 (22%) - 5 (17%) 8 (24%) 
Body weight (kg), mean (SD) 76.5 ± 15.2 75.1 ± 16.5 77.5 ± 16.0 75.4 ± 14.6 
Height (cm), mean (SD) 169.7 ± 8.5 175.5 ± 8.1 170.9 ± 10.2 169.4 ± 6.7 
Diabetes, n (%) 14 (24%) 1 (20%) 9 (30%) 6 (18%) 
Time since transplantation (years)   
 
 
Mean (SD) 4.2 ± 4.6 3.4 ± 5.0 4.0 ± 4.1 4.2 ± 5.1 
Median 2.2 1.3 2.2 1.8 
Donor type, n  
   
 
Living / Deceased 22/37 4/1 12/18 14/20 
Serum creatinine (µmol/L) 125.3 ± 41.5 114.6 ± 11.5 120.1 ± 41.4 128.5 ± 38.8 
Serum albumin(g/L) 38.8 ± 2.9 38.5 ± 5.2 38.8 ± 3.1 38.8 ± 3.1 
Haemoglobin, (g/L) 128.9 ± 22 137.8 ± 27.3 129.4 ± 15.8 129.8 ± 27.0 
Immunosuppression therapy 
   
 
Tacrolimus, n (%) 
   
 
Prograf®/ Adoport® 44 (75%) / 15 (25%) 3 (60%) / 2 (40%) 20 (67%) / 10 (33%) 27 (79%) / 7 (21%) 
Corticosteroids, n (%) 36 (61.0%) 3 (60%) 17 (57%) 22 (65%) 
Azathioprine, n (%) 12 (20%) 2 (40%) 7 (23%) 7 (21%) 
Mycophenolate, n (%) 19 (32%) - 9 (30%) 10 (29%) 
CYP3A5 Polymorphism     
CYP3A5 *1/*1/ *1/*3 30 (12/18) - 17 (6/11) 13 (6/7) 
CYP3A5 *3/*3 29 5 13 21 
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5.2.3.2 CYP3A4*22 & Tacrolimus Disposition  
The analysis has been done on 128 24-h PK profiles obtained from 64 patients with 
pooling of data for OD-Tac and TD-Tac. Tacrolimus blood concentrations Cmax, AUC0-
24 and C0 showed a log-normal distribution, and the data were therefore log-transformed 
before analysis. As shown in Table 30, a significant difference in dose-normalized C0 
was observed according to the patients CYP3A4*22 allelic status. Patients carrying a T 
variant allele had 1.8 fold higher dose-normalized C0 compared to homozygous CC 
allele carriers (P= 0.006). The dose-normalized Cmax was higher for the T variant 
carriers than for CC patients: 37.2 ±15.4µg/L vs 25.8 ±13.9µg/L (P=0.015). Moreover, 
a significant difference was observed in AUC0-24 between the two genotypes; 
CYP3A4*22CC and CYP3A4*22CT carriers (329.9 ± 198.6 vs. 562.0 ± 313.3, p = 
0.006). Despite that the T allele carriers required significantly lower tacrolimus doses 
than CC patients to reach this C0. The mean daily dose requirement of tacrolimus per 
body weight was 38.2% lower for T-variant allele carriers compared to CC allele 
carriers (p = 0.006; see Figure 36). 
Table 30: Tacrolimus Dose-Normalized PK Parameters According to CYP3A4*22 
Genotypes for the Whole Data of Once-and Twice-Daily Tacrolimus. 
PK-parameter CYP3A4*22 CC                                                 
(n= 118) 
CYP3A4*22 CT                                  
(n= 10) 
P-value 
Dose (mg/Kg/day) 0.08 ± 0.05 0.05 ± 0.04 <0.01 
Cmax (µg/L/mg/Kg) 25.8 ± 13.9 37.2 ± 15.4 <0.05 
AUC0-24 (µg*h/L/mg/Kg) 329.9 ± 198.6 562.0 ± 313.3 <0.01 
C0 (µg/L/mg/Kg) 10.6 ± 7.4 19.5 ± 13.0 <0.01 
Values were compared using ANOVA (General linear model). 
Upon comparing the influence of CYP3A4*22 polymorphism on both tacrolimus 
formulations, we found no association between CYP3A4*22 genotypes and tacrolimus 
dose-normalized AUC0–24, Cmax and C0 (p > 0.05), see Table 31 and Figure 37. In 
CYP3A4*22 CC group, the ratio of OD-Tac/TD-Tac AUC0–24 was 98% and its 90 % CI 
(82%–117%). In addition, the ratio of the OD-Tac/TD-Tac for Cmax was 90% (90% CI 
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79% –103%), falling outside 80% to 125% bioequivalence limits. Therefore, the two 
formulations were not bioequivalent. According to EMA guidelines, the confidence 
interval of the AUC0-24 ratio was outside the bioequivalence margin (90-111%). 
Therefore both formulations were not bioequivalent. These data are summarized in 
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Figure 36: CYP3A4*22 Genotype Associations with Tacrolimus Dose and Dose-Normalized Pharmacokinetic Parameters for the 
Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the values 
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Table 31: CYP3A4*22 Polymorphism Relationship with Dose-Normalized Tacrolimus Pharmacokinetic Parameters in Different 
Tacrolimus Formulation (Twice-Daily Tacrolimus; TD-Tac, and Advagraf®). 
PK-parameter 
CYP3A4*22 CC 
(n= 59)  
CYP3A4*22 CT 
(n= 5)  
 
TD-Tac Advagraf® P-value TD-Tac Advagraf® P-value 
Dose (mg/Kg/day) 0.08 ± 0.05 0.08 ± 0.05  0.048 ± 0.045 0.048 ± 0.045  
AUC0-24 (µg*h/L/mg/Kg) 340 ± 223 320 ± 173 0.85 582 ± 351 542 ± 311 0.92 
Cmax (µg/L/mg/Kg) 27.5 ± 15.8 24.2 ± 11.6  0.37 39.2 ± 17.6 35.3 ± 14.6 0.79 
C0 (µg/L/mg/Kg) 11.4 ± 8.8 9.7 ± 5.7 0.45 20.9 ± 14.5 18.2 ± 12.8 0.81 
Values were compared using ANOVA (General linear model). 
Table 32: Bioequivalence Statistics for AUC 0–24 and Cmax for Twice-Daily Tacrolimus (TD-Tac) and Once-Daily Tacrolimus (OD-
Tac) in CYP3A4*22 CC Carriers. 
Parameter CYP3A4*22 CC 
 
Ratio of geometric means (%) 90% CI 
AUC0–24 98% (82% – 117%) 
Cmax 90% (79% – 103%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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Figure 37: CYP3A4*22 Genotype and Tacrolimus Pharmacokinetic Parameters of Twice-daily Tacrolimus (TD-Tac) and 
Advagraf®. Boxes represent the interquartile range, line in the box represents the median value, symbol in the box represents 
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5.2.3.3 CYP3A5*3-CYP3A4*22 Combined Genotypes & Tacrolimus Disposition  
To investigate the combined associations between CYP3A5*3 and CYP3A4*22 
genotype and dose-normalized tacrolimus PK parameters, patients were divided with 
respect to CYP3A5 expressers (CYP3A5*1 allele carriers) or CYP3A5 non-expressers 
(CYP3A5*3/*3 carriers) and CYP3A4*22 high activity (CYP3A4*22 CC carriers) or 
medium-activity (CYP3A4*22 CT carriers) groups (Elens et al., 2011a). Three genotype 
groups were identified in our study population: extensive CYP3A metabolizers 
(CYP3A5*1 allele carriers /CYP3A4*22CC, n=30), intermediate CYP3A metabolizers 
(CYP3A5*3/*3 /CYP3A4*22CC, n=29) and poor CYP3A metabolizers (CYP3A5*3/*3 
/CYP3A4*22CT, n=5). The analysis has been done on 128 24-h PK profiles obtained 
from 64 patients with data for TD-Tac and OD-Tac pooled.  
Extensive CYP3A metabolizers required a significantly higher daily dose of tacrolimus 
compared to both the intermediate CYP3A metabolizers (P< 0.001) and poor CYP3A 
metabolizers groups (P< 0.001). However, the difference between the intermediate 
metabolizers and poor metabolizers was not statistically significant (p= 0.2). On the 
other hand, poor CYP3A metabolizers showed 95% higher dose-normalized tacrolimus 
Cmax compared to extensive metabolizers (p < 0.0001) and 13% higher dose-normalized 
tacrolimus Cmax compared to intermediate metabolizers (p= 0.4). The same trend was 
observed for tacrolimus dose-normalized AUC0-24 and C0. The intermediate CYP3A 
metabolizers had a slight, but not statistically significant, decrease in dose-normalized 
AUC0-24 (p= 0.3) and C0 (p= 0.4) compared to poor CYP3A metabolizers, see Figure 38 
& Table 33.  
No significant differences were found in tacrolimus dose and pharmacokinetic 
parameters between tacrolimus formulations in each group of the combined CYP3A 
genotypes (Figure 39; Table 34). The ratio of means (90% CI) of AUC0–24 for OD-Tac 
versus TD-Tac was as follows: extensive CYP3A metabolizers, 101% (88% –116%); 
Intermediate CYP3A metabolizers, 92% (81% –104%). Whereas the ratio of means 
(90% CI) of Cmax for OD-Tac versus TD-Tac was as follows: extensive CYP3A 
metabolizers, 93% (77% –111%); Intermediate CYP3A metabolizers, 88% (74% –
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104%). These ratios did not achieve bioequivalence limits of 80–125%. Based on Cmax 
results, TD-Tac and OD-Tac are no longer bioequivalent on a 1:1 conversion (Table 
35). According to EMA guidelines, the confidence intervals of the AUC0-24 ratios were 
outside the bioequivalence margin (90-111%). Therefore both formulations were not 
bioequivalent in all the genotype groups. 
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Figure 38: CYP3A5*3 and CYP3A4*22 Combined Genotypes and Dose-Normalized Tacrolimus Exposure and Dose Requirement 
for the Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the box represents 
the median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the 
values beyond the whiskers (asterisks) are outliers Extensive CYP3A metabolizers are CYP3A5*1 allele /CYP3A4*22CC 
carriers. Intermediate CYP3A metabolizers are CYP3A5*3/*3 /CYP3A4*22CC carriers. Poor CYP3A metabolizers are 
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Table 33: CYP3A5*3 and CYP3A4*22 Combined Genotypes and Dose-Normalized Tacrolimus Exposure and Dose for the Whole 













Dose (mg/Kg/day) 0.11 ± 0.05 0.05 ± 0.02 0.05 ± 0.04 <0.001 0.2 
AUC0-24 (µg*h/L/mg/Kg) 223.4 ± 140.3 440.1 ± 190.3 562 ± 313.3 <0.001 0.3 
Cmax (µg/L/mg/Kg) 19.1 ± 10.6 32.8 ± 13.5 37.2 ± 15.4 <0.001 0.4 
C0 (µg/L/mg/Kg) 6.9 ± 5.1 14.3 ± 7.6 19.5 ± 13.0 <0.001 0.4 
Extensive CYP3A metabolizers are CYP3A5*1 allele /CYP3A4*22CC carriers. Intermediate CYP3A metabolizers are CYP3A5*3/*3 
/CYP3A4*22CC carriers. Poor CYP3A metabolizers are CYP3A5*3/*3 /CYP3A4*22CT carriers. Data are shown as mean ± SD. 
a
   p-Values refer to comparisons to extensive metabolizers. 
b
   p-Values refer to comparisons between intermediate and poor metabolizers 
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Figure 39: CYP3A5*3 and CYP3A4*22 Genotypes Relationship with Dose-Normalized Tacrolimus Exposure and Dose 
Requirement in Both Tacrolimus Formulations. Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value and the values 
beyond the whiskers (asterisks) are outliers. Extensive CYP3A metabolizers are CYP3A5*1 allele /CYP3A4*22CC carriers. 
Intermediate CYP3A metabolizers are CYP3A5*3/*3 /CYP3A4*22CC carriers. Poor CYP3A metabolizers are CYP3A5*3/*3 
/CYP3A4*22CT carriers. 
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Table 34: Tacrolimus Dose-Normalized Pharmacokinetic Parameters for Twice-Daily Tacrolimus (TD-Tac) and Advagraf® in 
CYP3A Combined Genotype Groups 
PK-parameter 
Extensive metabolizers 
(n= 30)  
Intermediate metabolizers 
(n= 29)  
Poor metabolizers 
(n= 5)  
  TD-Tac Advagraf® p-value TD-Tac Advagraf® p-value TD-Tac Advagraf® p-value 
Dose (mg/Kg/day) 0.11 ± 0.05 0.11 ± 0.05 
 
0.05 ± 0.02 0.05 ± 0.02 
 
0.05 ± 0.05 0.05 ± 0.05 
 
AUC0-24 (µg*h/L/mg/Kg) 223 ± 130 224 ± 152 0.9 419 ± 155 461 ± 221 0.6 542 ± 311 582 ± 351 0.9 
Cmax (µg/L/mg/Kg) 18.1 ± 9.2 20.1 ± 11.8 0.6 30.5 ± 10.4 35.2 ± 15.9 0.3 35.3 ± 14.6 39.2 ± 17.6 0.8 
C0 (µg/L/mg/Kg) 6.7 ± 4.5 7.2 ± 5.7 0.7 12.8 ± 5.1 15.8 ± 9.4 0.3 18.2 ± 12.8 20.9 ± 14.5 0.8 
Extensive CYP3A metabolizers are CYP3A5*1 allele /CYP3A4*22CC carriers. Intermediate CYP3A metabolizers are CYP3A5*3/*3 
/CYP3A4*22CC carriers. Poor CYP3A metabolizers are CYP3A5*3/*3 /CYP3A4*22CT carriers. Data are shown as mean ± SD. Values 
were compared using ANOVA (General linear model). 
Table 35: Bioequivalence Statistics for AUC 0–24 and Cmax for Twice-Daily Tacrolimus (TD-Tac) and Once-Daily Tacrolimus OD-
Tac in CYP3A Combined Genotype Groups. 
Parameter Extensive metabolizers Intermediate metabolizers 
 
Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 101% (88% – 116%) 92% (81% – 104%) 
Cmax 93% (77% – 111%) 88% (74% – 104%) 
Extensive CYP3A metabolizers are CYP3A5*1 allele /CYP3A4*22CC carriers. Intermediate CYP3A metabolizers are CYP3A5*3/*3 
/CYP3A4*22CC carriers. 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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5.2.3.4  The Relationship between POR*28 Polymorphism and Tacrolimus 
Pharmacokinetics  
The analysis has been done on 128 24-h PK profiles obtained from 64 patients with data 
for TD-Tac and OD-Tac pooled. The relationship between POR*28 polymorphism and 
the pharmacokinetic parameters of tacrolimus is shown in Table 36. When considering 
only the POR*28 allelic status, no significant difference in the dose-normalized AUC0–
24, Cmax, C0 values and the daily of tacrolimus was observed between the POR*28 
genotype groups (p > 0.05). The mean daily dose and plasma concentrations of 
tacrolimus in individuals with different POR*28 genotypes are shown in Figure 40. 
When considering both POR*28 allelic status and tacrolimus formulations, this 
difference remained not significant (Table 37 & Figure 41).      
In POR*28 CC group, AUC0-24 OD-Tac / AUC0-24 TD-Tac was 97% (90% CI 85% -
112%) and Cmax OD-Tac / Cmax TD-Tac was 88% (90% CI 75% -103%). While in the 
POR*28 CT/TT group, AUC0-24 OD-Tac / AUC0-24 TD-Tac was 96% (90% CI 84% -
109%) and Cmax OD-Tac / Cmax TD-Tac was 93% (90% CI 77% -111%). The Cmax OD-
Tac/ Cmax TD-Tac ratios in both groups were falling outside 80% to 125% 
bioequivalence limits. Consequently, both formulations were not bioequivalent. Based 
on EMA guidelines, the confidence intervals of the AUC0-24 ratios were outside the 
bioequivalence margin (90-111%). Therefore, both formulations were not 
bioequivalent. These data are summarized in Table 38.  
Table 36: Dose-Normalized Pharmacokinetics of Tacrolimus in Renal Transplant 
Recipients with Different POR*28 Genotypes for the Whole Data of 
Once-and Twice-Daily Tacrolimus.  
PK-parameter 
POR*28 CC                                                  
(n= 60) 
POR*28 CT/TT                                   
(n= 68) 
p-value 
Dose (mg/Kg/day) 0.08 ± 0.05 0.07 ± 0.05 0.72 
Cmax (µg/L/mg/Kg) 26.6 ± 14.5 26.9 ± 14.2 0.96 
AUC0-24 (µg*h/L/mg/Kg) 353 ± 239 344 ± 198 0.68 
C0 (µg/L/mg/Kg) 11.8 ± 9.6 10.8 ± 7.0 0.89 
Data are shown as mean ± SD. Values were compared using ANOVA (General linear 
model). 
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Figure 40: The Dose-Normalized Mean Pharmacokinetic Parameters of Tacrolimus in Renal Transplant Recipients with Different 
POR*28 Genotypes for the Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line 
in the box represents the median value, symbol in the box represents the mean value, outer lines represent the minimal and 
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POR*28 CC  
(n= 30)   
  
POR*28 CT/TT  
(n= 34) 
  
TD-Tac Advagraf® p-value TD-Tac Advagraf® p-value 
Dose (mg/Kg/day) 0.08 ± 0.05 0.08 ± 0.05 
 
0.07 ± 0.05 0.07 ± 0.05 
 
AUC0-24 (µg*h/L/mg/Kg) 361 ± 260 344 ± 221 0.94 357 ± 226 331 ± 168 0.81 
Cmax (µg/L/mg/Kg) 28.7 ± 16.4 24.5 ± 12.3 0.44 28.2 ± 16.2 25.5 ± 12.0 0.59 
C0 (µg/L/mg/Kg) 12.5 ± 10.9 11.0 ± 8.1 0.76 11.9 ± 8.4 9.8 ± 5.3 0.40 
TD-Tac: Twice daily tacrolimus.  
Values were compared using ANOVA (General linear model). 
Table 38: Bioequivalence Statistics for AUC 0–24 and Cmax for TD-Tac and OD-Tac in POR*28 Genotypes. 
Parameter POR*28 CC POR*28 CT/TT 
 
Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 97% (85% – 112%) 96% (84% – 109%) 
Cmax 88% (75% – 103%) 93% (77% – 111%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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Figure 41: Dose-Normalized Mean Pharmacokinetic Parameters of Tacrolimus with Different POR*28 Genotypes in Once- and 
Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the box represents the median value, symbol in the 
box represents the mean value, outer lines represent the minimal and maximal value and the values beyond the whiskers 
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5.2.3.5 POR*28 Polymorphism Association with Tacrolimus Pharmacokinetics in 
CYP3A5 Expressers and Non-Expressers. 
According to the likely level of CYP3A5 expression, subjects were divided into 
CYP3A5 expressers (CYP3A5*1 allele carriers) and CYP3A5 non-expressers 
(CYP3A5*3/*3 carriers). The effect of the POR*28 polymorphism on the 
pharmacokinetics of tacrolimus was studied in each group. The demographic 
characteristics of each subgroup are shown in Table 39. We observed no differences in 
these characteristics between POR*28 genotypes in both CYP3A5 expressers and non-
expressers. The analysis has been done on 128 24-h PK profiles obtained from 64 
patients with data for TD-Tac and OD-Tac pooled. 
CYP3A5 non-expressers carrying at least one POR*28 T allele had a significant 
increase in tacrolimus daily dose compared to CYP3A5 non-expressers carrying the 
POR*28CC genotype [median (IQR): 0.05 (0.02 – 0.13) mg/Kg/day vs. 0.04 (0.02 –
0.08) mg/Kg/day; P < 0.01). In CYP3A5 non-expressers, the dose-normalized 
tacrolimus C0 was significantly higher in POR*28 CC carriers than POR*28 T variant 
allele carriers (18.7 ± 10.3 vs. 12.9 ± 6.7, P<0.01). There was no statistically significant 
association between POR*28 genotype and the CYP3A5 expresser group. The dose-
normalized tacrolimus AUC0-24 for POR*28 T allele carriers expressing CYP3A5 was 
not significantly different to that in POR*28 CC homozygote patients (P = 0.41). By 
contrast to the CYP3A5 expresser group, POR*28 CT/TT individuals not expressing 
CYP3A5 had a 24% reduction in the dose-normalized AUC0-24 (90%CI 4 to 40%; 
p<0.01). Moreover, no significant difference was found in tacrolimus dose-normalized 
Cmax between the POR*28 genotype groups, neither in the CYP3A5 expresser group (P 
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Table 39: Patients Demographic Characteristics According to CYP3A5 and POR*28 Genotypes. 
Characteristic 
CYP3A5 Expressers  
(*1/*1 & *1/*3) 
CYP3A5 Non-expressers 
(*3/*3) 
POR*28 CC (n=17) POR*28 CT/TT ( n=13) POR*28 CC (n=13) POR*28 CT/TT ( n= 21) 
Sex  
  
    
Male/female 10/7 8/5 9/4 16/5 
Age (y) , mean (SD) 51.7 ± 11.1 54.8 ± 14.2 57.2 ± 15.5 55.0 ± 11.5 
Race, n (%) 
  
    
White 10 (59%) 9 (69%) 7 (54%) 13 (62%) 
Black 4 (24%) 2 (15%) 3 (23%) 3 (14 %) 
Asian 3 (18%) 2 (15%) 3 (23%) 5 (24 %) 
Body weight (kg), mean (SD) 83.4 ± 19.5 73.6±9.4 72.1 ± 9.1 75.1 ± 16.1 
Height (cm), mean (SD) 171.7 ± 9.5 168.4±8.6 173.0 ± 9.9 168.2 ± 6.5 
Diabetes, n (%) 3 (18%) 3 (23%) 3 (23%) 6 (29%) 
Time since transplantation (years) 
  
    
Mean (SD) 3.6 ± 5.7 6.2 ± 4.2 3.8 ± 4.0 3.4 ± 4.2 
Median (interquartile range, QR) 1.3 6.1 1.1 1.7 
Donor type, n  
   
  
Living / Deceased 10/7 4/9 5/8 10/11 
Serum creatinine (µmol/L) 125.1 ± 33.4 112 ± 27 122.2 ± 61.9 132.9 ± 33.2 
Serum albumin(g/L) 38.7 ± 2.6 38.4 ± 3.2 38.3 ± 2.4 39.4 ± 3.8 
Haemoglobin, (g/L) 129.3 ± 14.1 140.2 ± 18.1 127.5 ± 13.5 124.5 ± 31.6 
Immunosuppression therapy  
  
    
Tacrolimus, n (%) 
  
    
Prograf®/ Adoport® 10 (59%) / 7 (41%) 11 (85%) / 2 (15%) 10 (77%) / 3 (23%) 16 (76%) / 5 (24%) 
Corticosteroids, n (%) 5 (29%) 13 (100%) 10 (77%) 11 (52%) 
Azathioprine, n (%) 6 (35%) _ 3 (23%) 5 (24%) 
Mycophenolate mofetil, n (%) 7 (41%) 2 (6%) 4 (31%) 6 (29%) 
CYP3A4*22 Polymorphism       
CYP3A4*22 CC 17 (100%) 13 (100%) 10 (77%) 19 (90%) 
CYP3A4*22 CT 0 (0%) 0 (0%) 3 (23%) 2 (10%) 
Associations of CYP3A4*22 and POR*28 Genotypes with Tacrolimus PK  
Page 202 of 377 
Table 40: Dose-Normalized Tacrolimus PK Parameters According to CYP3A5*3 and POR*28 Genotypes for the Whole Data of 
Once-and Twice-Daily Tacrolimus. 
PK-parameter 
CYP3A5 Expressers  





POR*28 CC POR*28 CT/TT 
 
POR*28 CC POR*28 CT/TT 
 
(n= 34) (n= 26) 
 
(n= 26) (n= 42)   
Dose (mg/Kg/day) 0.11 ± 0.05 0.10 ± 0.05 0.56 0.04 ± 0.02 0.06 ± 0.03 0.006 
Cmax (µg/L/mg/Kg) 19.1 ± 10.2 19.1 ± 11.2 0.72 36.4 ± 13.6 31.7 ± 13.8 0.16 
AUC0-24 (µg*h/L/mg/Kg) 212 ± 105.7 238 ± 177 0.41 537 ± 241 409 ± 183 0.02 
C0 (µg/L/mg/Kg) 6.5 ± 4.0 7.5 ± 6.3 0.40 18.7 ± 10.3 12.9 ± 6.7   0.007 
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Figure 42: Dose-Normalized Mean Pharmacokinetic Parameters of Tacrolimus in Different CYP3A5 and POR*28 Combined 
Genotypes for the Whole Data of Once-and Twice-Daily Tacrolimus. Boxes represent the interquartile range, line in the box 
represents the median value, symbol in the box represents the mean value, outer lines represent the minimal and maximal value 
and the values beyond the whiskers (asterisks) are outliers. CYP exp refers to CYP3A5 expressers (CYP3A5 *1/*1 & *1/*3 




















































































































































































Associations of CYP3A4*22 and POR*28 Genotypes with Tacrolimus PK  
Page 204 of 377 
Additionally, when considering both the combined effects of CYP3A5*3 and POR*28 
allelic status and tacrolimus formulations, no significant difference in tacrolimus dose-
normalized pharmacokinetic parameters and dose was found between the POR*28 
genotypes within both the CYP3A5 expressers and non-expressers (P >0.05; Table 41 
& Figure 43). 
In CYP3A5 expressers carrying POR*28 CC genotype, the ratios of geometric means 
were 104% (90% CI of 88 –123%, p = 0.77) for AUC0–24 and 92% (90% CI 74 –115%, 
p = 0.71) for Cmax. For POR*28 CT/TT carriers the ratios of geometric means were 98% 
(90% CI of 71 –136%, p = 0.92) for AUC0–24 and 93% (90% CI 59 –146%, p = 0.70) for 
Cmax. While in CYP3A5 non-expressers carrying POR*28 CC genotype, the ratios of 
geometric means were 98% (90% CI of 71% –136%, p = 0.21 for AUC0–24 and 82% 
(90% CI 64–106%, p = 0. 57) for Cmax. For POR*28 CT/TT carriers the ratios of 
geometric means were 94% (90% CI of 80–112%, p = 0.64) for AUC0–24 and 92% (90% 
CI 73 –117%%, p = 0.78) for Cmax. The confidence intervals of AUC0-24 OD-Tac / 
AUC0-24 TD-Tac ratios were within the bioequivalence limits in CYP3A5 expressers 
having POR*28 CC genotype and CYP3A5 non-expressers having POR*28 CT/TT 
genotype. Whereas the confidence intervals of the other ratios were falling outside 80% 
to 125% bioequivalence limits. As a result, both formulations were not bioequivalent in 
all the genotype groups. Based on EMA guidelines, the confidence intervals of the 
AUC0-24 ratios were outside the bioequivalence margin (90-111%) in all the genotype 
groups. Consequently, the two formulations were not bioequivalent. These data are 
summarized in Table 42. 
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Table 41: Dose-Normalized Tacrolimus Pharmacokinetic Parameters for Different Combination of CYP3A5*3 and POR*28 
Genotypes in Both Once- and Twice-Daily Tacrolimus. 
PK-parameter 
CYP3A5 Expressers 







TD-Tac  Advagraf® P-value TD-Tac  Advagraf® P-value 
Dose (mg/Kg/day) 0.11 ± 0.05 0.11 ± 0.05 
 
0.10 ± 0.05 0.10 ± 0.05 
 
C0 (µg/L/mg/Kg) 6.4 ± 3.4 6.6 ± 4.7 0.96 8.2 ± 7.8 6.8 ± 4.5 0. 66 
Cmax (µg/L/mg/Kg) 19.9 ± 10.5 18.3 ± 10.0 0. 71 20.2 ± 13.8 17.9 ± 8.3 0.70 





POR*28 CC  





TD-Tac  Advagraf® P-value TD-Tac  Advagraf® P-value 
Dose (mg/Kg/day) 0.04 ± 0.02 0.04 ± 0.02 
 
0.06 ± 0.03 0.06 ± 0.03 
 
C0 (µg/L/mg/Kg) 20.5 ± 12.2 16.8 ± 8.1 0.51 14.1 ± 8.1 11.6 ± 4.9 0.38 
Cmax (µg/L/mg/Kg) 40.1 ± 15.8 32.7 ± 10.3 0.21 33.1 ± 15.8 30.2 ± 11.6 0.64 
AUC0-24 (µg*h/L/mg/Kg) 563 ± 266 511 ± 220 0.57 427 ± 216 392 ± 146 0.78 
TD-Tac: Twice daily tacrolimus.  
Values were compared using ANOVA (General linear model). 
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(*1/*1 & *1/*3) 
POR*28 CC POR*28 CT/TT 
Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 104% (88% – 123%) 98% (71% – 136%) 




POR*28 CC POR*28 CT/TT 
Ratio of geometric means (%) 90% CI Ratio of geometric means (%) 90% CI 
AUC0–24 98% (71% – 136%) 94% (80% – 112%) 
Cmax 82% (64% – 106%) 92% (73% – 117%) 
90% CI for geometric mean are based on the ANOVA model (General linear model). 
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Figure 43: Dose-Normalized Mean Pharmacokinetic Parameters of Tacrolimus with Different CYP3A5*3 and POR*28 Combined 
Genotypes in Twice-Daily Tacrolimus (TD-Tac) and Advagrf®. Boxes represent the interquartile range, line in the box 
represents the median value, symbol in the box represents the mean value, and outer lines represent the minimal and maximal 
value and the values beyond the whiskers (asterisks) are outliers. CYP exp refers to CYP3A5 expressers (CYP3A5 *1/*1 & 
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5.2.3.6 Factors Associated with Dose Requirements of Tacrolimus. 
The analysis has been done on 128 24-h PK profiles obtained from 64 patients with data 
for TD-Tac and OD-Tac pooled. As we mentioned before, univariate regression analysis 
showed that age, sex, haematocrit, ethnicity, time since transplant, ABCB1 3435 and 
CYP3A5*3 are factors associated with tacrolimus dose requirements. However, 
CYP3A4*22 served as a borderline significant factor (p= 0.06) and POR*28 had no 
association with tacrolimus dose requirement. 
In multiple regression analysis by stepwise selection, neither CYP3A4*22 nor POR*28 
had any association with tacrolimus dose requirement. Whereas multiple regression 
analysis identified the combined CYP3A5*3/ ABCB1 3435 genotypes, age, sex, 
ethnicity, haematocrit, corticosteroids treatment and diabetic status as independent 
variables associated with tacrolimus dose (Table 27) as mentioned before in chapter 4. 
Therefore, these independent factors explain exactly the same percentage of variability 
in tacrolimus dose requirements (59.9%) as shown in chapter 4. 
5.2.4 Discussion 
In addition to CYP3A5 activity which explains 29–35% of the variability in the studied 
tacrolimus pharmacokinetic parameter. CYP3A4 activity, explains an additional 23–
29% of the variability in the studied tacrolimus pharmacokinetic parameters (de Jonge 
et al., 2012). In line with recent studies that demonstrated increased tacrolimus daily 
dose and dose-adjusted concentrations in renal transplant recipients carrying a 
CYP3A4*22 T variant allele (Elens et al., 2011b) , we found that there was a significant 
reduction in tacrolimus adjusted dose in CYP3A4*22 CT than CC genotype. Similarly, 
we found that tacrolimus dose-normalized C0, Cmax and AUC0-24 were significantly 
lower in CYP3A4*22 CC in comparison with CYP3A4*22 CT variant. Those results 
were also confirmed by Elens colleague in another study in kidney transplant patients. 
They found that CYP3A4*22 polymorphism significantly altered tacrolimus metabolism 
and dose requirement early after transplantation, T allele carriers require 33% lower 
tacrolimus doses than wild-type CC carriers to reach the target C0 (Elens et al., 2011a). 
Furthermore, de Jonge et al. (2014) reported that steady-state oral clearance of 
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tacrolimus was reduced in CYP3A4*22 T-allele carriers compared with CC carriers, 
resulting in 50% lower tacrolimus daily dose requirements. However, different results 
were reported by Santoro et al. (2013) who did not find any association between 
CYP3A4*22 and tacrolimus C0/dose, Beatriz et al. (2013) who found no significant 
differences between the CYP3A4*22 genotypes and daily dose requirement and dose-
normalized C0 and Tavira et al. (2013) who reported no association between 
CYP3A4*22 variant and tacrolimus dose at 1week and 6 month after transplantation. It 
is not clear why these authors found no association, but sample size may have played a 
part. 
CYP3A4 mRNA level and enzyme activity in livers with CC genotype were reported as 
1.7- and 2.5-fold, respectively, greater than in CT and TT carriers (Wang et al., 2011). 
CYP3A4 variants that result in higher enzymatic activities could be linked to reduced 
tacrolimus blood concentration. The discrepancy between our results and other studies, 
might be due to the absence of CYP3A4*22 TT variants or could be attributed to the 
very high CYP3A4*22 CC and low CYP3A4*22 CT allelic frequencies in our subjects 
population. However, statistical power is not likely to be a key limiting factor in the 
current study. A confounding factor is the fact that none of the CT heterozygotes were 
CYP3A5 expressers. When combining CYP3A5 and CYP3A4*22, we found a 
significantly higher daily dose of tacrolimus in extensive CYP3A metabolizers 
compared to the intermediate CYP3A metabolizers and poor CYP3A metabolizers. 
After excluding CYP3A5 expressers having CYP3A4*22 CC carriers (Extensive 
CYP3A metabolizers) from the analysis we found no significant differences in 
tacrolimus dose and pharmacokinetics between the CYP3A4*22 CC (intermediate 
CYP3A metabolizers) and the CT (poor CYP3A metabolizers) genotype subgroups in 
CYP3A5 non-expresser group, suggesting that the significant difference in tacrolimus 
pharmacokinetics between CYP3A4*22 CC and CYP3A4*22 CT was due to the fact that 
all CYP3A4*22T allele carriers are CYP3A5 non-expressers. Similar findings were 
obtained by Gijsen et al. (2013) showing no significant difference between poor and 
intermediate metabolites. In contrast to our findings, Elens et al. (2011b) reported a 
strong correlation between CYP3A combined genotypes and tacrolimus disposition. 
CYP3A poor metabolizer group presented dose-adjusted tacrolimus concentration 1.6- 
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and 4.1-fold higher than the intermediate metabolizer and extensive metabolizer groups, 
respectively. This was confirmed by another study showing that CYP3A extensive 
metabolizers required 2.1-fold higher doses than intermediate CYP3A metabolizers or 
2.7-fold higher doses than CYP3A poor metabolizers (Bruckmueller et al., 2014). 
It is well-known that P450 oxidoreductase (POR) is essential for cytochrome P450 
(CYP) activity in humans and it has been associated with increased in vivo CYP3A 
activity (de Jonge et al., 2011). In this work, we studied the effect of the POR*28 
genetic polymorphism on the pharmacokinetics of tacrolimus. Up to date, very few 
studies were carried out to explore the influence of genetic variations in the POR gene 
on tacrolimus metabolism. Our findings showed that there were no significant 
differences in the pharmacokinetics between the POR*28 CC genotype and the POR*28 
CT/TT genotype with respect to dose-adjusted Cmax, AUC0-24, tacrolimus trough blood 
concentrations and the daily dose (mg/kg). This confirms the previous results obtained 
after a single dose tacrolimus in a cohort of healthy Chinese volunteers (Zhang et al., 
2013). Conversely, another study demonstrated that the POR*28 SNP was associated 
with significant increases in early tacrolimus dose-requirements in patients carrying a 
CYP3A5*1 allele (CYP3A5 expressers) and had no effect on tacrolimus trough blood 
concentrations and daily dose requirements in CYP3A5 non-expressers (de Jonge et al., 
2011). However, our findings were in line with previous observations by Elens et al. 
(2014) who found that in the CYP3A5 expresser group, POR*28 carriers (POR*1/*28 
and POR*28/*28) had low tacrolimus dose-adjusted C0 when compared with POR*1/*1 
patients. They also found a significant decrease in dose-adjusted C0 in POR*28/*28 
individuals not expressing CYP3A5 compared to POR*1/*28 and POR*1/*1carriers. 
The inconsistency between these results and our findings might be due to our relatively 
small study population. The inconsistency in the POR*28 influence makes it a poor 
candidate for inclusion in pharmacogenetic algorithms based on currently available 
data. More powerful studies are needed to reach a definitive conclusion. 
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6 Chapter 6. 4β-hydroxycholesterol 
Measurement as a Potential Biomarker for 
CYP3A4 and CYP3A5 Activity in Informing 
Tacrolimus Dosing. 
6.1 Introduction 
CYP3A enzymes exhibit a large variation in hepatic expression and biological activity 
between different individuals (Diczfalusy et al., 2009). 4β-hydroxycholesterol (4β-
OHC) concentration increases with the number of active CYP3A5*1 alleles. Recently, 
4β-HC has been shown to be an endogenous marker of P450 3A activity in clinical 
practice and it is appropriate for the assessment of CYP3A activity in stable kidney 
transplant recipients (Diczfalusy et al., 2011). 
6.2 Objective of the Study: 
The aim of this study was to investigate the relationship between genetically determined 
variation in CYP3A expression in comparison to the phenotypic marker 4β-OHC and 
tacrolimus pharmacokinetics and dose requirement in adult renal transplantation 
recipients. 
6.3 Materials and Methods  
6.3.1 Patients and Study Design 
This study is part of a larger pharmacokinetic study; detailed information on the study 
participants and procedure can be found in Chapter 4. None of the patients were treated 
with any medications known to inhibit or induce CYP3A activity. All the study samples 
were collected at 12.5 hour post-dose for twice daily tacrolimus. Five mL of EDTA 
anticoagulated blood was collected for 4β-hydroxycholesterol measurement. Plasma 
samples were prepared by centrifugation for 10 minutes at 2500 g at room temperature 
and stored frozen at approximately -20ºC until analysis.  
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6.3.2 4β-hydroxycholesterol Analysis 
This study has been conducted in collaboration with Professor Ron van Schaik’s team, 
in Rotterdam. As we had some difficulty in establishing this new method in our 
laboratory, I had to travel to Professor Ron van Schaik’s laboratory at Erasmus MC 
University of Netherlands in Rotterdam asking for the assistance from his team who 
validated the method. I have been trained by Evert de Jonge on this analytical method 
and he supervised me while doing the analysis of my samples. 
This analysis procedure was conducted following the method previously validated at 
Clinical Chemistry Department; Erasmus MC University of Netherlands titled 
“Quantification of endogenous CYP3A marker 4β-hydroxycholesterol in human plasma 
by LC-ESI-MS/MS using picolinyl derivatisation.” It allows the analysis of the plasma 
4β-hydroxycholesterol at concentrations ranging from 4.3-137 µg/L with a correlation 
coefficient of 0.999. The lower limit of quantitation was 1.8 µg/L. Both the within-day 
and between-day precision values were all < 15%. 
6.3.2.1 Instrumentation 
Solvent delivery was achieved using a Waters Acquity
TM
 binary solvent manager set at 
0.3mL/minute. Sample injection was performed using Waters Acquity
TM
 sample 
organizer and sample manager which adjusted to keep samples at 15ºC. 
Chromatography was on an Acquity ultra-performance liquid chromatography (UPLC®) 
BEH phenyl, 1.7µm, 2.1×100 mm column (Waters, Etten-Leur, The Netherlands) 
maintained at 27ºC with Waters Acquity
TM
 column manager. Detection was by a Waters 
Quattro Premier XE
TM
 Mass spectrometer (Waters, Etten-Leur, The Netherlands). 
MassLynx 4.1 software was used to control the UPLC/MS, record the output from the 
detector and for the data acquisition, processing and quantification. The MassLynx 
software was supplied by Waters, The Netherlands. The calibration curves were 
generated using 4β- OHC to 4β- OHC-d7 peak area ratio versus the nominal 4β-OHC 
concentrations with linear regression weighting 1/x. MS Settings: A Waters Quattro 
Premier XE tandem quadrupole mass spectrometer equipped with Z spray interface was 
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used to introduce the sample into the mass spectrometer. Argon was used as the 
collision gas. 
6.3.2.2 Chemicals and Reagents  
4β-hydroxycholesterol was supplied by Steraloids Inc., Newport, USA and 4β-
hydroxycholesterol-d7 (I.S) was obtained from Toronto Research Chemical (North 
York, Canada), while 4α-hydroxycholesterol was synthesized by SYNCOM, 
Groningen, The Netherlands. LC-MS-grade methanol, acetonitrile and water were 
obtained from Biosolve BV (Valkenswaard, The Netherlands). Ethanol and n-hexane 
were supplied by Sigma-Aldrich (Darmstadt, Germany). Sodium hydroxide, formic 
acid, picolinic acid, pyridine, triethylamine, 2-methyl-6-nitrobenzoic anhydride and 4-
dimethylaminopyridine were purchased from sigma-aldrich (Zwijndrecht, The 
Netherlands). Deionised water was prepared on site (Millipore). 
6.3.2.3 Stock Solutions 
Calibrators and control samples were prepared in EDTA-anticoagulated plasma, using 
separate stock solutions prepared in ethanol. Six non-zero calibrators (nominal values of 
4.3, 8.6, 17.2, 34.5, 68.9, and 137.8 µg/L) and two control samples (nominal values of 
14.5, and 50.4 µg/L) were prepared. Calibrators and controls were aliquoted and stored 
at approximately -80°C until the day of analysis. Stock solution of 4β-
hydroxycholesterol-d7 (internal standard) was prepared in ethanol to give a 
concentration of 20 mg/mL and then stored at -20°C until use. On the day of the 
analysis, 250µL of the stock solution was freshly diluted with 50 ml of deionized water 
to give a concentration of 100 µg/L.  
6.3.2.4 Extraction Procedure 
For sample preparation, 50µL of calibrators, quality control, or patient samples; 50µL 
of internal standard and 500µL of 1 M ethanolic potassium hydroxide (5.61 g KOH/100 
mL ethanol) were pipetted into a 4.5-mL glass tube. After mixing and incubation at 
37°C for 30 minutes, 300µL of deionized water was added and samples were extracted 
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twice by the addition of 1 mL n-hexane to each tube. In each extraction step the tubes 
were vigorously shaken for 15 minutes using Denley Reciprocal Mixer (Denley 
Instruments Ltd) and centrifuged at 800g for 3 minutes. The organic layers were then 
transferred to 4.5-mL glass tubes, placed in a Savant SpeedVac Plus Model Sc210A 
(Thermo Life Sciences) at 60°C, and evaporated to dryness. 170 µL of freshly prepared 
derivatization mixture (10mg 2-methyl-6-nitrobenzoic anhydride, 3mg 4-
dimethylaminopyridine, 8mg picolinic acid, 150µL pyridine and 20 µL triethylamine 
per reaction) was added to the dried residues and after mixing and incubation at 37°C 
for 45 minutes, 500µL of LC-MS grade water and 1 mL n-hexane were added to each 
tube. The tubes then were vigorously shaken for 15 minutes and centrifuged at 800g for 
3 minutes. The organic layers were then transferred to 1.1mL polypropylene vials, 
placed in a Savant SpeedVac Plus Model Sc210A (Thermo Life Sciences) at 60°C, and 
evaporated to dryness. The dried extracts were reconstituted with 200 µL of the mobile 
phase mixture (LC-MS grade Water: methanol/acetonitrile (2:1), 2:8) mixed for 1 min, 
and then transferred to autosampler tray set at 15°C temperature. The autosampler 
injected a 10µL aliquot of each extract onto the analytical column (Figure 44). To 
correct 4β-hydroxycholesterol levels, total cholesterol was measured on Roche Modular 
P800 analyzer.  
6.3.2.5 Chromatographic Condition: 
Validated LC-MS/MS method was used for the analysis of 4β-hydroxycholesterol in 
plasma. The Acquity UPLC® BEH phenyl, 1.7µm, 2.1×100 mm column (Waters, 
Etten-Leur, The Netherlands) was used for the separation of 4β-hydroxycholesterol and 
internal standard at temperature of 27°C. The mobile phase was pumped isocratically at 
a flow rate of 0.3 mL/min and consisted of a mixture of mobile phase A (LC-MS water 
+ 1 mL/L formic acid) and mobile phase B (Methanol/Acetonitrile (2:1 (w/w)) at a ratio 
of 21:79 respectively. The sample injection volume was 10 µL. Tandem mass 
spectrometric detection and quantification was performed in the positive electrospray 
ionization mode using multiple reaction monitoring (MRM) mode. Mass transitions 
selected were m/z 635/146 and 613/490 for 4β-OHC quantifier and qualifier ions, 
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respectively and m/z 642/146 for 4β-OHC-d7. Ms Settings were optimized manually. 
The source temperature was set at 130°C and the desolvation temperature was 
maintained at 350°C. The desolvation gas flow and cone gas flow were set at 800L/hr 
and 150L/hr, respectively. The capillary voltage and cone voltage were kept at 1.5kV 
and 38V, respectively for all compounds. The dwell times were set at 100 msec. The 
collision cell was set at 7.42 e-3 mbar with argon gas. The collision energy was 25eV 
for both 4β-OHC and 4β-OHC-d7. A Windows PC running MassLynx software was 
used to control the LC-MS/MS, record the output from the detector and integrate the 
peak areas of the drug and the internal standard. For quantitative calculation of 4β-
hydroxycholesterol, an excel sheet was generated using 4β- OHC to 4β- OHC-d7 peak 
area ratio versus the nominal 4β- OHC concentrations with linear regression weighting 
1/x (Figure 44). 
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Figure 44: Schematic Diagram of the 4β-hydroxycholesterol Extraction Procedure. 
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6.3.3 Tacrolimus Blood Concentration Measurement 
Blood concentration of tacrolimus was determined using the liquid chromatography-
mass spectrometry (LC - MS - MS) method according to the procedures that described 
previously (Chapter 4). Both the within-day and between-day accuracy values were 
within 93.1-109.4% and 95.1-105.3%, respectively. The lower limit of quantitation was 
250ng/L. 
6.3.4 Determination of CYP3A5 Genotype. 
DNA was extracted from peripheral blood samples using QIAamp DNA Blood Mini Kit 
(QIAGEN®, West Sussex, UK). CYP3A5*1/*3 polymorphism was genotyped using real 
time polymerase chain reaction (PCR), a LightCycler based technique, as described in 
detail in Chapter 4. 
6.3.5 Statistical Analysis 
4β-hydroxycholesterol and cholesterol individual plasma concentrations were 
determined for each genotype. Statistical analysis was performed using Minitab 
statistical software (Minitab17) to assess the statistical significance of differences in 4β-
hydroxycholesterol and 4β-hydroxycholesterol: cholesterol ratios in tacrolimus kinetics 
between different genotype groups. The log-transformed data was analysed using 
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6.4 Results 
6.4.1 Demographic Data. 
Table 43 shows the demographic data of the 59 stable kidney transplant recipients. 
Twelve patients were homozygous for CYP3A5*1, 31 were homozygous for CYP3A5*3 
and 16 were heterozygous. The CYP3A5*3 genotype frequency of the recipients 
deviated from Hardy-Weinberg equilibrium (p < 0.05). Of the 59 subjects, 36 patients 
were treated with prednisolone. Regarding ethnic origin, 36 patients were from white 
background, 12 Asian and 11 Black. 
Table 43: Demographic Characteristics of Kidney Transplant Recipients. 
Characteristics Results 
Age (yr), mean (SD) 54.1 (12.9) 
Body weight (kg), mean (SD) 76.7 (15.3) 
Male gender, n (%) 40 (68%) 
Ethnic group, n (%)  
White / Black/ Asian 36/11/12 
Time since transplantation (years)  
Median (range) 2.1 (0.3-22.8) 
Diabetes 12 (20%) 
Haemoglobin (Hb, g/L) 130.8 ± 16.1 
Haematocrit 0.4 ± 0.05 
Immunosuppression at baseline:  
Tacrolimus, n (%)  
Prograf®/ Adoport® 45 (76%) /14 (24%) 
Corticosteroids, n (%) 36 (61%) 




CYP3A4 polymorphism  
CYP3A4*22 CC 56 
CYP3A4*22 CT 3 
ABCB1 polymorphism  
ABCB1 CC 14 
ABCB1 CT/TT 45 
POR*28 polymorphism  
POR*28 CC 28 
POR*28 CT/TT  31 
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6.4.2 CYP3A5 Genotype Relationship with 4β-OHC and 4β-OHC/C Ratio  
The plasma 4β-OHC concentrations and 4ß-OHC/C ratios showed a log-normal 
distribution, and the data were therefore log-transformed before analysis. As shown in 
Table 44, a significant difference in 4β-OHC and 4β-OHC/C ratios was observed 
between CYP3A5*1/*1 and *1/*3 in comparison with the *3/*3 carriers (p<0.01). 
However, there was no corresponding significant difference in 4β-OHC and 4β-OHC/C 
ratios between CYP3A5*1/*1 and *1/*3 genotypes (p>0.05). Plasma concentrations of 
4β-hydroxycholesterol were 32.1 ± 12.6, 28.2 ± 16.5 and 20.9 ± 8.7 µg/L in patients 
with CYP3A5*1/*1, *1/*3 and *3/*3 genotypes, respectively (Figure 45 A). The same 
trend was found in 4β-OHC/C ratio. The mean 4β-OHC/C for CYP3A5*1/*1, *1/*3 
compared to *3/*3 genotypes were 7.64 ± 2.3, 7.09 ± 4.1 and 5.03 ± 2.0, respectively 
(p<0.01 by ANOVA, general linear model) and no difference was observed between 
CYP3A5*1 variant allele carriers (Figure 45 B). Based on the above mentioned results 
patients were divided into two groups CYP3A5 expressers (CYP3A5*1/*1 and *1/*3) 
and CYP3A5 non-expressers (CYP3A5*3/*3). Plasma concentrations of 4β-
hydroxycholesterol were 29.9 ±14.8 and 20.9 ± 8.7 µg/L in recipients with CYP3A5*1 
allele (n =28) and recipients with *3/*3 (n = 31) genotype, respectively (P<0.01, Figure 
45 C). Additionally, there was a significant increase in 4β-OHC/C ratio in the CYP3A5 
expresser group (*1/*3 and *1/*1, n = 28) in comparison with the CYP3A5 non-
expresser group (*3/*3, n = 31). The mean 4β-OHC/C ratio for CYP3A5*1 carriers and 
*3/*3 genotype were 7.3 ± 3.4 and 5.0 ± 2.0 µg/L, respectively (P<0.001, Figure 45 D). 
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Table 44: Plasma Concentrations of 4β-hydroxycholesterol in Stable Kidney Transplant Recipients with Different Ethnic 
Backgrounds and CYP3A5*3 Genotypes. 
 4β-OHC (µg/L) p-value 4β-OHC/C Ratio p-value 
CYP3A5*3     
All patients     
*1/*1 (n = 12) 32.1 ± 12.6  7.6 ± 2.3  
*1/*3 (n = 16) 28.2 ± 16.5 0.25 7.1 ± 4.1 0.33 
*3/*3 (n = 31) 20.9 ± 8.7 0.01 5.0 ± 2.0 0.007 
     
*1/*1 + *1/*3 (n =28) 29.9 ±14.8  7.3 ± 3.4  
*3/*3 (n =31) 20.9 ± 8.7 0.001 5.0 ± 2.0 <0.001 
Non-black patients     
*1/*1 + *1/*3 (n = 3) 25.3 ± 7.0  6.4 ± 2.1  
*3/*3 (n = 14) 20.9 ± 8.7 0.02 5.0 ± 2.0 <0.01 
Black patients     
*1/*1 (n = 9) 34.0 ± 13.6  8.0 ± 2.6  
*1/*3 (n = 2) 50.6 ± 47.8 0.71 12.1±11.3 0.70 
Ethnicity     
Black (n = 11) 36.9 ± 6.2  8.8 ± 4.6  
White (n = 36) 22.7 ± 1.4 <0.01 5.4± 1.9 <0.01 
Asian (n = 12) 21.5 ± 2.6 <0.05 5.8 ± 2.7 <0.05 
Ethnicity in CYP3A5 Expressers (*1*1/*1*3)     
Black (n = 9) 37.0 ± 20.6  8.8 ± 4.6  
White (n = 11) 26.0 ± 4.7 0.23 6.1 ± 1.3 0.13 
Asian (n = 8) 24.5 ± 9.3 0.07 6.7 ± 2.8 0.20 
The results were compared with the top group in each sub-table. Values were compared using ANOVA (General linear model). 
Data are shown as mean ± SD. 
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Figure 45: The Relationship of Different CYP3A5*3 Genotypes with 4β-hydroxycholesterol Plasma Concentrations (A & C) and 
4β-hydroxycholesterol / Cholesterol Ratio (B & D) in Stable Kidney Transplant Recipients. Boxes represent the 
interquartile range, line in the box represents the median value, symbol in the box represents the mean value, outer lines 
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By studying the relationship of ethnicity with the 4ß-OHC plasma concentration, it was 
found that 4β-OHC/C ratio was higher in Black subjects than White and Asian ethnic 
groups. The mean plasma concentrations of 4β-OHC in White, Asian and Black patients 
were 22.7 ± 1.4, 21.5 ± 2.6 and 36.9 ± 6.2 µg/L, respectively. Black subjects had 
significantly higher 4β-OHC concentrations in comparison to Whites (P<0.01) and 
Asian (P<0.05) and no significant difference was observed between White and Asian 













Figure 46: Ethnicity Relationship with 4β-OHC Concentration and 4β-OHC/C 
Ratio. Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines 
represent the minimal and maximal value and the values beyond the 
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The analysis was repeated excluding black patients. Again, CYP3A5 expressers (*1/*1, 
n=3 and *1/*3, n = 14) demonstrated a significant increase in 4β-OHC/C ratio 
compared with the CYP3A5 non-expressers (*3/*3, n = 31). The mean 4β-OHC/C ratio 
was 6.4 ± 2.1 for CYP3A5*1 carriers and 5.0 ± 2.0 for CYP3A5 non-expresser (P<0.05, 
Figure 47). In addition, we observed no differences in the mean of 4β-OHC/C ratio 
between CYP3A5*1/*1 (n=9) versus CYP3A5*1/*3 (n=2) genotypes in black patients (P 
= 0.7; Table 44 ). By repeating the analysis in CYP3A5 expressers only, no significant 














Figure 47: 4β-hydroxycholesterol Plasma Concentrations in Stable Non-black 
Kidney Transplant Recipients with Different CYP3A5*3 Genotypes. 
Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines 
represent the minimal and maximal value and the values beyond the 
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6.4.3 CYP3A5 Genotype Association with Tacrolimus Pharmacokinetics 
and Dose Requirement 
As shown in Table 45, highly significant differences in tacrolimus exposure and dose 
requirements were observed between CYP3A5 expresser and CYP3A5 non-expresser 
patients. CYP3A5*1 allele carriers have a significant decrease in dose-normalized 
AUC0-24, Cmax and C0 compared to CYP3A5*3 carriers (P<0.001). On the other hand, 
there was a significant increase in tacrolimus dose requirement between the two 
genotype groups (P<0.001, Figure 48). Similar results were obtained from a larger 
cohort of patients in Chapter 4.  
Table 45: CYP3A5*3 Genotype Relationship with Dose-Normalized Tacrolimus PK 
Parameters and Dose Requirement. 
PK-parameter 
CYP3A5 Expressers 






Dose (mg/Kg/day) 0.11 ± 0.05 0.05 ± 0.02 < 0.001 
Cmax (µg/L/mg/Kg) 20.4 ± 12.2 34.5 ± 14.3 < 0.001 
AUC0-24 (µg*h/L/mg/Kg) 227 ± 157 462 ± 215 < 0.001 
C0 (µg/L/mg/Kg) 7.4 ± 5.8 16.0 ± 9.3 < 0.001 
Values were compared using ANOVA (General linear model).  
Data are shown as mean ± SD. 
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Figure 48: CYP3A5*3 Genotype Relationship with Tacrolimus Pharmacokinetic Parameters and Dose Requirement. Boxes 
represent the interquartile range, line in the box represents the median value, symbol in the box represents the mean value, outer 
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6.4.4 The Relationship of 4β-OHC with Tacrolimus Exposure and Dose 
Requirement 
A significant positive correlation was observed between log 4β-OHC/C ratio and 
tacrolimus dose (r = 0.45, p < 0.001). On the other hand, A significant negative 
correlation was observed between log 4β-OHC/C ratio and tacrolimus pharmacokinetic 
parameters, dose-normalized Cmax (r = -0.35, p < 0.01), dose-normalized AUC0-24 (r = -
0.41, p < 0.01) and dose-normalized C0 (r = -0.41, p < 0.01). The relationships of 
tacrolimus dose and PK parameters with 4β-OHC/C ratio in stable kidney transplant 
recipients are shown in Figure 49. Factors associated with dose requirements of 
tacrolimus were studied using univariate regression analysis. The P value was highly 
significant with ethnicity, CYP3A5*3 genotype and log-transformed 4β-OHC/C ratio (p 
< 0.001 for each) and ABCB1 3435 genotype (p<0.01). The P values for sex and 
haematocrit were < 0.05 and it was 0.071 for age and 0.09 for CYP3A4*22 genotype.  
Multiple regression analysis by stepwise selection; alpha to enter or remove was 0.15; 
identified 4β-OHC/C ratio, CYP3A5*3 genotype, age, ethnicity, haematocrit and 
CYP3A4*22 genotype, as independent variables associated with tacrolimus dose and 
this explains 62.5% of the variability in tacrolimus dose. The contributions of the 
individual variables are shown in Table 46. After adjusting for these independent 
predictors of tacrolimus dose, CYP3A5*3 genotype had a strong association with 
tacrolimus dose (p <0.001) and accounts for 34.1% of the variability in tacrolimus dose 
requirement. Patient age became strongly associated with tacrolimus dose (P <0.05, 
Table 46). Furthermore, when we repeat the multiple regression analysis by using the 
CYP3A5*3/ABCB1combined genotype instead of CYP3A5*3 and ABCB1 separately, the 
percentage of tacrolimus dose variability explained by these variables increased to be 
63.4%, Table 46. After adjusting for these independent predictors of tacrolimus dose, 
patient age became strongly associated with tacrolimus dose (P <0.05). The log-
transformed 4β-OHC/C Ratio, CYP3A5/ABCB1 Genotype and haematocrit were 
responsible for 23.2%, 19.7% and 10.4%, respectively, of the variability in tacrolimus 
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Figure 49: The Fitted Line Plot for 4β-OHC/C Ratio Effect on Dose-Normalized Tacrolimus Pharmacokinetic Parameters and 






















































































































Log C0 = 1.498 - 0.7060 Log 4B-OHC/C Ratio
p<0.01          
r = -0.35 
p<0.01          
r = -0.41 
p<0.01          
r = -0.41 
p<0.001          
r = 0.45 
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Table 46: Stepwise Regression Equation of Tacrolimus Dose (mg/kg) Requirement after Renal Transplantation. 
Stepwise regression equation R
2
 Independent variables  
A. CYP3A5 and ABCB1 separate genotypes  
Dose (mg/kg) = 0.1209 + 0.0838*Log 4β-OHC/C Ratio - 
0.000880*Age - 0.248* Haematocrit - 0.0391(if Asian) -
0.0104 (if White) + 0.0374 (if CYP3A5 *1/*1 & *1/*3) + 
0.0369 (if CYP3A4*22 CC). 
62.5% 
Age (p = 0.021, R
2 
= 2.5%)                                         
Ethnicity (p = 0.013, R
2 
= 8.3%)                             
Haematocrit (p = 0.018, R
2 
= 9.2%)                         
CYP3A4*22 genotype (p = 0.084, R
2 
= 2.3%)                     
CYP3A5*3 genotype (p = 0.001, R
2 
= 34.1%)                     




B. CYP3A5 and ABCB1 combined genotypes 
Dose (mg/kg) = 0.1112 + 0.0835*Log 4β-OHC/C Ratio - 
0.000951*Age - 0.235* Haematocrit - 0.0322 (if Asian) - 
0.0032 (if White) + 0.0399 (if CYP3A4*22 CC) + 0.045 
(if CYP3A5*1/*1&*1/*3/ABCB1CC) + 0.0342 (if 
CYP3A5*1/*1&*1/*3/ABCB1CT/TT) - 0.0207 (if 
CYP3A5 *3/*3/ABCB1CC). 
63.4% 
Age (p = 0.016, R
2 
= 3.1%)                                             
Ethnicity (p = 0.039, R
2 
= 4.5%)                                         
Haematocrit (p = 0.028, R
2 
= 10.4%)                                         
CYP3A4*22 genotype (p = 0.067, R
2 
= 2.7%)                     
CYP3A5/ABCB1 Genotype (p = 0.011, R
2 
= 19.7%) 
Log 4β-OHC/C Ratio (p = 0.007, R
2 
= 23.2%)                       
R
2
 gives the % variability explained by the independent variables in the multiple regression analysis model.  
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6.5 Discussion 
4β-hydroxycholesterol has been reported as a marker of CYP3A activity and it is 
suitable for CYP3A activity evaluation in stable kidney transplant recipients; 4β-OHC 
was stable 90 days after kidney transplantation (Suzuki et al., 2013b). Additionally, 
tacrolimus is known as CYP3A5 substrate and CYP3A5 polymorphisms influence 
tacrolimus trough blood concentration and dose requirements in stable kidney transplant 
patients (Macphee et al., 2005). In this study, we investigated the changes in tacrolimus 
dose in relation to CYP3A activity and 4β-OHC/C ratio in stable kidney transplant 
patients.  
First, our study showed that there was a reduction in 4β-OHC concentration with 
increasing number of the CYP3A5*3 allele. However, this decrease was not significant 
between CYP3A5 expressers subgroups (*1/*1 and *1/*3), this was different from the 
previous reports which showed that 4β-OHC concentration decreased significantly with 
increasing number of the CYP3A5*3 allele (Diczfalusy et al., 2008, Suzuki et al., 2014). 
After excluding black patients from the analysis, we still found a significant difference 
between CYP3A5 expressers and non-expressers. CYP3A4*22 was not included in this 
study because the low frequency of this genotypes in our population. In addition, 
ABCB1 polymorphism had a significant effect on 4β-OHC/C ratio.  Moreover, POR*28 
had no significant effect on 4β-OHC/C ratio. 
Second, we found that Black subjects had significantly higher 4β-OHC concentrations 
in comparison to White and Asian subjects. The majority of our population were of 
Caucasian ethnic background and mainly males. This is different from previously 
published report showing that Tanzanian subjects (Black-Africans) had the lowest mean 
4β-hydroxycholesterol concentration followed by Swedes (Caucasians) and Koreans 
(Asians) who had the highest 4β-hydroxycholesterol concentration (Diczfalusy et al., 
2008). The discrepancy between the results may be due to the genetic difference in both 
studies’ populations. In our study, Black patients were North African, whereas in the 
other study they were Western African. They also found a significant difference in the 
mean 4β-hydroxycholesterol concentration between the three ethnic groups in women. 
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In contrast, no difference was observed between Swedish (Caucasians) and Korean 
(Asians) men (Diczfalusy et al., 2008). However, it is likely that the ethnic difference is 
simply a reflection of the distribution of the CYP3A5 genotype. After excluding 
CYP3A5 non-expressers from the analysis, we didn’t find any significant difference in 
4β-OHC concentration and 4β-OHC/C ratio among the Black, White and Asian ethnic 
groups. 
Third, we confirmed that CYP3A5*3 allele had a significant impact on tacrolimus 
disposition and dose requirement in this patient sample. Patients carrying at least one 
CYP3A5*1 allele had a significantly lower dose-normalized tacrolimus Cmax, AUC0-24 
and C0 compared to CYP3A5*3/*3 and required a higher tacrolimus dose than CYP3A5 
non-expressers (MacPhee et al., 2004, Tada et al., 2005, Cusinato et al., 2014).  
Fourth, a significant correlation was observed between plasma concentrations of 4β-
hydroxycholesterol or 4β-OHC/C ratio and tacrolimus dose requirement, suggesting that 
the higher 4β-hydroxycholesterol levels, indicating high CYP3A activity and increase 
tacrolimus dose requirement in stable kidney transplant recipients. 
Finally, multiple regression analysis by stepwise selection identified CYP3A5*3 
genotype (or CYP3A5*3/ ABCB1 combined genotype), log 4β-OHC/C ratio, age, 
ethnicity, haematocrit and CYP3A4*22 genotype as independent variables associated 
with the required tacrolimus dose. Our findings suggest that these independent variables 
may explain 62.48% to 63.37% of the between-patient variability in tacrolimus dose. 
This is the first report of plasma 4β-hydroxycholesterol concentration as a biomarker of 
CYP3A activity in addition to CYP3A5*3 polymorphism to predict the required 
tacrolimus dose in stable kidney transplant recipients. These findings may help to 
explain the variability in tacrolimus dose between individuals which cannot be 
explained only by the genetic factors. Further studies are required to validate the clinical 
importance and utility of these findings.  
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7 Chapter 7. Tacrolimus Within-Patient 
Variability: the Impact of Conversion from 
Immediate (Prograf® or Adoport®) to Prolonged 
Release (Advagraf®) Tacrolimus Formulations 
in Stable Renal Transplant Patients. 
7.1 Objective of the Study:   
1. To study the effect of switching stable renal transplant patients from a twice 
daily formulation of tacrolimus (Prograf® or Adoport®) to once daily 
formulation (Advagraf®) on within patient variability in pre-dose blood 
tacrolimus concentration. 
2.  To investigate tacrolimus within-patient variability correlation to CYP3A5 
genotype in stable kidney transplant recipients for twice a day tacrolimus 
(Prograf® or Adoport®) and once a day tacrolimus, Advagraf®. 
7.2 Materials and Methods 
7.2.1 Patients and Study Design: 
A retrospective, cross-sectional study was performed for 100 renal transplant recipients 
attending routine follow-up clinical evaluations at the kidney transplant clinic, St 
George’s Hospital. Clinically stable patients underwent scheduled switching from 
twice- to once- daily tacrolimus between January 2010 and March 2014. As part of St 
George’s Hospital routine care, patients only switched to once-daily tacrolimus if they 
had a stable graft function without evidence of acute rejection episodes over the 
previous 3 months. Patients qualified for the study if they were above 18 years old, had 
completed at least 3 months of transplantation, had a stable graft function for at least 6 
weeks, and were treated with no more than 5 mg prednisolone daily at the beginning of 
the study period and were followed-up for at least 12 months. Exclusion criteria 
included patients under 18 years old or treated with more than 5 mg prednisolone daily. 
Conversion from tacrolimus twice-daily to once-daily was made on a 1mg: 1mg basis of 
the total daily dose with target tacrolimus trough concentration 5-8 µg/L) during both 
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periods (pre-conversion and post-conversion). For each patient, demographic and 
transplant characteristics, relevant clinical data, all tacrolimus dose changes, all 
tacrolimus trough blood concentrations and co-medications were obtained 
retrospectively from medical records. Estimated glomerular filtration rate (eGFR) was 
calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
Equation among OD-Tac converted patients (Levey et al., 2009). 
7.2.2 Within-Patient Variability (WPV) Calculation: 
During the study period, Tacrolimus trough concentrations obtained as a component of 
routine care were determined using the Dade-Behring immunoassay (Thermo Scientific, 
2011). The limit of detection was 2.0 ng /mL and the total imprecision of the method 
was < 16.5% coefficient of variation. The accuracy and precision were evaluated by the 
International Tacrolimus Proficiency Testing Scheme. All tacrolimus concentration 
measurements and time of blood sampling were obtained from the electronic hospital 
database. Dose-normalized trough concentrations were calculated to obtain comparable 
values that are independent of the individual dose and body weight. Analysis of dose-
normalized tacrolimus trough blood concentrations (Tac C0) was made during periods 
of stable tacrolimus doses and over the periods before and after conversion. The 
duration of follow-up was 12 months after conversion. For all the patients, at least three 
daily tacrolimus doses and their corresponding trough blood concentrations were 
collected from the electronic patient records at St George’s Hospital. The mean number 
of samples per patient was 6.3 ± 2.7 for periods of tacrolimus stable dose. The mean 
number of samples per patient was 13.4 ± 10.6 and 14.3 ± 6.5 for twice- and once-daily 
tacrolimus, respectively, over the periods before and after conversion, including the 
whole period and not just periods of stable dosing. Within-patient variability (WPV) of 
dose-normalized tacrolimus trough blood concentrations was calculated using the 
following equation: 
%CV = (SD x 100) / X 
Where, SD is the standard deviation and X is the mean value of all the analysed 
tacrolimus concentration samples. 
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Patients were characterized as having a high or low WPV using the median value of 
WPV as the cutoff value, the approach used previously by Borra et al. (2010). Analysis 
of WPV of tacrolimus trough blood concentrations (Tac C0) after conversion to 
Advagraf® was made during periods of stable tacrolimus doses and additionally, another 
analysis was made over the whole periods before and after conversion. To investigate 
the relation between within-patient variability and CYP3A5 polymorphisms in both 
tacrolimus formulations, all patients who participated in our previous studies and whose 
CYP3A5 genotype was known (n=72) were included in this study. 
7.2.3 Statistical Analysis 
The WPV was calculated using Microsoft Excel 2010. Statistical analysis was 
performed using Minitab statistical software (Minitab 17). Data on patients’ baseline 
characteristics were expressed as mean or range. Differences in WPV between the 
treatment periods were assessed using ANOVA. The log-transformed data were 
analysed using analysis of variance (ANOVA) with factors for genotype group and 
treatment. Kruskal–Wallis test was also used to compare medians of CV% between 
different treatments and CYP3A5 genotypes when the values were non-normally 
distributed. 
7.3 Results 
7.3.1 Patients’ Characteristics at Baseline (Pre-Conversion Patient 
Characteristics)  
This study of tacrolimus formulation conversion included 100 patients (60 men and 40 
women) in the period January 2010 to March 2014. The baseline characteristics of the 
study population are shown in Table 47. All recipients had at least 1-year follow-up. 
The mean age of recipients at the time of conversion from twice-daily to once-daily 
tacrolimus was 52.9 ± 12.6 years. The median [range] interval post-transplant at 
conversion was 2.9 (0.3-22.8) years. Fifty-seven patients were cases of deceased donor 
kidney transplantation. The concomitant immunosuppression included prednisolone 
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(n=60), Mycophenolate mofetil (n=34), and azathioprine (n=21). At baseline, 63 
patients (63%) had hyperlipidaemia and 27 patients (27%) had diabetes mellitus.  
Table 47: Patient Demographics and Baseline Characteristics. 
Characteristics 
 
Number of subjects (%) 
Sex: n (%)  
Male / Female 60 (60%) / 40 (40%) 
Age, mean  52.9 ± 12.6 
Ethnicity:  
White n (%) 59 (59%) 
Black n (%) 19 (19%) 
Asian n (%) 22 (22%) 
Primary kidney disease: n (%)  
Hypertensive nephropathy 10 (10%) 
Polycystic kidney disease 22 (22%) 
Diabetic nephropathy 10 (10%) 
IgA nephropathy 9 (9%) 
Glomerulonephritis (other) 12 (12%) 
Congenital /other  14 (14%) 
Reflux disease 3 (3%) 
Unknown 20 (20%) 
Donor type: n (%)  
Living / Deceased 43 (43%) / 57 (57%) 
Time since transplantation (years)  
Median (range) 2.9 (0.3-22.8) 
Diabetes mellitus n (%) 27 (27%) 
Hyperlipidemia n (%) 63 (63%) 
Immunosuppression at baseline:  
TD-Tac (monotherapy) 2 (2%) 
TD-Tac and MMF 17 (17%) 
TD-Tac and prednisolone 43 (43%) 
TD-Tac, MMF and prednisolone 17 (17%) 
TD-Tac and Azathioprine 21 (21%) 
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7.3.2 Post-conversion Follow-Up 
7.3.2.1 Graft Renal Function: One Year Follow-Up  
Renal function was assessed just before and at all times after tacrolimus conversion. Mean serum creatinine, serum albumin and estimated 
glomerular filtration rate (eGFR) remained stable during follow up (Table 48). Moreover, haemoglobin concentration and systolic (SBP) 
and diastolic blood pressure (DBP) did not change significantly during follow up (Table 48). The data were obtained in 100 patients at all 
times 
Table 48: Patient Clinical Parameters during the 12 Months after Conversion from TD-Tac to OD-Tac. 
Parameters 
t=0        
(n=100)    
2 Weeks 
(n=82)               
1 month 
(n=95)               
3 months 
(n=99)              
6 months 
(n=98)               
9 months 
(n=97)                
12 months 
(n=100)            
Serum creatinine (μmol/L) 126.1 ± 42.0 125.8 ± 39.0 123.4 ± 38.3 124.4 ± 43.4 121.7 ± 41.2 121.4 ± 39.0 123.0 ± 40.7 
eGFR (mL/min) 57.5 ± 19.9 58.3 ± 20.7 58.9 ± 21.1 59.1 ± 21.6 60.5 ± 21.9 60.5 ± 21.4 60.15 ± 22.9 
Albumin (g/L) 38.9 ± 3.2 39.5 ± 4.2 38.8 ± 3.5 39.5 ± 7.8 39.3 ± 7.5 38.2 ± 3.6 38.3 ± 3.4 
Haemoglobin (g/L) 130.9 ± 16.9 128.7 ± 15.6 129.3 ± 15.1 131.7 ± 17.7 131.1 ± 15.3 131.0±15.1 130.8 ± 16.7 
SBP (mmHg) 129.9 ± 14.1 126.5 ± 12.0 128.3 ± 12.8 126.1 ± 11.3 128.5 ± 12.5 129.9 ± 14.0 127.7 ± 13.3 
DBP (mmHg) 78.6 ± 9.5 80.0 ± 8.2 78.9 ± 8.4 79.1 ± 8.7 78.1 ± 8.2 78.8 ± 9.7 79.6 ± 9.3 
Data are shown as mean ± SD. 
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7.3.2.2 One Year Follow-Up of Tacrolimus Exposure and Dosing after Conversion 
to Advagraf®  
For evaluation, one tacrolimus trough blood concentration and its coinciding tacrolimus 
dose were retrieved from the clinic database just before conversion and at 0.5, 1, 3, 6, 9 
and 12 months after conversion. Before conversion, the mean morning trough blood 
concentration of tacrolimus (TD-Tac) was 6.6 ± 1.9 µg/L and the mean total daily dose 
of tacrolimus was 5.2 ± 3.4 mg. At 0.5, 1, 3 and 6 months after conversion, mean 
tacrolimus trough concentrations were 6.0 ± 2.3, 6.0 ± 1.8, 6.1 ±1. 9 and 5.9 ± 2.0 µg/L, 
respectively, with mean OD-Tac doses (mg) of 5.2 ± 3.4, 5.2 ± 3.4, 5.2 ± 3.3 and 5.2 ± 
3.2, respectively. Then, in the following months, the trough blood concentrations of 
tacrolimus were kept at 6.2 ± 2.0 and 6.2 ± 1.8 µg/L at 9 and 12 months, respectively, 
with mean OD-Tac doses (mg) of 5.2 ± 3.2, 5.1 ± 3.2, respectively (Figure 50 & 
Figure 51).  
 
Figure 50: Tacrolimus Trough Concentrations before Conversion and in 0.5, 1, 3, 
































Tacrolimus Daily Dose 
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Despite no change in the OD-Tac dose during follow-up period, Tac C0 were slightly 
reduced in the majority of the patients with a significant decrease in tacrolimus blood 
concentrations after 6 months and then it reached initial levels at 9 and 12 months post-
conversion. The daily doses of TD-Tac and OD-Tac doses in the analysed period are 
shown in Figure 50.  
 
Figure 51: Tacrolimus Daily Dose before Conversion and in 0.5, 1, 3, 6, 9 and 12 
Months after Conversion (Pre= Pre-Conversion, w=week and 
m=month). Values were compared using ANOVA (General linear model). 
* Significantly Different from Pre-Conversion.  
7.3.3 Effect of the Switch to Advagraf® during Stable Dosing Periods and 
the Entire Time Pre- and Post- Conversion. 
Conversion of tacrolimus from twice-daily to once-daily formulation was based on 1: 1 
mg. For all patients, at least 3 samples were available for calculation of the within-
patient variability of Tac C0. Tacrolimus trough concentrations were analysed for WPV 
in this ethnically diverse population during periods of stable tacrolimus doses. For each 
patient, only one stable dosing period was used for each formulation. Additionally, the 
analysis was repeated for the whole periods before and after conversion. The 
relationship between within-patient variability and CYP3A5 polymorphisms in both 
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7.3.3.1 Tacrolimus Exposure and Daily Dosing during Stable Dosing Periods and 
the Entire Time Pre- and Post- Conversion 
During the period of stable tacrolimus dosing before conversion, the mean tacrolimus 
trough concentration (µg/L) was 7.3 ± 1.8 with a TD-Tac dose of 5.4 ± 3.3 mg. The 
percent change in tacrolimus dose was calculated using the last stable Prograf® or 
Adoport® dose before conversion versus the final stable Advagraf® doses after 
conversion. Advagraf® dose was modified from TD-Tac dose in 68 cases after 
conversion, increasing in 29/100 and decreasing in 39/100 kidney transplant recipients, 
based on tacrolimus trough blood concentration (Tac C0) measurements in order to 
remain in therapeutic range (Figure 52). The mean Tac C0 was 6.1 ± 1.0 µg/L with 
mean OD-Tac doses (mg) of 5.1 ± 3.1. The total daily tacrolimus dose was significantly 
different before and after the switch (p < 0.05). Moreover, the mean tacrolimus trough 
concentration was significantly decreased by 15% after conversion (P < 0.001). The 
dose-normalized Tac C0 also decreased by 10 % [90%CI 11 to 19%] (p < 0.01; Table 
49). 
 
Figure 52: Percentage Change in Tacrolimus Dose after Conversion from Twice to 
Once-Daily Tacrolimus during Stable Dosing Periods. 
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Table 49: The Mean Trough Concentration (Tac C0) and Dose of Twice-Daily (TD-














5.4 ± 3.3 5.1 ± 3.1 <0.05 5.5 ± 3.4 5.1 ± 3.1 <0.01 
Tacrolimus dose 
(mg/Kg/day) 
0.074 ± 0.04 0.070 ± 0.04 <0.05 0.077 ± 0.05 0.071 ± 0.04 <0.001 
Tac C0 (µg/L) 7.3 ± 1.8 6.1 ± 1.0   <0.001 7.5 ± 1.6 6.2 ± 0.91  <0.001 
Tac C0        
(µg/L / mg/kg) 
14.6 ± 11.0 13 ± 9.8 <0.01 14.6 ± 10.7 12.6 ± 8.7  <0.001 
*Pre-conversion: the whole period before switching to OD-Tac where patients were on 
TD-Tac treatment. Post-conversion: the whole period after switching to OD-Tac where 
patients were on OD-Tac treatment. Data are shown as mean ± SD. Values were 
compared using ANOVA (General linear model). 
The analysis was repeated to include not only the periods of stable tacrolimus dose, but 
also the whole period before and after conversion allowing inclusion of a greater 
number of data points. Again, the mean tacrolimus C0 concentration fell from 7.5 µg/L 
SD 1.6 to 6.2 µg/L SD 0.1 with a 16% reduction [90%CI 13 to 19%]. The dose-
normalized Tac C0 also decreased by 11% [90%CI 7 to 14%] (p < 0.001). Both the daily 
dosage of tacrolimus and the weight-adjusted tacrolimus dose (mg/kg) were statistically 
significantly different before and after the conversion. The total daily Tacrolimus dose 
was 5.5 ± 3.4 vs. 5.1 ± 3.1 mg/day; p < 0.01. The percent change in tacrolimus dose was 
calculated using the starting versus the final Advagraf® doses. The daily Tacrolimus 
dose had been left unchanged in 6/100 but was increased in 39/100 and decreased in 
55/100 patients. A summary of the untransformed twice- and once-daily tacrolimus 
mean trough blood concentrations and doses are given in Table 49. 
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7.3.3.2 Effect of Conversion to OD-Tac on Tacrolimus WPV during Stable Dosing 
Periods and the Entire Time Pre- and Post- Conversion 
During TD-Tac treatment with stable tacrolimus dosing, the mean and median WPV of 
dose-normalized tacrolimus C0 were 26.9 % SD 18.2 and 22.9% (range, 5.7%–149.2%), 
respectively. After conversion to OD-Tac, WPV of dose-normalized tacrolimus C0 did 
not show any significant change, the mean and median WPV for TD-Tac was 24.9% SD 
13.0 and 23.3% (range, 4.7%–79.2%); p = 0.39, by Balanced ANOVA and p=0.79,by 
Kruskal-Wallis Test, respectively, Figure 53. 
 
Figure 53: The Individual Change of Percent Coefficient of Variation (CV %) 
During Periods of Stable Tacrolimus Dose before and after Conversion 
from Twice-Daily Tacrolimus (TD-Tac) to Advagraf®. 
After including the whole period before and after conversion, again, there was no 
difference in tacrolimus WPV between TD-Tac and Advagraf®. The mean and median 
WPV of dose-normalized tacrolimus C0 were 29.2% SD 17.1 and 26.3% (range, 6.8%–
147.5%), respectively, for TD-Tac vs. 29.2% SD 10.9 and 27.0% (range, 5.8%–60.0%), 
respectively for Advagraf® (p = 0.98, by Balanced ANOVA and p = 0.24, by Kruskal-
Wallis Test, respectively, Figure 54) 
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Figure 54: The Individual Change of Percent Coefficient of Variation (CV %) 
During the Whole Period before and after Conversion from Twice-
Daily Tacrolimus (TD-Tac) to Advagraf®. 
The patients then were divided into low and high tacrolimus variability groups based 
upon their variability using the median as the cutoff value. 
The analysis was first conducted during the periods of stable tacrolimus dose. Although 
no significant difference in the WPV was observed in the whole population after 
conversion, patients with low-variability before conversion demonstrated a significant 
increase in WPV after conversion, WPV increased from 16.2 ± 4.6% and 17.4% 
(range,4.7% – 22.9%) to 21.6 ± 9.8% and 21.3% (range, 4.7% – 48.6%, p <0.001 for 
each). The reverse was observed in high-variability group, WPV decreased significantly 
from 37.7 ± 20.4 % and 31.6% (range, 22.9% – 149.2%) to 28.2 ± 15.9% and 25.9% 
(range, 5.1% – 79.2%, p < 0.01 for each; Table 50 & Figure 55. In the whole period 
analysis again patients with low variability before conversion demonstrated a significant 
increase in WPV after conversion: the mean within-patient %CV of tacrolimus C0 
increased significantly from 19.3% ± 4.7% and 20.8% (range, 6.8% – 26.2%) to 26.9 % 
± 9.9% and 26.6% (range, 5.8% – 57.8%, p <0.001 for each). In contrast patients with 
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high WPV had a significant change between the two formulations (p < 0.01). The WPV 
reduced from 39.1 ± 19.0 % and 32.2% (range, 26.5 % – 147.5%) to 31.6 ± 11.4 % and 
28.2% (range, 12.8 % – 59.9%, p < 0.01 for each; Table 50 & Figure 56). 
Table 50: The Individual Change of Tacrolimus WPV in High and Low Variability 
Patients before and after Conversion from Twice-Daily Tacrolimus to 
Advagraf®.  
Parameter Twice-daily tacrolimus Advagraf® p-value 
Stable periods  
   High WPV  
   Mean 37.7 ± 20.4   28.2 ± 15.0  <0.01 
Median (range) 31.6% (22.9% – 149.2%) 25.9% (5.1% – 79.2% <0.01 
Low WPV 
   
Mean 16.2 ± 4.6 21.6 ± 9.8 <0.001 
Median (range) 17.4% (4.7% – 22.9%) 21.3% (4.7% – 48.6%, <0.001 






Mean 39.1 ± 19.1 31.6 ± 11.4 <0.01 
Median (range) 32.2% (26.5 % – 147.5%) 28.2% (12.8 % – 59.9%) <0.01 
Low WPV 
   
Mean 19.3 ± 4.7 26.9 ± 9.9 <0.001 
Median (range) 20.8% (6.8% – 26.2%) 26.6% (5.8% – 57.8% <0.001 
Values were compared using Kruskal-Wallis Test and ANOVA (Balanced ANOVA): 
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Figure 55: The Individual Change of Percent Coefficient of Variation (CV%) 
During Periods of Stable Tacrolimus Dose before and after Conversion 
from Twice-Daily Tacrolimus (TD-Tac) to Advagraf® in Patients with 










Figure 56: The Individual Change of Percent Coefficient of Variation (CV%) 
During the Whole Period before and after Conversion from Twice-
Daily Tacrolimus (TD-Tac) to Advagraf® in Patients with High and 
Low WPV before Conversion. 
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7.3.4 Genetic Polymorphisms and WPV 
7.3.4.1  The Relationship between CYP3A5*3 Genotype and WPV 
Of the 100 patients included in our original study cohort, CYP3A5 genotyping was 
available for 72 patients. For all patients, at least three C0 results were used to calculate 
the within-patient variability of dose-normalized Tac C0. Analysis of tacrolimus trough 
blood concentrations (C0) was made during periods of stable tacrolimus doses and over 
the whole periods before and after conversion. 
The wild-type genotype CYP3A5*1/*1 was observed in 13 patients (18.1%), whereas 18 
(25.0%) were heterozygous (CYP3A5*1/*3) and 41 (56.9%) homozygous 
(CYP3A5*3/*3) for the variant allele. The subjects were grouped according to CYP3A5 
genotype based on the presence or absence of the CYP3A5*1 allele into 2 groups 
CYP3A5 expressers (n= 31); CYP3A5*1/*1 (n = 13, male = 9: female = 4) + 
CYP3A5*1/*3 (n = 18, male = 11: female = 7) and CYP3A5 non-expressers; 
CYP3A5*3/*3 (n = 41, male = 25: female = 16). The baseline characteristics of these 72 
patients are shown in Table 51. Demographic characteristics, except ethnicity were not 
significantly different between the genotype groups. The CYP3A5*1 allele was more 
prevalent among black transplant recipients compared with that among white patients 
and CYP3A5*3 allele was more prevalent in white patients than in black patients, which 
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Table 51: Patient Demographics and Baseline Characteristics. 
 Characteristics 
CYP3A5 expressers 
(*1/*1 plus *1/*3)         
(n=31) 
CYP3A5 non-expressers 
(*3/*3)                                    
(n=41) 
Sex: 
  Male / Female 20/11 25/16 
Age 55.2 ± 11.2 55.2 ± 12.9 
Body weight (kg) 73.0 ± 14.4 74.7 ± 14.8 
Ethnicity: 
  White 11 33 
Black 12 3 
Asian 8 5 
Donor type: 
  Living / Deceased 11/20 19/23 
Primary kidney disease: 
  Hypertensive nephropathy 2 3 
Polycystic kidney disease 9 7 
Diabetic nephropathy 4 5 
IgA nephropathy 4 3 
Glomerulonephritis (other) 3 7 
Congenital / Reflux disease 2 2 
other 2 5 
Unknown 5 9 
All values are shown in mean ± SD 
Within-individual coefficients of variation (CV %) were calculated from analysis of 
variation in CYP3A5 expresser and CYP3A5 non-expresser groups were compared. 
Patients in each group were then divided into low and high within-individual variability 
subgroups using the WPV median as the cutoff value. Out the 72 patients included, 36 
were considered as a low within-patient variability group, whereas 36 patients were 
considered as a high within-patient variability group. 
During the entire pre-conversion period, the mean twice-daily tacrolimus (TD-Tac) dose 
was 5.6 ± 3.6 mg with dose normalized Tac C0 of 14.5 ± 10.5 µg/L. Tacrolimus dose 
requirement was 1.8-fold higher in CYP3A5 expressers compared with that in CYP3A5 
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non-expressers (Table 52). The mean Tacrolimus dose and dose-normalized trough C0 
changed considerably between both genotype groups (P<0.001). Moreover, the mean of 
tacrolimus WPV did not differ between CYP3A5 expressers and non-expressers (28.7% 
± 12.3% versus 26.3% ± 12.0%, P = 0.41, Table 52). Almost exactly half of CYP3A5 
expresser (n = 31) and non-expressers (n = 41) exhibited low variability and the other 
half exhibited high variability. There was no significant difference in CV% within 
patients with low or high variability in each group; p= 0.26 and p= 0.43, respectively 
(Table 53).  
The analysis was repeated in periods of stable tacrolimus dose. The mean of twice-daily 
tacrolimus dose was 5.5±3.5 mg with dose-normalized Tac C0 of 14.4 ±10.7 µg/L. 
Again CYP3A5 expressers required 1.8-fold higher tacrolimus dose than CYP3A5 non-
expressers. There was a significant difference in tacrolimus dose and dose-normalized 
trough C0 between CYP3A5 expressers and CYP3A5 non-expressers; P<0.001, Table 
52). The %CV of tacrolimus trough blood concentrations was significantly lower in 
CYP3A5 non-expressers in comparison with CYP3A5 expressers (22.4 ± 10.9% to 30.0 
± 14.5%; P =0.014). Analysis of patients with low variability demonstrated significantly 
lower WPV for CYP3A5 non-expressers in comparison with CYP3A5 expressers: 19.5 
± 5.9% vs. 15.5 ± 3.2 % (p < 0.05; Table 52). This effect was even stronger in high 
variability patients (41.2 ±12. 4% vs. 29.8 ±11.4%, p<0.01; Table 53). 
During the Advagraf® post-conversion period, the results were similar to the period 
under twice-daily tacrolimus treatment. The mean Tacrolimus dose was 5.2 ± 3.3 mg 
with dose-normalized Tac C0 of 12.9 ± 9.0 µg/L. CYP3A5 non-expressers required 
significantly lower Advagraf® doses (-50%, P<0.001) compared with CYP3A5 non-
expressers (Table 52). No significant difference was observed in WPV of dose-
normalized Tac C0 between CYP3A5 expressers and CYP3A5 non-expressers (29.4% ± 
11.1% versus 28.9% ± 9.6%, P = 0.82; Table 52). When comparing CYP3A5 
expressers with non-expressers in low–variability patients no differences in the within-
patient variability of dose-normalized Tac C0 were observed (p=0.94). The same is 
evident for the high–variability patients (p= 0.65; Table 53). 
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The analysis was repeated in periods of stable tacrolimus dose, Advagraf® mean 
Tacrolimus dose was 5.1 ± 3.3 mg with dose-normalized Tac C0 of 13.4 ± 10.2 µg/L. 
Again Tacrolimus dose requirement was 2.1-fold higher in CYP3A5 expressers 
compared with that in CYP3A5 non-expressers. A significant difference in Tacrolimus 
dose and dose-normalized trough C0 was observed in both genotype groups (p<0.001). 
We observed no differences in tacrolimus WPV between CYP3A5 expressers and non-
expressers in Advagraf® treatment (28.1% ± 17.4% versus 23.3% ± 9.2%, P = 0.13; 
Table 52). Only patients with high variability demonstrated a significant reduction in 
WPV in CYP3A5 non-expressers compared with CYP3A5 expressers: WPV decreased 
from 41.4 ± 15.7% to 30.3 ± 6.9% (p < 0.01). Additionally, no differences were 
observed in the within-individual variability of dose-normalized Tac C0 between low 
variability patients with the CYP3A5*1/*1 or *1/*3 versus CYP3A5*3/*3 genotypes (P 
= 0.59; Table 53). 
Conversion from TD-Tac to Advagraf® did not show any significant difference in 
tacrolimus dose requirement and WPV in both genotype groups either in periods of 
stable tacrolimus dose or periods pre-conversion or post-conversion. Additionally, WPV 
did not change in either CYP3A5 expressers or CYP3A5 non-expressers in both high 
and low variability patients after the switch. 
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Table 52: Within-Patient Variability in Dose-Normalized Tacrolimus Trough Concentration (Tac WPV) and CYP3A5 Genotype. 
Parameters 
Twice-daily Tacrolimus Once-daily Tacrolimus 
*Pre-conversion period Stable period *Post-conversion period Stable period 
Tacrolimus dose (mg/day) 
    
CYP3A5 nonexpressers (*3/*3) 4.1 ± 2.3 4.0 ± 2.2 3.5 ± 1.7 3. 4 ± 1.7 
CYP3A5 expressers (*1/*1 plus *1/*3) 7.8 ± 3.9 7.6 ± 3.9 7.5 ± 3.5 7.4 ± 3.6 
  p<0.001 p<0.001 p<0.001 p<0.001 
Tac C0 (µg/L / mg/kg)      
CYP3A5 nonexpressers (*3/*3) 18.1 ± 9.3 17.9 ± 9.6 16.4 ± 9.2 17.1 ± 10.7 
CYP3A5 expressers (*1/*1 plus *1/*3) 9.8 ± 10.3 9.8 ± 10.6 8.2 ± 6.5 8.6 ± 7.4 
  p<0.001 p<0.001 p<0.001 p<0.001 
Tac WPV (CV%) 
    
CYP3A5 nonexpressers (*3/*3) 26.3 ± 12.0 22.4 ± 10.9 28.9 ± 9.6 23.3 ± 9.2 
CYP3A5 expressers (*1/*1 plus *1/*3) 28.7 ± 12.3 30.0 ± 14.5 29.4 ± 11.1 28.1 ± 17.4 
P (*1/*1 plus *1/*3 vs. *3/*3) p = 0.41 p < 0.05 p = 0.82 p = 0.13 
*Pre-conversion: the whole period before switching to OD-Tac where patients were on TD-Tac treatment. Post-conversion: the whole 
period after switching to OD-Tac where patients were on OD-Tac treatment. All values are shown in mean ± SD. Data are shown as mean 
± SD. Values were compared using ANOVA (General linear model). 
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Table 53: High and Low Within-Patient Variability in Dose-Normalized 
Tacrolimus Trough Concentration and CYP3A5*3 Genotype. 
CYP3A5 Genotype 







  CYP3A5 nonexpressers (*3/*3) 18.0 ± 4.5 35.0 ± 11.2 
CYP3A5 expressers (*1/*1 plus *1/*3) 20.0 ± 6.1 38.0 ± 10.3 
 
p= 0.26 p= 0.43 
Post-conversion period 
  
CYP3A5 nonexpressers (*3/*3) 22.1 ± 4.8 35.9 ± 8.1 
CYP3A5 expressers (*1/*1 plus *1/*3) 22.0 ± 4.9 37.4 ± 10.3 
 
p=0.94 p= 0.65 
TD-Tac Stable period  
  
CYP3A5 nonexpressers (*3/*3) 15.5 ± 3.2 29.8 ± 11.4 
CYP3A5 expressers (*1/*1 plus *1/*3) 19. 5 ± 5.9 41.2 ± 12.4 
 
p < 0.05 p<0.01 
OD-Tac Stable period 
  
CYP3A5 nonexpressers (*3/*3) 16.7 ± 5.5 30.3 ± 6.9 
CYP3A5 expressers (*1/*1 plus *1/*3) 15.7 ± 5.6 41.4 ± 15.7 
  p =0.59 p < 0.01 
High variability refers to patients having high within-patient variability and Low 
variability refers to patients having low within-patient variability using the median as 
the cutoff value. All values are shown in mean ± SD. Values were compared using 
ANOVA (One way ANOVA). 
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7.4 Discussion and Conclusion 
This retrospective analysis studied stable patients switched from TD-Tac to OD-Tac 
after kidney transplantation. There were no adverse events associated with conversion 
with stable graft function. The serum creatinine and estimated glomerular filtration rate 
did not show any significant change after conversion. Stable function after conversion 
has been reported by other studies
 
(Guirado et al., 2011, Kurnatowska et al., 2011, 
Shuker et al., 2014). However, the study by Tinti et al. (2010) showed an improvement 
in the renal graft function after conversion from TD-Tac to OD-Tac. Serum creatinine 
and GFR showed significant improvements after conversion. 
In this study, we found a significant decrease in Tac C0 by 16% and in Tacrolimus dose-
normalized C0 by 11% after conversion and almost all the recipients required dose 
adjustments. This is in line with the previous observations showing that conversion 
from TD-Tac to OD-Tac on a 1:1 (mg: mg) basis, resulted in considerably lower Tac C0 
concentrations and sometimes required dose adjustments (Shuker et al., 2014, Tinti et 
al., 2010, Wehland et al., 2011). During periods of stable tacrolimus doses, the 
reduction was 15% in Tac C0 and 10% in dose-normalized Tac C0 and the majority of 
the recipients required dose changes. This supports our findings of the whole period 
analysis in which the dose-normalized Tac C0 and dose reduced significantly after 
switching from TD-Tac to OD-Tac. In contrast to what would be expected from the 
published literature, tacrolimus C0 concentration actually increased in a significant 
proportion of patients leading to dose reduction on conversion from twice daily 
tacrolimus to Advagraf®.  
Regarding WPV, our patients converted to Advagraf® did not show any significant 
decrease in WPV of dose-normalized Tac C0 compared to a twice-daily tacrolimus and 
the same results were obtained during analysis of periods of stable tacrolimus dose. 
Similar observations were made in other conversion studies where they failed to show 
any change in Tac WPV after conversion either in small populations (van Hooff et al., 
2012, Wehland et al., 2011) or large populations (Shuker et al., 2014). However, other 
reports demonstrate that conversion from Prograf® to Advagraf® was associated with a 
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significantly lower within-patient variability of tacrolimus trough concentration. A 
study by Alloway et al. (2005) reported a greater decrease in within patient variability 
of tacrolimus exposure with modified release tacrolimus versus Prograf® for African-
American patients compared to Caucasian patients, although only limited data were 
provided. It has been reported that the conversion from twice-daily Prograf® to once-
daily Advagraf® was associated with a significant decrease of within-patient variability 
of tacrolimus C0 (Wu et al., 2011). The discrepancy in the results may be due to 
differences in the study design, sample size and the inclusion and exclusion criteria of 
these studies. In the study by Wu et al. (2011), all patients were from a Chinese 
background (Taiwanese) and only patients with stable renal function and tacrolimus C0 
were included. In addition, an important limitation of their study is that the study was 
not randomized or double blind so patients may improve or modify their behaviour in 
response to the fact that they are being studied, not in response to any particular 
experimental manipulation. 
In addition, we found that patients with low variability before conversion demonstrated 
a significant increase in WPV after conversion and patients with high variability before 
conversion associated with a significant decrease in WPV after conversion. The same 
results were obtained in a recent study (Shuker et al., 2014). It can be argued that the 
changes observed in Tac WPV after conversion is not clinically relevant. This is likely 
to be due to regression to the mean. From the available published data, there is certainly 
no clear indication that WPV is reduced on conversion from twice daily to once daily 
tacrolimus preparations. 
In this study, we investigated the influence of CYP3A5 genotype on tacrolimus WPV 
Tac C0 in stable kidney transplant patients at least 3 months after transplantation. In this 
population, only 10 patients were less than 6 months post-transplantation. Our findings 
showed that patients treated with twice daily tacrolimus did not show any significant 
association between WPV of dose-normalized Tac C0 and CYP3A5 genotype. 
Moreover, no difference in CV% was observed between low or high variability patients 
in each group. This is in line with the previous studies investigating the impact of 
CYP3A5 genotype on the Tac WPV. Pashaee et al. (2011) on mixed ethnicity patients 
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found no association between within-patient variability of TD-Tac clearance and 
CYP3A5 genotype. A study in Korean patients demonstrated that CYP3A5 
polymorphism had no impact on TD-Tac within- patient variability (Ro et al., 2012). In 
both studies, they used data between 6 and 12 months post transplantation to calculate 
tacrolimus WPV. Additionally, these results parallel those obtained by Wu et al. (2014) 
who found no significant difference in TD-Tac WPV between CYP3A5 high- and low-
expression.  
However, during periods of stable tacrolimus dose the WPV of dose-normalized Tac C0 
was significantly lower in CYP3A5 expressers compared to CYP3A5 non-expressers. 
Furthermore, low and high variability patients demonstrated the same significant 
difference in WPV for both genotype groups. Our findings are in agreement with the 
observations of Yong Chung et al. (2010) who reported an association between CYP3A5 
genotype and the within individual variability of tacrolimus PK parameters in healthy 
volunteers of two way crossover bioequivalent study. They are in contrast with the 
findings of Spierings et al. (2013) study on TD-Tac using 3 coinciding tacrolimus doses 
and showing that the within-patient variability of tacrolimus clearance was not 
associated with CYP3A5 genotype in stable renal transplant recipients. This discrepancy 
may be due to the difference in sample size as they used only 3 tacrolimus blood 
concentrations and 3 coinciding tacrolimus doses and in our study at least 3 doses and 3 
concentrations were used for each patient.  
For once-daily tacrolimus only one study addressed the effect of CYP3A5 genotype on 
Tac WPV (Wu et al., 2014). In our study, patients treated with once- daily tacrolimus, 
no differences in the within-patient variability of dose-normalized Tac C0 were 
observed between CYP3A5 expressers and non-expressers. For high- and low-
variability patients, we found no significant difference in WPV between CYP3A5 
expressers and non-expressers. This is similar to results obtained from a recent study 
showing no significant difference in %CV of tacrolimus trough concentration between 
high- and low-expressers (Wu et al., 2014). During periods of stable Advagraf® dose, 
we observed no differences in the WPV between CYP3A5 expressers and non-
expressers. We also found that only patients with high variability demonstrated a 
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significant reduction in WPV in CYP3A5 non-expressers compared with CYP3A5 
expressers.  
Conversion from TD-Tac to Advagraf® did not show any significant difference in 
tacrolimus WPV in both genotype groups. Additionally, WPV did not change between 
CYP3A5 expressers and CYP3A5 non-expressers in both high-and low-variability 
patients after the switch. This is partially in line with the Wu et al. (2014) study 
showing a specific reduction in %CV of tacrolimus trough level in patients with high-
expression CYP3A5 genotype when they converted to once-daily Advagraf®. Our study 
has some limitations, including the retrospective nature of the study and lack of 
compliance data.  
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8 Chapter 8. Pharmacogenetic Associations with 
Prednisolone and Prednisone Exposure 
  
Prednisolone Prednisone 
Figure 57: Structure of Prednisolone and Prednisone. 
Corticosteroids are an important component of clinical immunosuppressive therapy, and 
they have been used from the advent of transplantation in the 1960s. Prednisolone, a 
synthetic corticosteroid, is a widely used immunosuppressive agent and is commonly 
used to treat and prevent acute rejection after organ transplantation (Figure 57). 
Prednisone is the main  metabolite of prednisolone and they are integral components of 
induction and maintenance immunosuppressive regimens in solid organ transplantation 
(Bergmann et al., 2012). Evaluating the plasma concentration of prednisolone, 
endogenous cortisol and their inactive metabolites, prednisone and cortisone, may help 
in the assessment of therapeutic response to corticosteroids or their side-effects. CYP3A 
and P-glycoprotein (P-gp) are involved in the metabolism of both tacrolimus and 
steroids. Steroids are a well-known inducer of both CYP3A and P-glycoprotein activity. 
It has been reported that the higher the steroid dosage used, the higher the tacrolimus 
dosage required to achieve target trough blood concentration (Anglicheau et al., 2003a).  
Objectives of the Study 
1. To develop and validate a new method for measurement of prednisolone and its 
metabolite prednisone in plasma using HPLC-MS/MS.  
2. To explore the relationship between the CYP3A5*3, ABCB1 3435, CYP3A4*22 
and POR*28 SNPs and prednisolone- prednisone exposure.  
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8.1 Validation of Liquid Chromatography – Mass Spectrometry 
(LC-MS/MS) Method for the Analysis of Prednisolone and 
Its Metabolite in Human Plasma. 
8.1.1 Introduction 
Several high performance liquid chromatography (HPLC) methods were reported in the 
published literature for determination of prednisolone and prednisone in plasma. The 
disadvantage of these HPLC methods is that they consume large volumes of plasma 
(Gai et al., 2005, Cheng et al., 1988) and are less sensitive (Gai et al., 2005, Huber et 
al., 1990, Alvinerie et al., 1990) and have long run times (Cheng et al., 1988, Lasic et 
al., 1989). Ionita and Akhlaghi (2010) described an LC-MS/MS method that achieved a 
good sensitivity for determination of unbound prednisolone and prednisone. The 
samples were separated by the ultrafiltration of plasma using Microcon centrifugal filter 
devices. Methlie et al. (2013) developed an LC–MS/MS method that quantifies 
endogenous and synthetic corticosteroid as prednisolone and prednisone in serum using 
long extraction method. Evaluating the plasma concentration of prednisolone, 
endogenous cortisol and their inactive metabolites, prednisone and cortisone, may help 
in the assessment of therapeutic response to corticosteroids or their side-effects. 
8.1.2 Materials and Methods 
8.1.2.1 Prednisolone-Prednisone Analysis 
Prednisolone and prednisone plasma concentration were measured using validated 
HPLC based assay with tandem mass spectrometry detection. The analytical method 
was based on using the following 
8.1.2.1.1 Instrumentation 
Solvent delivery was achieved using an Agilent series 1100 pump. Sample injection was 
performed by using an Agilent series 1100 auto injector. The column temperature was 
adjusted using an Agilent series 1100 column oven. Detection was by an API4000 Mass 
spectrometer (AB Sciex, England). A Windows PC computer running Analyst 1.3.2 
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software was used to control the HPLC/MS, record the output from the detector, 
perform integration of peak areas and calculate the prednisolone and prednisone 
concentrations. The Analyst software was supplied by Applied Biosystems, England. 
The NM20ZA high purity nitrogen and air generators were supplied by Peak Scientific 
Instruments, Scotland. 
8.1.2.1.2 Chemicals & Reagents  
Prednisolone, prednisone, cortisol, cortisone, dexamethasone (internal standard) and 
orange G were supplied by Sigma-Aldrich. Plasma samples containing EDTA 
anticoagulant were obtained from Biological Specialty Corp. HPLC-graded ethyl 
acetate and acetic acid (100%) were purchased from VWR together with sodium 
hydroxide. HPLC-graded methyl-tert-butyl ether and methanol (HPLC grade) were 
obtained from Rathburn Chemicals Ltd. Sodium chloride was supplied by BDH 
Prolabo. De-ionised water was prepared on site using Millipore (water purification 
system).  
8.1.2.1.3 Stock Solutions 
Stock solutions of prednisolone (1 mg/L) and prednisone (200.0µg/mL) were prepared 
in methanol and a combined sub-stock of prednisolone and prednisone stocks was 
prepared by further dilution in drug-free human plasma to obtain calibration and quality 
control (QC) stocks. 
Calibration standards were spiked with prednisolone-prednisone calibration stock 
solution to give final concentrations of 2.5, 5.0, 12.5, 50.0, 125.0, 250.0 and 375.0 µg/L 
for prednisolone and 0.5, 1.0, 2.5, 10.0, 25.0, 50.0 and 75.0 µg/L for prednisone. 
Aliquots of these standard solutions were then stored at -20°C until analysis. Three QC 
samples were prepared by using the same procedure at concentrations of 25.0, 125.0 and 
250.0 µg/L for prednisolone and 5.0, 25.0 and 50.0 µg/L for prednisone in human 
plasma. Dexamethasone stock solutions (1000 mg/L) was prepared in methanol and the 
internal standard stock solution of dexamethasone was prepared by further dilution in 
deionized water at a concentration of 1 mg/L and stored at approximately 4ºC. 
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8.1.2.1.4 Extraction Procedure: 
Calibrators / Controls / Patients samples (100µL), internal standard solution (50µL), 
alkaline sodium chloride solution (250µL) and 1mL extracting solvent (ethyl acetate: 
methyl-tert-butyl ether 1:1) were pipetted into pre-labelled 2mL polypropylene tubes. 
The alkaline sodium chloride solution consists of sodium chloride (23g), 1ml of sodium 
hydroxide solution 40% (w/w), orange G (10 mg) and de-ionized water (100ml) The 
contents of the tubes were mixed for 5 min and then centrifuged at; 13,200 rpm for 2.5 
min using Eppendorf 5415D Centrifuge (Eppendorf, England, UK). The entire top 
solvent layer was then transferred to a 4.5 mL conical polypropylene tube and 
transferred to the SpeedVac and evaporated to dryness at high heat setting. The dried 
extracts were reconstituted with 1 mL of 25% methanol, vortex mixed for 20 seconds 
and then centrifuged at approximately 3500 RPM for approximately 2 minutes using 
Heraeus Megafuge 11 Centrifuge (Thermo Scientific, England, UK). The extract was 
then transferred to labelled auto-sampler tubes and a 10µL aliquot of each extract was 
injected onto the column (Figure 58).  
8.1.2.1.5 Chromatographic and Mass Spectrometric Conditions 
LC-MS/MS method was validated for the analysis of prednisolone and its metabolite 
prednisone in plasma. The separation was performed using an analytical Hypercarb 
30mm x 3mm, 5µm column (Thermo Scientific, UK) at temperature of 50°C. The 
mobile phase was pumped isocratically at a flow rate of 0.6 mL/min and consisted of 
0.1% acetic acid in methanol. The sample injection volume was 10 µL. Tandem mass 
spectrometric detection and quantification was performed in the negative electrospray 
ionization mode using multiple-reaction monitoring (MRM) mode. The transition 
selected were m/z 419.3/329 for prednisolone, 417.13 /327 for prednisone and m/z 
451.2/361.1 for dexamethasone (Figure 58). MS Settings: An API4000 triple quadruple 
mass spectrometer equipped with a turbo-ion spray (heated electro-spray, ESI) was used 
to introduce the sample into the mass spectrometer. Nitrogen was used as the collision 
gas. Gas settings in ml/min were: Collision gas: 4, curtain gas: 10, ion source gas 1: 40, 
ion source gas 2: 40. Ion spray voltage: 4200 V, and temperature: 500°C. Entrance 
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potential (EP) and collision energy (CE) in voltage were 10 and 22 V, respectively for 
all compounds and the dwell times were set at 300 ms. Declustering Potential (DP) was 
50 for both prednisolone and prednisone and 20 for dexamethasone. The collision cell 
exit potential (CXP) in voltage was 7, 9 and 15 V, for prednisolone, prednisone and 
dexamethasone, respectively. 
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Figure 58: Schematic Diagram of the Prednisolone and Prednisone Extraction 
Procedure. 
To a 2mL polypropylene tube add:
100µL plasma calibrator / quality control / sample
50µL internal standard (Dexamethasone 1µg/mL)
250µL Sodium Chloride/ Sodium hydroxide solution
1 mL Extraction solvent
(Methyl-tert-butyl ether: Ethyl Acetate 1:1)
Mix for 5 minutes (minimum)
Centrifuge for 2.5 minutes (Microfuge, 12,000 - 13,200 rpm)
Transfer top solvent layer to a 4.5mL propylene
 tube and evaporate to dryness in the SpeedVac
Reconstitute in 1mL 25% methanol
Vortex mix for 5 minutes
(minimum, IKA-Viber-VXR mixer)
Centrifuge for approx. 2 minutes (3000 - 3500 rpm)
(Optional)
Transfer all the extract to labelled autosampler vials
Inject 5 - 30µL of each extract onto the analytical column
Prednisolone LC-MS/MS
HPLC Conditions:
Column: Hypercarb  (30mm x 3mm, 5µm)
Mobile phase:
 Methanol + 1mL/L 100%Acetic acid
Elution: Isocratic
Flow rate: 0.6 mL/minute (range allowed 0.40 - 0.60)
MS Conditions:
MS type: MRM
Ionisation type: Turbo Ion-Spray
Ionisation polarity: Negative
Resolution: Unit/Low
Prednisolone:           419.3/ 329
Prednisone:             417.13/ 327
Dexamethasone: 451.2 / 361.1
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  
Page 260 of 377 
8.1.2.2 Method Development and Validation 
An analytical method for determination of prednisolone and prednisone plasma 
concentration was developed and validated according to FDA guidelines. The method 
included determination of accuracy, precision, selectivity, sensitivity, reproducibility, 
and stability (FDA., 2001). 
8.1.2.2.1 Specificity 
The specificity and selectivity of the assay were investigated by comparing the retention 
times of prednisolone and prednisone detected in an assay of six drug-free and four 
prednisolone and prednisone spiked plasma samples. These samples were extracted 
using the above mentioned extraction method. The signal to noise ratio should be more 
than 5. 
8.1.2.2.2 Matrix Effect 
The matrix effect of the method was evaluated by analysis of 6 different batches of 
human plasma. Matrix effects were assessed by comparison of peak area measurements 
obtained from human plasma extracts spiked with prednisolone and prednisone at the 
QC2 level after extraction  with those obtained from aqueous solutions.  
8.1.2.2.3 Calibration/Linearity 
Linearity was assessed by analysis of 7 non-zero calibrators of prednisolone and 
prednisone calibration curve in duplicate over a range 2.5 – 375.0 µg/L for prednisolone 
and 0.5 – 75.0 µg/L for prednisone with the internal standard (Dexamethasone). The 
concentrations of these calibrators were 2.5, 5.0, 12.5, 50.0, 125.0, 250.0 and 375.0 
µg/L for prednisolone and 0.5, 1.0, 2.5, 10.0, 25.0, 50.0 and 75.0 µg/L for prednisone. 
The calibration curve also consisted of a blank sample (plasma sample analysed with 
internal standard), double blank sample (plasma sample analysed without internal 
standard). The correlation coefficient (r) between concentration and peak area ratio 
should be equivalent to, or better than 0.98. 
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The following conditions were met in developing a calibration curve for the back 
calculated concentrations for calibration standards: 
• No more than ±20% deviation of the lower limit of quantitation (LLOQ) from actual 
concentration 
• No more than ±15% deviation of calibrators other than LLOQ from actual 
concentration. 
At least 75% of the non-zero standards should meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration, upper limit of 
quantitation (ULOQ). Excluding the standards should not change the regression model 
used. 
8.1.2.2.4 Accuracy and Precision 
Accuracy was determined by analysis of low, medium and high quality control samples. 
The low, medium and high quality control values were 25.0, 125.0 and 250.0 µg/L, 
respectively, for prednisolone and 5.0, 25.0 and 50.0 µg/L, respectively, for prednisone. 
Accuracy should be measured using a minimum of five determinations per 
concentration. The mean values should be within 15% of the actual value. 
The precision or repeatability were measured both within-batch and between-batch by 
the analysis of three quality control (QC) samples. Within-run, intra-batch precision 
assesses precision during a single analytical run. While between-run, inter-batch 
precision measures precision with time, and may involve different analysts, equipment, 
reagents, and laboratories. Precision should be measured using a minimum of five 
determinations per concentration so the QCs were assayed six times in five separate 
essays on separate days. The precision determined at each concentration level should 
not exceed 15% of the coefficient of variation (CV), the ratio of the standard deviation 
to the mean. For calculating accuracy and precision the following formulae were used: 
 
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  






Absolute recovery of prednisolone and prednisone was performed by comparing the 
analytical results for the extracted samples, using human plasma spiked with three 
different concentrations (Quality control concentrations), with non-extracted standards 
that represent 100% recovery. Recovery was tested in quadruplicate with the same batch 
of human plasma used to prepare the quality control samples. Absolute recovery of 
dexamethasone was tested at a nominal concentration of 50 µg/L. Mean and standard 
deviation were calculated from at least three measurements at each level. The absolute 
recovery relates to the extraction efficiency of the analytical method and it does not 
need to be 100%, but it should be consistent, precise, and reproducible. The extraction 
recovery of the test compound was calculated as follows: 
 
8.1.2.2.6 Stability 
For stability determination samples were prepared from freshly prepared stock 
solutions. Stability evaluation includes the stability during sample collection and 
handling, after short-term (bench top, room temperature) storage, and after going 
through freeze and thaw cycles and the analytical process. Conditions used in stability 
experiments reflect situations likely to be encountered during actual sample handling 
Acc [%] = 100 x
Mean Measured Concentration
Nominal Concentration






 = [%]Recovery  
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and analysis. The procedure also includes an evaluation of analyte stability in stock 
solution. 
8.1.2.2.6.1 Short term temperature stability  
The stability of three quality control samples was examined at ambient temperature, 
approximately 20ºC and at approximately 4ºC for a period of 24 hours. Four 
measurements were made at each concentration of these QC samples. 
Sets of stability samples subjected to 3 freeze and thaw cycles at nominal –20°C were 
determined against freshly prepared calibration standards. Four measurements were 
made at each concentration of these QC samples. 
8.1.2.2.6.2 Stability of Extracted Samples 
The stability of processed samples’ extracts, including the resident time in the auto-
sampler, was measured in quality control samples. These quality control samples were 
kept in the auto-sampler at room temperature. The run was injected at t0 and 
approximately 16 h later. Each sample was quantified with the calibration curve injected 
at the same time. For each level, the mean value, the standard deviation, the precision 
and the accuracy were calculated at t0 and t16 h. 
Acceptance criteria:  
At t0 and t16 h, the precision should be equal to or less than 15% and the accuracy 
should be between 85% and 115% of the nominal concentration for each level to 
demonstrate the stability of the compound. Moreover, for each level, at least 4 replicates 
out of 6 should have a relative error within 15%. 
8.1.2.2.7  Batch analysis and data reporting 
Each analytical batch contained seven, non-zero, calibrators, assayed in duplicate. The 
three quality control samples, assayed in duplicate, were dispersed throughout the 
analytical batch. A minimum of two sets of quality control samples at each 
concentration was included in each full analytical batch. 
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The calibration curves and calculation of prednisolone and prednisone concentrations 
used 1/x
2
 weighted least-squares regression to describe the concentration-response 
relationship. The peak area ratio, correlation coefficient (r) and the slope of the 
calibration line were calculated using the peak area data by the Analyst 1.3.2 software. 
 Assay Acceptance Criteria 
For study sample results to be accepted the following acceptance criteria must be met 
for the analytical batch. In the case of a rejected analytical batch, all study samples of 
that analytical batch should be re-analysed. 
A. Calibration Curve 
The correlation coefficient (r) between concentration and peak area ratio should be 
equivalent to, or better than, 0.98. 
B. Calibration Standards 
The following conditions should be met in developing a calibration curve for the back 
calculated concentrations for calibration standards: 
 no more than ±20% deviation of the LLOQ from actual concentration 
 no more than ±15% deviation of calibrators other than LLOQ from actual 
concentration 
At least 75% of the non-zero standards should meet the above criteria, including the 
LLOQ and the calibration standard at the highest concentration. Excluding the standards 
should not change the regression model used. 
C. Quality Control Samples 
The concentrations of both the quality control samples and the patient samples were 
calculated by using the peak areas of each analyte with respect to the peak areas of the 
appropriate internal standard. 
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The following conditions should be met for batch acceptance: 
 no more than ±15% deviation of quality controls from their actual concentration 
At least 67% of the controls must meet the above criteria. 
8.1.3 Results 
Optimization of detector parameters for tandem mass spectrometric detection of the 
analytes (prednisolone and prednisone) was determined through direct infusion of each 
analyte or internal standard (Dexamethasone) at a flow rate of 0.6 mL/min. Each of the 
drugs was dissolved in 10% acetic acid: methanol (50:50) with a concentration of 
1µg/mL.  
The molecular structure and molecular weight of prednisolone, prednisone, 
dexamethasone and endogenous steroids (Cortisone and Cortisol) is shown in Figure 
59. Parent ion scan (Q1 scan) and product ion scan (Q3). The fragment ions selected for 
the assay are shown in Table 54. Endogenous steroids (Cortisone and Cortisol) were 
tested to make sure there is no interfering peak at the retention times for prednisone and 
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Prednisolone MWt: 360.44 
 
Prednisone MWt: 358.43 
 
Dexamethasone MWt: 392.461 
     
Cortisone MWt: 360.44  
 
Cortisol MWt: 362.460 
Figure 59: Molecular Structure and Molecular Weight of Separated Steroids. 
Table 54: Analyte Mass Transitions 
Analyte Name Prednisolone Prednisone Dexamethasone Cortisone Cortisol 
Initial ion (m/z) 
Q1 Mass (amu) 
419.25 417.25 451.22 419.3 421.1 
Product ion (m/z) 
Q3 Mass (amu) 
329.00 327.00 361.10 329.0 331.0 
Ionisation mode Negative Negative Negative Negative Negative 
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  
Page 267 of 377 
 
Figure 60: Chromatogram Displayed Separation of Steroids. 
8.1.3.1 Specificity 
No significant interfering peaks were found at the retention time of prednisolone, 
prednisone and the internal standard as shown in Figure 61& Figure 62. The peak to 
noise ratio was greater than 5 for all of them. Figure 61 shows the chromatograms 
obtained from blank plasma, plasma spiked with 2.5 µg/L and 375 µg/L for 
prednisolone and 0.5 µg/L and 75 µg/L for prednisone. Figure 62 shows the 
chromatograms of blank plasma and 50 µg/L dexamethasone spiked plasma. 
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Figure 61: Chromatograms Obtained from Extracted Blank Plasma Free from 
Prednisolone and Prednisone (a), Blank Plasma Spiked with 2.5 µg/L 
Prednisolone and 0.5 µg/L Prednisone (b) and Blank Plasma Spiked 
with 375 µg/L Prednisolone and 75 µg/L Prednisone (c). 
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Figure 62: Chromatograms Obtained from Extracted Blank Plasma (a) and Blank 
Plasma Spiked with 50 µg/L Dexamethasone (b). 
8.1.3.2 Matrix Effect 
Prednisolone and prednisone were tested at the same nominal concentration as the 
middle quality control sample, with six different plasma samples. Peak area 
measurements obtained from post extracted plasma spiked with prednisolone and 
prednisone and the internal standard at the same concentrations as the middle quality 
control sample were compared to the peak area measurements obtained from the spiking 
solutions. From the obtained results, the matrix effects were considered acceptable 
(Table 55). 
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Table 55: Matrix Effect for Prednisolone, Prednisone and the Internal Standard. 
Prednisolone 





Matrix. N = 4 of 4 6 of 6  
 Data Point #1 7777956 7702121 -0.9% 
 Data Point #2 7606603 7545712 -2.9% 
 Data Point #3 7788381 7691022 -1.0% 
 Data Point #4 7905249 7327626 -5.7% 
 Data Point #5  7606565 -2.1% 
 Data Point #6  7579525 -2.5% 
 Mean 7769547 7575429 -2.5% 
Prednisone 





Matrix. N = 4 of 4 6 of 6  
 Data Point #1 1046568 1052493 -0.6% 
 Data Point #2 1038420 1045274 -1.3% 
 Data Point #3 1075698 1050858 -0.8% 
 Data Point #4 1075516 1063013 0.4% 
 Data Point #5  1055722 -0.3% 
 Data Point #6  1048737 -1.0% 
 Mean 1059051 1052683 -0.6% 
Dexamethasone 





sample / mean 
100% 
Matrix. N = 4 of 4 6 of 6  
 Data Point #1 35500987 34880804 -0.9% 
 Data Point #2 34515090 35085701 -0.3% 
 Data Point #3 35363333 35125057 - .2
 Data Point #4 35361783 33931612 -3.6% 
 Data Point #5  34733210 -1.3% 
 Data Point #6  35297598 0.3% 
 Mean 35185298 34842330 -1.0% 
All values show the peak area for each analyte 
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8.1.3.3 Calibration 
The calibration curves contained seven, non-zero, calibrators, containing both 
prednisolone and prednisone, assayed in duplicate. Nominal values for prednisolone 
were 2.5, 5.0, 12.5, 50.0, 125.0, 250.0 and 375.0 µg/L. Nominal values for prednisone 
were 0.5, 1.0, 2.5, 10.0, 25.0, 50.0 and 75.0 µg/L. Two prednisolone and prednisone-
free samples were analysed, one with the internal standard and one without the internal 
standard; neither were included when fitting the calibration line. 
The peak area ratios, regression coefficients and the slopes of the calibration lines, etc. 
were calculated from the peak area data by the Analyst program. The correlation 
coefficient (r) between concentration and peak area ratio is ≥ 0.9976 for all curves. This 
meets the acceptance criteria that the correlation coefficient (r) should be equivalent to, 
or better than, 0.98. Table 56 & Table 57 summarised the mean of the results obtained 
from five curves. 
Table 56: Prednisolone Calibration Curve Parameters 
Analytical run a0 a1 a2 Correlation coefficient (r) 
Batch1 0.000233 0.00237 -0.000000967 0.9998 
Batch2 0.001510 0.00235 -0.000000929 0.9997 
Batch3 0.000448 0.00249 -0.000001150 0.9997 
Batch4 0.000508 0.00245 -0.000001120 0.9997 





Table 57: Prednisone Calibration Curve Parameters 
Analytical run Slope Intercept Correlation coefficient (r) 
Batch1 0.0000335 0.00116 0.9989 
Batch2 0.0001740 0.00108 0.9993 
Batch3 0.0000765 0.00106 0.9993 
Batch4 0.0000596 0.00107 0.9997 
Batch5 0.0001470 0.00117 0.9976 
y= a1x+a0 
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8.1.3.4 Accuracy and Precision 
The three quality control samples were, initially, each extracted six times in three 
batches. Subsequently, the three quality control samples were each extracted six times 
in two additional batches. On each occasion a separate calibration curve was extracted. 
The criteria for the acceptance of the quality control samples were that both the 
precision and the mean measured concentration should be within ±15% of the expected 
value. Using these criteria, accuracy of the quality control samples for both 
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Table 58: Prednisolone Within and Between-Assay Repeatability.  
  QC1 QC2 QC3 
Batch1 Expected Conc.(µg/L) 25.0 125.0 250.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 24.8 110.1 260.1 
 Data Point #2 26.3 135.2 252.5 
 Data Point #3 25.1 140.8 232.5 
 Data Point #4 23.6 138.1 255.0 
 Data Point #5 26.0 132.1 258.3 
 Data Point #6 25.8 135.4 250.0 
 Mean 25.3 132.0 251.4 
 Standard Dev. 1.0 11.1 9.9 





Accuracy 101.0 105.6 100.6 
     
Batch2 Expected Conc.(µg/L) 25.0 125.0 250.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 25.9 139.2 258.0 
 Data Point #2 25.3 125.5 251.2 
 Data Point #3 25.0 128.4 253.2 
 Data Point #4 26.6 132.9 255.6 
 Data Point #5 25.9 130.4 258.5 
 Data Point #6 25.2 119.3 254.6 
 Mean 25.6 129.3 255.2 
 Standard Dev. 0.6 6.7 2.8 
 %CV 2.2 5.2 1.1 
 Accuracy 102.6 103.4 102.1 
     
Batch3 Expected Conc.(µg/L) 25.0 125.0 250.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 26.7 139.9 248.2 
 Data Point #2 26.5 138.6 248.8 
 Data Point #3 25.6 138.9 246.0 
 Data Point #4 27.2 125.3 243.0 
 Data Point #5 26.5 122.8 244.3 
 Data Point #6 27.1 119.7 239.5 
 Mean 26.6 130.9 245.0 
 Standard Dev. 0.6 9.3 3.5 
 %CV 2.2 7.1 1.4 
 Accuracy 106.4 104.7 98.0 
     
Batch4 Expected Conc.(µg/L) 25.0 125.0 250.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 27.1 139.0 247.6 
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 Data Point #2 26.0 136.3 240.9 
 Data Point #3 25.3 137.3 243.1 
 Data Point #4 26.8 126.7 242.1 
 Data Point #5 26.8 123.7 249.1 
 Data Point #6 26.6 121.2 245.1 
 Mean 26.4 130.7 244.7 
 Standard Dev. 0.7 7.7 3.2 
 %CV 2.5 5.9 1.3 
 Accuracy 105.7 104.5 97.9 
     
Batch5 Expected Conc.(µg/L) 25.0 125.0 
0 
250.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 24.5 121.3 247.3 
 Data Point #2 24.9 117.6 233.0 
 Data Point #3 23.1 114.4 232.3 
 Data Point #4 25.5 123.5 260.0 
 Data Point #5 25.0 121.6 241.9 
 Data Point #6 24.9 118.0 239.6 
 Mean 24.6 119.4 242.4 
 Standard Dev. 0.8 3.4 10.3 
 %CV 3.4 2.8 4.3 
 Accuracy 98.6 95.5 96.9 
 
Within-assay repeatability 
 QC1 QC2 QC3 
Expected Conc.(µg/L) 25.0 125.0 250.0 
N = 30 of 30 30 of 30 30 of 30 
Mean 25.7 128.4 247.7 
Standard Dev. 1.0 8.8 8.0 
%CV 4.0 6.9 3.2 
Accuracy 102.9 102.8 99.1 
 
Between-assay repeatability 
 QC1 QC2 QC3 
Expected Conc.(µg/L) 25.0 125.0 
 
250.0 
N = 5 of 5 5 of 5 5 of 5 
Mean 25.7 128.4 247.7 
Standard Dev. 0.8 5.1 5.4 
%CV 3.2 4.0 2.2 
Accuracy 102.9 102.8 99.1 
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Table 59: Prednisone Within and Between-Assay Repeatability.  
 Data QC1 QC2 QC3 
Batch1 Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
 N= 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.1 21.3 50.3 
 Data Point #2 5.3 26.1 48.1 
 Data Point #3 5.2 27.8 45.2 
 Data Point #4 4.9 27.2 47.7 
 Data Point #5 5.2 26.5 49.2 
 Data Point #6 5.1 27.3 47.8 
 Mean 5.1 26.0 48.0 
 Standard Dev. 0.1 2.4 1.7 
 %CV 2.7 9.3 3.5 
 %Accuracy 102.5 104.1 96.1 
     
Batch2 Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.3 27.6 49.8 
 Data Point #2 5.2 24.6 48.9 
 Data Point #3 4.9 26.3 49.0 
 Data Point #4 5.6 26.5 46.6 
 Data Point #5 5.4 26.3 49.4 
 Data Point #6 5.1 23.5 49.2 
 Mean 5.2 25.8 48.8 
 Standard Dev. 0.2 1.5 1.1 
 %CV 4.3 5.7 2.3 
 Accuracy 104.7 103.3 97.6 
     
Batch3 Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.5 27.4 46.1 
 Data Point #2 5.3 26.8 46.0 
 Data Point #3 5.1 26.5 43.9 
 Data Point #4 5.2 24.1 46.5 
 Data Point #5 5.4 22.9 44.5 
 Data Point #6 5.2 22.7 43.4 
 Mean 5.3 25.1 45.1 
 Standard Dev. 0.1 2.1 1.3 
 %CV 2.3 8.3 2.9 
 Accuracy 105.5 100.2 90.1 
     
Batch4 Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.4 27.3 46.4 
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 Data Point #2 5.1 26.7 45.1 
 Data Point #3 5.1 26.2 43.3 
 Data Point #4 5.0 24.3 45.9 
 Data Point #5 5.4 23.4 45.5 
 Data Point #6 5.2 23.5 43.5 
 Mean 5.2 25.2 44.9 
 Standard Dev. 0.2 1.7 1.3 
 %CV 3.4 6.8 2.9 
 Accuracy 104.4 100.9 89.9 
     
Batch5 Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.7 23.0 47.7 
 Data Point #2 5.2 24.7 43.7 
 Data Point #3 4.5 23.9 44.4 
 Data Point #4 4.8 23.3 53.8 
 Data Point #5 4.9 25.5 52.8 
 Data Point #6 4.7 24.7 45.1 
 Mean 5.0 24.2 47.9 
 Standard Dev. 0.4 0.9 4.4 
 %CV 8.4 3.9 9.2 
 Accuracy 99.3 96.8 95.8 
 
Within-assay repeatability 
 QC1 QC2 QC3 
Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
N = 30 of 30 30 of 30 30 of 30 
Mean 5.2 25.3 47.0 
Standard Dev. 0.3 1.8 2.7 
%CV 4.9 7.1 5.8 
Accuracy 103.3 101.1 93.9 
 
Between-assay repeatability 
 QC1 QC2 QC3 
Expected Conc.(µg/L) 5.0 25.0 
0 
50.0 
N = 5 of 5 5 of 5 5 of 5 
Mean 5.2 25.3 47.0 
Standard Dev. 0.1 0.7 1.8 
%CV 2.4 2.9 3.9 
Accuracy 103.3 101.1 93.9 
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8.1.3.5  Recovery 
Recovery was assessed by comparison of peak area measurements obtained from human 
plasma spiked prior to extraction with those obtained from human plasma extracts 
spiked after extraction. The recovery percentage was 77.7% to 79.2% for prednisolone 
and 72.9% to 73.5% for prednisone (Table 60). The extraction recovery for 
dexamethasone was 82.1%. The recovery for all three analytes was acceptable. 
Table 60: Prednisolone, Prednisone and Internal Standard Relative Recovery.  
Prednisolone  
 QC1 100% QC1 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 1908337 1465785 76.8% 
Data Point #2 1819192 1440493 79.2% 
Data Point #3 1816171 1410251 77.7% 
Data Point #4 1805942 1412439 78.2% 
Mean 1837411 1432242 78.0% 
 QC2 100% QC2 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 8157898 6290393 77.1% 
Data Point #2 8054867 6494499 80.6% 
Data Point #3 8111873 6089051 75.1% 
Data Point #4 8163250 6355247 77.9% 
Mean 8121972 6307298 77.7% 
 QC3 100% QC3 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 14466815 11297546 78.1% 
Data Point #2 14439308 11113930 77.0% 
Data Point #3 14583767 11712547 80.3% 
Data Point #4 14740886 12006762 81. 5% 
Mean 14557694 11532696 79.2% 
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Prednisone    
 QC1 100% QC1 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 230571 167942 72.8% 
Data Point #2 222306 164727 74.1% 
Data Point #3 228459 166724 73.0% 
Data Point #4 223172 165728 74.3% 
Mean 226127 166280 73.5% 
 QC2 100% QC2 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 1055920 782741 74.1% 
Data Point #2 1040078 801541 77.1% 
Data Point #3 1054412 753180 71.4% 
Data Point #4 1060692 760615 71.7% 
Mean 1052776 774519 73.6% 
 QC3 100% QC3 Ext Recovery 
N = 4 of 4 4 of 4  
Data Point #1 1988749 1424481 71.6% 
Data Point #2 2005401 1408663 70.2% 
Data Point #3 2014388 1487534 73.9% 
Data Point #4 1989498 1512129 76.0% 
Mean 1999509 1458202 72.9% 
Dexamethasone    
 IS 100% IS Ext Recovery 
N= 12 of 12 12 of 12  
Data Point #1 37532289 30566385 81.4% 
Data Point #2 36384499 30401293 83.6% 
Data Point #3 36717119 30194001 82.2% 
Data Point #4 36230810 30282588 83.6% 
Data Point #5 37200017 29458118 79.2% 
Data Point #6 37112266 30783098 83.0% 
Data Point #7 36588946 29154129 79.7% 
Data Point #8 36481255 29946647 82.1% 
Data Point #9 36467918 29159559 80.0% 
Data Point #10 36049318 29567495 82.0% 
Data Point #11 36078791 30029494 83.2% 
Data Point #12 35970806 30701427 85.4% 
Mean 36567836 30020353 82.1% 
All values show the peak area for each analyte 
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8.1.3.6 Short-Term Stability in Matrix 
The stability of prednisolone and prednisone in the three control samples was evaluated 
by the analysis of 6 replicates at each level. A set at each level was analysed as follows:  
• On the day of preparation, t0  
• After a minimum of 24 hours at ambient temperature.  
• After a minimum of 24 hours at approximately 4°C.  
• After three freeze-thaw cycles at nominal –20°C.  
Prednisolone and prednisone stability data show that they are stable in these 
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Table 61: Prednisolone Short-Term Stability Data. 
  
QC1 t0 QC2 t0 QC3 t0 
Batch1 Expected Conc.(µg/L) 25.0 125.0 250.0 
 
N = 6 of 6 6 of 6 6 of 6 
 
Data Point #1 24.8 110.1 260.1 
 
Data Point #2 26.3 135.2 252.5 
 
Data Point #3 25.1 140.8 232.5 
 
Data Point #4 23.6 138.1 255 
 
Data Point #5 26.0 132.1 258.3 
 
Data Point #6 25.8 135.4 250 
 
Mean 25.3 132 251.4 
 
Standard Dev. 1.0 11.1 9.9 
 
%CV 3.9 8.4 4.0 
 
Accuracy 101.0 105.6 100.6 
     
 
 
QC1 Rt QC2 Rt QC3 Rt 
Batch2 Expected Conc.(µg/L) 25.0 125.0 250.0 
 
N = 4 of 4 4 of 4 4 of 4 
 
Data Point #1 26.6 127.8 262.9 
 
Data Point #2 26.2 124.9 263.1 
 
Data Point #3 25.9 131.2 264.2 
 
Data Point #4 25.5 131 267 
 
Mean 26.1 128.8 264.3 
 
Standard Dev. 0.5 3.0 1.9 
 
%CV 2.0 2.3 0.7 
 
Accuracy 104.2 103.0 105.7 
     
  
QC1 4°C QC2 4°C QC3 4°C 
Batch2 Expected Conc.(µg/L) 25.0 125.0 250.0 
 
N = 4 of 4 4 of 4 4 of 4 
 
Data Point #1 25 126 263.6 
 
Data Point #2 23.8 128.9 268 
 
Data Point #3 24.8 129.9 271.3 
 
Data Point #4 25.3 127.5 274.5 
 
Mean 24.7 128.1 269.4 
 
Standard Dev. 0.6 1.7 4.7 
 
%CV 2.6 1.3 1.7 
 
Accuracy 99.0 102.5 107.7 
     
     
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  
Page 281 of 377 
 
 
QC1 F/T 1 QC2 F/T 1 QC3 F/T 1 
Batch2 Expected Conc. (µg/L) 25.0 125.0 250.0 
 
N = 4 of 4 4 of 4 4 of 4 
 
Data Point #1 26.9 129.6 259 
 
Data Point #2 26.2 130 240.2 
 
Data Point #3 24.9 123.1 256.9 
 
Data Point #4 24.5 129.6 251.7 
 
Mean 25.6 128.1 252 
 
Standard Dev. 1.1 3.3 8.4 
 
%CV 4.4 2.6 3.3 
 
Accuracy 102.5 102.5 100.8 
     
 
 
QC1 F/T 2 QC2 F/T 2 QC3 F/T 2 
Batch3 Expected Conc. (µg/L) 25.0 125.0 250.0 
 
N = 4 of 4 4 of 4 4 of 4 
 
Data Point #1 24.6 125.6 252 
 
Data Point #2 24.8 124 243.4 
 
Data Point #3 24.7 125.6 249.3 
 
Data Point #4 25.7 126.2 243.8 
 
Mean 24.9 125.4 247.1 
 
Standard Dev. 0.5 0.9 4.2 
 
%CV 2.1 0.7 1.7 
 
Accuracy 99.8 100.3 98.9 
     
  
QC1 F/T 3 QC2 F/T 3 QC3 F/T 3 
Batch5 Expected Conc. (µg/L) 25.0 125.0 250.0 
 
N = 4 of 4 4 of 4 4 of 4 
 
Data Point #1 26.2 113.9 247.1 
 
Data Point #2 24.7 114.5 244.8 
 
Data Point #3 23.5 123.9 246.2 
 
Data Point #4 22 121.1 240.3 
 
Mean 24.1 118.3 244.6 
 
Standard Dev. 1.8 4.9 3.0 
 
%CV 7.4 4.2 1.2 
 
Accuracy 96.5 94.7 97.8 
t0, On the day of preparation. Rt, After 24 hours at ambient temperature. 4°C, After 24 
hours at approximately 4°C. F/T1, Freeze-thaw cycle 1. F/T2, Freeze-thaw cycle 2. F/T3, 
Freeze-thaw cycle 3.  
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Table 62: Prednisone Short-Term Stability Data.   
  QC1 t0 QC2 t0 QC3 t0 
Batch1 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 6 of 6 6 of 6 6 of 6 
 Data Point #1 5.1 21.3 50.3 
 Data Point #2 5.3 26.1 48.1 
 Data Point #3 5.2 27.8 45.2 
 Data Point #4 4.9 27.2 47.7 
 Data Point #5 5.2 26.5 49.2 
 Data Point #6 5.1 27.3 47.8 
 Mean 5.1 26.0 48.0 
 Standard Dev. 0.1 2.4 1.7 
 %CV 2.7 9.3 3.5 
 Accuracy 102.5 104.1 96.1 
  QC1 Rt QC2 Rt QC3 Rt 
Batch2 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 4 of 4 4 of 4 4 of 4 
 Data Point #1 5.2 23.9 49.1 
 Data Point #2 5.0 23.3 49.3 
 Data Point #3 5.0 24.7 49.4 
 Data Point #4 5.1 24.7 49.1 
 Mean 5.1 24.1 49.2 
 Standard Dev. 0.1 0.7 0.1 
 %CV 1.9 2.9 0.2 
 Accuracy 101.9 96.6 98.4 
  QC1 4°C QC2 4°C QC3 4°C 
Batch2 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 4 of 4 4 of 4 4 of 4 
 Data Point #1 5.1 24.7 51.7 
 Data Point #2 4.7 25.6 51.9 
 Data Point #3 4.9 25.5 52.7 
 Data Point #4 5.1 25.1 53.5 
 Mean 5.0 25.2 52.4 
 Standard Dev. 0.2 0.4 0.8 
 %CV 4.3 1.7 1.5 
 Accuracy 99.2 100.9 104.9 
  QC1 F/T 1 QC2 F/T 1 QC3 F/T 1 
Batch2 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 4 of 4 4 of 4 4 of 4 
 Data Point #1 5.6 26.3 50.9 
 Data Point #2 5.3 26.3 45.6 
 Data Point #3 5.0 24.8 51.8 
 Data Point #4 4.9 26.3 49.0 
 Mean 5.2 25.9 49.3 
 Standard Dev. 0.3 0.7 2.7 
 %CV 5.8 2.9 5.5 
 Accuracy 103.7 103.7 98.6 
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  QC1 F/T 2 QC2 F/T 2 QC3 F/T 2 
Batch3 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 4 of 4 4 of 4 4 of 4 
 Data Point #1 4.7 23.9 47.0 
 Data Point #2 4.9 23.7 43.3 
 Data Point #3 5.1 23.4 45.0 
 Data Point #4 5.1 23.3 45.7 
 Mean 5.0 23.6 45.2 
 Standard Dev. 0.2 0.3 1.5 
 %CV 4.1 1.1 3.4 
 Accuracy 99.3 94.3 90.5 
  QC1 F/T 3 QC2 F/T 3 QC3 F/T 3 
Batch4 Expected Conc. (µg/L) 5.0 25.0 50.0 
 N = 4 of 4 4 of 4 4 of 4 
 Data Point #1 5.1 27.8 47.9 
 Data Point #2 4.8 26.7 47.4 
 Data Point #3 5.7 26.2 47.9 
 Data Point #4 5.2 24.1 49.5 
 Mean 5.2 26.2 48.2 
 Standard Dev. 0.4 1.5 0.9 
 %CV 7.0 5.9 1.8 
 Accuracy 103.7 104.9 96.3 
t0, On the day of preparation. Rt, After 24 hours at ambient temperature. 4°C After 
24 hours at approximately 4°C. F/T1, Freeze-thaw cycle 1. F/T2, Freeze-thaw cycle 
2. F/T3, Freeze-thaw cycle 3.  
8.1.3.7 Autosampler Stability 
The stability of the extracted samples was evaluated when kept inside the autosampler 
for ~16 h. A full set of calibration standards assayed in duplicate, a blank sample 
containing internal standard, a blank sample without internal standard and the six 
replicates of each of the three control samples. The autosampler was operated at 
ambient temperature. The run was injected at time 0 and approximately 16 h later. The 
same calibrator set was assayed at the start and end of the stability test. Each control 
sample was quantified with the calibration curve injected at the same time. The mean 
accuracy ranged between 99.9% and 105.8% for prednisolone and between 95.5% and 
105.0% for prednisone and the precision (%CV) < 9.3 for all three quality control 
samples. All three quality control samples were stable for at least 16 hours in the 
autosampler and they were in the acceptable range (Table 63 & Table 64). 
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Table 63: Prednisolone Autosampler Stability Data 
Analytical Run: Batch1 
Assay start date / time: 01/04/2013 18:56 
 QC1 QC2 QC3 
Expected Conc. (µg/L) 25.0 125.0 250.0 
N = 6 of 6 6 of 6 6 of 6 
Data Point #1 24.8 110.1 260.1 
Data Point #2 26.3 135.2 252.5 
Data Point #3 25.1 140.8 232.5 
Data Point #4 23.6 138.1 255.0 
Data Point #5 26.0 132.1 258.3 
Data Point #6 25.8 135.4 250.0 
Mean 25.3 132.0 251.4 
Standard Dev. 1.0 11.1 9.9 
%CV 3.9 8.4 4.0 
Accuracy 101.0 105.6 100.6 
Analytical Run: Batch1R 
Assay start date / time: 02/04/2013 11:18 
 QC1 QC2 QC3 
Expected Conc. (µg/L) 25.0 125.0 250.0 
N = 6 of 6 6 of 6 6 of 6 
Data Point #1 24.7 111.7 256.7 
Data Point #2 26.5 136.6 254.9 
Data Point #3 24.6 141.4 231.9 
Data Point #4 23.8 138.6 252.4 
Data Point #5 26.1 130.8 253.5 
Data Point #6 25.2 134.7 248.6 
Mean 25.2 132.3 249.7 
Standard Dev. 1.0 10.7 9.1 
%CV 4.0 8.1 3.7 
Accuracy 100.7 105.8 99.9 
 
  
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  
Page 285 of 377 
Table 64: Prednisone Autosampler Stability Data 
Analytical Run: Batch1 
Assay start date / time: 01/04/2013 18:56 
 QC1 QC2 QC3 
Expected Conc. (µg/L) 5.0 25.0 50.0 
N = 6 of 6 6 of 6 6 of 6 
Data Point #1 5.1 21.3 50.3 
Data Point #2 5.3 26.1 48.1 
Data Point #3 5.2 27.8 45.2 
Data Point #4 4.9 27.2 47.7 
Data Point #5 5.2 26.5 49.2 
Data Point #6 5.1 27.3 47.8 
Mean 5.1 26.0 48.0 
Standard Dev. 0.1 2.4 1.7 
%CV 2.7 9.3 3.5 
Accuracy 102.5 104.1 96.1 
Analytical Run: Batch1R 
Assay start date / time: 02/04/2013 11:18 
 QC1 QC2 QC3 
Expected Conc. (µg/L) 5.0 25.0 50.0 
N = 6 of 6 6 of 6 6 of 6 
Data Point #1 4.9 21.5 48.9 
Data Point #2 5.3 26.7 49.0 
Data Point #3 5.2 28.0 45.0 
Data Point #4 4.9 27.5 47.4 
Data Point #5 5.3 26.5 49.0 
Data Point #6 5.3 27.2 47.2 
Mean 5.2 26.2 47.7 
Standard Dev. 0.2 2.4 1.6 
%CV 3.5 9.1 3.3 
Accuracy 103.1 105.0 95.5 
 
Pharmacogenetic Associations with Prednisolone and Prednisone Exposure  
Page 286 of 377 
8.1.4 Discussion and Conclusion 
All validation results obtained met the FDA guideline requirements. In this study, a very 
simple liquid –liquid extraction method has been developed and validated. Cortisone 
and prednisolone have molecular weights less than 1 amu apart and the same product 
ion and this makes it difficult to separate them from each other. Hence, it was difficult 
to measure prednisolone concentrations in renal transplant patients.  This study showed 
that there is no interference between cortisone with prednisolone and between 
prednisone with hydrocortisone. However, we cannot separate cortisone from 
hydrocortisone. In this method, all the analytes eluted at a very short retention time, run 
time 3 min, which make it easy to run a large number of samples in a short period of 
time. This method is a sensitive method and a very small amount of plasma (100 µL) 
was used. HPLC–UV methods are not an adequate for analysing low concentrations of 
simultaneous corticosteroids in biological fluids and require long retention time. The 
sensitivity, accuracy and precision achieved by this method enable us to use it for 
assessment of prednisolone and prednisone pharmacokinetics in renal transplant 
patients’ samples.  
In this study, we present a sensitive, simple and rapid method to be used to selectively 
quantitate prednisolone and prednisone in plasma from stable post- transplant patients. 
All the validation results met the international requirements as defined in the guideline 
for analytical method validation (FDA., 2001). Previously published methods using 
radioimmunoassay (Adachi et al., 1991) and detection by high-performance liquid 
chromatography (HPLC)-ultraviolet (UV) (Majid et al., 2001) or gas chromatography–
mass spectrometry (GC–MS) (Shibasaki et al., 2008) have higher limits of 
quantification and involve difficult extraction and derivatization steps. Several of the 
previously reported LC–MS/MS methods do not or hardly achieve baseline separation 
of prednisolone and cortisol (Frerichs and Tornatore, 2004, Ionita and Akhlaghi, 2010). 
In this study, a simple liquid-liquid extraction which only needs 100µL of plasma has 
been developed and validated. Prednisolone, its metabolite prednisone and the 
endogenous cortisol and cortisone are very similar in structure (Figure 59). Most 
reverse phase columns (C8, C18, etc.) would result in very long run times (Majid et al., 
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2001). The Hypercarb column used in this method offers the separation of highly polar 
compounds with closely related structures. Using Hypercarb column, prednisolone and 
prednisone were baseline separated from each other and from cortisol and cortisone; 
however the latter two were only partially separated. Compared to previously published 
methods, this method requires only 100µL volume of plasma, has a simple and short 
extraction procedure and achieves suitable chromatographic separation of the 
compounds of interest from each other and from endogenous corticosteroids in 3 
minutes. The method developed is selective enough to distinguish between these 
synthetic and endogenous corticosteroids.  
In addition, this study demonstrated the validity of the analytical method developed for 
the quantitative determination of prednisolone and prednisone in human plasma 
samples. The developed method is a simple and rapid analytical method with 
chromatographic separation in 3 minutes. Therefore, it enables us to assess prednisolone 
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8.2 The Genetic Association between CYP3A5*3, CYP3A4*22, 
POR*28 and ABCB1 3435 and the Pharmacokinetics of 
Prednisolone and Prednisone. 
8.2.1 Introduction 
Prednisolone is a known inducer of both CYP3A and P-glycoprotein (Anglicheau et al., 
2003a). It is also a substrate for both CYP3A4/3A5 and P-glycoprotein. Data obtained 
from a study carried out on Japanese population, suggests that individuals with the 
combined CYP3A5 expresser and wild-type (CC) ABCB1 3435 genotype have lower 
maximum concentrations of prednisolone in the plasma (NTV, 2011). 
8.2.2 Objective of the Study: 
Measurement of prednisolone and prednisone concentration in samples collected for 
tacrolimus measurement to explore the relationship between the CYP3A5, ABCB1 3435, 
CYP3A4*22 and POR*28 genotypes and prednisolone- prednisone exposure. 
8.2.3 Materials and Methods  
8.2.3.1 Patients and Study Design 
This study is part of a larger pharmacokinetic study; detailed information on the study 
participants and procedure can be found in Chapter 4. The daily tacrolimus dose was 
adjusted according to achieve whole trough blood concentrations  of 8-12 µg/L during 
the first three months after transplantation and 5-8 µg/L thereafter. 
During once and twice daily tacrolimus sample collection, five mL of blood were 
collected for prednisolone measurement at each time point into EDTA tubes. A series of 
blood samples were collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose with 
twice daily tacrolimus samples and at  0, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose 
with Advagraf® samples. Plasma was prepared by centrifugation for 10 minutes at 2500 
g at room temperature. Plasma samples were stored frozen at approximately -20ºC until 
the drug bioanalysis. 
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8.2.3.2 Genotyping  
DNA was extracted from a peripheral blood sample using a QIAamp DNA Blood Mini 
Kit (Qiagen®, West Sussex, UK) and then was stored at −20◦C until analysis. 
CYP3A5*3 allele was identified by performing Real-time polymerase chain reaction 
(RT-PCR) method (Fredericks et al., 2005). The ABCB1 gene C and T alleles in exon 
26 (C3435T) were identified using the RT-PCR method described by (Nauck et al., 
2000). The C and T alleles of POR*28 gene and in intron 6 of CYP3A4*22 gene were 
identified by the new developed RT-PCR using LightCycler as described previously. 
Full methodology is provided in Chapter 4 and Chapter 5. 
8.2.3.3 Prednisolone and Prednisone Analysis in Plasma 
Plasma concentration of prednisolone and its metabolite prednisone in the collected 
samples was analysed using the liquid chromatography-mass spectrometry (LC-
MS/MS) method as described above. 
8.2.3.4 Pharmacokinetic and Statistical Analysis 
Prednisolone and prednisone individual pharmacokinetic parameters were determined 
for each genotype group. The area under the plasma concentration-time curve (AUC) 
was calculated using the linear trapezoidal method. The maximal plasma concentration 
(Cmax) and time required to reach the peak (tmax) were directly obtained from the profile.  
Statistical analysis was performed using Minitab statistical software (Minitab 17) to 
assess the statistical significance of differences in prednisolone and prednisone kinetics 
between different genotype groups. The log-transformed data was analysed using 
analysis of variance (ANOVA). Data are expressed as mean ± standard deviation (SD). 
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8.2.4 Results 
8.2.4.1 Patient Population 
Out of the sixty-four patients participating in tacrolimus study, thirty-eight renal 
transplant recipients on treatment with 5mg prednisolone were included in this study. 
However, the whole area under time concentration curve (AUC0-24) was available for 27 
patients because of sampling problems; some patients took their 5 mg prednisolone dose 
before collection of the pre-dose sample. The demographic characteristics and 
immunosuppression therapy are summarized in Table 65.  
Table 65: Population Characteristics and Immunosuppression Therapy 
Characteristics Results 
Age (yr), mean (SD) 55.4 (13.8) 
Male gender, n (%) 20 (74%) 
Ethnic group, n (%)  
White 17 (63%) 
Black 5 (19%) 
Asian 5 (19%) 
Body weight (kg), mean (SD) 76.7 (14.3) 
Height (cm), mean (SD) 171 (8.7) 
Diabetes, n (%) 6 (22.2%) 
Time since transplantation (years)  
Mean (SD) 5.5 (4.3) 
Median (range) 5.2 (0.3-15.6) 
Donor type, n (%)  
Living / Deceased 9 (33%) / 18 (67%) 
Immunosuppression at baseline:  
Tacrolimus, n (%)  
Prograf®/ Adoport® 25 (92.4%) / 2 (7.4%) 
Mycophenolate, n (%) 6 (22.2%) 
8.2.4.2 Sample Analysis 
During analysis of the study samples, all the batches met the acceptance criteria for this 
study. Samples from these batches were successfully analysed. The quality control 
sample data for prednisolone, prednisone obtained during the analysis are shown in 
Table 66 & Table 67, respectively. The calibration curve data for prednisone achieved 
during the analysis are shown in Table 68 & Table 69.  
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Table 66: Quality Control (QC) Samples Achieved During Prednisolone Analysis. 
Quality Control Levels QC1 QC2 QC3 
Prepared Concentrations (µg/L) 25.0 125.0 250.0 
Batch ID Measured Concentration (µg/L) 
    
Batch 1 23.6 119.9 239.3 
 24.3 122.7 242.1 
 24.9 116.5 224.3 
 24.9 116.2 228.4 
    
Batch 2 25.1 126.7 247.8 
 26.9 124.3 244.1 
 25.6   
 25.9   
    
Batch 3 24.3 121.0 241.9 
 24.8 119.3 249.7 
 23.3   
 23.3   
    
Batch 3R 23.9 137.3 244.3 
 24.4 137.8 247.4 
 25.8   
 25.3   
    
Batch 4 24.7 125.2 239.2 
 24.4 126.6 249.5 
 24.8 120.1 232.5 
 24.7 116.7 257.3 
 24.4  237.3 
 24.3  253.5 
    
Batch 5 26.1 120.3 234.6 
 25.5 119.7 235.6 
 24.6 117.6 229.9 
 25.7 116.6 222.0 
 23.4  222.4 
 22.9  222.3 
    
Batch 6 24.8 123.9 245.3 
 24.3 127.9 245.9 
 24.2 129.0 242.6 
 24.2 136.6 240.9 
 25.6   
 25.2   
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Batch 7 23.2 134.7 255.6 
 24.0 138.4 250.8 
 26.7 114.5 245.0 
 25.4 119.0 254.2 
    
Batch 8 25.0 133.7 265.1 
 25.0 141.5 280.6 
 28.7 118.7  
 28.7 113.8  
    
Mean (µg/L) 24.9 124.5 242.9 
SD 1.2 8.1 12.8 
Precision (%CV) 5.0 6.5 5.3 
Accuracy (%) 99.7 99.6 97.1 
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Table 67: Quality Control (QC) Samples Achieved During Prednisone Analysis. 
Quality Control Levels QC1 QC2 QC3 
Prepared Concentrations (µg/L) 5.0 25.0 50.0 
Batch ID Measured Concentration (µg/L) 
    
Batch 1 5.0 22.8 44.6 
 4.9 23.5 43.3 
 4.9 22.4 43.7 
 5.1 23.6 44.6 
    
Batch 2 4.8 22.5 43.5 
 5.0 22.4 44.5 
 5.0   
 5.0   
    
Batch 3 5.0 24.3 48.4 
 4.9 24.1 49.7 
 4.3   
 4.3   
    
Batch 3R 4.8 24.7 44.1 
 5.0 25.7 44.7 
 4.8   
 4.6   
    
Batch 4 5.2 25.5 48.1 
 5.1 26.5 49.6 
 5.2 24.4 45.7 
 5.2 23.3 50.9 
 5.0  46.6 
 4.8  49.5 
    
Batch 5 5.3 23.9 46.1 
 5.2 22.9 46.7 
 5.1 24.1 47.2 
 5.3 23.6 46.2 
 4.8  44.6 
 4.7  44.6 
    
Batch 6 5.1 24.9 47.8 
 5.0 26.5 47.9 
 4.5 23.0 43.2 
 4.7 25.1 42.8 
 4.7   
 4.6   
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Batch 7 4.9 27.9 52.5 
 4.9 28.7 51.8 
 #5.9 26.2 51.5 
 5.7 26.2 53.8 
    
Batch 8 5.0 25.3 51.1 
 4.9 25.7 #60.5 
 #6.2 22.8  
 5.7 21.7  
    
Mean (µg/L) 5.0 24.5 47.1 
SD 0.3 1.7 3.1 
Precision (%CV) 5.8 6.9 6.6 
Accuracy (%) 99.1 97.9 94.1 
N 40 of 42 30 of 30 31 of 32 
# 
# 
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a0 a1 a2 Correlation Coefficient (r) 
Batch1 0.00018 0.00197 -7.84E-07 0.9996 
Batch2 0.00249 0.00177 -5.25E-07 0.9954 
Batch3 0.00079 0.00189 -8.44E-07 0.9989 
Batch3R 0.00040 0.00176 -7.33E-07 0.9987 
Batch4 0.00077 0.00188 -9.34E-07 0.9992 
Batch5 0.00068 0.00184 -6.42E-07 0.9997 
Batch6 0.00157 0.00180 -8.39E-07 0.9994 
Batch7 0.00074 0.00185 -1.19E-06 0.9993 
Batch8 0.00088 0.00116 -1.45E-07 0.9998 
Table 69: Calibration Curve Parameters Data Achieved During Prednisone 
Analysis. 
Batch ID 
Curve parameters (y = A*x + B) 
Slope (A) Intercept (B) Correlation Coefficient (r) 
Batch1 0.00102 3.84E-05 0.9989 
Batch2 0.00096 0.000188 0.9966 
Batch3 0.00112 0.000113 0.9989 
Batch3R 0.00109 0.000111 0.9989 
Batch4 0.00101 0.000117 0.9993 
Batch5 0.000999 5.9E-05 0.9995 
Batch6 0.00101 0.000176 0.9982 
Batch7 0.00092 0.000121 0.9964 
Batch8 0.00069 0.000104 0.9989 
The time–concentration profiles for prednisolone and prednisone mean blood 
concentrations are shown in Figure 63. The individual time–concentration profiles of 
the 27 patients are presented in Figure 64. The prednisolone and prednisone 
pharmacokinetic parameters, Cmax, AUC0-24 and C0 are summarised in Table 70. The 
between-patient coefficients of variation (CV%) of Cmax, AUC0-24 and C0 for 
prednisolone were 24.4%, 23.2% and 55.6%, respectively. The between-patient 
coefficients of variation (CV%) of Cmax, AUC0-24 and C0 for prednisone were 24.2%, 
24.9% and 73.0%, respectively. Prednisolone and prednisone exposure AUC0–24, Cmax 
and C0 of the individual patients are presented in Figure 65. 
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Figure 63: Mean Blood Concentration-Time Profiles for Prednisolone (A) and 
Prednisone (B) in 27 Stable Kidney Transplant Recipients. 
(A) 
(B) 
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Figure 64: Whole-Blood Concentration-Time Profiles for Prednisolone (A) and 
Prednisone (B) in 27 Stable Kidney Transplant Recipients.  
(A) 
(B) 
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Table 70: Prednisolone-Prednisone Pharmacokinetic Parameters for Individual 
Patients Treated with 5mg Prednisolone. 
Patient Cmax (µg/L) AUC0-24 (µg∗h/L) C0 (µg/L) 
 
Prednisolone Prednisone Prednisolone Prednisone Prednisolone Prednisone 
1 150 11.9 844.5 112.2 1.0 0.1 
2 115.6 9.3 1066.9 93.4 4.6 0.5 
3 130.6 15.0 690.9 127.8 1.3 0.3 
4 159.3 17.4 1396.6 180.4 4.5 0.8 
5 159.1 17.3 1281.7 187.2 1.5 0.3 
6 184 17.8 1183.9 146.6 2.7 0.4 
7 116.8 12.7 683.5 93.2 1.2 0.1 
8 143.9 15.0 1159.1 109.7 2.0 0.2 
9 166.7 12.4 1068.5 116.3 3.2 0.3 
10 136.7 16.6 1177.8 149.9 2.8 0.3 
11 169.6 12.4 898.5 105.4 1.0 0.1 
12 128.5 11.4 1130.0 96.0 2.7 0.2 
13 210.8 11.4 1467.6 100.3 1.8 0.1 
14 116.0 16.9 823.6 126.1 1.4 0.2 
15 178.7 12.2 1332.1 102.9 2.7 0.1 
16 98.7 10.7 909.1 102.9 1.8 0.2 
17 194.5 14.8 1227.8 137.8 2.9 0.3 
18 134.8 15.6 722.9 100.9 0.4 0.1 
19 147.2 20.3 965.2 138.7 1.0 0.2 
20 136.1 9.7 922.2 77.9 0.8 0.04 
21 217.3 12.9 1398.1 111.3 2.9 0.3 
22 195.1 16.1 1008.8 124.6 0.9 0.1 
23 180.7 16.7 1275.9 154.3 4.3 0.7 
24 143.7 20.3 1076.7 166.6 1.3 0.1 
25 280.8 22.1 1722.1 195.5 4.5 0.6 
26 142.6 8.3 1277.7 93.8 4.4 0.2 
27 147.1 12.0 1428.3 126.6 4.1 0.2 
Mean 160.5 14.5 1116.3 125.1 2.4 0.3 
SD 39.1 3.5 259.1 31.1 1.3 0.2 
CV% 24.4 24.2 23.2 24.9 55.6 73.0 
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Figure 65: Individual Value Plot of Prednisolone and Prednisone AUC0–24, Cmax 











































































































































































Prednisolone AUC0-24 Individual Values 
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There was a good correlation between AUC0–24 and trough concentrations (C0) for 
prednisolone and prednisone at steady state, with similar correlation coefficients for 
prednisolone and prednisone (r = 0.71 and r = 0.64, respectively); see Figure 66. 
Moreover, there was a strong correlation between AUC0–24 and Cmax for prednisolone 


















Figure 66: Correlation between Prednisolone (A) and Prednisone (B) Exposure 

































Prednisolone Exposure vs Trough Concentration
AUC
0-24































Prednisone Exposure vs Trough Concentration
AUC
0-24 
= 98.80 + 105.1 C0 
r = 0.71 
 P < 0.001 
 
r = 0.64  
P < 0.001 
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Figure 67: Correlation between Prednisolone (A) and Prednisone (B) Exposure 
and Maximum Concentration using Regression Analysis (Fit 

































Prednisolone Exposure vs Cmax
AUC
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Prednisone Exposure vs Cmax
AUC
0-24
= 18.96 + 7.369 C
max
 
r = 0.70  
P < 0.001 
 
r = 0.84  
P < 0.001 
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8.2.4.3 The Relationship between CYP3A5*3 Genotype and Prednisolone-
Prednisone Pharmacokinetics. 
Prednisolone and prednisone blood concentrations Cmax, AUC0-24 and C0 showed a log-
normal distribution and the data were therefore log-transformed before analysis. In the 
overall study population, no significant association was observed between the different 
CYP3A5 genotypes with prednisolone pharmacokinetic parameters; AUC0–24, Cmax and 
trough concentration (C0). Dissimilar to the prednisolone results, there were significant 
differences in the mean AUC0–24 and Cmax of prednisone between these genotype 
groups. The mean prednisone Cmax and AUC0–24 in recipients having the CYP3A5*3/*3 
genotype were significantly lower than in those patients having the CYP3A5*1/*1 + 
*1/*3 genotype (P = 0.006 and P = 0.027, respectively). However, there was no 
significant change in prednisone C0 between CYP3A5 expressers and non-expressers. 
After adjustment for the body weight, we continued to have the same statistically 
significant results. The pharmacokinetic parameters in recipients with the CYP3A5*1/*1 
+ *1/*3 and CYP3A5*3/*3 genotypes for prednisolone and prednisone are shown in 
Table 71 & Figure 68. 




(*1/*1 & *1/*3)      
(n= 12) 
CYP3A5 Non-expressers                                       




   
Cmax (µg/L) 170.2 ± 43.5 149.5 ± 32.8 0.13 
AUC0-24 (µg*h/L) 1170.6 ± 278.7 1072.8 ± 243.1 0.32 
C0 (µg/L) 2.3 ± 1.2 2.4 ± 1.5 0.75 
Prednisone 
   
Cmax (µg/L) 16.4 ± 3.4 12.8 ± 2.8 0.006 
AUC0-24 (µg*h/L) 139.3 ± 31.7 113.7 ± 26.5 0.027 
C0 (µg/L) 0.29 ± 0.19 0.21 ± 0.19 0.16 
 
The values are shown as the mean ± S.D. Cmax, Maximum plasma concentration; AUC0–
24, Area under the plasma concentration–time curve from 0 to 24h. C0, Pre-dose plasma 
concentration at 24h. Values were compared using ANOVA (General linear model). 
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Figure 68: The Mean Prednisolone-Prednisone Pharmacokinetic Parameters in 
Renal Transplant Recipients with Different CYP3A5*3 Genotypes. 
Boxes represent the interquartile range, line in the box represents the 
median value, symbol in the box represents the mean value, outer lines 
represent the minimal and maximal value and the values beyond the 
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8.2.4.4 The Association between ABCB1 3435 Genotype and Prednisolone -
Prednisone Pharmacokinetics. 
The prednisolone-prednisone pharmacokinetic parameters stratified by ABCB1 3435 
polymorphisms are shown in Table 72. No significant difference was found in the 
AUC0–24, Cmax and C0 of prednisolone between the different genotypes of ABCB1 3435 
gene. However, a significant difference was observed in prednisone pharmacokinetic 
parameters (Cmax, AUC0-24 and C0) between the ABCB1 CC and the CT/TT genotypes. 
The mean prednisone Cmax for ABCB1 CC genotype was significantly higher than for 
ABCB1 CT/TT genotype (16.8 µg/L versus 13.7 µg/L, P = 0.04). Moreover, ABCB1 CC 
carriers had a significantly higher AUC0–24 compared to ABCB1 CT/TT carriers (153.9 
µg*h/L versus 116.9 µg*h/L, P = 0.005). Likewise, the difference in prednisone C0 
between ABCB1genotype groups was statistically. The mean prednisone C0 for 
ABCB1CC carriers and for CT/TT patients were 0.37 ± 0.14 and 0.22 ± 0.19 µg/L, 
respectively (Figure 69 & Table 72). After adjustment for the body weight, we 
continued to have the same statistically significant results. 
Table 72: Pharmacokinetic Parameters of Prednisolone- Prednisone in ABCB1 
3435 Genotype Groups. 
Study group ABCB1 CC Carriers                                                 
(n= 6) 
ABCB1 CT/TT Carriers                                
(n= 21) 
p-value 
Prednisolone       
Cmax (µg/L) 176.3 ± 54.8 153.7 ± 32.6 0.08 
AUC0-24 (µg*h/L) 1187.0 ± 333.0 1095.9 ± 239.9  0.22 
C0 (µg/L) 2.7 ± 1.2 2.3 ± 1.4  0.30 
Prednisone       
Cmax (µg/L) 16.8 ± 3.2 13.7 ± 3.4 0.04 
AUC0-24 (µg*h/L) 153.9 ± 31.6 116.9 ± 26.3 0.005 
C0 (µg/L) 0.37 ± 0.14 0.22 ± 0.19 0.03 
Values were compared using ANOVA (General linear model). 
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Figure 69: The Mean Prednisolone-Prednisone Pharmacokinetic Parameters in 
Renal Transplant Recipients with Different ABCB1 Genotypes. Boxes 
represent the interquartile range, line in the box represents the median value, 
symbol in the box represents the mean value, outer lines represent the 
minimal and maximal value and values beyond the whiskers (asterisks) are 
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8.2.4.5 Association of CYP3A5*3 and ABCB1 3435 Combined Genotypes with 
Prednisolone and Prednisone Pharmacokinetics. 
Prednisolone and prednisone pharmacokinetic parameters in the two different CYP3A5 
genotype groups in relation to ABCB1 3435 polymorphisms are shown in Table 73. 
Because there was only one patient in CYP3A5 *3/*3 / ABCB1 CC group, it was 
excluded from the analysis. Regarding prednisolone, no significant difference was 
found in prednisolone Cmax, AUC0-24 and C0 between the three genotype groups. 
However, the mean Cmax and AUC0-24 of prednisone in CYP3A5 *3/*3 patients having 
the ABCB1 CT/TT genotype were lower than in CYP3A5 *1/*1&*1/*3 patients having 
either ABCB1 CC or ABCB1 CT/TT genotypes. No significant difference was noted in 
CYP3A5 expressers between ABCB1 CT/TT and ABCB1CC carriers for prednisolone 
and prednisone Figure 70. After adjustment for the body weight, we continued to have 
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Table 73: Pharmacokinetic Parameters of Prednisolone- Prednisone in CYP3A5-ABCB1 3435 Genotype Groups. 
Study group 
CYP3A5 *1/*1 &*1/*3/ 
ABCB1 CC Carriers   
(n= 5) 
CYP3A5 *1/*1 &*1/*3/ 
ABCB1 CT/TT Carriers                                  
(n= 7) 
CYP3A5 *3/*3/       









Prednisolone           
Cmax (µg/L) 184.2 ± 57.3 160.1 ± 31.6 150.4 ± 33.8 0.37 0.12 0.52 
AUC0-24 (µg*h/L) 1189 ± 373 1157 ± 222 1065 ± 250.5 0.99 0.48 0.43 
C0 (µg/L) 2.6 ± 1.3 2.1 ± 1.1 2.4 ± 1.5 0.56 0.42 0.97 
Prednisone       
Cmax (µg/L) 16.9 ± 3.6 16.1 ± 3.5 12.5 ± 2.7 0.55 0.01 0.03 
AUC0-24 (µg*h/L) 155 ± 35 128 ± 26 111 ± 25 0.10 0.004 0.17 
C0 (µg/L) 0.4 ± 0.2 0.2 ± 0.2 0.2 ± 0.2 0.15 0.04 0.58 
a   
p-values refer to comparisons between CYP3A5 *1/*1& *1/*3 (CYP3A5 Expressers) subgroups. 
b  
p-values refer to comparisons between CYP3A5 *1/*1& *1/*3 / ABCB1 CC carriers and CYP3A5 *3/*3 (CYP3A5 Non-expresser) /ABCB1 
CT/TT group. 
c  
p-values refer to comparisons between CYP3A5 *1/*1& *1/*3 / ABCB1 CT/TT carriers and CYP3A5 *3/*3 /ABCB1 CT/TT group. 
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Figure 70: The Mean Prednisolone-Prednisone Pharmacokinetic Parameters in 
Renal Transplant Recipients with Combined CYP3A5*3-ABCB1 
Genotypes. CYP exp is CYP3A5 expressers and CYP non-exp is 
CYP3A5 non-expressers. Boxes represent the interquartile range, line in 
the box represents the median value, symbol in the box represents the mean 
value, outer lines represent the minimal and maximal value and values 
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8.2.4.6 The Relationship between POR*28 and Prednisolone and Prednisone 
Pharmacokinetics. 
No statistically significant differences in prednisolone pharmacokinetics were observed 
between patients carrying POR*28 CC and CT/TT genotypes (Table 74). The mean 
Prednisolone Cmax for POR*28 CC carriers and for CT/TT patients were 169.0 ± 47.0 
and 161.2 ± 35.0 µg/L, respectively. The mean Prednisolone AUC0–24 for POR*28 CC 
and for CT/TT carriers were 1063 ± 304 µg*h/L, 1084.3 ± 279 µg*h/L and 1158 ± 219 
µg*h/L, respectively. Similarly, we found no difference in prednisone pharmacokinetic 
profile between POR*28 different genotypes (P > 0.05, Figure 71). 
Table 74: Pharmacokinetic Parameters of Prednisolone- Prednisone in POR*28 
Genotype Groups. 
Study group 
POR*28 CC Carriers                                                 
(n= 13) 




   
Cmax (µg/L) 161.9 ± 46.5 155.7 ± 31.1 0.56 
AUC0-24 (µg*h/L) 1095 ± 312 1136 ± 209 0.78 
C0 (µg/L) 2.2 ± 1.4 2.5 ± 1.3 0.61 
Prednisone 
   
Cmax (µg/L) 14.9 ± 3.8 14.0 ± 3.3  0.51 
AUC0-24 (µg*h/L) 128.7 ± 36.6 121.8 ± 26.1  0.66 
C0 (µg/L) 0.28 ± 0.26 0.22 ± 0.10 0.82 
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Figure 71: The Mean Prednisolone-Prednisone Pharmacokinetic Parameters in 
Renal Transplant Recipients with POR*28 Different Genotypes. Boxes 
represent the interquartile range, line in the box represents the median value, 
symbol in the box represents the mean value, outer lines represent the 
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8.2.4.7 Non-genetic Factors Associated with Prednisolone and Prednisone Plasma 
Concentrations.  
No correlation was seen among different ethnic backgrounds for prednisolone or 
prednisone blood concentrations. Moreover, patient sex was shown to influence 
prednisolone Cmax, but have no effect on the AUC0-24 and the trough concentration 
(Table 75). In the current study, twenty-seven patients were analysed; Twenty of them 
were males, and they all had a significantly lower prednisolone Cmax compared to 
females (p<0.05; Figure 72). After adjustment for the body weight, the statistically 
significant difference vanished. In addition, there was no correlation between patient 
age and prednisolone and prednisone blood concentrations. Multiple regression analysis 
by stepwise selection; alpha to enter or remove, specified value to enter or remove 
significance level, was 0.15; identified patient weight and tacrolimus dose, as 
independent variables associated with prednisolone Cmax and identified tacrolimus dose 
as independent variables associated with prednisolone AUC0-24. However, multiple 
regression analysis for prednisone identified patient weight as an independent variable 
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Table 75: Prednisolone and Prednisone Pharmacokinetic Parameters in Renal 
Transplant Recipients in Relation to Ethnicity and Sex. 
Study group 
Prednisolone 
Cmax (µg/L) AUC0-24 (µg*h/L) C0 (µg/L) 
Ethnicity 
   
Black (n=5) 170.7 ± 64.9 1117 ± 407 2.4 ± 1.4 
White (n=17 157.5 ± 34.8 1125 ± 249 2.4 ± 1.3 
Asian (n=5) 150.7 ± 19.0 1085 ± 148 2.0 ± 1.5 
p-value 0.56 0.81 0.73 
Sex 
   
Male (n=20) 147.6 ± 28.1 1066 ± 243 2.3 ± 1.3 
Female (n=7) 190.4 ± 48.8 1260 ± 266 2.6 ± 1.5 
p-value 0.04 0.28 0.78 
Study group 
Prednisone 
Cmax (µg/L) AUC0-24 (µg*h/L) C0 (µg/L) 
Ethnicity 
   
Black (n=5) 16.7 ± 3.6 151 ± 38 0.33 ± 0.18 
White (n=17 13.5 ± 2.4 118 ± 25 0.24 ± 0.21 
Asian (n=5) 15.3 ± 5.8 125 ± 37 0.20 ± 0.15 
p-value 0.25 0.14 0.40 
Sex       
Male (n=20) 14.2 ± 3.5 125.1 ± 29.2 0.24 ± 0.17 
Female (n=7) 15.0 ± 4.0 125.2 ± 38.7 0.29 ± 0.25 
p-value 0.74 0.83 0.80 
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Figure 72: The Interval Plot of the Mean Prednisolone Cmax in Renal Transplant 
Recipients in Accordance with Patient Sex. 
8.2.5 Discussion 
In this study, we determined the pharmacokinetic parameters of prednisolone and 
prednisone in 38 renal transplant recipients. Due to some sampling problems, some 
patients took their prednisolone dose before collection of the pre-dose sample; the 
AUC0-24 was available for only 27 patients. Prednisolone is known as a substrate of 
CYP3A and P-glycoprotein (Anglicheau et al., 2003a). To improve the treatment of 
kidney transplant recipients, genetic markers that predict steroid response might be 
useful.  
In this study, we found a wide variation between patients in prednisolone and 
prednisone blood concentration achieved by 5 mg prednisolone daily. This is in 
agreement with the recent study by Saeves et al. (2012) in 16 liver transplant recipients 
early after transplantation. Their findings demonstrated large within- and between-
individual variabilities in prednisolone and prednisone pharmacokinetics, indicating the 
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transplantation. The same findings were obtained from pharmacokinetic study after 
single dose administration of prednisone by showing high between-individual 
variability in systemic exposure to prednisolone in systemic lupus erythematosus 
patients (Sagcal-Gironella et al., 2011). Similarly, Morton et al. (2006) found a wide 
between-individual variation in prednisolone pharmacokinetics among 52 lung 
transplant recipients. The majority of the patients were overdosed on the conventional 
protocols, suggesting the use of TDM to optimize prednisolone dosing and minimize 
morbidity. Moreover, Barraclough et al. (2011b) reported wide between-subject 
variability in prednisolone exposure in kidney transplant patients, justifying a role for 
TDM and suggested the use of limiting sampling strategies (LSSs) for accurate 
estimation of both total and free prednisolone AUC0-12. Hence, to achieve a balance 
between toxicity and efficacy of prednisolone, therapeutic drug monitoring may be 
useful and would be worthy of a clinical trial. 
In our data, prednisolone and prednisone behaved differently. Although the CYP3A5 
genotype plays an important role in drug metabolism, including prednisolone, no 
association between CYP3A5 genetic polymorphisms and prednisolone 
pharmacokinetics was observed. In addition, no significant differences were found in 
prednisolone pharmacokinetics for ABCB1 3435 polymorphisms. This finding is in 
agreement with the previous report by Miura et al. (2008), Miura et al. (2009) and 
showed that prednisolone is unaffected by either the CYP3A5*3 or ABCB1 3435 genetic 
polymorphisms. Moreover, POR*28 gene was not associated with prednisolone 
pharmacokinetics. 
In addition, the AUC0-24 and Cmax of prednisolone showed no significant difference 
among CYP3A5 expressers having either ABCB1 3435 CC or CT/TT genotypes and 
CYP3A5 non-expressers having ABCB1 3435 CT/TT genotype. This is in agreement 
with Miura et al. (2008) who found no significant difference in prednisolone AUC0-24, 
Cmax and C0 in CYP3A5 expressers having either ABCB1 3435 CC , CT or TT alleles. 
They also found a significant increase in prednisolone Cmax in CYP3A5 non-expressers 
having ABCB1 3435 CC allele compared to ABCB1 3435 TT carriers. They also 
concluded that the intestinal CYP3A5 and P-glycoprotein may play important roles in 
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prednisolone absorption but they have low contribution to prednisolone 
pharmacokinetics. However, we could not make this comparison in our study cohort 
because of the limited number of patients in the CYP3A5*3/*3 / ABCB1 3435 CC 
group. Moreover, we found no correlation between the different ethnic backgrounds and 
prednisolone blood concentrations. This indicates that neither the genetic factors nor 
ethnicity can predict prednisolone plasma concentration. However, patient sex had a 
significant effect on prednisolone Cmax.  
Similar to prednisolone, prednisone is also known  as a substrate and inducer of CYP3A 
enzymes and P-glycoprotein (Anglicheau et al., 2003a); however, prednisone 
pharmacokinetics differed significantly between CYP3A5 genotypes, suggesting 
preferential generation of prednisone as a metabolite in CYP3A5 expressers. Like 
prednisone, 20β- dihydroprednisolone was one of the main metabolites of prednisolone 
in a recent study by Matabosch et al. (2015) who identified 20 metabolites of 
prednisolone in urine samples of two healthy male Caucasian volunteers following 
administration of 10 mg prednisolone. Interestingly, the maximum prednisolone 
concentrations were similar in the excretion profiles of prednisolone metabolites in both 
volunteers. However, 20β- dihydroprednisolone maximum concentration was similar to 
prednisone maximum concentration in one volunteer and higher in the other one despite 
that they are both males and Caucasians. This may explain prednisone low 
concentration in CYP3A5 non-expressers, suggesting that 20β- dihydroprednisolone 
could be produced more than prednisone in CYP3A5 non-expressers. Additionally, our 
results showed that ABCB1 3435 gene was strongly associated with prednisone 
pharmacokinetics. Conversely, POR*28 was not associated with prednisone PK. Our 
results showed that patients carrying at least one CYP3A5*1 allele had a significantly 
higher mean prednisone Cmax and AUC0-24 compared to CYP3A5*3 homozygotes. 
Similarly, we found that ABCB1 3435 CC carriers achieved higher mean prednisone 
Cmax and AUC0-24 than ABCB1 3435 CT/TT Carriers.  This finding may be due to over-
representation of CYP3A5 expressers in the ABCB1 3435 CC group. When combining 
CYP3A5 and ABCB1 3435 genotypes, we found a significantly lower prednisone C0 and 
Cmax for CYP3A5 non-expresser patients having the ABCB1 3435 CT/TT genotype 
compared to CYP3A5 expresser patients having ABCB1 3435 CC genotype. Similar 
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results were found in prednisone AUC0-24 when compared to ABCB1 3435 CC carriers, 
but not when compared to ABCB1 3435 CT/TT carriers. The difference in prednisone 
C0, Cmax and AUC0-24 between CYP3A5 expressers subgroups (ABCB1 3435 CC or 
ABCB1 3435 CT/TT carriers) was not statistically significant, confirming the 
predominant influence of CYP3A5 in prednisone exposure.  
With regard to CYP3A5 polymorphisms, we expected the prednisone Cmax and AUC0-24 
to be unaffected like in prednisolone or to be lower in the CYP3A5 expressers than in 
the CYP3A5 non-expressers, because CYP3A5 expressers should have high CYP3A5 
expression and activity. Likewise, regarding ABCB1 polymorphisms, we expected the 
prednisone Cmax and AUC0-24 to be unchanged like in prednisolone or to be lower in the 
ABCB1 3435 CC Carriers than in the ABCB1 3435 CT/TT Carriers, because Pg-p 
production and activity is higher in ABCB1 3435 CC Carriers. However, the results 
were not as expected. The small sample size is likely to be a key limiting factor in the 
current study. Hence, a larger number of patients need to be studied to confirm the 
impact of CYP3A5 and ABCB1 3435 polymorphisms on prednisone pharmacokinetics. 
To our knowledge, our data constitute the first report on the pharmacokinetics of 
prednisone as an immunosuppressive agent describing the influence of CYP3A5, 
ABCB1 3435 and POR*28 genetic polymorphisms. Further studies would be helpful to 
understand the effects of these polymorphisms on prednisone plasma concentrations. 
CYP3A4*22 gene polymorphisms were not included in this study because of the low 
frequency of this genotype in our population. Ethnic factors and patients’ sex were 
shown to have no influence on prednisone Cmax and AUC0-24.  
Prednisone is a well-known substrate of CYP3A and/or P-gp. Effect of prednisone on 
tacrolimus concentration in renal transplant patients should be taken into consideration. 
Anglicheau et al. (2003a) found that tacrolimus dose requirement was greatly affected 
by prednisone dose. The higher the prednisone dosage used, the higher the tacrolimus 
dosage required to achieve target trough blood concentrations in these patients. The 
interaction also occurs even with low prednisone dosage. This is due to enzymatic 
induction of CYP3A and/or P-gp by glucocorticoid. These findings were confirmed by 
Park et al. (2009) who found an inverse correlation between prednisone daily dose and 
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tacrolimus exposures. Prednisone dose reduction was associated with an increase in 
tacrolimus drug exposure. Similarly, a more recent study demonstrated that during the 
first 6 months after transplantation, prednisone dose significantly influenced tacrolimus 
blood concentration. Prednisone tacrolimus interaction has more effect on male than 
female patients (Velickovic-Radovanovic et al., 2012). Differential generation of 
prednisone in CYP3A5 expressers may influence the prednisolone/tacrolimus 
interaction. 
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9 Chapter 9. General Discussion & Conclusions 
Tacrolimus has a narrow therapeutic window of blood concentration and wide variation 
between individuals in blood concentration achieved by a given dose which is a matter 
of concern in the clinical practice. Therefore, determination of the optimal tacrolimus 
dose is necessary to minimize the undesired side effects of tacrolimus while maintaining 
its efficacy, especially in the early period after transplantation. Different oral 
formulations of tacrolimus are available and another once daily formulation, Envarsus 
has recently been given marketing authorisation in the UK. Advagraf® is once-daily 
tacrolimus with prolonged-release characteristics compared to the initially authorised 
preparation, Prograf® which has immediate-release absorption profile (Soto et al., 
2015). Generic twice-daily tacrolimus preparations that are bioequivalent to Prograf® 
are now available. A body-weight-based dose of tacrolimus results in a marked 
variation between individuals in tacrolimus blood concentration. A number of factors 
are considered to contribute to low and variable bioavailability of tacrolimus, including 
extensive first pass metabolism and activity of the drug-efflux pump, p-glycoprotein. 
Tacrolimus is a substrate of CYP3A4, CYP3A5, and Pg-p, which are proteins expressed 
by CYP3A4, CYP3A5, and ABCB1 3435 genes (Hebert, 1997). Hence differences in the 
level of expression and the bioactivity of these proteins may contribute to the individual 
variations of tacrolimus pharmacokinetics. 
In this study, Advagraf® showed a comparable pharmacokinetic profile to twice-daily 
tacrolimus confirming that once-daily tacrolimus, Advagraf® is bioequivalent to twice-
daily tacrolimus preparations according to the FDA guidelines; 80-125% (FDA., 2003). 
It also met the bioequivalence acceptance criteria of the European Medicines Agency 
for tacrolimus; (90-111%) for AUC and (80-125%) for Cmax (EMA, 2015). We 
confirmed the repeatedly reported strong correlation between AUC0–24 and C0 for 
immediate and modified release tacrolimus indicating that measurement of C0 is 
appropriate for therapeutic monitoring of Advagraf®. Our results are in accordance with 
the previous findings in Phase II studies on Advagraf® showing that a given dose of 
Advagraf® delivered 90% of the area under the concentration-time curve (AUC) 
General Discussion  
Page 319 of 377 
obtained with Prograf® (EMEA, 2007) . However, the mean tacrolimus ratio for Cmax 
following the administration of Advagraf was up to 20% less when compared with 
Prograf®. They noted that the AUC0-24 may need to be monitored to ensure maintenance 
of similar systemic exposure and they found a good correlation between AUC0-24 and C0 
for Advagraf® and Prograf® at steady state, as found in the current study. They also 
observed less between- and within-subject variability in exposure when compared 
Advagraf® to Prograf®(EMEA, 2007). 
Our data showed that switching from immediate to extended release tacrolimus has an 
impact on between-patient variability of tacrolimus exposure in this cohort of patients. 
Advagraf® has less between-individual differences in tacrolimus exposure when 
compared to immediate release tacrolimus. 
In addition, we demonstrated that the between-patient variability in tacrolimus daily 
dose requirement was related to CYP3A5*3, CYP3A4*22 and ABCB1 3435 gene 
polymorphisms in stable kidney transplant recipients, as reported previously, suggesting 
that the pharmacogenetic assessment of CYP3A5*3, CYP3A4*22 and ABCB1 3435 
genotypes may offer an effective tool for individualizing drug therapy by optimizing 
tacrolimus dosage for both twice daily tacrolimus and Advagraf®.  
It is becoming apparent that all individuals express CYP3A4 and CYP3A4 poor 
metabolizers are rare. However, CYP3A5 expression varies between different 
individuals. The CYP3A5*3 allele reduces CYP3A5 production and results in the loss of 
hepatic CYP3A5 activity (Hustert et al., 2001, Kuehl et al., 2001). Thus, it has been 
repeatedly reported that patients with the CYP3A5*3/*3 genotype (CYP3A5 non-
expressers) require lower doses to reach similar dose-normalized tacrolimus trough 
concentrations than patients carrying at least one CYP3A5*1 allele (CYP3A5 
expressers) (Macphee et al., 2005, Vannaprasaht et al., 2013, Ferraris et al., 2011). In 
our study, we clearly could confirm this effect. Several studies have examined the effect 
of P-gp on tacrolimus exposure, and conflicting results have been obtained. Some 
studies reported no correlation between ABCB1 3435 genotypes and tacrolimus dose 
and pharmacokinetics (Haufroid et al., 2004, Jun et al., 2009, Vannaprasaht et al., 
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2013). However, other studies displayed a significant influence of ABCB1 3435 
genotypes on tacrolimus pharmacokinetics and dose requirements (Zheng et al., 2003, 
Lopez-Montenegro Soria et al., 2010, Yu et al., 2011), which is in line with our 
findings. In addition, upon evaluation of CYP3A5*3 and ABCB1 3435 genotypes in 
combination, significant differences in tacrolimus pharmacokinetics were evident 
between ABCB1 3435 polymorphisms in CYP3A5 expressers suggesting that ABCB1 
3435 genotype is an important factor in tacrolimus pharmacokinetics particularly in the 
case of CYP3A5 expressers. These findings support previous findings by Loh and 
colleagues who reported the same outcome between ABCB1 3435 and CYP3A5*3 
variants (Loh et al., 2008) and contrast with other studies demonstrating no significant 
differences in tacrolimus bioavailability between the ABCB1 3435 polymorphisms in 
both CYP3A5 expressers and non-expressers (Rong et al., 2010, Tada et al., 2005). 
Additionally, our data showed the contribution between CYP3A4*22 polymorphisms 
and tacrolimus pharmacokinetics confirming the findings of the recently published 
studies (Elens et al., 2011a, Tavira et al., 2013, Kurzawski et al., 2014).  
Interestingly, we found that the influence of CYP3A5, CYP3A4 and ABCB1 3435 
genotypes on tacrolimus exposure was the same for once- and twice daily tacrolimus. 
No significant difference was observed between these polymorphisms and tacrolimus 
pharmacokinetics and dose requirements in both tacrolimus preparations. 
It has been reported that CYP3A expression reduces progressively along the length of 
the gut. However, the level of cellular expression of  Pg-p increases continuously along 
the gut length (Thorn et al., 2005). We hypothesised that the influence of these 
genotypes would apply differently between tacrolimus formulations. Our assumption 
was that CYP3A5 polymorphisms may have less effect on the oral bioavailability of 
extended release tacrolimus formulation, Advagraf® which is mostly absorbed lower 
down the gut than the immediate release preparations of tacrolimus such as Prograf® 
and Adoport® that are absorbed in the upper part of the gastrointestinal tract (GIT), 
mainly around the stomach and proximal small intestine (MacPhee, 2012). Our data 
showed that the impact of CYP3A5, CYP3A4 and ABCB1 3435 polymorphisms and their 
combinations had no clear difference between twice-daily tacrolimus and Advagraf®. 
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This is in accordance with the recently published studies finding that tacrolimus 
exposure was significantly higher in CYP3A5 non-expressers than in 
CYP3A5expressers and the degree of difference was similar between Prograf® and 
Advagraf® (Benkali et al., 2010, Glowacki et al., 2011b, Niioka et al., 2012, Wehland et 
al., 2011). This may indicate a dominant effect of the liver CYP3A5 on the first-pass 
metabolism of tacrolimus and a minor influence of intestinal enzymes in tacrolimus 
metabolism. However, earlier studies in liver transplant recipients have revealed the 
influence of the intestinal CYP3A5 on tacrolimus absorption. A study by Uesugi et al 
indicates that intestinal CYP3A5, as well as hepatic CYP3A5, plays an essential role in 
the first-pass metabolism of orally administered tacrolimus in liver transplantation 
(Uesugi et al., 2006). Another study in liver transplantation recipients found that 
tacrolimus pharmacokinetics is mainly influenced by the intestinal CYP3A5 and P-gp 
expression during the first week; after that, it is mostly affected by the hepatic 
metabolism (Goto et al., 2004). This can be explained by the minor effect of the 
intestinal CYP3A5 on tacrolimus metabolism that only appears in the absence of the 
liver CYP3A5 enzymes. It is also possible that the gradient of CYP3A5 and P-gp 
expression along the length of the gut was over-estimated in previously published 
reports (Thorn et al., 2005).  
Moreover, this study showed that switching from immediate to extended release 
tacrolimus formulations did not make any significant difference in WPV of dose-
normalized C0 in both tacrolimus preparations. Similar observations were made in other 
conversion studies (van Hooff et al., 2012, Wehland et al., 2011, Shuker et al., 2014). 
However, other studies showed that conversion from Prograf® to Advagraf® was associated 
with a significantly lower WPV of Tac C0 (Wu et al., 2011, Alloway et al., 2005). Our 
findings showed that neither patients treated with twice daily tacrolimus nor patients treated 
with once- daily tacrolimus show any significant association between WPV of dose-
normalized Tac C0 and CYP3A5 genotype. This in line with previous published studies 
(Pashaee et al., 2011, Ro et al., 2012, Wu et al., 2014). The balance of published evidence 
suggests that conversion from twice daily tacrolimus to Advagraf® is unlikely to impact 
significantly on WPV in routine renal transplantation. 
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Additionally, in our data, we found that in spite of being a known substrate of CYP3A 
and P-glycoprotein (Anglicheau et al., 2003a), prednisolone pharmacokinetics were not 
associated with CYP3A5*3 and ABCB1 3435 polymorphisms. Prednisone behaved 
differently and CYP3A5*3 and ABCB1 3435 genotypes were strongly associated with 
prednisone pharmacokinetics. CYP3A5 expressers had higher concentrations of 
prednisone, presumably reflecting preferential metabolism of prednisolone to 
prednisone. It is worth noting that patient sex had a significant effect on prednisolone 
Cmax. Ethnic factors and tacrolimus dose were shown to have no influence on the Cmax 
and AUC0-24 of prednisolone and prednisone. This indicates that neither the genetic 
factors nor ethnicity can predict prednisolone plasma concentration. Given the wide 
variation between individuals in prednisolone blood concentration achieved by a dose of 
5 mg prednisolone daily, it may actually be appropriate to consider using TDM, in 
particular for patients with efficacy failure or toxicity. 
Moreover, our study showed that 4β-OHC concentration increased significantly in 
CYP3A5*1 allele carriers compared to recipients having CYP3A5*3*3 genotype 
(Diczfalusy et al., 2008, Suzuki et al., 2014). The 4β-OHC/C ratio was significantly 
correlated with tacrolimus exposure and dose requirement. 4β-OHC/C ratio may be a 
useful biomarker for tacrolimus dosing in renal transplanted patients. While the effect of 
CYP3A5*3 genotype and CYP3A activity measured by plasma 4β-OHC/C ratio on 
tacrolimus exposure were closely linked, they were both found to be independent 
predictors and would be additive in developing an algorithm for predicting optimal 
initial tacrolimus dose. 
Of note, tacrolimus dose requirement may be modified and its pharmacokinetics can be 
affected by several parameters including genetic and non-genetic factors. In order to 
secure the optimal tacrolimus administration, both genetic and non-genetic factors must 
be taken into account. Most studies search for the genetic polymorphisms that affect the 
response of individuals to tacrolimus. However, non-genetic factors may have an 
influence in tacrolimus pharmacokinetics and dose requirements. Hence, we tried to 
model tacrolimus kinetics based on both genetic and non-genetic factors. 
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In the present study, we demonstrated that CYP3A5*3 genotype is a key factor in the 
prediction of tacrolimus blood concentrations and dose requirement. Many studies 
highlighted the influence of CYP3A5 in tacrolimus pharmacokinetics and dose 
requirement and reported that CYP3A5 could be useful to predict the optimal 
tacrolimus dose (Niioka et al., 2015, Thervet et al., 2008, Birdwell et al., 2015). In a 
randomized controlled study, kidney transplant recipients receiving tacrolimus doses 
according to the CYP3A5 genotype reached the target C0 significantly earlier than 
recipients used a standard regimen. Although more patients were within the desired 
tacrolimus target range early after transplantation, a considerable proportion of patients 
still did not have tacrolimus C0 levels within the target range points (Thervet et al., 
2010) indicating that CYP3A5 genotype alone is unlikely to be sufficient for successful 
individualisation of initial tacrolimus dose. Another study found no association between 
pharmacogenetic adaptation of tacrolimus daily dose and earlier achievement of the 
tacrolimus target exposure range. No improvement in the clinical outcome was observed 
(Shuker et al., 2015). In addition to CYP3A5*3 genotype, our results also confirm a 
minor role of the ABCB1 3435 variant allele. This supports previous studies showing a 
weak association between ABCB1 3435 polymorphism and tacrolimus dose 
requirements (Li et al., 2006a, MacPhee et al., 2002, Anglicheau et al., 2003b). 
However, other studies failed to identify such an association (Tsuchiya et al., 2004, 
Haufroid et al., 2004, Quteineh et al., 2008, Shi et al., 2013). The reason for the 
discrepancies between these studies is unclear, but may be due to the food, the genetic 
effect of other genes, or studies lacking sufficient statistical power.   
Moreover, we studied some non-genetic factors, including age, sex, haematocrit, 
ethnicity, diabetic status, steroid therapy, donor type, time since transplantation and 
tacrolimus formulation. We found that the donor type, time since transplantation and 
tacrolimus formulations had no significant effect. Although sex had a significant effect 
on tacrolimus dose in univariate analysis, this effect was diminished in multivariate 
regression analysis. Stratta et al reported that sex differences affect tacrolimus dose 
requirements (Stratta et al., 2012). 
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Furthermore, we demonstrated that the haematocrit value was strongly correlated with 
tacrolimus dose, consistent with previous reports showing the influence of haematocrit 
values in tacrolimus blood concentration (de Jonge et al., 2012, Stratta et al., 2012). 
Tacrolimus is extensively bound to FK-binding proteins in red blood cells. Hence the 
haematocrit plays an important role in tacrolimus pharmacokinetics and may need to be 
considered in tacrolimus dosage regimens especially with significant changes in their 
levels. In multivariate analysis, diabetic status was significantly associated with 
tacrolimus dose requirements, confirming previous findings by Chitnis et al who found 
that diabetic patients have significantly higher dose adjusted tacrolimus blood 
concentrations compared to non-diabetic patients (Chitnis et al., 2013). Our findings 
confirm the effect of age on tacrolimus dose requirement. Younger patients required 
higher tacrolimus dose than older patients. This is in accordance with previous findings 
indicating the strong correlation of age with tacrolimus dose in both adults (Kim et al., 
2012) and paediatric patients (Gijsen et al., 2011). We also demonstrated that ethnicity 
had a significant effect on tacrolimus dose, black patients required higher tacrolimus 
dose than white and Asian subjects, which is consistent with previous findings 
(Macphee et al., 2005). However, the CYP3A5*3 polymorphism cannot be replaced by 
ethnicity to predict the tacrolimus dose requirement, even though they are strongly 
linked. 
In this study, different tacrolimus formulation has no influence on tacrolimus dose 
either in univariate or multivariate analysis. This means that factors were reported to 
influence tacrolimus dose including age, sex, ethnicity, haematocrit, diabetic status, 
corticosteroid treatment and CYP3A5*3/ ABCB1 3435 polymorphisms are the same for 
both tacrolimus formulations. From our study prediction of tacrolimus dose can be 
achieved from the following equation: 
Dose (mg/kg) = 0.2199 - 0.000622 * Age - 0.1636 * Haematocrit - 0.0387 (if Asian) - 
0.0217 (if White) - 0.02665 (if diabetic) + 0.01043 (if treated with 
corticosteroids) + 0.00974 (if female) + 0.0017 (if CYP3A5*1/*1/*1/*3 
/ABCB1CT/TT genotype) - 0.0457 (if CYP3A5*3/*3 /ABCB1CC 
genotype) - 0.0534 (if CYP3A5*3/*3 /ABCB1CT/TT genotype). 
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Our findings suggest that taking all these aforementioned factors into consideration may 
account for 59.9% of the between-individual variability in tacrolimus dose 
requirements. However, the impact of other factors, including different diet habits, 
comorbidity and concomitant treatment schemes could not be estimated. These findings 
may have potential clinical application for initiation and adjustment of tacrolimus 
therapy. Given the modest impact, if any, of using CYP3A5 genotype to predict the 
optimal initial dose of tacrolimus, it may now be appropriate to test algorithms 
including genetic and non-genetic factors as described here.  As a first step, it would be 
useful to test the predictive value of this equation in an independent group of transplant 
recipients.  Demonstration of clinical utility of an algorithm would require a clinical 
trial statistically powered to demonstrate improvement in hard clinical endpoints. 
Conclusion  
The findings of the studies presented have demonstrated that the between-patient 
variability in tacrolimus daily dose requirement was related to CYP3A5*3, CYP3A4*22 
and ABCB1 3435 gene polymorphisms and that CYP3A5 *3 genotype is a key factor in 
the prediction of tacrolimus blood concentrations and dose requirement. Furthermore, 
the influence of CYP3A5*3, CYP3A4*22 and ABCB1 3435 genotypes on tacrolimus 
exposure was the same for once- and twice daily tacrolimus. CYP3A5*3 polymorphism 
cannot be replaced by 4B-OHC to predict tacrolimus dose requirement, even though 
they are strongly linked. Moreover, our data showed that switching from immediate to 
extended release tacrolimus has an impact on between-patient variability of tacrolimus 
exposure in this cohort of patients. On the other hand, conversion from immediate to 
extended release tacrolimus did not make any significant difference in WPV of dose-
normalized C0 and CYP3A5*3 genotype had no impact on within-patient variability of 
tacrolimus clearance in once- and twice-daily tacrolimus formulations. In addition to the 
genetic factors associated with tacrolimus dose, some non-genetic factors, including 
age, ethnicity, haematocrit, diabetic status and steroid treatment seems to have an 
influence in tacrolimus dose. This can be applied for both tacrolimus formulations. 
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10 Chapter 10. Future Options 
Based on the data presented in this thesis, I would propose the following follow-on 
work.  
Development of an algorithm to predict the optimal initial tacrolimus dose based on the 
genetic polymorphisms and non-genetic factors is worthy of further investigation. To 
test, this would require a large number of patients to deliver sufficient statistical power.  
Proposed next steps include: 
1) A retrospective study to validate a predictive equation for initial tacrolimus 
dose in an independent cohort of renal transplant recipients 
In an independent cohort of transplant patients, tacrolimus dose will be estimated based 
on CYP3A5*3/ ABCB1 3435 polymorphisms, age, ethnicity, haematocrit, 4β-
hydroxycholesterol /cholesterol ratio, CYP3A4*22 and compared to the actual 
tacrolimus dose that achieved target blood concentration. The relationship defined in 
Chapter 6 page 228 will be used in this study. 
2) Testing of a population pharmacokinetic model in a prospective clinical 
trial  
A population pharmacokinetic model for tacrolimus will be developed on basis of the 
theoretical expectation of a relationship between tacrolimus dose and CYP3A5*3/ 
ABCB1 3435 polymorphisms, age, ethnicity, haematocrit, 4β-hydroxycholesterol 
/cholesterol ratio, diabetic status and steroid therapy being the same for the prolonged 
release preparation Advagraf® as for the immediate release preparation, Prograf® or 
Adoport®. The clinical trial will need to show that the combination of genetic and non-
genetic factors to tacrolimus dose requirement would improve patient outcome based on 
measurable clinical endpoints including incidence of acute rejection and NODAT. 
The expectation following the identification of a number of gene polymorphisms 
involved in tacrolimus metabolism is to achieve a better immunosuppressive therapy for 
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each individual patient with less rejections or adverse effects. However, even if patients 
are genotyped for gene polymorphisms involved in tacrolimus absorption and 
metabolism, still a large percentage of tacrolimus dose variability remains unclear. For 
example, tacrolimus pharmacokinetics is strongly correlated with the expression and 
activity of the metabolizing enzyme CYP3A5. CYP3A5 expressers required 2-fold 
higher tacrolimus dose than non-expresser. Two recent clinical studies showed either no 
association between CYP3A5 adaptation of tacrolimus daily dose and earlier 
achievement of the target tacrolimus exposure range (Shuker et al., 2015) or some 
improvement in the number of patients reaching the target concentration with a 
considerable proportion of patients outside the target range (Thervet et al., 2010). The 
Liver is the main site of metabolism of tacrolimus. Detection of CYP3A5 expression 
helps to explain 30-35% of tacrolimus variability. It cannot give an accurate prediction 
of tacrolimus trough concentration and dose requirement. While 4β-hydroxycholesterol 
/cholesterol ratio provided a measure of systemic CYP3A activity, it adds relatively 
little to the predictive value of CYP3A5 genotype. An alternative approach that has 
been used to measure systemic CYP3A activity employed midazolam as a drug probe as 
an adjunct to genotyping (de Jonge et al., 2012).  
3) Individualisation of steroid therapy 
In this study, we found variation between patients in prednisolone and prednisone blood 
concentration achieved by 5 mg prednisolone daily, confirming the recent findings 
demonstrating large within- and between-individual variabilities in prednisolone and 
prednisone pharmacokinetics, indicating the need for personalizing dosing of 
glucocorticoids (including prednisolone and prednisone) in organ transplantation 
(Sagcal-Gironella et al., 2011, Saeves et al., 2012). Interestingly, this study showed a 
significantly lower concentration of prednisolone metabolite, prednisone in CYP3A5 
non-expressers, suggesting that the other main metabolite of prednisolone, 20β- 
dihydroprednisolone could be produced more than prednisone in the case of CYP3A5 
non-expresser. A clinical trial is needed to identify the pharmacodynamics of this 
metabolite and to see if it is responsible for any of prednisolone adverse effects. 
Furthermore a TDM clinical trial is also required to find the basis of a definable 
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relationship between prednisolone dose and plasma concentration and consequently 
between plasma concentration and the therapeutic effect in order to optimize the clinical 
outcomes in patients. Therefore, the dose can be adjusted to reach the target therapeutic 
concentration. 
4) Do the factors that predict pharmacokinetics for Advagraf® apply to 
Envarsus® 
Different oral formulations of tacrolimus are available. Generic once daily formulation, 
Envarsus® has recently been given marketing authorisation in the UK. Each formulation 
of tacrolimus has different excipients which are considered the inactive ingredients that 
do not have therapeutic role. Some studies have revealed that excipients can cause 
various side effects (Strauss and Greeff, 2015). Excipients can affect the 
pharmacokinetics of drugs through their effects on drug absorption (Andrysek, 
2006). Therefore, a clinical study is required to study the influence of the 
pharmacogenetic differences in this new formulation and to study the effect of 
switching stable renal transplant patients from a twice daily formulation of tacrolimus 
(Prograf® or Adoport®) or once daily formulation (Advagraf®) to the new once daily 
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Appendix 3. List of the Concomitant Medications 
Concomitant medication Patients 
No. 
Concomitant medication Patients 
No. Adalat La 2 Ismn 1 
Alendronic Acid (As 
Alendronate Sodium) 
4 Lansoprazole 5 
Alfacalcidol 35 Lantus Insulin 2 
Alfuzosin 2 Levimir Insulin 1 
Allopurinol 6 Losartan 2 
Amlodipine 31 Metoprolol 13 
Amoxicillin 2 Metronidazole (Metrotop) 1 
Aspirin 19 Minoxidil 1 
Atorvastatin 35 Mircera 1 
Azathioprine 14 Moxonidine 1 
Bendroflumethiazide 
(Bendrofluazide) 
5 Mycophenolate Mofetil 19 
Bisoprolol 9 Nifedipine 7 
Calcichew 1 Nitrofurantoin 1 
Calcitriol 2 Normacol 1 
Candesartan 12 Olanzapine 1 
Carvedilol 2 Omacor 1 
Cefalexin 1 Omeprazole 30 
Cefuroxime 1 Paracetamol 1 
Cinacalcet 6 Paroxetine 1 
Ciprofloxacin 3 Pravastatin 3 
Citalopram 1 Prednisolone 39 
Co-Amoxiclav 3 Pregabalin 1 
Colchicine 1 Pregaday 1 
Co-Trimoxazole 4 Propranolol 1 
Darbepoetin Alfa (Aranesp) 1 Pyridoxine 3 
Dorzolamide Eye Drops 1 Ramipril 16 
Doxazosin 20 Ranitidine 1 
Esomeprazole 1 Risedronate 1 
Ezetimibe 4 Salbutamol 1 
Ferrous Sulphate 6 Sildenafil 1 
Fluoxetine 1 Sodium Valproate 2 
Folic Acid 2 Sotalol 2 
Furosemide(Frusemide) 2 Tamsulosin 3 
Appendices 
Page 377 of 377 
Gliclazide 9 Telmisartan 1 
Hepatitis B  Vaccine 17 Thyroxine 1 
Hydralazine 1 Tibolone 1 
Hydroxocobalamin 1 Tramadol 1 
Insulin Detemir 1 Trimethoprim 1 
Insulin Glargine 2 Valganciclovir 6 






Insulin Novorapide 7 Vitamin D 2 
Irbesartan 1 Warfarin 1 
 
